ahead
of the curve
   annual report 2017

ahead
of the curve
in an environment of constant technological
disruption success hinges on the ability to stay
ahead of the curve
to strike ahead biocon broke from the pack


02    ahead of the curve  annual report 2017

                                                                           biocon limited




w     e evaluated the prospects and
      pitfalls of being a technology
pioneer and took eclectic scientific
                                           in the face of market skepticism
                                           we encouraged a culture of
                                           experimentation constantly acquired
bets to generate new knowledge we         new knowhow focused on breakthrough
plunged into uncharted waters of           innovation and ran rd programs to
innovationled biotechnology research     bring new drugs with the potential to
we believed that the audacious wagers      change the course of disease
we were making today would pay off
disproportionately tomorrow               to evenly spread risk and reward we
                                           sought the right partners and forged
the path we chose was capital intensive   enduring relationships we pursued
researchintensive and ipintensive        an incisive ip strategy to create robust
with inherently long gestational time      intellectual capital
lines for product commercialization
undaunted we made countercyclical        in a market place where leadership
investments we took proactive steps to    is transient and innovation is king
be futureready and equipped ourselves     biocon now stands ahead of the curve
to manage the uncertainties of the         committed to make a difference to
economic cycles                           global healthcare




                                                                ahead of the curve    03

         biocons strengths have been derived from
       s t r at e g i c c l a r i t y a n d i n v e s t m e n t co m m i t m e n t




          robust infrastructure and a        capabilities and expertise in an     proprietary technology based on
       talent pool with extensive global    array of expression platforms that    the pichia pastoris platform for
       product development experience      include microbial and mammalian        the expression of recombinant
                                                         systems                            proteins




         robust analytical capability        scientifically rigorous ethically    400member strong scientific
        anchored in cuttingedge tools     compliant and stage gatebased        team including mds phds and
       latest orthogonal approaches and     structured preclinical and clinical   masters degree holders drawn
           world class technology                 development strategy            from within india and global
                                                                                     biopharma organizations




          products approved by key            strategic global and regional       globalscale complex biologics
         regulatory agencies from us           partnerships across novel           manufacturing capabilities
       eu japan france brazil mexico      molecules and biosimilars
          turkey and gulf countries




04      ahead of the curve  annual report 2017

                                         biocon limited




 strong foundation in process
   sciences that enables the
 development of biologics with
economical scalability and high
          productivity




comprehensive presentation in
biologics across drug substance
  drug products liquid vials
 lyophilized vials cartridges 
prefilled syringes and delivery
devices reusable  disposable
        prefilled pens




 wide presence with marketing
footprint across 120 countries




                                   key strengths    05

06    ahead of the curve  annual report 2017

                                                                                                   biocon limited




              b i o c o n i s a di f f e r e n tiat e d p l a y e r
           i n t h e g l o ba l p h ar m a c e uti c a l s s pa c e




among a handful of indian           first and only listed pure play     globally recognized
pharma companies working in the     biopharmaceuticals company in         biopharmaceuticals enterprise
area of biologics                  india                                with a unique business model
                                                                          that straddles both products and
                                                                          services




extensive experience and            diversified portfolio of biosimilar   rd strategy covers early mid
demonstrated expertise in taking    insulin analogs and antibodies in     and latestage novel assets
two novel biologics and five        advanced stages of development
biosimilars from lab to market




inhouse expertise across the       incisive intellectual property        experience of multiple global
drug value chain pipeline          strategy recognized by several        regulatory filings in insulins
includes proprietary and            national and international awards    biosimilar antibodies and
partnered programs                                                       complex generic formulations




                                                                                      key differentiators     07

                                                 a motivation to enter
                                                 niche areas where we
           a strategy of being                   perceive the potential    a collaborative model
            profitably smart                     to moderate costs and     that allows us to share
          and socially good to                   widen patient access    risk and reward of drug
           provide affordable                                              development through
           access to advanced                                              research partnerships
           biopharmaceuticals                                              and extend our global
            for global patient                                             footprint through local
              populations                                                  marketing alliances
                                            biocons
                                            business
                                          model woven
                                             around
         a business philosophy                                                an unwavering
                                          commitment
          built around the core                                           commitment to stringent
            values of quality
                                            to core                          quality controls in
         affordability reliability
                                             values                       compliance with bestin
             and innovation                                               class global standards




          a relentless focus on                                           an obligation to develop
         chronic disease spaces                  a portfolio approach     affordable blockbuster
          like diabetes cancer                   focused on chronic      drugs with the potential
           and autoimmune                       disease segments and        to benefit a billion
              inflammation                 integrating well validated            patients
                                            targettoclinictocounter
                                                      capabilities




08    ahead of the curve  annual report 2017

                                                                                                                 biocon limited




     global biologics landscape presents
        a good opportunity for biocon




            of the top 15                     worldwide                            worldwide
            global pharma                  prescription drug                  biotechnology drug
          brands by revenue                 market in 2022                  market in 2022 projected
               in 2016                   forecasted to grow to                     to grow to


                 10
             were biologics
                                               us  11
                                                    trillion
                                                                                   us   337
                                                                                         billion


                  global biosimilars market in 2020 projected to be between


                            us     25           billion  us      35           billion




emerging markets have                          markets such as the                            in the us actions at the
historically seen a very                     us eu and japan have                             payer and regulatory
 high penetration of                            defined regulatory                              levels and increased
generic drugs similar                           requirements for                              political noise around
trends could apply to                       registration of biosimilar                         drug pricing are very
      biosimilars                          products and payers are                            encouraging towards
                                            pushing to contain costs                       acceptance of biosimilars



              source genetic engineering  biotechnology news evaluate pharma allied market research




                                                                                                       key opportunities    09

                         first indian company to manufacture and
               1979
                         export enzymes to the us  europe


                                     first biotechnology company in india to get iso 9001
                           1993
                                     certification from the german authority rwtuv


                                            indias first custom research services
                                  1994
                                            organization syngene set up


                                                 indias first clinical research
                                      2000
biocon                                           organization clinigene set up
has grown
through                                            first indian company to get us fda
                                        2001
the years by                                       approval for manufacturing lovastatin

c o n s i s t e n t ly
investing                               2004
                                                   first indian company to submit a dmf drug
                                                   master file for rhinsulin api to the us fda
and planning
ahead of the
                                                 first company globally to commercialize rhinsulin
curve                                 2004
                                                 manufactured through pichia fermentation technology


                                            first biotech company in india to
                                  2004
                                            list on the indian stock exchanges


                                     indias first indigenously produced novel monoclonal antibody
                           2006
                                     for head  neck cancer biomab egfr launched in india




10    ahead of the curve  annual report 2017

       biocon park indias first private corporate
2006
       biotechnology sez became operational


                   signed with mylan one of the earliest partnerships in the global
        2009
                   pharma industry for the codevelopment of biosimilars


                           evertor indias first generic everolimus for the treatment of
                2010
                           advanced renal cell carcinoma launched


                                the worlds first novel anticd6 monoclonal antibody for psoriasis
                    2013
                                alzumab itolizumab launched in india

                                  first indian biopharmaceuticals company to venture into the
                       2013       exciting space of sirnabased small interfering rna therapeutics
                                  through a partnership with quark pharma

                                  the first biosimilar trastuzumab to be approved anywhere in the
                       2014
                                  world launched as canmab in india


                                the first biosimilar to be approved in mexico as per the
                    2015
                                biocomparable approvals pathway is biocons insulin glargine


                           the first indian company to launch a biosimilar insulin glargine
                2016
                           pen in japan


                    biocons insugen is the first locally manufactured biosimilar product
        2017
                    to be approved for sale by the malaysian drug regulator




                                                                                 key achievements       11

                                         f y 1 7 at a g l a n c e


              revenue                          profit for the year         ebitda margin


              40787                           6121                       28
              h million                        h million



              rd spend gross                eps                         employees


              4019                            31                          9000
              h million                        h




          business revenue mix                                    geographic distribution 



                              4

                                                                           30
                  28
                                          40




                                                                                                70
                       14
                                  14




               small molecules h16330 million                                  international
                   biologics h5793 million                                      domestic
             branded formulations h5489 million
              research services h11604 million
                       others h1571 million




12    ahead of the curve  annual report 2017

                                                                  biocon limited




contents




           chairpersons review 14         branded formulations 54
           qa with the ceo 22             global marketing 57
           financial review by cfo 28      research services 59
           board of directors 34           enablers
           scientific advisory board 38    research  development 62
           core committee 39                  quality 68
           vision mission and values 40   supply chain management 69
           financial highlights 41         human resources 74
           business segment review 44      environment health  safety 77
           biologics 46                    corporate social responsibility
              biosimilars 47                 biocon foundation 81
              novel biologics 50             biocon academy 90
           small molecules 52              financial report 93




                                                               contents       13

 chairpersons
   review
       kiran mazumdarshaw chairperson




14    ahead of the curve  annual report 2017

                                                                                                                biocon limited




dear shareholders

the era of biologics
the global pharmaceuticals industry           it is noteworthy that 10 of the top 15 drugs by sales in 2016 were biologics
is witnessing transformative change          and it is forecast that by 2022 biologics will contribute up to 50 of the value
biologic drugs or protein therapeutics        of the top 100 drug products sold globally global sales of biotechnology
like antibodies interleukins and vaccines   drugs are projected to grow to usd 337 billion by 2022
derived from microbial and mammalian
cells have ushered in a paradigm shift        getting ahead of the curve
in treating chronic diseases targeted        at the turn of the millennium biocon chose to embark on a biologicsled
therapies and precision medicine are
                                              pharmaceutical journey with a differentiated business strategy we invested
poised to disrupt the future of disease
                                              ahead of the curve in the promising future of targeted biologics that are
management
                                              revolutionizing the treatment of chronic diseases we recognized that for a
the indian pharmaceuticals sector built       company of our size it was an audacious plan we took the plunge because
global scale and leadership by reverse        we believed it would provide us with a head start in an overcrowded generics
engineering expensive chemically             market place we decided to take on the complex development manufacturing
synthesized small molecule drugs to
                                              and regulatory challenges inherent to biologics as we were confident of our
produce cost effective generic
                                              capabilities this stemmed from our knowledge and expertize in enzyme
alternatives in doing so it earned the
                                              technology with which we started our biotechnology business we pursued an
label of being the pharmacy of the
                                              innovation strategy rooted in affordability by leveraging indias cost base and
world after dominating the traditional
generic drugs industry for decades many
                                              set out to address the unfolding opportunities by choosing to lead rather than
indian companies are now in the race          follow we have been able to transform scientific discoveries into advances in
to create generic versions of biologic        human healthcare and generate incremental value for our shareholders
drugs or biosimilars which are far more
                                              biologics at the cutting edge
complex to make but offer a large global
opportunity                                  in 2006 biocon earned the distinction of being the first company in india to
                                              launch a novel biologic nimotuzumab a humanized antiegfr epidermal
biocon is ahead in the pursuit to develop
                                              growth factor receptor monoclonal antibody mab for head  neck cancer
the first wave of biosimilars for global
                                              patients
markets and expand access to a number
of essential and lifesaving biologic drugs    we followed up with the launch of our second novel biologic itolizumab in
that are facing patent expiry we are         2013 for psoriasis patients in india this was a pathbreaking anticd6 mab
also developing a pipeline of patented
                                              that offered a less aggressive dosing regimen and a longer treatment free
biologics to address unmet medical
                                              period
needs
                                              we had entered into a codevelopment partnership with usbased mylan for
source                                       a portfolio of biosimilars in 2009 this collaboration led to the launch of the
genetic engineering  biotechnology news
                                              worlds first biosimilar trastuzumab in 2014 patients suffering from
evaluate pharma world preview 2016





                                                                                                 chairpersons review        15

                                       her2positive metastatic breast cancer in india gained access to an affordable
                                       version of this lifesaving drug when the rest of the emerging world only had
we have put three                      recourse to the expensive innovator product
of our advanced
                                       biocon and mylan have one of the longeststanding partnerships in the global
biosimilar assets on
                                       biosimilars space we have leveraged our mutual strengths to build one of the
track for anticipated
                                       largest and most diverse biosimilar pipelines spanning insulin analogs and
regulatory approvals
                                       monoclonal antibodies
in developed
markets                               first off the blocks
                                       as early movers in the biosimilars space we have put three of our advanced
                                       biosimilar assets on track for anticipated regulatory approvals in developed
                                       markets these address an aggregate market opportunity of usd 20 billion

                                       during fy17 we filed two biologics license applications blas in the us and
                                       three marketing authorization applications maas in eu

                                       we were the first to file regulatory applications for a proposed biosimilar of
                                       trastuzumab in both the us and eu this has positioned biocon and mylan
                                       among the first companies to be able to address the critical need for a
                                       highquality biosimilar to treat certain her2positive breast cancers in the
                                       us and eu

                                       our applications for biosimilar pegfilgrastim have also been accepted for
                                       review in the us and eu

                                       we submitted a marketing authorization application for our biosimilar
                                       bevacizumab with the indian drug regulator after completing an emerging
                                       markettargeted india clinical trial the maa has recently been granted

                                       the global clinical trials for our biosimilar adalimumab in plaque psoriasis
                                       have been completed we expect regulatory submissions in various
                                       geographies to start in fy18

                                       our biosimilars development capability was endorsed this year with the
                                       publication of the heritage study by the prestigious journal of the american
                                       medical association jama the study results confirmed the efficacy safety




16    ahead of the curve  annual report 2017

                                                                                                    biocon limited




                         and immunogenicity of the proposed biosimilar trastuzumab codeveloped by
                         biocon and mylan in comparison to the reference product
we are now moving
                         the presentations of the study results at the american society of clinical
steadfastly towards
                         oncology asco annual meeting in chicago us and the european society for
our aspiration of
                         medical oncology esmo congress in copenhagen denmark in 2016 by
providing our insulins
                         dr hope rugo were appreciated immensely by the scientific community
to one in five
insulindependent        consolidating market leadership
people with diabetes    we have built market leadership in insulins on the back of our global
around the world        manufacturing scale we are now moving steadfastly towards our aspiration of
                         providing our insulins to one in five insulindependent people with diabetes
                         around the world

                         we achieved a key milestone in our journey towards this visionary goal
                         when we launched our readytouse disposable insulin glargine pen in
                         japan through our partner fujifilm pharma our insulin glargine is the first
                         biosimilar from india to be launched in japan it is also our first biosimilar in a
                         developed market the confidence our product has gained among prescribers
                         and patients in japan has endorsed the quality and efficacy of our product and
                         enhanced brand biocons reputation across the world

                         we also started commercial supplies from our first overseas insulins
                         manufacturing facility in malaysia this year our recombinant human insulin
                         rhinsulin became malaysias first locally manufactured biosimilar product
                         to be sold in the southeast asian nation after we signed a threeyear
                         myr 300 million offtake agreement with the malaysian government

                         we are looking forward to our insulins foray into larger developed markets
                         following the submission and acceptance of our filings for insulin glargine
                         with the european medicines agency ema and the us fda

                         the commercialization of the malaysia facility in fy17 will strengthen our
                         position among the top 3 biosimilar players globally for insulins
                         in terms of volume market shareunits source ims year end 2016
                         




                                                                                       chairpersons review    17

                                       novel molecules poised for the leap
                                       as practitioners of frontier science we have built a pipeline of novel biologics
the successful
                                       to address local as well as global unmet medical needs in diabetes cancer and
journey of itolizumab                  autoimmune diseases the basket of novel assets under clinical development
from the laboratory                    represents an interesting combination of early and advanced stage assets
to the market in india
                                       we believe insulin tregopil a firstinclass oral prandial insulin is the most
has put us ahead in
                                       advanced program in the global oral insulin space and promises to transform
the race of anticd6
                                       diabetes management we have set the stage for pivotal studies with insulin
antibody to unlock
                                       tregopil on different diabetic populations in india which will form the
the potential of its
                                       foundation of a broad global program envisioned for this novel molecular entity
unique mechanism
of action in multiple                  the successful journey of itolizumab from the laboratory to the market in india
autoimmune                             has put us ahead in the race to unlock the potential of its unique mechanism
indications                           of action in multiple autoimmune indications in fy17 we reported
                                       encouraging progress in our tests with a patientfriendly subcutaneous form of
                                       itolizumab

                                       small molecules enabling partners
                                       the significant brand equity that we have built worldwide for our
                                       fermentationderived small molecule apis across statins immunosuppresants
                                       and other specialty products has made us a leading global supplier of these
                                       products we built on this reputation to emerge among the first wave of
                                       suppliers of rosuvastatin api to our partners for the us launch upon patent
                                       expiry in 2016 during the year we received our first generic formulation
                                       approval for rosuvastatin calcium from the us fda

                                       to become a vertically integrated player in the niche space of difficultto
                                       make generic formulations we have leveraged our strengths in fermentation
                                       technology and molecular characterization

                                       branded formulations india  uae
                                       we initiated our branded formulations business in india in 2004 with the
                                       launch of the countrys first indigenously developed rhinsulin which brought
                                       down the cost of insulin therapy by a third since then we have aimed at
                                       staying ahead of the curve by deftly balancing innovation and affordability



18    ahead of the curve  annual report 2017

                                                                                         biocon limited




                        with an intent to bring costeffective biologics and differentiated small
                        molecule formulations for chronic conditions to patients in india uae and
as a frontrunner       other select markets
in the contract
                        this year the business reported an overall growth of 24 on a like to like
research services
                        basis this segment was down marginally compared to last year though sales
space syngene
                        in india were sluggish we continued to improve prescription share for some of
further expanded its    our key brands such as insugen basalog and canmab our robust growth
role in fy17 as an      in uae placed us among the top 15 pharma companies this year with most of
innovation partner   our products ranked among the top 5 brands in their respective segments

                        the recently announced leadership changes across our india branded
                        formulations business will provide us the ability to pursue a strong growth
                        trajectory

                        syngene integrated research services provider
                        syngene our research services subsidiary is the only publicly listed contract
                        research organization cro in india that offers endtoend drug discovery
                        and development services for novel molecular entities to the global life
                        sciences sector as a front runner in the contract research space syngene
                        further expanded its role in fy17 as an innovation partner through new
                        strategic partnerships with amgen and herbalife nutrition with dedicated
                        rd centers

                        in december 2016 a fire accident at one of syngenes research blocks in
                        bengaluru affected the strong revenue momentum of the business syngenes
                        value proposition to its customers remains strong as it expanded its capacities
                        and acquired new capabilities during the year an important acquisition to this
                        effect was that of a bioinformatics business from a bengaluru based genomics
                        company strand lifesciences on a standalone basis it reported a revenue
                        growth of 14 with a healthy ebitda margin

                        quality unwavering focus
                        a culture of quality excellence has helped biocon maintain a strong
                        compliance track record in regulatory inspections over the years during fy17
                        we underwent multiple regulatory audits from various international regulators



                                                                          chairpersons review          19

                                       best employer brand
                                       we continue to be the only asian company on the global best biotech
we continue to
                                       employers list brought out by the prestigious science careers magazine which
be the only asian                      i believe is a great testament to our work culture and the opportunities our
company on the                         scientists get within the company in 2016 we featured among the top 10
global best biotech                    employers globally
employers list
                                       financial highlights
                                       we matched our operational performance in fy17 with an equally strong
                                       financial performance we grew our topline by 18 to h40787 million while
                                       simultaneously improving the quality of our earnings our ebitda margin for
                                       the year expanded to 28 from 24 a year ago adjusting for the exceptional
                                       item that boosted the bottomline in fy16 net profit for fy17 jumped 54 to
                                       h6199 million

                                       declaration of bonus shares  final dividend
                                       the board of directors of the company has recommended the issue of
                                       two bonus shares for every one share held in biocon which has been
                                       subsequently approved by the shareholders the board also recommended a
                                       final dividend of h3 per share for fy17 pre bonus which works out to be
                                       h1 per share post approval

                                       being socially responsible
                                       we strongly believe that the use of technology can address several challenges
                                       associated with public health delivery in our country biocon foundation
                                       the csr arm of biocon has taken ahead this belief to develop a unique
                                       ehealthcare model and introduced elaj smart clinics a few years ago

                                       these clinics are designed to facilitate effective preventive and primary
                                       healthcare intervention in the rural areas of india for the benefit of communities
                                       with poor access to healthcare the foundation currently runs 14 elaj smart
                                       clinics covering over 30 gram panchayats across karnataka and rajasthan

                                       through the elaj smart clinics we are paving the way for evidencebased
                                       public health interventions in these locations by enabling multiple diagnostic
                                       tests and generation of electronic medical records emrs of patients over


20    ahead of the curve  annual report 2017

                                                                                           biocon limited




                        the past year patient footfall at elaj clinics has gone up by 50 to more than
                        9000 a month
through the elaj
                        the elaj model is facilitating ontime treatment helping reduce outofpocket
smart clinics we
                        healthcare spending and cutting down the need for trips to tertiary hospitals
are paving the
                        which is in line with our commitment to enable the right to healthcare for
way for evidence
                        every citizen
based public health
interventions using     biocon academy our oneofakind initiative in the area of skills development
technology for          delivered on its commitment to prepare industryready students for the
                        biotech sector fy17 saw the successful completion of three batches of the
multiple diagnostic
                        biocon kgi certificate program in biosciences and the second batch of the bits
tests and generation
                        biocon program in applied industrial microbiology the academy maintained
of electronic medical
                        a 100 placement record this year too even as more than 35 companies
records emrs of
                        visited it for recruiting fresh talent more than 60 of our students are being
patients
                        employed outside of biocon and syngene

                        looking ahead
                        fy18 promises to be an exciting year for biocon as some of the developed
                        market regulatory submissions for our biosimilars could translate into
                        marketing approvals opening up immense growth opportunities for the
                        company

                        finally i would like to thank our shareholders for the trust they have placed
                        in us we are in a humanitarian business of making a difference to peoples
                        lives it is this mission that has spurred us on to fight our way through years of
                        credibility challenges and market skepticism and emerge as the leading indian
                        company working in the cuttingedge sphere of biosimilars



                        best wishes




                        kiran mazumdarshaw
                        chairperson  managing director
                        june 8 2017


                                                                           chairpersons review        21

      qa
  with the ceo
           dr arun chandavarkar
        ceo  joint managing director




22    ahead of the curve  annual report 2017

                                                                                           biocon limited




                         how has biocon consistently stayed ahead of the curve
                         biocons focus on innovation and differentiation predates our entry into
                         the pharmaceuticals sector our entrepreneurial culture rooted in building
                         strengths in the then nascent field of biotechnology was instrumental in us
                         identifying opportunities based on market and technology trends both during
                         our initial years as an enzyme company and during our subsequent foray into
                         biopharmaceuticals this led us to proactively invest in capabilities aligned to
                         these opportunities to be ahead of the curve

                         biocon commenced its pharma journey in 1999 by leveraging its
                         capabilities in fermentation technologies derived from its long experience
                         in manufacturing enzymes this was unlike other companies in india which
                         were largely focused on generics made by chemical synthesis furthermore
                         we were amongst the early movers in developing a portfolio of fermentation
                         derived statins which gave us a leadership position in this segment we
                         simultaneously chose to expand our strategic options from small molecules
                         like statins to recombinant proteins like insulin to address the growing
                         healthcare challenges associated with diabetes

                         we did not hesitate to exploit differentiated technologies such as a
                         proprietary yeast platform based on pichia pastoris to create a portfolio
                         of insulins in 2003 we initiated work on mammalian cell culture based
                         expression systems to develop monoclonal antibodies mabs targeting
                         cancer and autoimmune diseases our product portfolio was not limited to
                         generics or biosimilars we sought opportunities to be ahead of the curve
                         in addressing unmet needs in these therapeutic segments through novel
                         biologics and novel targets these were marked by high entry barriers wherein
the early anticipation   we were required to make significant investments in a full range of rd
of the increasing        capabilities spanning process and analytical development to preclinical and
dominance of             clinical research
biologics in global      the early anticipation of the increasing dominance of biologics in global
development              development pipelines helped us to be ahead of the curve in crafting a
pipelines helped us      differentiated product portfolio based on fermentation and recombinant
to be ahead of the      technologies we believe these would provide us a sustainable competitive
curve                  advantage in the years ahead



                                                                                       ceos qa        23

                                       how did being ahead of the curve translate into tangible
                                       achievements at biocon
                                       the strategic choice of focusing on biotech and fermentationderived
                                       biopharmaceuticals resulted in a unique and differentiated product portfolio
                                       straddling fermentationderived small molecules recombinant proteins
                                       including insulins and mabs

                                       biocons growth in the mid 2000s triggered by the first approval of our
                                       statin api facility by the us fda was driven by our early mover advantage
                                       in lovastatin pravastatin and simvastatin we were amongst only a few
                                       companies with approved apis for these fermentationderived statins which
                                       helped lower the competitive intensity otherwise typical of chemistrybased
                                       apis we expanded our portfolio of fermentationderived apis to establish
                                       a strong competitive position in immunosuppressants and certain other
                                       speciality apis

                                       likewise we were one among just two nonoriginator companies to
                                       commercialize recombinant human insulin in india in 2004 and subsequently
                                       rapidly expand our footprint into multiple emerging markets this was
during the year                        followed by the launch of insulin glargine in india in 2009 and more recently
gone by we further                    by an important endorsement of our product quality on account of the
demonstrated                           approval and launch of glargine disposable pens in japan in 2016
our capabilities
                                       we were also pioneers in developing manufacturing and launching a couple
through the dossier
                                       of novel biologics in india namely an antiegfr mab nimotuzumab for head
submissions in
                                       and neck cancer in 2006 and an anticd6 mab itolizumab for psoriasis in
europe by our
                                       2013
partner mylan for
three biosimilar                       when we embarked on our biosimilar journey we anticipated some of the
products based on                      risks the long gestation period for development the evolving regulatory
diverse technology                     landscape and significant financial outlay for rd and manufacturing
platforms and scale                    infrastructure we proactively mitigated some of these risks by entering into
of operations                         regional and global partnering agreements such as the one with mylan for




24    ahead of the curve  annual report 2017

                                                                  biocon limited




biosimilar mabs in 2009 which was then expanded to insulin analogs in 2013
these partnerships structured as a sharing of risks and rewards leveraged
the complementary strengths of each partner and were a forerunner of many
global partnerships that exist today in the biosimilar space including those
involving many innovator companies i believe that partnering as a strategic
choice early in the investment cycle of biosimilars is another example of how
we have been ahead of the curve

a tangible outcome of our partnership with mylan has been the launch of
biosimilar trastuzumab in 2014 in india and other emerging markets our
collaboration also reached important milestones in fy17 with our trastuzumab
and pegfilgrastim dossiers being accepted for review by the us fda and ema
followed by our glargine filing in europe

what does biocons ahead of the curve strategy mean for its
prospects
biocons annual report to shareholders for fy16 highlighted our efforts and
initial successes at being credibly capable this was based on our first
approval for a biosimilar product namely insulin glargine in a very demanding
developed market like japan and the progress we had made in advancing our
other biosimilar programs through the clinic

during the year gone by we further demonstrated our capabilities through
the dossier submissions in europe by our partner mylan for three biosimilar
products based on diverse technology platforms and scale of operations
namely trastuzumab pegfilgrastim and insulin glargine last year we also had
the us fda accept the dossiers of trastuzumab and pegfilgrastim for review
with insulin glargine to follow in early fy18 these three products target a
market opportunity of about usd 1820 billion at current innovator pricing
we continue to develop the other biosimilar assets in our collaboration with
mylan

our nearterm growth in biosimilars will be driven by expanding our footprint
in key emerging markets through strong local partnerships product approvals




                                                              ceos qa         25

                                       and commercial success in the developed markets of the us and europe would
                                       be significant milestones that can help the company reinvent itself and lay
                                       a strong foundation to stay ahead of the curve in the next decade these
                                       will be supported by capacity expansions as needed in a phased manner and
                                       additions to our product portfolio to cater to the next wave of opportunities
                                       we will continue to adopt a riskbalanced approach to advance our promising
                                       firstinclass novel biologics that target critical unmet needs

                                       we will strive to remain ahead of the curve in developing fermentation
                                       derived complex potent or niche small molecule generic apis and forward
                                       integrate them to finished dosage forms

                                       we believe that our strategy of being ahead of the curve through a well
                                       diversified portfolio of small molecules biosimilars and novel biologics can
                                       help us overcome the headwinds facing the generic pharmaceutical sector
                                       today in terms of pricing pressure tougher regulatory expectations and
                                       increased competition

                                       what are biocons key priorities for fy18
                                       fy18 positions us at a key inflection point in our journey to be amongst
the successful
                                       the first wave of successful entrants in the global biosimilar arena we look
commissioning of our
                                       forward to receiving approvals in the us and europe for the biosimilar filings
malaysian facility for
                                       done in fy17 and launch of some of these products in a few markets we also
insulins in fy17 and
                                       expect to have a couple of additional filings in fy18 in these markets
the threeyear
myr 300 million                        the successful commissioning of our malaysian facility for insulins in fy17
contract from the                      and the threeyear myr 300 million contract from the malaysian ministry
malaysian ministry of                  of health augur well as we seek approvals in other key emerging markets
health augur well as                   these approvals and the commercial launches thereafter expected in the

we seek approvals in                   latter part of fy18 would help partly defray the annual fixed costs of about

other key emerging                     usd 48 million associated with our malaysian facility the approvals will also
                                       debottleneck the capacity constraint we had for insulins in our indian facility
markets




26    ahead of the curve  annual report 2017

                                                                                            biocon limited




                       we will continue to seek approvals and expand our commercial footprint for
                       biosimilars in the key emerging markets of latam mena cis and southeast
                       asia this can unlock value for our first set of assets whilst waiting for
                       the developed markets to open up we expect to break ground for a new
                       brownfield mabs facility in bengaluru

                       on the rd front we will continue to invest in progressing our biosimilars
                       and novel biologics whilst we completed an rowfocused phase iii trial in
                       metastatic colorectal cancer for our proposed biosimilar bevacizumab in fy17
                       a separate global phase iii trial in nonsmall cell lung cancer is on track with
                       patient recruitment we will continue to develop rapidacting insulin analogs
                       to enable progress to the clinical stage we will shortly initiate a significant
                       clinical study of our novel insulin tregopil oral insulin to validate its
                       positioning as an orallydelivered rapidacting prandial insulin and establish
                       its safety and efficacy in type 2 diabetes patients we expect to conclude the
                       stage 2 study of our novel anticd6 mab itolizumab in australia which can
                       provide valuable data in terms of a subcutaneous route of administration

                       our small molecules segment is expected to see steady growth on the
                       back of increased volume offtake in our base products comprising statins
our small molecules    and immunosuppressants we will continue to invest in developing the
segment is expected    next portfolio of small molecules and forward integrating them from apis
to see steady growth   to finished dosage forms we expect our newly constructed oral solids
on the back of         formulations facility to be operational in the latter part of fy18 which will

increased volume       reduce our current dependence on outsourced manufacturing

offtake in our base    a key focus in fy18 will be rebooting our branded formulations business
products comprising    under a recently revamped leadership team with the intent of gaining market
statins and            share profitably through our anchor brands this will be augmented through
immunosuppressants    new launches of inhouse and inlicensed products




                                                                                        ceos qa       27

                                                               financial
                                                                review
                                                                by cfo
                                                                      siddharth mittal
                                                                  presidentfinance  cfo




                                 revenue                      ebitda

                                 h40787             million   h11366                  million
                                 18                           34

                                 net profit                   ebitda margin

                                 h6121          million       28
                                 11                           4




28    ahead of the curve  annual report 2017

                                                                                       biocon limited




                      can you comment on your transition to the new indian accounting
                      standards from fy17
                      biocon is amongst the early adopters of the new indian accounting standards
                      referred commonly as ind as the transition from the older standard to
                      ind as starting april 1 2016 applied to both our standalone and
                      consolidated financial statements

                      in line with ind as we changed our segment reporting to better reflect the
                      way we view and measure our overall business we started reporting four
                      segments  small molecules biologics branded formulations and research
                      services  instead of just two biopharmaceuticals and research services
                      which we used to report under the previous accounting standard this is in
                      line with the growth strategies represented by the four business segments and
                      provides a clearer picture of those segments to our shareholders than earlier

                      how do you rate the performance this year
                      the overall financial performance during the year was very satisfactory and
                      in line with our expectations in fy17 our consolidated revenue at h40787
                      million grew by 18 while net profit at h6121 million reported 11 growth
                      adjusting for an exceptional income in fy16 net profit actually jumped 54
                      to h6199 million during the year earnings before interest taxes depreciation
                       amortization ebitda for the year rose 34 to h11366 million while
                      ebitda margin markedly improved to 28 from 24 last year

                      the extraordinary gain recorded in the previous year was on account of the
                      deferred revenue recognition pertaining to rhinsulin development and
                      impairment of an intangible asset in biocon sa
adjusting for an      the companys strong performance during the year was led by the small
exceptional income    molecules business reporting a growth of 12 at h16330 million and
in fy16 net profit   biologics business at h5793 million reporting a growth of 43 branded
actually jumped 54   formulations business which now includes sales in uae reported a growth of
to h6199 million     24 at h5489 million and research services through syngene contributed
during the year      h11604 million to biocons sales




                                                                             financial review      29

                                       what does your operating margins trajectory look like in the medium
                                       term
                                       the companys core operating margins which is operating margins adjusted
                                       for licensing income rd expenses and forex gains or losses continue to
                                       remain healthy in spite of increased operational expenses like salaries and
                                       other costs in fy17 our ebitda margin was at 28 while core operating
                                       margins stood at 32 resulting from growth in our small molecules business
                                       and biosimilars business in the emerging markets

                                       in the mediumterm we will endeavor to maintain our core operating
                                       margins at 30 levels despite an increase in rd expenses and inclusion of
                                       malaysian expenses in the pl we anticipate margins to improve once we
                                       launch biosimilar products in the developed markets and enjoy a reasonable
                                       penetration that reflects in the optimum utilization of our manufacturing
                                       assets

                                       with goods  services tax gst expected to be rolled out nationwide
                                       on july 1 2017 what would be its anticipated impact on biocon
                                       from a longterm perspective gst is good for the nation as it will replace a
                                       number of different taxes companies have to deal with currently with a single
                                       nationwide tax that would simplify operations

                                       we do expect a shortterm impact on the branded formulations india business
                                       as it is anticipated that the distribution channel could destock market
                                       inventory before gst rollout and hence sales in q1 fy18 could be impacted
                                       the impact could rollover into q2 fy18 as well depending on how quickly the
                                       channel becomes gstready and compliant we expect things to normalize by
                                       the second half of the fiscal
in the mediumterm                    under gst the company can claim input credit for certain items which
we will endeavor to                    was not possible in the earlier tax structure however these savings would
maintain our core                      ultimately have to be passed on to customers given the antiprofiteering
operating margins                      clause in the gst bill
at 30 levels
despite an increase                    what is the expected tax rate for biocon at the consolidated level for
in rd expenses                        fy18
and inclusion of                       at a consolidated level the effective tax rate for fy17 was 19 after
malaysian expenses                     adjusting for onetime deferred tax benefit that the company availed the
in the pl                            effective tax rate was 22 for the year




30    ahead of the curve  annual report 2017

                                                                   biocon limited




this rate is expected to go up by 200300 bps 100 bps  1 in fy18 due to
the expiry of the 10year tax holiday for some of our manufacturing facilities
further the government is gradually phasing out the rd tax benefit availed
by biocon thus far the 200 weighted deduction will reduce to 150 in
fy18 and be completely eliminated in the next couple of years

biocon has stopped capitalization of expenses from the malaysia plant
at the end of fy17 how will it affect the bottomline in fy18
we stopped capitalizing preoperating expenses relating to malaysia plant at
the end of fy17 consequently depreciation and fixed expenses related to
the malaysia plant will be charged to the pl account starting q1 fy18 we
estimate annual depreciation of approximately usd 18 million and fixed plant
operating expenses which includes the finance cost to be approximately
usd 30 million

we have already commenced commercialization from malaysia plant with
supply of rhinsulin for the domestic market in fy18 we also anticipate
approvals followed by commercial supplies in other emerging markets where
previously our india plant was qualified lastly we will partly utilize the plant
for development of other pipeline insulin products wherein the costs will be
shared with our partner mylan or will be accounted under rd expenses

as a result of the above we do expect an adverse impact on our bottomline
from malaysian operations in fy18 however we will endeavour to minimize
the impact

what will be the trajectory of rd expenditure across the foreseeable
future
the company will continue to focus on development of biosimilars complex
generics and novel biologics these programs require intensive rd efforts
and have long gestation periods we have guided for gross annual rd
expenses to be in the range of 1215 of sales excluding syngene we
expect rd expenses in fy18 to be in line with that guidance




                                                         financial review      31

                                       what is the rationale behind the capitalization of rd expenses for
                                       select biosimilar products
                                       in accordance with requirements of ind as 38 intangible assets development
                                       costs are capitalized as intangible assets based on the recognition parameters
                                       summarized below

                                       a the product is technically and commercially feasible ie future economic
                                          benefits are probable and the group intends to complete development
                                          with an intent to use or sell the asset

                                          we establish technical feasibility once we have demonstrated biosimilarity
                                          of our product in terms of safety and efficacy through various preclinical
                                          and clinical activities this occurs upon receipt of regulatory approval for
                                          the product in a major territory

                                          we establish commercial feasibility once we have demonstrated that
                                          the intangible asset will generate probable future economic benefits
                                          this occurs when it is probable that we will be able to successfully
                                          commercialize the product in the intended markets

                                          once the technical and commercial feasibilities are established and we
                                          believe we have adequate technical financial and other resources to
                                          complete the development activity we capitalize all future development
                                          costs incurred
we also have
sufficient leverage                    b the expenditure can be measured reliably
on the balance                            costs of development are identified at a product level and hence
sheet to raise                            development cost eligible for capitalization can be measured reliably
additional debt to                        broad category of expenses capitalized include the cost of materials
fund the remaining                        salaries and other appropriate overheads used in product validation costs
portion of capex                         for conducting clinical trials etc
we do not foresee
raising fresh equity                   what are biocons capex plans for fy18
funding from the                       we are nearing the completion of two capex projects an oral solid dosage
capital markets to                     facility and the biologics fillfinish line in bengaluru which are expected to
fund any of our                        be commissioned in fy18 after which we will commence the qualification
shortterm capex                       process our maintenance capex is estimated to be between h750 million and
requirements                          h1 billion for the year




32    ahead of the curve  annual report 2017

                                                                   biocon limited




in terms of a new large project we expect to start construction of our second
monoclonal antibodies facility in bengaluru during fy18 after receipt of all
regulatory approvals the investment will be phased over a period of three to
four years and the associated capex will be shared with our partner mylan

what is the debt position of the company how does biocon plan to
fund the upcoming capex would biocon need to raise funds from the
markets to fund its future growth plans
biocon has a consolidated gross debt long term plus short term debt of
h23025 million as on march 31 2017 with corresponding cash  liquid
investments of h22551 million excluding syngene the gross debt and cash 
liquid investments stood at h14961 million and h11875 million respectively

cash  liquid investments on our balance sheet coupled with free cash flow
from operations will be used to fund a significant portion of the capex we
also have sufficient leverage on the balance sheet to raise additional debt
to fund the remaining portion of capex we do not foresee raising fresh
equity funding from the capital markets to fund any of our shortterm capex
requirements

from a longterm perspective we have restructured our legal entities to reflect
each of our key business segments the new structure provides us flexibility to
unlock value and raise capital if required for any of our business segments in
the future

does biocon have a specific dividend policy
yes biocon does have a dividend policy the dividend if any will be
distributed to our shareholders depending upon multiple factors including
but not limited to our future earnings financial condition cash flows
planned capital expenditures and working capital requirements the
declaration and payment of dividends will be recommended by our board of
directors and approved by the shareholders at their discretion subject to the
provisions of the articles of association and the companies act
for more details please read page 107




                                                        financial review       33

board of directors




sitting from left    dr vijay kuchroo john shaw mary harney kiran mazumdarshaw
                      russell walls daniel m bradbury

standing from left   dr jeremy levin m damodaran dr arun chandavarkar prof ravi mazumdar




34       ahead of the curve  annual report 2017

                                                                                                       biocon limited




kiran mazumdarshaw                    people across the globe in the           played a pivotal role in the evolution
chairperson  managing director        field of medicine being recognized      of biocon over the last 27 years
first generation entrepreneur with     consecutively for the third year since
                                                                                phd in biochemical engineering
nearly 42 years experience in         2015
                                                                                from the massachusetts institute of
biotechnology                          conferred with the highest french        technology mit cambridge usa
well recognized global business        distinction  chevalier de lordre
                                                                                btech in chemical engineering from
leader                                 national de la lgion dhonneur
                                                                                the indian institute of technology
                                       knight of the legion of honour in
independent member of the board                                                 mumbai
                                       2016
of infosys limited                                                              chairman confederation of indian
                                       most recently bestowed with the
chairperson of the board of                                                     industrys national committee on
                                       advancing women in science
governors of the indian institute of                                            biotechnology
                                       and medicine awsm award for
management bangalore
                                       excellence 2017 by the feinstein         prof ravi mazumdar
recipient of two most prestigious      institute for medical research usa      nonexecutive director
national awards the padma shri and                                             university research chair professor
                                       john shaw
the padma bhushan                                                               department of electrical and
                                       vice chairman and wholetime
recipient of othmer gold medal                                                 computer engineering university of
                                       director
2014 from us based chemical                                                  waterloo canada
                                       foreign promoter and a wholetime
heritage foundation                                                             jd gandhi distinguished visiting
                                       director
recipient of 2014 global economy                                               professor at iit mumbai
                                       masters degree in arts economic
prize for business from germanys                                              member of several advisory
                                       hons in history and political
kiel institute                                                                  committees and working groups
                                       economy from glasgow university
featured in 100 most powerful         uk                                       including the us congress sub
women and asiapacifics 48                                                    committee on science and
                                       served as the finance and managing
heroes of philanthropy by forbes                                              technology
                                       director of coats viyella group
magazine                                                                        fellow of the royal statistical
                                       served in senior corporate positions
recognized as the 100 leading                                                  society
                                       around the world
global thinkers of 2014 by us                                                 over 150 referred publications
based foreign policy magazine          former chairman madura coats ltd
                                                                                ph d from the university of
fortune magazines top 25 most        dr arun chandavarkar                    california los angeles ucla
powerful women in asiapacific         chief executive officer  joint
                                                                                msc dic from imperial college
2014                                  managing director
                                                                                london
featured among the top 10              core member of biocons leadership
                                       team                                     btech in electrical engineering from
medicine maker power list an
                                                                                iit mumbai
index of the 100 most influential




                                                                                           board of directors        35

                                       russell walls                         daniel m bradbury
                                       independent director                  independent director
                                       chairman aviva life holdings ltd    on the board of trustees of the keck
                                       experience of more than 47 years in   graduate institute california usa
                                       the field of finance
                                                                             member san diegos rady school of
                                       fellow member of the association of   managements advisory council
                                       chartered certified accountants uk
                                                                             member miamis innovation
                                       board of mytrah energy ltd aviva     corporate advisory council
                                       italia holdings spa and signet
                                                                             life sciences executive with over
                                       jewelers ltd
                                                                             30 years of experience in creating
                                       mary harney                           and implementing strategies
                                       independent director                  transforming businesses

                                       tnaiste deputy prime minister of   honoured with the corporate
                                       the irish republic from 1997  2006   directors forum director of the
                                                                             year award for enhancing economic
                                       longest serving woman ever in the
                                                                             value 2012
                                       irish parliament for over 30 years
                                                                             the ernst  youngs entrepreneur of
                                       member of the board of crann
                                                                             the year finalist
                                       trinity college dublins largest
                                       research institute                    holds a postgraduate diploma in
                                                                             management studies
                                       chair of amber the advanced
                                       materials and bioengineering         diploma of the chartered institute
                                       research centre at trinity a joint   of marketing from harrow and ealing
                                       research enterprise with university   colleges of higher education uk
                                       college cork the royal college of
                                                                             bachelors degree in pharmacy
                                       surgeons in ireland and industry
                                                                             hons from nottingham university
                                       honorary member of the                uk
                                       international womens forum
                                                                             dr jeremy levin
                                       economics graduate of trinity         independent director
                                       college dublin
                                                                             former president and ceo of teva
                                                                             pharmaceuticals




36    ahead of the curve  annual report 2017

                                                                                                        biocon limited




former executive committee               center for immunologic diseases at      chairing government of india task
member of bristolmyers squibb           harvard medical school usa             force to set up the resolution
                                                                                 corporation of india
was responsible for global               codirector center for infection
strategy alliances and operational      and immunity brigham research          former chairman securities
transactions                             institutes boston                      exchange board of india sebi unit
                                                                                 trust of india uti and industrial
led string of pearls strategy at       named distinguished eberly
                                                                                 development bank of india idbi
bms which helped transform the           lecturer in 2014
company pipeline                                                                 former chief secretary government
                                         obtained nobel laureate peter
                                                                                 of tripura
served as global head of strategic       doherty lecture  prize in 2014
alliances at novartis                                                            set up excellence enablers private
                                         holds 25 patents
                                                                                 limited eepl a corporate
recognized among the top 25
                                         has founded 5 different biotech         governance and board advisory
most influential people in the
                                         companies including costim              consultancy firm
biopharmaceutical industry
                                         pharmaceuticals and tempero
                                                                                 on the boards of leading indian
recipient of kermode prize for work      pharmaceuticals
                                                                                 corporates as well as on the
on novel hypertension drugs
                                         published over 325 original research    advisory boards of a few foreign
albert einstein award for leadership     papers in the field of immunology      entities
in life sciences awarded by mr          costimulation and the role of th17
shimon peres                             cells

officers cross of the order of merit    won the fred z eager research prize
of the republic of hungary               and medal for his phd research
                                         work at the university of queensland
bachelors degree in zoology master
of arts ma and a doctorate d phil   specialization in pathology at the
from the university of oxford            university of queensland brisbane
                                         australia where he obtained a phd
degrees of bachelor of medicine
bachelor of surgery mb b chir        m damodaran
from the university of cambridge         independent director

dr vijay kuchroo                        founder  chairman indian institute
independent director                     of management tiruchirappalli

samuel l wasserstrom professor of       chairman glocal healthcare systems
neurology  director of evergrande       private limited




                                                                                              board of directors        37

scientific advisory board



prof alan d cherrington                                    dr brian kotzin
phd professor  chairman of molecular physiology          medical degree  postdoctoral fellowship in
 biophysics and professor of medicine  diabetes            immunology  rheumatology from stanford university 
research vanderbilt university  past president of the      vice president of global clinical development and head
american diabetes association                                of the inflammation therapeutic area amgen  vice
                                                             president  head of medical sciences  member of the
dr david m essayan
                                                             advisory council of the national institute of arthritis and
md key research interests  clinical and regulatory       musculoskeletal and skin diseases nih  associate editor
development for small molecules and biologics  clinical     at clinical investigation
immunologist former fda supervisory medical officer
former executive director at amgen                           dr brian daniels
                                                             md ms and bs from mit  venture partner of 5am
dr g alexander fleming
                                                             venture management llc  former svp bms  directed
md president and ceo of kinexum llc  member              and conducted clinical research at merck research
of numerous scientific advisory boards and expert            laboratories and at genentech  extensive experience
committees                                                   in clinical development medical affairs and corporate
                                                             strategy across a broad range of therapeutic areas
dr harold e lebovitz
md face professor of medicine endocrinology            dr jugnu jain
diabetes division state university of new york health      phd from cambridge university  launched sapien and
science center brooklyn                                     saarum in india  molecular geneticist and cell biologist
                                                              led vertexs global immune inflammation team 
dr lawrence steinman
                                                             research on cytokine gene regulation at harvard 
md key research interests  remission  relapse in ms
                                                             published over 30 papers  2 patents
vaccine against ms brain inflammation  coinventor of
leading ms drug natalizumab and several new therapies        prof huub schellekens
for autoimmune diseases                                      md phd professor at medical biotechnology at
                                                             utrecht university  published more than 300 papers on
dr vijay kuchroo
                                                             development of therapeutic proteins  member of the
dvm phd key research interests  multiple sclerosis
                                                             dutch medicine evaluation board and national expert of
costimulation th17  currently on scientific review
                                                             the ema
board of the national multiple sclerosis society new york




38    ahead of the curve  annual report 2017

                                                                                                    biocon limited




core committee
                                    1




                                                          2




                                                                                 3




                                                     5


                                                                                                         4




                                                                             6




                                                                                                    7




1 kiran mazumdarshaw                  4 dr narendra chirmule
  chairperson  managing director         sr vice president  head rd
  founder biocon limited
                                        5	siddharth mittal
2 john shaw                              president finance  cfo
  vice chairman
                                        6 ravi limaye
3 dr arun chandavarkar                  president marketing
  chief executive officer 
                                        7 amitava saha
  joint managing director
                                          sr vice president  head
                                          human resources



                                                                  scientific advisory board  core committee    39

vision mission  values




vision                                   through discovery research and      management of research and
                                         development                            business partnerships
to enhance global healthcare
                                       stateoftheart manufacturing
through innovative and affordable
                                         capabilities
                                                                              values
biopharmaceuticals for patients
partners and healthcare systems                                               integrity and ethical behaviour
                                       internationally benchmarked
across the globe                        quality and regulatory systems       performance driven work culture

                                       new medical insight through          value creation through innovation
mission
                                         disease specific clinical research     and differentiation
to be an integrated biotechnology
                                       customer relationship through        quality through compliance and
enterprise of global distinction
                                         outstanding products and services      best practices
essential to this mission is
                                       human resource development           collaboration team work and
excellence in
                                         through training mentoring and        mutual respect
intellectual asset creation            empowering




40    ahead of the curve  annual report 2017

                                                                                                                      biocon limited




financial highlights

segmentwise revenue
small molecules                             biologics                                   branded formulations
h million                                   h million                                   h million
 13240 14475 14432 14546 16330          2244      2788   2857   4046   5793    3684       4242    5212     4409   5489




 2013       2014    2015    2016   2017    2013       2014    2015    2016   2017    2013        2014     2015     2016    2017




research services                           others                                      total revenue
h million                                   h million                                   h million
 5722      7346   8514   10809 11604     490       481     414     792     1571    25380 29332 31429 34602 40787




 2013       2014    2015    2016   2017    2013       2014    2015    2016   2017    2013        2014     2015     2016    2017


                                                                                             
                                                                                                 2016 and 2017 figures are as per ind as




                                                                                                    financial highlights           41

                                        profit                                     debt  equity
                                        h million                                   h million
                                         5089      4138   4974   5504   6121     2488      8497   10350 24777 23025
                                                                                     26946 30267 32706 40338 48377

                                                                                      debt
                                                                                      equity




                                         2013       2014    2015    2016   2017    2013        2014     2015     2016    2017




                                        total assets                                current ratio
                                        h million                                   h million
                                         44161 57506 63754 84581 93943           226        191     165     238     241




                                         2013       2014    2015    2016   2017    2013        2014     2015     2016    2017


                                                                                         includes exceptional income for the years
                                                                                        2013 2015 2016
                                                                                        
                                                                                            2016 and 2017 figures are as per ind as



42    ahead of the curve  annual report 2017

                                                                                                                            biocon limited




net worth                                   eps  book value per share                     eps  dividend per share
h million                                   h million                                       h million
 26946 30267 32706 40338 48377            26       21       25        28       31         26          21       25         28       31
                                               135      151      164       202      242        75          5        5          5        3

                                              eps                                             dividend per share
                                              book value per share                            eps




 2013       2014    2015    2016   2017     2013      2014     2015     2016    2017      2013        2014     2015      2016     2017




gross rd spend                             return on net assets                           return on net equity
h million                                   h million                                       h million
 1860      1580   3284   4267   4019     15        9      10       8       8        20         14      16        15      14
                                              34262    43710   48207   67924   77159     24835      28607   31487     36480   44358
                                              5089     4138    4974    5504    6121      5089       4138    4974      5504    6121

                                              return on net assets                            return on equity
                                              net assets                                      average equity
                                              pat                                             pat




 2013       2014    2015    2016   2017    2013       2014     2015     2016    2017     2013        2014      2015      2016     2017

                                                                                                 includes exceptional income for the years
                                                                                                2013 2015 2016
                                                                                                
                                                                                                    2016 and 2017 figures are as per ind as




                                                                                                        financial highlights             43

sitting from left    suresh subramanian sr vice president  head  branded formulations india
                      dr narendra chirmule sr vice president  head  rd and novel biologics

standing from left   paul thomas vice president  head  biosimilars  mabs
                      prasad bsv sr vice president  head  small molecules
                      shreehas tambe sr vice president  head  insulins




44       ahead of the curve  annual report 2017

                                                                                                        biocon limited




             business segment review

               biologics
  total                                   small                     branded                     research
               biosimilars
revenue                                  molecules                formulations                  services
                  novels




 18              43                        12                         24                         7
 growth           growth                     growth                      growth                    growth


h40787         h5793                    h16330                     h5489                    h11604
 million          million                    million                     million                   million



            biocons greenfield       audits conducted          canmab featured          expanded business
           insulins manufacturing     by us fda mexicos        among the top 10           with two additional
           facility in malaysia       cofepris and korean        oncology brands in the     dedicated rd centers
           commercialized             fda                        country                    for amgen and herbalife
                                                                                            nutrition
            regulatory filings for    continued work on the     oral paper
           biosimilar trastuzumab     development of niche       presentation                expanded capability in
           and pegfilgrastim          and marginaccretive       on alzumab                bioinformatics through
           accepted for review by     api molecules              at international           the purchase of assets
           the us fda and the ema                                conference of psoriasis    of strand life sciences
                                       development
                                                                 in the us                  related to systems
            heritage study           laboratory for oncology
                                                                                            biology heptox and
           data on biosimilar         apis commissioned           initiated physician
                                                                                            pharma bioinformatics
           trastuzumab published                                 centric registry
                                       progressed the                                      services
           in jama                                               programs for
                                      construction of biocons
                                                                 alzumab and
            progressed on a          first oral solid dosage
                                                                 cytosorb
           key clinical study for     facility
           subcutaneous version of                                neobiocon jumped
           itolizumab in australia                               five places and ranked
                                                                 among the top 15
                                                                 pharma companies in
                                                                 the uae




                                                                                           segmental review             45

biologics




                                              biocons innovationled strategy is aligned with the global trend of increased
  43 growth                                  use of biologics to address unmet medical needs as one of the earliest


  h5793                   million
                                              players in the realm of biologics in india we have created a rich pipeline of
                                              novel and biosimilar assets some of which are available to patients in india
                                              and other emerging markets
  revenue
                                              biocon is poised to enter developed markets with its biosimilar products at a
                                              time of increasing acceptance of biosimilars us pharmacy benefit managers
                                              pbms have taken steps to exclude originator products from formularies
                                              in favour of biosimilars a group of european regulators has published a
                                              paper supporting the appropriateness of switching patients from originator
                                              to biosimilar and a study conducted by the norwegian government
                                              has established further evidence supporting the safety of biosimilar
                   source biodrugs 2017    interchangeability scandinavian and other countries have also taken
             apr3128391 doi 101007
               s4025901702100 the       strong national level steps to encourage biosimilar uptake at the same time
                  lancet volume 389 issue   emerging markets are also showing an inclination for wider biosimilars use
            10086 1016 june 2017 pages
                              23042316     the who is expected to launch a pilot project for prequalifying biosimilars



46    ahead of the curve  annual report 2017

                                                                                                               biocon limited




a step towards making expensive          pens the business recorded strong
treatments for cancer and other          doubledigit growth during the year
chronic diseases more widely
available in low and middleincome
                                         led by higher offtake in some of our
                                         existing markets and the expansion
                                                                                    a   s one of the leading global
                                                                                        players in insulins we are
                                                                                    committed to deliver affordable
countries                               of our commercial presence to more         diabetes therapy options
                                         markets worldwide including japan        through our range of basal rapid
during fy17 the biologics segment                                                  and intermediate acting generic
reported a strong growth of 43          revenue growth in the emerging             insulins our insulins portfolio
to h5793 million driven largely        markets was propelled by robust            is complemented by highend
                                                                                    patientfriendly devices that
by sales of biosimilars including       sales of rhinsulin cartridges and
                                                                                    offer ease of use to people with
rhinsulin insulin glargine and         reusable insulin pens to the ministry      diabetes resulting in improved
trastuzumab in global markets           of health moh malaysia under the        compliance to therapy
our novel biologics also advanced        threeyear myr 300 million contract
through their clinical development       we won during the year                    shreehas tambe
                                                                                    sr vice president  head  insulins
programs during the year
                                         besides malaysia we also launched
                                         insulin glargine and rhinsulin in
                                                                                  augur well for our insulin glargine
biosimilars                              some emerging markets in the
                                         regions of latin america africa and     to address a usd 64 billion global
biocon has a portfolio of 10                                                      market opportunity at current
                                         middle east
biosimilars spanning insulins                                                    innovator pricing
monoclonal antibodies and other          in japan our readytouse prefilled
                                         disposable insulin glargine pen has      the marketing authorization
recombinant proteins that address
                                         been well accepted by prescribers        application maa for insulin
critical chronic diseases such as
                                         and patients we are the second          glargine submitted to the european
diabetes cancer and autoimmune
                                         player to have received regulatory       medicines agency is the first
disorders and collectively target a
                                         approval to sell biosimilar insulin      filing in a developed market that
global market opportunity of over
                                         glargine in this estimated usd 118       incorporates product validated at
usd 60 billion
                                         million source ims year end 2016      our new stateoftheart malaysia
                                                                                  facility
insulins  analogs                       market

                                         the successful japan launch has          other molecules from our insulin
biocon is among the top 3 biosimilar
                                         enhanced our credibility to expand       analogs portfolio insulin aspart and
players globally for insulins in terms
                                         our footprint in other developed         insulin lispro are under preclinical
of volume market share measured
                                         markets the european union             development
in number of units sold source
ims year end 2016 the company          canada and australia accepted for        commercialization of malaysia
has a diversified portfolio spanning     review our regulatory submissions        insulins facility
recombinant human insulin and            for insulin glargine codeveloped
                                                                                  an important milestone during the
longacting insulin analog glargine      with mylan we expect to file our
                                                                                  fiscal was the commercialization
complemented by a comprehensive          marketing authorization application
                                                                                  of our greenfield insulins
product presentation across vials       for insulin glargine with the us fda
                                                                                  manufacturing facility in malaysia
cartridges disposable and reusable      shortly these key developments


                                                                                                             biologics      47

one of the largest in asia the          diabetes management through our        and pegfilgrastim were accepted for
malaysian government contract            affordable biosimilar insulins and     review by the us fda and the ema
enabled us to start supplying inulin     analogs                               which mark key milestones for the
products from this overseas facility                                            business in fy17
                                         in india too we made significant
in which we have invested nearly
                                         investments in capacity                the global addressable market
usd 250 million
                                         debottlenecking to meet projected      opportunity for trastuzumab
our rhinsulin is malaysias first       demand for both our insulins drug      indicated for treating her2positive
locally manufactured biosimilar          substance and drug product in          breast and gastric cancers is
product to be approved for               emerging markets                      usd 69 billion for pegfilgrastim
commercial sales in the country our                                            which is administered to patients
insulin glargine manufactured in        monoclonal antibodies                  undergoing chemotherapy the
india has also been approved for         other recombinant                    market opportunity is usd 46
sale in malaysia                        proteins                               billion

biocon is distributing its insulin and   biocon and mylan are codeveloping     biocon and mylan are the first to file
insulin delivery devices through a       a highvalue portfolio of six          for regulatory approvals of biosimilar
leading local pharmaceutical player     biosimilar mabs and recombinant        trastuzumab in both the us and eu
which has an extensive supply            proteins trastuzumab bevacizumab    the fdas target action dates for
chain network to service primary         adalimumab pegfilgrastim             trastuzumab and pegfilgrastim are
healthcare clinics and hospitals         etanercept and filgrastim targeting   in september and october 2017
across malaysia                         chronic diseases such as cancer and    respectively which indicates that we
                                         a range of autoimmune disorders       could be one of the first biosimilar
our products are enabling the
                                                                                entrants for these products in the us
malaysian government expand              we commenced sales of our
                                                                                and eu markets
access to affordable insulin therapy     biosimilar trastuzumab in emerging
for the nearly 33 million people        markets in fy16 during the year      our regulatory submissions for
with diabetes in the southeast asian     we took this product to newer          biosimilar pegfilgrastim have also
country                                 geographies including some            been accepted in australia and
                                         of the larger emerging markets        canada
several regulatory filings and audits
are underway at the malaysian            trastuzumab boosted the biologics
                                                                                bevacizumab  adalimumab
manufacturing facility we expect        business revenue as well as our
                                                                                in fy17 we completed the emerging
the facility to be qualified by a few    licensing income for the year
                                                                                market targeted clinical trial for our
more emerging markets which will        we continue to seek regulatory
                                                                                proposed biosimilar bevacizumab in
ramp up commercial sales from the        approvals for trastuzumab as
                                                                                metastatic colorectal cancer patients
site in fy18                            we increase our presence in the
                                                                                and submitted our marketing
                                         emerging markets
the unlocking of additional capacity                                            authorization application in india
in malaysia through emerging market      trastuzumab  pegfilgrastim
                                                                                an additional global phase iii
approvals would help accelerate our      our regulatory submissions for         trial in nonsmall cell lung cancer
journey of making global impact in       proposed biosimilar trastuzumab        commenced in late fy17


48    ahead of the curve  annual report 2017

                                                                                                                  biocon limited




the global clinical trial for biosimilar    the results of this trial were first       conjunction with chemotherapy on
adalimumab in plaque psoriasis              presented at the american society          patients being treated for her2
patients is complete we will begin         of clinical oncology asco annual         positive metastatic breast cancer
our regulatory submission after             meeting in chicago us and the
completion of sample data analysis         european society for medical
we expect submissions in various            oncology esmo congress in
geographies to start in fy18               copenhagen denmark in 2016
                                            the presentations made by
biocon mylan study published
                                            dr hope s rugo the chair of
in jama
                                            the steering committee for the
during the year the results of the
heritage study for biosimilar
                                            heritage study were appreciated
                                            immensely by the scientific
                                                                                        b    iocon had a vision to be
                                                                                             global leaders in the field of
                                                                                         biosimilars several years ago and
trastuzumab were published in the           community                                   that is manifesting itself now
prestigious journal of the american                                                      with several biosimilar assets on
                                            jama has recognized the results of           track for anticipated regulatory
medical association jama which
                                            the heritage study which was the            approvals in developed markets
is the flagship publication of the                                                       its a real tribute to what
                                            last major step of a multiphased
american medical association                                                            team biocon has been able to
                                            program to demonstrate that                  accomplish in this complex area
this is a significant development
                                            bioconmylans proposed biosimilar           in a relatively short period of
considering studies published in                                                         time
                                            trastuzumab meets the criteria for
jama are highly respected as they
                                            equivalence in comparison to the
undergo a very rigorous peer review                                                      paul thomas
                                            reference product when used in               vice president  head  biosimilarmabs
process



our global generic insulins  biosimilars portfolio
 category                         molecule                          status
 regular acting insulin           recombinant human insulin         preclinical us market marketed in emerging markets
 long acting insulin analog       insulin glargine                  filed in eu australia  canada us filing in h1 fy18
                                                                    marketed in japan since july 2016 and emerging
                                                                    markets
 rapid acting insulin analog      insulin aspart                    preclinical
 rapid acting insulin analog      insulin lispro                    preclinical
 cancer                           trastuzumab                       filed in us eu marketed in emerging markets
 autoimmune                       adalimumab                        global phase iii completed
 neutropenia                      pegfilgrastim                     filed in us eu canada  australia
 cancer                           bevacizumab                       indiaemerging markets phase iii completed
                                                                    global phase iii commenced
 neutropenia                      filgrastim                        early development
 autoimmune                       etanercept                        early development



                                                                                                                biologics           49

novel biologics                         insulin tregopil                        treating both type 1 and type 2
                                        biocons lead program in diabetes      diabetes a pivotal phase iii study
at biocon we are developing novel                                              for type 2 diabetes is expected to
                                        insulin tregopil is a firstinclass
biologics aimed at addressing local                                             start in india in fy18 a clinical trial
                                        oral insulin molecule for post
as well as global unmet medical                                                 application cta has been filed
                                        prandial glycaemic control we had
needs in the areas of diabetes                                                 with the indian regulator for this
                                        announced successful results from
autoimmune inflammation and                                                    study a multiple ascending dose
                                        the phase i clinical studies on the
oncology the basket of novel                                                   study in type 1 diabetes patient
                                        drug candidate that had concluded
assets under clinical development                                               population is also planned in fy18
                                        in the us in fy16 these studies
represents an interesting                                                       in collaboration with the juvenile
                                        established the target product
combination of early and advanced                                               diabetes research foundation
                                        profile of this molecule including
stage assets some of these                                                     these combined studies in different
                                        food effects drugdrug interaction
programs are now generating                                                     diabetes populations will form
                                        and pkpd profile in fy17 we
encouraging and exciting data the                                              the foundation of a broad global
                                        followed up on the positive
ultimate success of these programs                                              program envisioned for insulin
                                        phase i data to continue
will bring transformational growth to                                           tregopil
                                        development of this program in
our business


50    ahead of the curve  annual report 2017

                                                                                                             biocon limited




itolizumab                              organization in india to have             anticd20
in the autoimmune  inflammatory        forayed into the exciting space of        we have a second generation
diseases space our novel first        sirnabased small interfering rna       humanized antibody targeting cd20
inclass anticd6 humanized             therapeutics                             for which the path to ind has been
monoclonal antibody itolizumab        in fy17 we made progress on one of       mapped out and we plan to advance
is being marketed as alzumab           the high potential novel assets          this asset in neuroinflammatory
for the treatment of chronic plaque     qpi1007 we are developing               diseases eg multiple sclerosis
psoriasis in india since 2013 biocon   the asset on the sirna platform
is the first and the only company in    with quark pharma for a rare
the world to clinically validate cd6    ophthalmology indication the
as a target for autoimmune diseases    pivotal global phase iiiii studies for
in fy17 we have progressed on the      nonarteritic ischemic optic
key clinical studies using a sub       neuropathy naion initiated by
cutaneous version of itolizumab in      quark pharma in fy17 in the us
australia for evaluation in multiple   now includes patients randomized
indications the bridging phase i pk    in india
and safety study in normal healthy
                                        fmab2 fusion protein
volunteers in australia seeks to
                                        in immunooncology our lead
evaluate the pharmacokinetics
                                        molecule fmab2 combines a
and pharmacodynamics of a sub
                                        monoclonal antibody against egfr
cutaneous route of administration
                                        with tgf receptor fragment that
of itolizumab in comparison
                                        binds and neutralizes tgf this
to intravenous route for which
                                        fusion antibody which is currently
the company has marketing
                                        in preclinical development works
approval in india in stage 1
                                        on the concept of preferentially
dosing the subcutaneous route of
                                        delivering immune modulators to
administration showed equivalent
                                        tumor site thus enhancing efficacy
bioavailability of the drug we plan
                                        and delivering larger doses of tgf
to initiate stage 2 dosing shortly

                                                                                    w
                                        to the tumor microenvironment an                e are developing novel
understanding of the cd6 pathway
                                        ind for this molecule is planned for              biologics aimed at
being led by scientists in biocon has                                               addressing local as well as
                                        fy18 and is currently ready with
the potential for developing novel                                                  global unmet medical needs
                                        pharmacology and mechanism of               in the areas of diabetes
therapies for patients with immune
                                        action moa established in in             autoimmune inflammation and
dysfunctions
                                        vitro and invivo tumor models it          oncology
qpi1007 sirna                        provides us with a potentially broad
                                                                                    dr narendra chirmule
biocon is the first biopharma           clinical opportunity in multiple            sr vice president  head  rd and
                                                                                    novel biologics
                                        tumor types




                                                                                                           biologics       51

small molecules




                                         audits and an entrenched presence        complex immunosuppressants
  12 growth
                                         in the chronic therapies space
                                                                                  more recently our generic

  h16330                    million
                                         have made us a preferred partner
                                         for pharma customers in india and
                                         overseas
                                                                                  formulations strategy hinges
                                                                                  on leveraging our strengths in
  revenue                                                                         characterization and manufacturing
                                         when lovastatin went off patent          of biologics to build a robust
biocon is one of the leading global      in 2001 biocon was one of the           pipeline of difficulttomake niche
suppliers of complex small molecule      only three companies in the world        formulations for chronic conditions
active pharmaceutical ingredients        to get us fda approval to supply         in order to address global needs for
apis spanning cardiovasculars anti   the api for the drug since then         affordable therapy
obesity agents immunosuppressants       we have emerged as the worlds
and narrowspectrum antibiotics         largest statins manufacturer with       apis
antifungals                             our drug substance being used to
                                                                                  biocons ability to stay ahead of the
our unique strengths in fermentation     produce one in every three statin
                                                                                  curve placed it among the first wave
technology and complex chemistry a      pills globally over the years we have
                                                                                  of suppliers of rosuvastatin api to
successful track record of regulatory    also emerged as a leading player in
                                                                                  its partners the acquisition of new


52    ahead of the curve  annual report 2017

                                                                                                           biocon limited




customers for our other statins and     generic                                we made progress on the
immunosuppressant apis helped                                                  construction of our first oral solid
                                        formulations
drive the healthy performance of this                                          dosage facility which will play
business during the year               as part of our strategy to sustain     an important role in our generic
                                        longterm growth for the small         formulations strategy the work on
sales of rosuvastatin api to
                                        molecules business we are working     the facility is on track for us to start
key customers targeting the us
                                        on building a robust pipeline of       exhibit batches and various other
post patent expiry in 2016 were
                                        differentiated generic finished        product qualification activities in
supplemented by a higher offtake of
                                        dosages for the global markets        fy18
immunosuppressant apis especially
                                        from a commercial perspective this
in the latin american market
                                        strategy gives biocon a competitive
we maintained the momentum              advantage as it will enable us to be
of regulatory filings with 10 drug      an integrated player offering both
master files dmfs submitted in the    the drug substance and the drug
us and other key regulated markets     product in niche areas

during the year we successfully        this generic formulations business
completed audits by the us fda         obtained its first anda approval
mexicos cofepris and korean fda       from the us fda for rosuvastatin
                                        calcium tablets in 2016
going ahead the regulatory
submissions and the eight approvals     we plan to leverage this experience
that we received for our key apis       to scale up our regulatory
in us and eu augur well for this        submissions with the us fda and
business                               file more andas the launch of
                                        our generic formulations in the us
                                                                                 a   s a differentiated apis
                                                                                     player our focus has been
                                                                                 to provide our partners with
to meet the increase in demand
                                        will add to the profitability of the     best in class statins complex
we expanded capacity of our statins
                                        business which already enjoys           immunosuppressants and
and immunosuppressants during                                                    specialty molecules thus
                                        healthy operating margins
the year                                                                        enabling their formulations
                                        the completion of fullcycle           business we are committed
in our endeavour to expand                                                       to exploit new opportunities
                                        development of generic drug
the small molecule oncology                                                      within the small molecules
                                        products have positioned us to file      space through a niche portfolio
portfolio our development
                                        for regulatory approvals of five        of generic formulations that can
laboratory for oncology api has
                                        six molecules every year across          enhance access to affordable
been commissioned while the                                                      therapy for chronic diseases
                                        emerging markets and developed
investments towards enhancing our
                                        markets such as us and eu               prasad bsv
manufacturing capabilities is under
                                                                                 sr vice president  head  small molecules
progress




                                                                                               small molecules            53

branded formulations




                                       biocons branded formulations
  24 growth                           business was ahead of the curve


  h5489               million
                                       in anticipating the critical need
                                       for affordable therapy for chronic
                                                                              b   iocons unique combination
                                                                                  of world class products
                                                                              personalized patient support
                                       diseases in india and other            and physician engagement
  revenue
                                       emerging markets accordingly         initiatives have enabled us
                                       it prepared itself to address this     to make an impact in the
                                                                              therapeutic areas of diabetology
                                       challenge through differentiated       oncology and immunology in
                                       world class biopharmaceuticals         india focused execution and
                                       and personalized medical support      new launches will enable us to
                                                                              deliver superior results for the
                                       over the years the branded
                                                                              company going forward
                                       formulations business has enabled
                                       biocon to carve out a niche for        suresh subramanian
                                                                              sr vice president  head  branded
                                       itself as a biologicsled specialty
                                                                              formulations india
                                       pharmaceuticals company




54    ahead of the curve  annual report 2017

                                                                                                          biocon limited




india                                    have enabled biocons brands to         30 the publication of the results
                                         assume leadership positions in         of the heritage trial involving
we have been pioneers in bringing
                                         fy17 15 of our brands featured         biosimilar trastuzumab in the journal
innovative globally benchmarked
                                         among the top 3 brands in their         of the american medical association
biologics to patients in india
                                         respective categories in india the     has helped build additional
our strategy of highest quality
                                         top 10 brands in our india portfolio    confidence in the product among
at lowest cost has enabled us to
                                         accounted for over 70 of our           the medical fraternity in india we
build premium brands in chronic
                                         revenues in the year                   stopped offering abraxane a key
therapeutic areas such as diabetes
                                                                                 inlicensed oncology molecule to
cancer endstage renal disease         in fy17 we witnessed a significant
                                                                                 patients in fy17 due to a decision
immune disorders and other life         increase in the prescriptions share
                                                                                 taken by the licensor to discontinue
threatening conditions                  for insugen and basalog the
                                                                                 supplies
                                         flagship brands of the metabolics
over the years we extended our
                                         division basalog which is ranked     tacrograf a key
presence into niche areas where
                                         as the number two insulin glargine      immunosuppressant brand reported
we saw the potential to moderate
                                         brand in india registered strong       double digit growth in fy17 it is
costs and widen patient access we
                                         doubledigit sales growth during the    the number three tacrolimus brand
introduced patientcentric initiatives
                                         year insugen retained its position    in india
for disease awareness prevention
                                         among the top 3 brands of rhinsulin
and management we partnered with                                                psorid one of our key
                                         available in india
key stakeholders like governments                                               immunotherapy brands continued
healthcare professionals and             biomab egfr canmab                  to be the most prescribed brand of
advocacy groups to increase access       evertor and nufil from our           cyclosporine in india
to lifesaving medicines we licensed     oncotherapeutics portfolio featured
                                                                                 our novel biologic alzumab
products from global innovators in       among the top 3 brands in their
                                                                                 itolizumab has made psoriasis
our core therapeutics areas to bring     respective categories continuing
                                                                                 management easier for several
the latest in therapeutic advances to    to make a significant impact in the
                                                                                 hundred patients in india since its
india we engaged with physicians        realm of cancer care in india
                                                                                 launch in 2013 in fy17 an oral
through targeted educational
                                         biomab egfr our novel biologic        paper on the role of itolizumab
programs related to best treatment
                                         for head and neck cancer witnessed     in psoriasis management was
practices for complex medical
                                         more than 1000 new enrollments          presented at the international
conditions we adopted an evidence
                                         in fy17 canmab our biosimilar        conference of psoriasis and skin
based engagement strategy with
                                         trastuzumab brand has helped treat     specialists meeting in dallas us
key opinion leaders by leveraging
                                         several thousand her2positive          data generated from 155 patients
the clinical experiences of our novel
                                         metastatic breast cancer patients       treated with alzumab were also
biologics and biosimilars
                                         in india since its launch in 2014 in   accepted for publication in the
this unique combination of specialty     fy17 canmab continued to gain         indian dermatology online journal
products patient support and            traction and featured among the top     a multicenter panindia study has
physician engagement programs            10 oncology brands in the country       been initiated to identify potential
                                         with a volume market share of nearly    biomarkers for treating subgroups


                                                                                         branded formulations        55

                                                                                and jumped five places to be
                                                                                ranked among the top 15 pharma
                                                                                companies in uae

                                                                                the uae business is supported by
                                                                                27 brands and sales are diversified
                                                                                across a portfolio that includes
                                                                                cardiovascular drugs anti
                                                                                histamines proton pump inhibitors
                                                                                and oral antidiabetics
of chronic plaque psoriasis patients   based approach of abide helped
                                                                                several of our brands are ranked
with alzumab                         physicians improve their practice
                                                                                among the top 3 in their respective
                                       with enriched patient connect and
cytosorb a firstinclass                                                   therapy segments in the uae market
                                       enhanced clinical outcomes since
extracorporeal cytokine filter used                                             one of our key products statix
                                       its inception abide has empowered
to manage a wide range of life                                                 atorvastatin is the only generic
                                       nearly 3000 physicians spread
threatening conditions seen in the                                              brand to feature among uaes top
                                       across 300 townscities across india
intensive care unit underwent a                                                5 cardiovascular brands a segment
panindia study to evaluate clinical   abide was conferred the award
                                                                                dominated by innovator products
outcomes when administered in          of recognition by the prestigious
                                       research society for the study of        jalra  jalram two of the in
patients suffering from sepsis and
                                       diabetes in india rssdi for its        licensed innovator brands from
septic shock
                                       benefits coverage and impeccable        novartis made significant inroads in
we also initiated physiciancentric                                             the antidiabetes space since their
                                       quality of delivery during the 44th
registry programs for alzumab                                                  launch in fy16 positioning us as one
                                       annual conference of rssdi held in
and cytosorb during the year                                                  of the key players in this segment in
                                       hyderabad in 2016
abide awarded by rssdi                                                          uae
                                       this recognition from rssdi the
in 2012 biocon had introduced         largest organization for diabetes        we strengthened our alliance
abide a unique education initiative   researchers and healthcare               with novartis in fy17 through
for medical practitioners who treat    professionals in asia is a validation   a transaction to inlicense the
diabetes on a regular basis we        of the positive impact by biocon to      companys second brand of exforge
conduct a basic course for primary     enrich the healthcare ecosystem of       a high blood pressure medication
care physicians and an advanced        india                                   which will be launched shortly
course for consultant physicians
                                                                                the launch is expected to
and diabetologists the courses        uae                                      strengthen our position in the uae
are delivered in a noncommercial
                                       our branded formulations business        cardiovascular market where we
setting and offer learning
                                       in uae represented by neobiocon        currently rank among the top 10
opportunities through experience
                                       sustained its momentum with a            companies
sharing in small group engagements
                                       25 increase in sales in fy17
the pragmatic and application                                                   source ims fy16  fy17




56    ahead of the curve  annual report 2017

                                                                          biocon limited




global marketing




              biocons global marketing team        while sales in the asiapacific apac
              has been ahead of the curve in      and commonwealth of independent
              anticipating the growing worldwide    states cis regions almost doubled
              need for affordable high quality     over the previous year our revenue
              drugs to address the increasing       from the africa middle east 
              burden of noncommunicable            turkey afmet and latin america
              diseases we have consistently        latam regions witnessed strong
              aligned ourselves to the increasing   doubledigit growth we have started
              trend among governments to adopt      executing on our strategic roadmap
              generic formulations to cut their     to enter the top 10 emerging
              healthcare spends                    markets for our insulins and mabs
                                                    portfolio through multiple licensing
              during fy17 70 of our revenue
                                                    agreements
              came from international markets




                                                                global marketing      57

increasing our global biosimilars        widening the scope of our               so we have furthered our mission to
footprint                                differentiated small molecules          provide affordable access worldwide
biocons expertise in biologics has      portfolio                               to therapies for chronic diseases
given it the firstmover advantage for   we scaled up our leadership position
its biosimilars portfolio               in statins and immunosuppressants
                                         to enable our partners to launch
following the success of biocons
                                         formulations in the nafta afmet
insulin glargine launch in japan
                                         and latam regions
we made inroads in some of the
emerging markets which positions        biocon emerged among the first
us for a greater play in addressing a    wave of suppliers of rosuvastatin
market opportunity of over usd 220       api to its partners for the us
million we also introduced brand        market upon patent expiry in
insugen in one of the cis markets       2016 this enabled our partners
where it is currently the market         to capture a double digit share of
leader in the generic rhinsulin         the rosuvastatin market we also
space                                   experienced a revival of sales for
                                         our fidaxomicin api and increased
in the apac region we strengthened
                                         traction for tacrolimus api in the
our position by successfully winning
                                         us during the year our antiobesity
an exclusive malaysian government
                                         product orlistat api has made
contract for the supply of insugen
                                         significant inroads in emerging
and also introduced insulin glargine
                                         markets due to its safety profile and
we also introduced rhinsulin and
insulin glargine in some of the
                                         highend quality                          o    ur ability to make an
                                                                                         impact in global markets
                                                                                     with a strong portfolio
                                         another differentiated and complex
latam and nafta markets during                                                       of cuttingedge chronic
                                         api product glatiramer acetate for        therapeutics holds the key to
fy17
                                         multiple sclerosis was introduced in        unlocking the next level of
having significantly benefited           a key emerging market of the nafta          growth for biocon we plan
breast cancer patients in india with                                                 to address these markets
                                         region through our partner
                                                                                     through synergistic alliances
our biosimilar trastuzumab we                                                       and a diversified portfolio
                                         over the years we have built strong
increased our product penetration                                                    that reflects a strong
                                         global and regional partnerships to         orientation towards difficult
in algeria thus capturing a dominant
                                         provide affordable small molecule           tomake small molecule
market share and also prepared
                                         and speciality apis generic insulins       generics and biosimilars
ourselves for market entry through
                                         and biosimilars thus giving payers
licensing partnerships in some of the                                                ravi limaye
                                         physicians and patients greater             president marketing
latam and apac countries during
                                         choice of treatment options in doing
fy17




58      ahead of the curve  annual report 2017

                                                                                   biocon limited




research services




                      syngene began its journey in the        than 13 million sq ft syngene
7 growth             early 1990s as indias first contract   is positioned to address a global
                      research organization cro at          drug discovery outsourcing market
h11604     million   a time when the industry in the
                      country was still in its infancy
                                                              opportunity expected to grow at a
                                                              compounded annual rate of 7 to
revenue               over the years it has evolved           usd 29 billion in 2022
                      into an integrated discovery and
                                                              our research services business
                      development service provider
                                                              through syngene reported a revenue
                      for new molecular entities across
                                                              of h11604 million in fy17 on a
                      multiple platforms like small and
                                                              standalone basis syngenes total
                      large molecules antibody drug
                                                              revenue rose 14 to h12716
                      conjugates and oligonucleotides
                                                              million the growth was broad
                      today syngene is the only publicly
                                                              based across all its three business
                      listed pure play cro in india
                                                              verticals  dedicated rd centers
                      with a talented pool of over            discovery services and development
                      3000 scientists and worldclass         manufacturing services
                      infrastructure spread across more



                                                                        research services     59

capability expansion                       will also help meet its customers        us fda audits without any
                                           growing needs for bioinformatics          observations in the last three years
during the year the company
                                           and data analytics support
expanded its business to include                                                     the company also received
two new dedicated rd centers             a stateofthe art gmp good              environmental clearance for the
one each for amgen and herbalife           manufacturing practices and              commercialscale manufacturing
nutrition with this syngene now          glp good laboratory practices           facility that it is setting up in
has five dedicated rd centers             compliant viral testing facility was      mangalore to manufacture novel
including that of bms abbott              also set up to address the needs of       small molecules for innovator
nutrition and baxter                      several pharma and biotech clients        companies
                                           in this area
the growth in business was driven                                                    fire incident
by the addition of new customers as        as the key rd programs of a
                                           number of syngenes clients               in december 2016 there was a
well as the extension of its ongoing
                                           moves into advanced phases of             fire at one of syngenes research
collaborations
                                           development it opens up new              facilities in bengaluru this facility
the syngene amgen research                                                          including office and laboratory
                                           opportunities for expanding the
development center sarc will be                                                    space contributed approximately
                                           scope of work in line with this
staffed by a team of more than 100                                                   20 of its total revenues the
                                           strategy syngene commissioned
highly qualified syngene scientists                                                 fire was caused due to a chemical
                                           the first phase of its new
who will work closely with amgen                                                     reaction being conducted at the
                                           formulation facility which is
researchers around the world on                                                      facility there was no injury or loss
                                           capable of manufacturing clinical
the discovery and development of                                                     of life as a part of its business
                                           and commercial supplies of small
innovative medicines the dedicated                                                  continuity plan most of the client
                                           volume niche technology products
nutrition research center set up for                                                 related projects were redeployed
                                           and complies with regulatory
herbalife will develop and formulate                                                 to other labs and enhanced shift
                                           requirements of the us fda ema
worldclass nutrition products for                                                   working was introduced to minimize
                                           and other health authorities
indian consumers that will enable                                                    revenue impact
them to lead healthier lives syngene      during the year the company also
also extended its collaboration with       commissioned the first phase of its
abbott nutrition till end of cy 2017      syngene research center spread

during the year the company
also added new capabilities in
                                           across 50000 sq ft when fully
                                           commissioned the center will have          w     e made good progress
                                                                                             through the year on
                                                                                       our strategic priorities with
                                           a total area of 200000 sq ft that will
bioinformatics by acquiring the                                                        syngenes track record in
                                           support integrated discovery and            building successful longterm
assets related to systems biology
                                           development programs                       relationships with clients our
heptox and pharma bioinformatics                                                       newly expanded capabilities
services of bengalurubased strand         syngenes clinical development              worldclass scientists and
life sciences the deal also brought       facility successfully underwent             infrastructure we look forward
onboard a team of highly skilled           us fda and ema audits during the            to accelerating our growth in the
                                                                                       coming year
data scientists who will not only          year the companys commitment to
complement syngenes existing              quality and compliance is reflected
                                                                                       jonathan hunt
scientific intellectual capabilities but   in its track record of clearing six         chief executive officer  syngene



60    ahead of the curve  annual report 2017

                            biocon limited




enablers




r e s e ar c h 
development

supp ly c h ai n
ma n a g e m e n t

hu m a n
r e s o ur c e s

e n v ir o n m e n t 
h e a lt h 
sa f e t y

c o rp o rat e
s o c ia l
r e s p o n s ibi l it y




                           enablers    61

research  development




at biocon rd is poised to lead         the advent of genomics has
the future of biotechnology with        heralded the future of therapies for
several successful regulatory filings    difficulttotreat human diseases
of biologics dossiers in ich regulated
regions biocon has established itself
                                         biocon is one of the leading players
                                         in developing manufacturing and
                                                                                r  esearch and development
                                                                                   forms the bedrock of biocons
                                                                                endeavour to deliver affordable
as a wellrecognized significant        analytical processes for small         therapeutics globally to address
                                                                                unmet patient needs biocons
player in drug development we           interfering rna sirna technology
                                                                                unique rd story is built on
have led the way in the development      this unique method of treatment       worldclass competence and
of biosimilars and worked at the         which interferes with the nuclear      capability robust infrastructure
leading edge of science with top         machinery of the cell will enable     and a talent pool that has
                                                                                extensive global product
global regulatory agencies such as       development of novel molecules to      development experience
the us fda and ema exemplified          target many diseases with unmet
by the firsttosubmit biosimilar        medical needs                         dr narendra chirmule
                                                                                sr vice president  head  rd
trastuzumab antiher2 monoclonal
                                         biocon has leveraged cuttingedge
antibody for treatment of breast
                                         technologies since inception we
cancer



62    ahead of the curve  annual report 2017

                                                                                                        biocon limited




were the first to set up a biologics    rd capabilities  enablers              v regulatory sciences have helped
commercial bioreactor in india and      driven by our passion to impact          us position biocon ahead of many
today have the countrys largest        global health we have built             other pharma players in india
bioreactors developing protein          differentiated rd capabilities over
                                                                                 process  product development
therapeutics the ability to create     the years in the areas of biologics
global scale has made biocon one                                                 we have expertise in an array
                                        development for both novels and
of the top insulin manufacturers                                                 of expression platforms that
                                        biosimilars we leveraged these
in the world over time we have                                                  include both microbial 
                                        capabilities to be among the first to
established ourselves as indias                                                 mammalian systems biocons
                                        successfully complete submissions
foremost innovative science and                                                  pichia pastoris platform for
                                        of some key biosimilars in several
technology driven organization that                                              expression of recombinant protein
                                        jurisdictions across the world
is constantly working to address the                                             is our proprietary technology our
                                        including the us and eu our
global disease burden                                                           consistent and scalable mammalian
                                        structured approach to incorporate
                                                                                 cho and nso cellbased expression
biocon rd has nurtured a pool          cuttingedge science and technology
                                                                                 platforms are used to deliver
of highly talented scientists who       in order to deliver our exciting
                                                                                 novel and biosimilar monoclonal
are experts in their fields ranging    portfolio of biologics has brought
                                                                                 antibodies while our bacterial host
from bioengineering molecular          us reliability and credibility of an
                                                                                 system is utilized for numerous small
biology analytical science clinical   innovationled organization focussed
                                                                                 molecule apis and peptides
science regulatory science and         on providing affordable healthcare
intellectual property management       the impressive pipeline of approved      our highly robust process sciences
biocons reputation has enabled         and indevelopment biosimilars           significantly augment our ability
collaborations with leading academic    and novel molecules is testimony to      to develop worldclass biologics
institutions across the world the      biocon rds vision of being ahead      with economical scalability and
combination of high technology         of the curve                           high productivity coupled with high
talent and a culture of deep science                                            quality the upstream processes
                                        to support the exciting deliverables
at biocon has the potential to                                                   involving fermentation technologies
                                        in our molecule pipeline the
transform the field of biotechnology                                             and downstream processes for
                                        technological enablers and
in the world                                                                    protein purification to develop
                                        capabilities at rd have always
                                                                                 bulk drug substance have been
as indias top biotech company         been our strength our excellence in
                                                                                 established for more than a decade
our efforts and constant focus on       platform technologies spanning
                                                                                 to prepare for the next decade of
being ahead of the curve have         i process and product development
                                                                                 exponential growth we are working
been instrumental in establishing       ii analytical and bioanalytical
                                                                                 on improving process efficiencies
india among the top 12 biotech          capabilities iii preclinical and
                                                                                 through novel approaches such
destinations of the world and the       clinical development strengths
                                                                                 as flexible and continuous
second in asia                         iv intellectual property and




                                                                                    research  development            63

manufacturing for this we are            the high quality and consistency          a formulation and transferred into
working in collaboration with leading      of our products learning from our        vials and cartridges to make a drug
academic institutions such as the          extensive regulatory interactions         product this process requires
indian institutes of technology            in previous years we have evolved        extensive science complex
iit and national institute for           our process development this             technology and understanding of
pharmaceutical educational and             process has resulted in exponential       protein structures product stability
research niper in india as well as       improvements and being ahead of          and extractableleachables studies
harvard university massachusetts          the curve for future processes          our expertise in formulation 
institute of technology mit and                                                    product science has enabled us
                                           formulation  product science
several reputed international                                                        to manufacture high quality drug
                                           is an essential part of the drug
universities our analytical capability                                             products for patients worldwide
                                           development process of biologics
which is anchored in cuttingedge
                                           and biosimilars where the bulk
tools latest orthogonal approaches
                                           drug substance is converted into
and world class technology ensure



biological process sciences




              molecular                                  upstream
                                                                                                  formulation
               biology                                  cell culture




 development of recombinant clones         process development and scaleup of        development and scaleup of liquid
 gene knockouts pcr based analytical       perfusion and fed batch technologies      suspension high concentration and
             methods                             control of post translational               lyophilized formulation
                                                 modifications in cell culture




             purification                                upstream                                 purification
             cell culture                                microbial                                 microbial




 development of purification processes       process development and scaleup              scaling up high pressure
 to match characteristics of biosimiliar     bacteria fungi and yeast primary or      chromatography in large columns
               proteins                    secondary metabolites and recombinant
                                              protein and peptides fermentation




64    ahead of the curve  annual report 2017

                                                                                                              biocon limited




analytical  bioanalytical sciences
we have been a pioneer in process and product
development which in turn is a result of biocons
stateoftheart equipment and deep technical
expertise with nearly 20 years of experience
in analytical and bioanalytical sciences
physicochemical and functional analytical
technologies are the key components of the
process and product these analytical tools are
applied for inprocess as well as finished drug
substance and drug product analyses additionally
a major percentage of these methods are routed
towards the quality groups in manufacturing to be
utilized as product release assays



analytical sciences  characterization




                                                                                                   bioanalytical
              molecular                                    method
                                                                                                       mass
            characterization                             development
                                                                                                   spectrometry



    characterization of proteins small      method development for peptides and        development of methods for quantifying
    molecules nlinked and olinked         for quality control expertise in method     peptides and small molecules from
    glycosylation and glycations post       development for showing clearance of                  biological fluids
 translation modifications identification         process related impurities
 and characterization of low abundance
                impurities



  establishing similarity through analytics

  our rd strength in biosimilar and                           primary structure                      higher order
                                                                                                      structure
  biologics development is focused
  on a strategic qbd driven approach
                                                                                                      variants charge
  orthogonal techniques and                                        glycosylation
                                                                                                      size sequence
  fingerprint similarity
                                                  functional characteristics fab                     physiochemical
                                                      and fc function for mabs                       characteristics




                                                                                           research  development          65

drug discovery  preclinical               we have been able to achieve               structure moreover we are
sciences                                   relevant pharmacokinetic and               introducing innovative ways of
selecting the right molecule               pharmacodynamic endpoints and              predictive toxicology and adaptive
for clinical development is                establish the safety and efficacy          clinical trial designs hopefully it
prerequisite to drug development           of our products courtesy our              would significantly reduce costs and
and successful regulatory approval        scientifically rigorous ethically         increase the quality of our trials in
                                           compliant and stage gatebased             the future


translational research  development sciences




                                                         cell based                                   binding
             bioanalytical
                                                          assays                                      assays




development qualification and valuation     potency assays for insulins peptides      development and validation using
  of pk and immunogenicity measures               mab and mab conjugates               biacore radioligand binding and flow
using elisa and msd formats cell based                                                             cytometry
potency assays for neutralizing antibody
             determination




                                                                                                         drug
               invivo
                                                         toxicology                                 discovery and
            pharmacology
                                                                                                      preclinical



 mechanism of action moa studies         protocol development for glp and          moa pkpd clinical pd and patient
 development of invitro assays proof         nonglp studies evaluation of         selection markers and assays enable
  of concept animal model studies in          histopathology of animal tissues         pharmacodynamic and response
    diabetes autoimmune diseases             interpretation of pk pd and ihc in     biomarkers development of companion
             and oncology                      preclinical and clinical samples                   diagnostics




66    ahead of the curve  annual report 2017

                                                                                                           biocon limited




intellectual property                       and processes of each country is       strong regulatory capabilities in
biocon understands the importance           a formidable task drug regulators     rd coupled with a focused team
of ip in the biopharmaceutical              from the us fda european union      effort resulted in us being the
sector ip assumes a much greater           ema australia tga canada         first to file a proposed biosimilar
significance as it guides the rd           health canada brazil anvisa      trastuzumab with the us fda  ema
and commercialization strategy of           japan pmda etc have unique         our regulatory filing for two key
the company that enables protection         country specific processes which       biosimilar mabs trastuzumab and
of inventions and innovations it           have to be followed mandatorily       pegfilgrastim are being reviewed
also helps build credibility while          with patents expiring on novel         by the us fda and ema insulin
enabling a first mover advantage in         biologics several countries have      glargine is under review in europe
many cases ip also enables product         articulated their guidelines for       the launch of our insulin glargine in
positioning lifecycle management           ensuring biosimilarity the field      japan has been a major milestone
as well as asset monetization               is evolving with new regulatory        since the country is reputed as a
and valuation biocon rd has               submissions and industry players      stringent highly regulated market
consistently created intellectual           regulators payers physicians
                                                                                   the scientific culture of rd
wealth through an incisive ip               pharmacists are learning from each
                                            other biocons rd regulatory         the culture of science is in our
strategy that recognizes the
                                            team is playing a key role in this     dna we have always valued and
innovative potential of our products
                                            knowledge exchange and the             cherished our role in being part
and processes till date we have filed
                                            evolution of the regulatory pathway    of a rich scientific ecosystem at
nearly 1300 patent applications
                                            for establishing comparability        rd our employees have access
and hold over 1050 patents
                                            interchangeability and extrapolation   to special clubs for statistics and
and 555 trademark registrations
                                            of indications among biosimilars      medical writing a forum to access
globally the ip team has brought
                                                                                   international journals and journal
recognition for biocon through
various awards biocon was the only
indian biopharma company to make
it to the prestigious asia ip elite list
2016 we were also awarded the 9th
national ip award for 2017 in the
category top indian company for
creating global brand along with the
prestigious wipo users trophy

regulatory sciences
the regulatory sciences team has a
large number of talented individuals
who are the interface between
the company and regulators
understanding the guidelines rules


                                                                                       research  development             67

clubs our focus on the learning                                                product approvals and launches
                                         quality
curve has put us ahead of the curve                                          in most of the countries our
                                         excellence through quality and         manufacturing facilities for small
collaborations                           compliance is at the essence of        molecule apis also underwent
biocon believes in the strength          biocons strategy to be ahead of      a number of regulatory audits
of strategic partnerships and has        the curve we rigorously follow       including inspection by the us fda
invested in various partnerships         good manufacturing practice good
                                                                                during fy17 we underwent more
with global pharma companies like        laboratory practice and good
                                                                                than 10 international regulatory
mylan and quark pharma for several       documentation practice throughout
                                                                                audits to receive respective cgmp
projects since it is imperative         our operations with no compromise
                                                                                approvals some of the agencies that
to collaborate with academia             on compliance which in turn ensures
                                                                                approved our sites include anvisa
and government institutions             the highest standards of quality at
                                                                                brazil cofepris mexico mcc
biocon rd lays a lot of emphasis        all times
                                                                                south africa ministry of industry
on establishing relationships
                                         during fy17 biocons manufacturing    and trade russian federation npra
with national and international
                                         sites underwent several regulatory     malaysia and ministry of health
institutions these collaborations
                                         inspections by agencies of different   ukraine
include those with the trinity
                                         countries across the world as a part
college ireland queensland                                                    we expect to see an increase in
                                         of the new product approval process
institute of medical research                                                  regulatory inspections on account
                                         and verification of compliance
australia and the indian institutes of                                          of new product submissions as
technology among others the scope      our strong regulatory quality         well as periodic verification of
of collaborative research includes       and manufacturing capabilities         gmp compliance by agencies in
process development preclinical         have ensured continued global          the jurisdictions we supply to the
animal models exploratory               acceptance of our complex small        quality team is fully geared to meet
biomarker studies and fundamental       molecules and biosimilar products     the intensified quality scrutiny and
science research projects these         the successful conclusion of           address the increasingly demanding
collaborations that happen at            regulatory audits of our biologics     benchmarks of regulatory agencies
different levels are critical to the     drug substance and drug products       from around the globe
growth of a robust rd organization     manufacturing sites has facilitated




68    ahead of the curve  annual report 2017

                                                                                                     biocon limited




supply chain management




the supply chain management scm       during the year the scm function      demand for biocons biologic
function has put biocon ahead of       enabled us to build on our             products we also partnered
the curve by focusing on operational   reputation of being a trusted          with established global logistic
excellence in a space characterized     partner to global pharmaceutical       companies to meet the need for
by complex manufacturing processes      companies that rely on our apis for    effective cold chain systems that
and stringent regulatory norms         their formulations scm enabled        ensure shipment safety
we have built global scale end        the successful foray of our biologic
                                                                               we have created a dedicated
toend supply chain processes           products into several emerging
                                                                               logistics team to ensure business
encompassing multiple business          markets
                                                                               readiness for new markets this
verticals several manufacturing
                                        strengthening scm practices            enabled us to have shipping
locations and a diverse product
                                                                               channels ready ahead of business
portfolio meticulous planning smart   the scm function focused on
                                                                               initiation in some of the new key
sourcing and disciplined monitoring     building regulatory compliant
                                                                               markets
have enabled us to ensure ontime     systems and processes to meet the
delivery to our customers in over       demands imposed on the supply          in fy17 we initiated implementation
100 countries                          chain by the increased global          of the ctpat customs  trade




                                                                                 supply chain management           69

                                           strategic
                                           leverage supplier positions and global reach to create
                                             competitive advantage
                                           develop suppliers in new strategic regions
                                           lead industry in bestinclass practices
                                           focus on supply assurance mapping for critical materials

                                           financial
                                           cost management initiatives
                                           predict market price trends
                                           buildup of strategic inventory to address price fluctuations
                                           price benchmarking strategies for key cost drivers
         functional
                                           operational
         i m p e r at i v e s
                                           cultivate dynamic planning capabilities to enhance performance
                                           reduce transactional complexity
                                           identify scope for improvement and extend supplier performance
                                             to meet customer satisfaction
                                           focus on green initiatives
                                           integrated malaysia on uniform sourcing and operations platform

                                           training and development
                                           promote employee engagement
                                           encourage disruptive ideas
                                           identify and meet training needs for employees
                                           certificate programs for high performing employees
                                           inclusive talent pool in malaysia maintaining diversity




partnership against terrorism         priority customs clearance              and increased complexity of logistics
guidelines published by the us                                                  requirements we implemented a
                                       in malaysia we have made good
customs  border protection to                                                  system of checks and balances in
                                       progress in tying up with local
ensure that we are aligned with                                                 the areas of packaging sustainability
                                       vendors this has helped reduce
enhanced drug supply security                                                   terrainspecific transportation
                                       logistical challenges as well as
requirements in the key us                                                      modes material safety and delivery
                                       bridge sociocultural differences
market this will simplify logistics                                            efficiencies
procedures and help biocon obtain      to address the rising market diversity



70    ahead of the curve  annual report 2017

                                                                                                          biocon limited




we have also ensured seamless
operations for our key products
using best in class logistics service
providers and packaging vendors
warehouse facility consolidation at
one of our sites has helped enhance
capacity by 20 to better align with
business requirements

functioning with responsibility
while there is singleminded focus
on achieving business goals and
targets biocons scm maintains
high levels of ethics integrity and
                                         i sourcing  vendor consolidation        iii periodic vendor evaluation
process orientation this has enabled
us to maintain a spotless record           to reduce multiplicity of                 biocon has developed a process
of meeting mandatory compliance            transactions and minimize                 to periodically evaluate its
levels for our processes during            operational loads we have                 vendors for all critical materials
internal and external audits during       consolidated vendors for all our          on the basis of selected metrics
the year the warehouse team               plants in bengaluru this has also
                                                                                   contributing to the local
supported and facilitated about 30         helped in better planning and
                                                                                   economy
facility audits including by the us       effective negotiations
                                                                                   biocon has always strived to create a
fda and ema which were completed        ii green supply chain
                                                                                   strong local ecosystem by procuring
without any critical observations
                                         	moving from an animalorigin to          goods and availing of services from
we are also working on continuously        a recombinant supply base for           small and medium size vendors
improving our operations through           some of our key products have           based around its manufacturing
six sigma practices to ensure better       contributed significantly to our        locations about 1520 of our
working conditions and improved            efforts of ensuring an ecofriendly     total supplier base are small and
safety standards                          supply chain our sourcing team         medium enterprises local sourcing
                                           is also focusing on use of green       capabilities earn us multiple benefits
sustainable sourcing initiatives
                                           solvents eg ethanol at a majority   in terms of shorter turnaround times
the creation of a stable sourcing
                                           of our business units thereby          for delivery and quicker resolution of
platform is critical for our biologics
                                           reducing our dependence on non         issues pertaining to material quality
portfolio and scm has taken
                                           renewable forms of energy by           in return we help these vendors
steps to ensure longterm supply
                                           consolidating vendors for solvents      plan long term capacity by sharing
sustainability in this space some of
                                           deliveries we have reduced the         forecasts for up to 12 months in
the initiatives we have taken include
                                           fuel cost per unit of solvents          contributing to the local economy
                                           consumed at biocon                     we also enhance the sustainability of
                                                                                   our own operations


                                                                                     supply chain management            71

                           g l o ba l s o ur c i n g fra m e w o rk


              strategic sourcing                    procurement ops                      vendor risk mitigation
            sourcing processes and               execution and operational               dedicated teams created
                  compliance                             discipline                    for managing sourcing risks
                                                                                        in drug substance  drug
             cost management and                   securing logistics and
                                                                                                  product
            alignment to budgetary                     timely delivery
                  constraints                                                           geographic risks mapped
                                                     coordinating and
                                                                                        into vendor development
           crossfunctional interface            supporting global vendor
                                                                                                 platforms
          to address longterm supply               development plans
         risks and sourcing constraints                                                   supply assurance and
                                               monthly procurement review
                                                                                           vendor sustainability
         org level  procurement  data
                                                    integrated planning                     evaluations builtin
                   analytics
                                                    and procurement for
                                                                                          crossfunctional teams
             identify and mitigate                 operational dynamism
                                                                                       activated to review progress
                 sourcing risks
                                                                                       on riskmitigation activities

                                                                                          top of the house risks
                                                                                        mapped at corporate level

                         continuous improvement programs through review of performance and compliance




awards
biocon was conferred with
awards for overall excellence
in procurement  sourcing
and excellence in procurement
transformation at the cpo forum
india




72      ahead of the curve  annual report 2017

                                                               biocon limited




   a y o u n g d y n a m i c w o rk f o r c e p u s h i n g t h e
e n v e l o p t o k e e p b i o c o n  a h e ad o f t h e cur v e 




                                                       human resources    73

human resources




at biocon our innovative spirit puts   on excellence and high degree of       in helping bring some of our key
us ahead of our competitors we         empowerment we have instilled         projects closer to realization
believe in employing and fostering      confidence and a high sense of
the best talent as we believe           ownership in our people which has     global employee base
they are vital to the health of our     driven them to make a difference
                                                                                 9234     5245      497         3492
company over the years we have
                                        these qualities have led to us being
attracted some of the brightest
                                        recognized among the top 10 global
minds who have challenged
                                        biotech employers an annual survey
the status quo and pushed the
                                        conducted by science  science
boundaries of science to develop
                                        careers magazine ranked us at no 9
affordable therapies that can
                                        in 2016 up from no 13 the previous
impact global health their skills
                                        year we have the distinction of
have helped transform goals into
                                        being the only company from asia to
realities create new models for
                                        feature on this prestigious list
success and sustain high levels of
growth through our work culture        in the past 12 months the hr             total    india   malaysia    syngene
of unconventional thinking focus       team has played a significant role      biocon                 as on march 2017



74    ahead of the curve  annual report 2017

                                                                                                            biocon limited




attracting talent                        in fy17 we increased our hiring by
during the year we used social          30 over the last fiscal within the
                                         pool of new hires there was a 65
                                                                                 b
media extensively to attract the                                                     iocon is wellrecognized
best talent from todays techsavvy      rise in seniorlevel appointments          among the top global
generation we now hold the highest      to increase workplace diversity we      biotech employers and is highly
                                         also recruited from countries like       regarded by the scientific
talent brand index on linkedin
                                                                                  community in the us and
amongst peers making us the             us hong kong uae germany and
                                                                                  europe our performance
employer of choice following the        malaysia                                driven work culture encourages
digital integration of our recruitment                                            unconventional thinking
                                         we modified our internship
                                                                                  incubation of exciting new ideas
tools we have been receiving over        program this year to target young        and the pursuit of excellence
2500 applications per month             and promising life sciences talent       making biocon an innovationled
through linkedin social media           in international universities in        organization that is comparable
                                                                                  to the best in the world
platforms have enabled us to target      addition to various indian academic
talent groups at almost zero cost       institutes such as niper and iit        amitava saha
                                         we offered internships to students       sr vice president  head  hr
biocons positioning as a world
class employer brand enabled us to      from the university college cork
recruit top talent from some of the      ireland university of glasgow
countrys premier institutes several    imperial college london university
candidates from indian school of         of california san diego university
business accepted biocons offer         of melbourne and university of
on priority during the campus            queensland from among the 650
recruitment                             candidates who interned with us we
                                         offered jobs to nearly 150 in fy17




learning  development                   to manage and lead change several     in addition to these programs
learning  development plays a           employees underwent this focussed      close to 3000 employees attended
critical role in a knowledgedriven      group training program during the      various training programs organized
organization like biocon isurge our    year                                  by the learning  development
leadership development program                                                 team over 30000 learning people
                                         biowin  isurge our womens
implemented several initiatives                                                 hours were clocked during the year
                                         leadership program also conducted
around business excellence and           a focussed workshop for several
interpersonal excellence designed        women leaders




                                                                                              human resources         75

a young organization                      checkup practice we introduced         biocon malaysia have joined the
biocon has been the preferred             free thyroid health checkup for the    industryacademia panel of the
destination of young aspiring             women employees                        universiti teknologi malaysia
biotech professionals a fact which                                               utm and universiti kebangsaan
                                          with an intent to provide employees
is reflected in the age profiles of our                                           malaysia ukm these industry
                                          a platform to pursue their interests
employees almost half the size of                                                academia collaborations enable
                                          beyond work and connect with like
our human capital is under 34 years                                              universities to tailor their curriculum
                                          minded people we launched the
which makes biocon an incubator for                                               to emerging industry trends and
                                          biocon adventure and sports club
exciting new ideas                                                               talent requirements industrial
                                          basc various events were ideated
                                                                                  visits to our new integrated insulins
                                          and executed by employees which
employees age profile                                                            manufacturing facility in malaysia
                                          received a good response across the
                                                                                  by students from several public
                                          organization
                                                                                  and private malaysian universities
                                          invivo 2016 the annual day             provided them with practical
               14
                                          celebrations of biocon and syngene     insights into the working of the
          4
                                          was marked with great fanfare          biopharmaceutical industry
                                          in the runup to invivo 2016
        21
                              61          several events were conducted for       effective performance
                                          employees to showcase their talent     management
                                          over 250 employees were felicitated     our robust performance
                                          for long service while several others   management program is designed
                                          were recognized for their valuable      to encourage and reward talent
  1824       2534   3544        45    contributions to the organization      that harmonizes achievement of
                                                                                  organizational goals with personal
employee engagement initiatives           biocon malaysia growing in
                                                                                  aspirations and milestones our
the employee engagement                   strength
                                                                                  comprehensive talent management
initiatives during the year were          biocon malaysias manpower              framework identifies and develops
aimed at motivating our employees         strength has gone up by 12 to          critical talent crucial to biocons
to give their best and stay committed     nearly 500 employees in the last        growth strategy
to the organizational goals and           year learning initiatives have been
values with an enhanced sense of          intensified and we are leveraging       awards
their own wellbeing                     biocon academy programs to              biocon was recognized for best
                                          address specific technical and          corporate hr practices at the
apart from our regular employee
                                          functional training needs              nhrd for its comprehensive
engagement activities this year we
                                                                                  talent management framework
conducted customized programs             through biocon malaysia we are also
                                                                                  the company was also felicitated
aimed at addressing early burnout       making a significant contribution to
                                                                                  at the world hrd congress 2016
and healthy living through our          build the biotechnology industry
                                                                                  for excellence in human resource
wellness initiative  biopulse as        ecosystem in the southeast asian
                                                                                  management
an extension to our annual health         nation three senior leaders from



76    ahead of the curve  annual report 2017

                                                                                                     biocon limited




environment health  safety




for biocon staying ahead of the      and safety are integral parts of a      received iso 140012015  ohsas
curve extends beyond business to      broader environment and the core        180012007 accreditation from tv
adopting the best global practices     of our leadership decision process      nord after a successful transition
in environment health and             is focused on providing a safe and      from the earlier 2004 standard
safety ehs our comprehensive        healthy work environment at biocon     in line with the new globally
governance systems are bolstered       a singleminded pursuit of this         harmonized system ghs of hazard
by bestinclass infrastructure       philosophy has ensured that there       communication we have migrated to
specialized ehs systems competent     were no reportable incidents at         safety data sheet sds
teams and comprehensive programs      biocon during the year under review
                                                                               ehs risk assessment
sustainable thinking is the            ehs management systems                  our ehs risk assessment programs
cornerstone of corporate
                                       as a responsible corporate              methodically detect and evaluate
responsibility at biocon it has
                                       organization we have established       risks on various parameters ranging
helped us move beyond statutory
                                       a best in class environment             from effects on full organization
compliances to create responsible
                                       management system to minimize our       to potential impacts on individual
business practices that guarantee
                                       ecological footprint in fy17 biocon   employees it also helps efficiently
environmental sustainability health



                                                                               environment health  safety         77

prioritize risks and determine the     industrial hygiene management           of resources have yielded significant
best ways to remove transfer         we are committed to industrial          cost savings during the year
or mitigate those risks based         hygiene excellence aligning our        in biocon we believe that small
on this assessment we define          practices with global standards and     steps can yield big results we
and document the ehs roles and         strengthening them further as a        achieved power savings of 32900
responsibilities for all employees     part of our new biocon  integrated    kwh in the year through the
at each operating facility in fy17   industrial hygiene systems              installation of ie3 motors switching
we conducted comprehensive             implementation initiative we carried   to led lights improving efficiency
enterprise risk assessments for all    out productwise industrial hygiene     of filter press and reduction of
blocks in addition to evaluations      studies and exposure reduction          operation hours our project to
in line with business continuity       drives we also upgraded our            reduce chemical consumption
management                            existing sewage treatment unit with     for effluent treatment led to cost
                                       new bioremediation technology          savings during the year
ehs training
                                       further we introduced dspa dry
our ehs training program                                                       with multiple plants operating
                                       sprinkler powder aerosol fire
emphasizes on safety practices and                                             simultaneously round the year it
                                       suppression systems in the chemical
enables our employees to identify                                              is imperative that we effectively
                                       synthesis blocks
and mitigate workplace safety                                                  manage our environmental impact
hazards to ensure zero reportable      energy conservation                     and find ways to reduce our carbon
incidents during fy17 over 12000    our energy conservation initiatives     footprint we successfully cut carbon
person hours were invested in ehs      helped us restrict the rise in energy   dioxide emissions by 36000 tons
training                              consumption to 10 despite a            during the year by sourcing 44
                                       nearly 20 yoy growth in business     million units of green power today
our employees actively participated
                                       in fy17 the identification of low      green power accounts for 28 of
in several external training
                                       cost power sources and optimization     our total energy consumption
programs covering safety aspects
in the pharmaceutical industry
prevention of dust explosions
and best practices for storage
and transportation of hazardous
chemicals onsite we also organized
a lead auditor and internal auditor
training for iso 140012015 as well
as a symposium on leadership in
safety management

additionally we steered various
activities and events across biocon
facilities to mark national safety
week fire service week and
chemical disaster prevention week


78    ahead of the curve  annual report 2017

                                                                                                               biocon limited




awards and recognitions
during fy17 we received recognitions at the state and national levels for our
progressive ehs practices and initiatives these included

first prize in best fuel efficient industrial boiler category for adopting best
safe practices by the karnataka state safety institute

4star rating for ehs best practices by the confederation of indian industry



    biocon volunteers to revive                                   dense vegetation in the lake which had resulted in
                                                                  the shrinking of the waterbody water inlets have
    hebbagodi lake
                                                                  been cleaned and covered and screens included
    biocon has taken the initiative to contribute to the          to prevent debris from being washed into the lake
    lake revival mission of bengaluru biocon foundation          land has been cleared to make place for childrens
    took the lead to sign an expression of interest               playground fencing of the cleared stretch has been
    eoi for the rejuvenation of hebbagodi lake at               undertaken and information board and streetlights
    the bring back the lakes workshop organized by              have been installed
    karnataka lake conservation and development
                                                                  as a result of these efforts the water catchment area
    authority klcda a detailed project report has been
                                                                  has grown and we have seen some of the birds return
    submitted and our teams have been working closely
                                                                  to their habitat this motivates us to push other
    with klcda and other relevant administrative bodies
                                                                  stakeholders to enable the fullfledged lake revival
    like the district commissioner govt of karnataka
                                                                  plan for hebbagodi
    and hebbagodi city municipal corporation cmc
    to obtain necessary approvals for implementing the            we have also engaged with the local communities
    detailed lake revival plan                                   to sensitize them on the importance of water bodies
                                                                  and their role in preserving them with their best civic
    meanwhile biocon has cleaned up the area removed
                                                                  behaviour it is critical for the local community to play
    debris and weeds in and around the lake including
                                                                  an active role in lake conservation and revival

     before                                                      after 




                                                                                         environment health  safety        79

       community programs
       the team of hope
       biocon accords high importance
       to the health and safety of
       its stakeholders including its
       neighboring communities in
       fy17 biocon employees came
       together under the aegis of namma
       biocommunity a community
       connect initiative of biocon to make
       a difference to peoples lives in
       urban and rural areas with a focus
       on ensuring a clean green and safe
       environment

       a 40 member strong team of biocon
       volunteers both men and women
       spearheaded several drives during
       the year to clean up and renovate
       a number of underpasses around
       hosur road hebbagodi huskur
       hennagara bommasandra etc
       which were in a very poor state
       thus making it impossible for use
                                               before   after 
       by public which added to their
       safety hazard namma biocommunity
       encouraged pedestrians in the area
       to use the underpass to avert road
       accidents

       namma biocommunity volunteers
       also helped renovate the
       government high school in the
       neighboring area and encouraged
       the community to participate in the
       tree plantation drive




80       ahead of the curve  annual report 2017

                                                                                                     biocon limited




corporate social responsibility




biocon foundation                      sustainable solutions in the area      treatment centre with systematic
                                       of basic health and addressing the     documentation of patient data
biocon foundation the csr arm         burden of chronic diseases like
of biocon has been engaged in         cancer diabetes and hypertension     elaj smart clinics
developing innovative solutions to                                            elaj clinics are technologyenabled
                                       given our propensity to
address critical gaps in healthcare                                          smart clinics equipped with multi
                                       stay ahead of the curve we
education and sanitation to make                                              parameter monitoring device which
                                       extensively leveraged information
an enduring impact amongst the                                                enables multiple diagnostic tests
                                        communication technology to
marginalized communities in india                                            and generation of electronic medical
                                       develop a unique ehealthcare
through its various initiatives the                                           records emrs of patients the
                                       model in 2015 to bring healthcare
foundation aims at empowering and                                             elaj model has been designed to
                                       services to the doorsteps of those
integrating the underprivileged into                                          deliver databased healthcare on
                                       who need them the most we
the social and economic mainstream                                           the basis of sociodemographic and
                                       designed the elaj smart clinics
                                       to strengthen primary healthcare       health indicators obtained from
healthcare                             delivery in india by converting        communitybased screenings this
our public health initiatives have     primary health centers phcs          innovative health delivery model is
been successful in providing           into a comprehensive singlepoint      facilitating effective preventive


                                                                            corporate social responsibility        81

and primary healthcare intervention       software all connected to a secure          secure server the elaj emr system
in the rural areas of karnataka           server the introduction of the elaj         is mapped to a unique id to ensure
and rajasthan for the benefit of          model in phcs can provide access             continuum of care
communities with poor access to           to affordable healthcare services in
                                                                                       by providing clinical consultation
quality healthcare                       remote rural areas
                                                                                       and essential diagnostic services
these clinics are staffed with            the diagnostic centre in an elaj             at fair prices to all patients elaj
doctors technicians and pharmacists      smart clinic can perform up to 50            clinics reduce outofpocket
who are trained to handle                 tests and results are available in           expenses improved diagnostics
stateoftheart diagnostic               under an hour patient records are           at the elaj clinic also reduce the
equipment and clinic management           digitized and stored on a central            burden on the tertiary hospitals




                                               objectives of elaj




       continuum of care    quality of       monitor disease        protocols for          examine            generation
                            healthcare      profile and trigger   care delivery are   prevalence of risk     of reports for
                                             alerts in case of        followed        factors to initiate   stakeholders at
                                            disease outbreaks                         preventive health     different levels
                                                                                          education




82       ahead of the curve  annual report 2017

                                                                                                             biocon limited




                              biocons elaj model is addressing gaps in
                                   public health delivery in india
    infrastructure                         training data entry operators         quality of care
    improving and upgrading                to collect health information         ensured that the iphs norms
    infrastructure of phcs                efficiently                          related to infrastructure
                                           training anms and health workers      manpower and facilities are
    renovating toilets  labor rooms
                                           in data collection immunization      followed
    installing diagnostic centres in
                                           and antenatal checkups              upgraded labor rooms to ensure
    each phc
                                                                                 institutional deliveries
                                           electronic medical records
    providing laptops to each phc for
                                           patient records digitized and         ensured proper power backup
    proper documentation
                                           mapped to a unique id to ensure       and water supply
    staffing                               continuum of care                    provided laptops for pregnancy
    recruiting doctors auxiliary                                                child tracking and health services
                                           secure server stores data and
    nurse midwives anms general                                               management system pcts data
                                           patient privacy is maintained
    nurse midwives gnms data                                                  entry
    entry operators pharmacists lab      multiparameter monitors
                                           installed to record vitals           ensured water sanitation 
    technicians  other support staff
                                                                                 hygiene wash practices are
    ensuring that all the vacancies are    three interconnected modules
                                                                                 followed
    filled                                registration clinical consultation
                                            diagnostics                        working with the government to
    ensuring that phcs are running                                               set up biomedical waste disposal
    as per indian public health            dashboard to capture data on
                                                                                 protocols
    standards iphs norms on              disease profile of a community
    staffing                              notifications to help tackle
                                           seasonal disease outbreaks
    training and capacity building
    training lab technicians to use        dashboards ensure followup
    semiautomatic lab devices            and disease surveillance of the
                                           patients


for treatment and insurance               profiles of communities and disease     bengaluru in 2015
schemes                                  trends the dashboard sends disease
                                                                                   the pilot at huskur provided the
                                          notifications and alerts to the
the organic workflow pattern                                                       proof of concept to scale up the
                                          administrator this enables forward
starts with baseline indicators and                                                model elsewhere by the end of
                                          planning for the implementation of
preventive health and culminates in                                                2016 the elaj smart clinic model
                                          needbased healthcare programs
treatment this enables surveillance                                              was installed at eight clinics in
                                          moreover notifications help
monitoring and evaluation of the                                                   karnataka run exclusively by
                                          healthcare providers plan for
health status of the population                                                   biocon foundation
                                          seasonal disease outbreaks
data from individual clinics or from
groups of clinics are available to        elaj smart clinics  scaling up
health administrators through live
                                          biocon foundation set up its first
dashboards which capture patient
                                          elaj smart clinic in huskur in
footfall vital parameters disease


                                                                                 corporate social responsibility        83

                                                           smart clinic



                      patient  doctor interface at elaj smart clinics

                                                    patient


                                 registration ehr  vitals mpm620


                               doctor                                 pharmacy


                            diagnostics                               test report


                                  referral to secondarytertiary care




                                             smart clinic footprint




84    ahead of the curve  annual report 2017

                                                                                                           biocon limited




by 2016 biocon foundation                 smart clinic model in 15 government       secondary healthcare with
completed the adoption of five             run phcs in karnataka the first         effective use of technology biocon
government phcs in rajasthan under         of these have been flagged off           foundation is recognized widely for
a public private partnership ppp         in february 2017 through this           implementing innovative healthcare
with the government of rajasthan          ppp biocon foundation aims at           models to create a sustainable
                                           strengthening the present public         health ecosystem by joining hands
in january 2017 biocon foundation
                                           healthcare system in karnataka by        with the government we aspire to
and the government of karnataka
                                           providing solutions around primary       benefit many more villages in
signed a mou to install the elaj



     disease profile of patients visiting elaj smart clinics in fy17
                                                         over the past year patient footfall at the elaj smart
                                                         clinics has gone up by 50 to more than 9000 a
                       7                                 month patient footfall spiked between july and october
                   4
               9                                         because of seasonal illnesses hitting a peak of 13330
                                 35
                                                         in september 2016 overall data show that the majority
             16                                          of patient visits to the elaj clinics were prompted by
                                                         infectious diseases 35 and fever  pain 29
                           29                            rajasthan where we run five elaj smart clinics also saw
                                                         a jump in patient footfall in the julyoctober period the
                                                         patients diagnosed at these clinics were mostly suffering
                                                         from pyrexia 31 and diarrhoea 27 we are also
        infectious diseases     fever  pain
                                                         seeing good traction in the laboratory tests conducted
          non communicable diseases
                                                         at the elaj clinics in rajasthan with numbers soaring 13
              trauma  orthopedics
                                                         times between april 2016 and february 2017
                   ent      others



                                                                                  corporate social responsibility      85

karnataka through the elaj model            per government requirements to        officers from health department
that combines good infrastructure          collect data                          to monitor hrps
latest technology and the best
                                          elaj phcs collaborate with           the dashboards help them
available medical expertise
                                            private doctors to be a part of        monitor hrp cases and ensure
the foundation currently runs 14            pmsma                                 that proper preparations are done
elaj clinics covering over 30 gram                                                 in case of referral
                                          all phcs are provided with fetal
panchayats across karnataka and
                                            doppler by the foundation to         in case of highrisk pregnancy cases
rajasthan
                                            check fetal heart rate              elaj phcs follow an action plan
pradhan mantri surakshit                  glucometers with strips are          referral to higher institution
matritva abhiyaan anc camps                provided to phcs to track blood        for delivery all hrps whose
india ranks first in the list of 10         sugar levels of pregnant women        deliveries are due in the next two
countries that account for 60 of all                                              months are referred to higher
                                          creating monthly action plans
preterm births yet india has little                                             institution
                                            for all health centres for smooth
more than 50 of antenatal care
                                            management of highrisk              birth and emergency
coverage in order to tackle the issue
                                            pregnancy hrp cases                 preparedness plan all pregnant
of premature births low birth weight
                                                                                   women expected to deliver in the
babies and stillbirths it is essential   as recommended for hrps in
                                                                                   next two months with a special
to increase the coverage of antenatal       pmsma guidelines all elaj health
                                                                                   focus on high risk cases
care in the country to enable this        centres use red stickers on the
the ministry of health and family           highrisk individuals mamta card   referral to higher institution for
welfare government of india has                                                   iron sucrose all severe anaemia
                                          elaj phcs provide vehicles to
launched a program called pradhan                                                  cases are referred as either
                                            pick up and drop off pregnant
mantri surakshit matritva abhiyaan                                                 inpatient to the phc if the facility
                                            women for antenatal checkups
pmsma                                                                           is available or to the higher
                                          elaj dashboards are given to           institution
the aim of the program is to provide        medical officers and senior
a comprehensive package of
antenatal care services to pregnant
women in their second or third
trimester at government health
institutions biocon foundation is
helping the rajasthan government
implement pmsma efficiently at the
elaj phcs

how biocon foundation is ensuring
smooth implementation of pmsma

all elaj phcs use a unique
   prescription form designed as


86     ahead of the curve  annual report 2017

                                                                                                        biocon limited




referral to higher institution for     the multipronged approach to ncd        breast cancer
   other treatments all pregnant        management at elaj smart clinics        biocon foundation runs the breast
   women identified with some            includes                               cancer screening program in
   clinical condition for which                                                  association with ue life sciences
                                         health promotion and prevention
   treatment cant be provided at phc                                           the screening includes clinical
                                           strategies for healthy lifestyles
in fy17 nearly 2500 pregnant             that prevent ncds and associated      breast examination and examination
women attended the pmsma camp             risk factors                         with a handheld device the
of which over 350 were found to                                                  intelligent breast examination ibe
                                         garner evidence for action
be high risk pregnancy cases over                                               a novel us fda approved medical
                                           through disease surveillance
34000 ironfolic acid tablets were                                              instrument for prescreening of
                                           monitoring and research
distributed to anaemic women                                                    breast lesions those who are found
biocon foundation also identified        psychosocial counselling to meet      to have lesions are then referred
about 450 women for family                 the emotional social and mental      for ultrasoundmammography
planning counselling                      needs of patients                    this device is able to identify
                                                                                 high priority patients who require
                                         human resources and their
non communicable                           capacity building for prevention
                                                                                 ultrasound or mammography at the
diseases                                   and treatment of ncds
                                                                                 first level therefore reducing their
                                                                                 risk of developing breast cancer
noncommunicable diseases ncds        early diagnosis through periodic
also known as chronic diseases are                                              of the 1755 persons screened for
                                           opportunistic screening of
not passed from person to person                                                breast cancer this year 185 were
                                           population
they are of long duration and                                                    found to have lesions in the breast
                                         treatment and care of ncd             among them over 90 underwent
generally slow progression
                                           patients in special health camps     mammography
india is transiting speedily to
                                         handholding and referrals as and
lifestyle diseases ncds contribute
                                           when required
to around 587 million deaths that
account for 60 of all deaths in
india there is an urgent need to put
ncds at the centre of the countrys
health policy plans and programs

at biocon foundation we believe
an integrated community based
risk factor management program
is a costeffective and efficient
approach to tackling ncds we have
been conducting populationbased
screenings for oral cervical and
breast cancers



                                                                               corporate social responsibility        87

oral cancer                               risk profiling the data so generated   malnutrition
early detection and prevention of         helps characterize the health status
                                                                                  the 2015 global hunger index ghi
oral cancer can drastically reduce        of communities identify new ncd
                                                                                  report ranked india 20th amongst
mortality and the economic burden         cases and assess vulnerability to
                                                                                  leading countries with a serious
on the communities of the nearly         associated risk factors this year
                                                                                  hunger situation one of the major
6900 patients screened during            more than 1200 individuals were
                                                                                  causes for malnutrition in india is
the year a third tested positive         screened
                                                                                  economic inequality due to the low
for potentially malignant lesions
                                          ncd health camps                        social status of some population
fortunately no positive case of oral
                                          biocon foundation also conducts         groups their diet often lacks in
cancer was detected
                                          monthly health camps for type 2         both quality and quantity women
cervical cancer                           diabetes and hypertension through       who suffer malnutrition are less
                                          its phcs located across karnataka      likely to have healthy babies in
cervical cancer can often be
                                          early diagnosis is carried out          india mothers generally lack good
successfully treated when diagnosed
                                          along with health screening in          nutritional knowledge consequently
early of the nearly 1000 women
                                          these camps the health checkup        newborn infants are unable to get
screened 133 tested positive for
                                          is free while medicines and lab         adequate amount of nutrition from
reproductive tract infections and 21
                                          investigations are subsidized this     their mothers
for abnormal pap smear one case of
cervical cancer was detected this year   year we witnessed a total footfall
                                                                                  well baby clinics
                                          of over 8000 in our ncd health
diabetes  hypertension                                                           malnutrition can be prevented
                                          camps over 2300 diabetes and
                                                                                  with adequate primary healthcare
biocon foundation has developed           hypertension cases were managed
                                                                                  and community education and
a comprehensive program for the           through these camps during the year
                                                                                  behavior change in order to
detection and management of type          at these camps we also provide
                                                                                  test this hypothesis biocon
2 diabetes and hypertension through       psychosocial counselling on stress
                                                                                  foundation established a pediatric
its phcs the foundation routinely        management blood glucose control
                                                                                  clinic in austin town bengaluru
conducts surveys for community            and quitting tobacco use
                                                                                  in collaboration with st johns
                                                                                  community health department in
                                                                                  2016 the clinic provides general
                                                                                  pediatric consultative services
                                                                                  followups for ill children and
                                                                                  supports both the physical and
                                                                                  emotional wellbeing of children and
                                                                                  their families

                                                                                  we have adopted communitybased
                                                                                  management of acute malnutrition
                                                                                  cmam approach which enables us
                                                                                  to identify and initiate treatment



88    ahead of the curve  annual report 2017

                                                                                                            biocon limited




for children with severe acute             progress through monthly health            fy13 our role is supplementary
malnutrition sam before they             camps organized in our clinic and          to the governments integrated
become seriously ill there are four       also provide home counselling             child development service icds
main components of the approach                                                      program and we have developed
                                           referrals as and when required
                                                                                      a comprehensive strategy to curb
community mobilization our                children with medical complication
                                                                                      malnutrition in the area
community health workers chws            are referred for inpatient medical
sensitize the community and do             treatment                                 this year we organized a total of
child anthropometric assessment to                                                    190 health camps and managed a
                                           this year we organized eight health
identify acute malnutrition cases                                                    total of 834 cases of malnutrition
                                           camps on malnutrition out of the
                                                                                      of these 216 sam cases showed
supplementary feeding program              155 cases that were managed in
                                                                                      improvement with an upward growth
sfp we provide readytouse             total five sam cases were identified
                                                                                      trend of 92 we recorded a 14
therapeutic food rutf to children
                                           balaspandandana  the bagalkot             reduction in anemia cases
rutf are energy dense and
                                           program
micronutrient enhanced pastes used
in therapeutic feeding                    biocon foundation started nutrition
                                           intervention for children below
outpatient therapeutic program
                                           five years in bagalkot district in
otp we monitor childrens



education                                  selfreliance in children they are        government schools in karnataka
                                           closely aligned to the directorate         during the year over 100000
biocon foundation is keenly                of secondary research and training         students across 1400 schools in
aware of the fact that the quality         curriculum for standards i to vii         karnataka received the workbook
of education children receive in           since 2006 we have distributed            we also trained 1200 teachers
school determines the quality of           these workbooks to the most                under this initiative
their future critical gaps in learning   underserved children in various
such as language and numeracy
skills could affect their ability to
attain sustainable livelihoods and
lead productive healthy lives
biocon foundation has attempted
to plug a critical gap in mathematics
learning through the chinnara
ganitha workbook developed
in collaboration with macmillan
publishers india this workbook
approaches mathematics through
activities and games in the local
language thereby inculcating



                                                                                    corporate social responsibility        89

biocon academy




biocon took its leadership role in     career in the biotech industry            by producing highly skilled bio
the field of biotechnology forward     it has collaborated with leading           scientists during the year a talented
to establish the biocon academy       global institutes like keck graduate       pool of over 100 students graduated
a premier center of excellence         institute kgi california us and bits   from the biocon academy and all
for advanced applied learning in       pilani india to offer global quality     of them were successfully placed
biosciences in bengaluru in 2014     learning to indian students               in leading life sciences companies
                                                                                  the graduates of the academy were
biocon academy a csr initiative      in a short span of three years biocon
                                                                                  hired for diverse roles in production
has leveraged the rich industry        academy has been instrumental
                                                                                  quality assurance regulatory affairs
experience of biocon and domain        in shaping the careers of more
                                                                                  research  development and
knowledge of international             than 300 aspiring bioscientists by
                                                                                  marketing
academic partners to empower both      imparting the requisite experiential
experienced as well as recent life     learning that serves to bridge the         more than 35 companies
science graduates with translational   existing industryacademia gap            participated in the academys
education and industrial proficiency                                              campus placement programs
                                       in doing so the academy has
through jobskills development                                                    during the year while 60 of
                                       contributed immensely to enrich
essential to build a promising                                                    the graduates found jobs outside
                                       the life sciences ecosystem in india


90    ahead of the curve  annual report 2017

                                                                                                          biocon limited




of biocon the rest were placed in       training at biocons quality control      global life sciences industry and
various departments of biocon and       and production laboratories and           opportunities for bioscientists in
syngene                                cgmp training at biocon to widen         india and abroad
                                        the scope of handson training
biocon kgi certificate program in                                                 bits biocon program in applied
                                        for its students the academy
biosciences                                                                       industrial microbiology
                                        collaborated with bengalurubased
the academys flagship program          biopharmaceutical services company        building on the success of the
offered in collaboration with keck      biozeen and the new horizon               first batch of bits biocon program
graduate institute the premier         college of engineering to offer           in quality control microbiology
american school for biosciences         practical training sessions at their      the academy broadened the
education saw the successful           facilities                               course curriculum and modified
completion of three batches in                                                    the program to rename it as bits
                                        the academy also introduced a
fy17 the fulltime certificate                                                   biocon program in applied industrial
                                        special mentorship session for
program spread over 18 weeks                                                    microbiology
                                        students with the faculty and some
includes classroom sessions on the
                                        of the best alumni of kgi california    the exclusive program is designed to
applications of biotechnology as
                                                                                  enhance the knowledge and skills of
well as industry assignments and        in fy17 90 students successfully
                                                                                  aspiring microbiologists pharmacy
handson training                      completed the program including
                                                                                  and biotech graduates it seeks
                                        eight from malaysia all of them were
the classroom sessions involve                                                    to accelerate learning in the fast
                                        placed with leading pharma and
synchronous transmission of courses                                               growing field of microbiology and
                                        biopharma companies
and learning material developed                                                   boost the job prospects of students
and offered by faculty at kgi from      alumni meet                               in microbiology and biosciences the
california these sessions are highly                                             program offers experiential learning
                                        the biocon kgi program alumni
interactive and create a personalized                                             by combining real world insights with
                                        were introduced to kgi connect
learning environment where kgi                                                    classroom learning on various aspects
                                        the alumni portal of kgi students in
faculty members and students                                                      of microbiology through an intensive
                                        california the portal will give biocon
engage in real time conversations                                                curriculum delivered by renowned
                                        academy graduates an opportunity
                                                                                  faculty of bits pilani biocon
the broadbased international           to network with kgi alumni as well
                                                                                  academy and subject matter experts
curriculum of the program               as provide access to extensive
                                                                                  smes of biocon in addition to
encompasses the domains of rd         learning resources
                                                                                  honing technical skills this program
production quality assurance
                                        the academy also organized its            also sharpens the professional
regulatory sciences  product
                                        second alumni meet which was             skills of candidates and provides an
development additionally
                                        attended by over 100 graduates the       opportunity for holistic development
professional skills training prepares
                                        event chaired by kiran mazumdar
biotech students with the necessary                                               in fy17 a batch of 20 students
                                        shaw chief mentor biocon academy
knowledge and skills that make them                                               completed the bits biocon program
                                        and dr sheldon schuster president
employable in the industry                                                       and all of them were placed in
                                        kgi california provided interesting
                                                                                  leading pharma and biopharma
students undergo functional             insights into the new trends in the
                                                                                  companies


                                                                                                biocon academy           91

international event                      to do so the event witnessed the       the faculty development program
biocon academy in association           participation of 95 scientists from     will seek to empower biotech
with american chemical society           more than 11 organizations globally    faculty from various educational
medicinal chemistry division                                                     institutes by helping them upgrade
                                         new programs
and pharma innovation sourcing                                                   their knowledge of emerging
                                         biocon academy has developed            industryspecific technologies these
center us organized the medicinal
                                         two new programs the biocon            programs will be rolled out in fy18
chemistry and drug discovery 
                                         kgi certificate program in clinical
development india 2017 mcaddi                                                   biocon offers scholarships of upto
                                         development and the biocon
2017 a residential course in                                                   75 to all the students which takes
                                         academyfaculty development
medicinal chemistry and drug                                                     care of the major portion of the cost
                                         program to expand its offering to
discovery at its campus in bengaluru                                            of these expensive international
                                         the biotech world the clinical
mcaddi 2017 presented the                                                        programs
                                         development program has been
principles of medicinal chemistry
                                         designed to equip pharmacy
drug discovery  development in
                                         graduates postgraduates and
a format designed for industrial
                                         diploma holders with the skills
and academic participants who are
                                         needed to build a successful career
currently working in this area or plan
                                         in the realm of clinical development


92    ahead of the curve  annual report 2017

financial report
boards report                       93
management discussion and analysis   130
corporate governance report          142
business responsibility report       156
standalone financial statements      167
consolidated financial statements    217




                                           boards reports    91

                                                                                                                                            biocon limited




biocon
limited




boards report
dear shareholders
we present you the thirtyninth annual report on business and operations along with the audited financial statements and the auditors report of your
company for the financial year ended march 31 2017

financial highlights
                                                                                                                                    in  million except eps

particulars                                                                                standalone results                  consolidated results
                                                                                               fy17              fy16              fy17               fy16
total revenue                                                                                27172             25085           40787             34602
expenses                                                                                     21810             20552           32453             28912
share in net profit of joint venture                                                                                               163               217
profit before tax and exceptional items                                                        5362             4533             8497              5907
exceptional items                                                                                               1061                               1606
profit before tax                                                                              5362             5594             8497              7513
income tax                                                                                     1211              845              1538              1299
income tax on exceptional items                                                              1042             1063                78               123
noncontrolling interest                                                                                                           760               587
profit for the year                                                                            5193             3686             6121              5504
other comprehensive income net                                                                   84              10               764               58
total comprehensive income                                                                     5277             3676             6885              5446
earnings per share eps before exceptional item                                               2115             1879             3159              2048
earnings per share eps after exceptional item                                                2645             1878             3118              2804

standalone and consolidated financial statements
the standalone and consolidated financial statements of your company have been prepared in accordance with indian accounting standards ind as
notified under the companies indian accounting standards rules 2015 for all periods up to and including the year ended march 31 2016 your company
along with subsidiaries associates and joint ventures prepared its financial statements in accordance with accounting standards notified under the section
133 of the companies act 2013 read together with paragraph 7 of the companies accounts rules 2014 indian gaap these financial statements for the
year ended march 31 2017 are the first that have been prepared by the company its subsidiaries and associates in accordance with ind as

further a statement containing the salient features of the financial statements of our subsidiaries pursuant to subsection 3 of section 129 of the companies
act 2013 in the prescribed form aoc1 is appended as annexure 1 to the boards report the statement also provides the details of performance and
financial positions of each of the subsidiaries




                                                                                                                             boards reports           93

state of affairs
the highlights of your companys standalone performance are as under

     revenue from operations grew by 12 to  26184 mn from  23354 mn in fy16 other income for fy17 at  988 mn fy16  1731 mn primarily
      due to foreign exchange gain  160 mn and dividend from subsidiaries  487 mn in fy16

     core operating margins ebidta excluding rd forex and dividend from subsidiaries remained at similar levels as compared to fy16

exceptional item
during the previous year the company had a gain net of tax from sale of equity shares of the companys subsidiary syngene international limited syngene
mat credit on such gain was not recorded in the previous year due to uncertainty of utilization during the current year pursuant to change in the income
tax law and other business restructuring the company believes that it will be able to utilize the mat credit entitlement accordingly during the year ended
march 31 2017 the company has recorded mat credit entitlement of  1042 mn in its standalone financial statements however in the consolidated
financial statements such entitlement is recognised as a credit in equity along with the underlying dilution gain on sale of equity stake in syngene as it did
not impact groups control

     profit for the year stood at  5193 mn up 41 from fy16 pat excluding exceptional income net of tax was  5193 mn fy16  3688 mn

     effective tax rate etr for the year was 3 due to mat credit recorded on exceptional income of fy16 etr before exceptional item was 23

during the year our consolidated revenues registered a growth of 18 to  40787 mn from  34602 mn in fy16 from a segment perspective the small
molecules recorded a growth of 12 while the research services business registered a yearonyear increase of 7 biologics and branded formulation
recorded an annual growth of 43 and 24 respectively

consolidated profits for the year grew by 11 to  6121 mn from  5504 mn profits of fy17 included tax on exceptional income of  78 mn as against an
exceptional gain of  1483 mn net of taxes in fy16 which has been explained in detail under the section management discussion and analysis

bonus
with a view to encouraging the participation of small investors by making equity shares of the company affordable increasing the liquidity of the equity
shares and to expand the retail shareholders base your directors at their meeting held on april 27 2017 recommended issue of bonus shares of two
equity shares for every one equity share held by the members as on the record date to be determined by the board of directors board consequent to the
proposal of issue of bonus shares the authorised share capital of the company was proposed to be increased from  110 crores 22 crores equity shares
of  5 each to  300 crores 60 crores equity shares of  5 each your directors have decided to seek the approval of the shareholders for the above
proposals by way of postal ballot

dividend
your directors are pleased to recommend a final dividend of  3 prebonus per equity share on the face value of  5 per equity share for the financial
year ended march 31 2017 amounting to  600 mn in view of net cash generated from operations being substantially deployed in capex and taking into
account the future capital commitments your directors consider it prudent to propose the above dividend the dividend payout is subject to approval of
members at the ensuing annual general meeting agm

the dividend will be paid to members whose names appear in the register of members as on the record date to be determined by the board in respect of
shares held in dematerialised form it will be paid to members whose names are furnished by national securities depository limited and central depository
services india limited as beneficial owners as on the record date

dividend distribution policy
as per the provisions of regulation 43a of sebi lodr the top 500 listed companies shall formulate a dividend distribution policy accordingly the policy
was adopted to set out the parameters and circumstances that will be taken into account by the board in determining the distribution of dividend to its
shareholders and or retaining profits earned by the company the policy is appended herewith as annexure 2 to the boards report and is also available on
the companys website at httpwwwbioconcomdocsdividend_distribution_policypdf

transfer of unpaid and unclaimed amounts to iepf
pursuant to the provisions of section 1245 of the companies act 2013 dividend which remains unpaid or unclaimed for a period of seven years from the
date of its transfer to unpaid dividend account is required to be transferred by the company to investor education and protection fund iepf established by
the central government under the provisions of section 125 of the companies act 2013 during the year under review the company has credited unpaid
unclaimed dividends of financial year 200809 amounting to  648003 lying in the unpaid dividend account to the investor education and protection fund
iepf

subsidiaries and joint ventures
your company has formulated a policy for determining material subsidiaries pursuant to the provisions of the listing agreement the said policy is available
at the companys website httpwwwbioconcomdocspolicydocument_materialsubsidiarypdf

during the year biocon biologics india limited was incorporated on june 08 2016 as a wholly owned subsidiary of biocon biologics limited uk buk as
on march 31 2017 your company has 10 subsidiaries a report on the performance and financial position of each of the subsidiaries is presented below




94        ahead of the curve  annual report 2017

                                                                                                                                          biocon limited



syngene international limited india
syngene international limited syngene is one of indias leading contract research organisation offering a suite of integrated endtoend discovery
and development services for novel molecular entities nmes across industrial sectors including pharmaceutical biopharmaceutical and biotechnology
amongst others syngene helps its clients in conducting discovery from hit to candidate selection development including preclinical and clinical studies
analytical and bioanalytical evaluation formulation development and stability studies and pilot manufacturing scaleup preclinical and clinical supplies
each with distinctive economic advantage unlike the traditional business models these services are offered through flexible business models ranging from
a fulltime equivalent fte to a feeforservice ffs model or a combination customized on the clients specific requirement

during the year ended march 31 2017 syngene registered a revenue growth of 14 to  12716 mn in fy17 fy16  11133 mn ebidta margin for the
year was 38 with the operating margin at  4783 mn fy16   3867 mn registering a growth of 3

pursuant to a fire incident on december 12 2016 at syngene certain fixed assets inventory and other contents in one of the buildings were damaged
syngene lodged an initial estimate of loss with the insurance company and the survey is currently ongoing during the year ended march 31 2017 syngene
has written off the net book value of assets aggregating to  795 mn and recognised a minimum amount of insurance claim receivable for an equivalent
amount in addition the group is in the process of determining its claim for business interruption and has accordingly not recorded any claim arising
therefrom at this stage

on april 27 2017 the board of directors of syngene recommended a dividend of  1 10 per equity share for fy17 entailing a payout of  200 mn
the dividend payout is subject to approval of members at their ensuing annual general meeting agm

biocon research limited india
biocon research limited brl a 100 subsidiary of the company undertakes discovery and development research work in biologics and provides
scientific support for various development programmes of the group

brls current business is largely directed towards rd services for monoclonal antibody molecules and proteins mabs insulin tregopil formally referred
to as in105 and other insulin products on behalf of other group companies the research programs undertaken by brl have made significant inroads to
the next level of global clinical trials brl continues to hold 093 shareholding in syngene

during fy17 brl registered a turnover of  1657 mn and reported a net profit of  661 mn compared to a turnover of  4100 mn and a net profit of  832
mn in fy16 fy16 turnover included outlicensing of development and commercialisation rights of mabs to buk for a consideration of  2820 mn

biocon pharma limited india
biocon pharma limited bpl is a wholly owned subsidiary of the company bpl would be engaged in the development and manufacture of generic
formulations for sale in global markets especially opportunities in us and eu bpl is in the process of setting up its formulations manufacturing facility for
oral solid dosages at biocon sez bengaluru during fy17 7 mn equity shares of face value of  10 each were issued to biocon limited at face value as of
march 31 2017 bpl has not commenced commercial operations and had capital workinprogress of  1130 mn fy16  150 mn

biocon pharma inc usa
biocon pharma inc bpi a wholly owned subsidiary of biocon pharma limited was incorporated in july 2015 in the united states of america bpi will be
engaged in commercialization of generic formulations in the united states as at march 31 2017 bpi has not commenced commercial operations

biocon biologics limited uk
biocon biologics limited buk is a wholly owned subsidiary of the company incorporated in the united kingdom in march 2016 buk houses biocons
biosimilar biologics business biocon sdn bhd is a wholly owned subsidiary of buk during the year ended march 31 2017 buk earned  1826 mn as
revenue and reported a net loss of  189 mn

biocon sdn bhd malaysia
biocon sdn bhd malaysia is a step down subsidiary of the company wholly owned by buk biocon sdn bhd was established with an objective to set up
the groups first overseas manufacturing facility at malaysia the facility is located within bioxcell a biotechnology park in nusajaya johor which is being
promoted by the malaysian government

the manufacturing facility designed to manufacture recombinant human insulin and insulin analogs received local cgmp certification from the national
pharmaceutical control bureau the plant was capitalised  16851 mn at the end of the current year based on its readiness to start commercial supplies
average useful life of the plant is expected to be 16 years biocon sdn bhd will seek approvals from leading regulatory agencies across the globe for
marketing its products in rest of the world from fy 18 approval from the developed markets are expected in the coming years

biocon sdn bhd will also continue the research and development activities pertaining to human insulin and analogues which it acquired from biocon sa

biocon sdn bhd reported a total revenue of  998 mn and net profit of  5 mn in fy17

biocon biologics india limited india
biocon biologics india limited bbil is a step down subsidiary of the company wholly owned by buk bbil was incorporated on june 08 2016 in india with
an objective to set up green field biosimilar biologics facilities as at march 31 2017 bbil has not commenced commercial operations




                                                                                                                              boards reports            95

biocon sa switzerland
biocon sa a wholly owned subsidiary of the company is primarily engaged in identifying and developing other novel molecules into commercial products
or licensable assets through strategic partnerships

for the current year biocon sa registered net profit of  684 mn against  1229 mn in fy16 exceptional gains as explained below resulted in increased net
profits for fy16

exceptional items comprises of
a   an amount of  2561 mn net of tax released from deferred balance pursuant to contract with laboratories pisa sa de cv pisa of mexico for the
      codevelopment and commercialization of generic recombinant human insulin rhinsulin for the us market

b   impairment charge of  1078 mn of the marketing rights of t1h product for us and canada region territory due to uncertainties over
      commercialisation of the products in the territory owing to ofac sanctions

c   during the year ended march 31 2017 biocon sa and biocon sdn bhd have entered into an assignment and license agreement pursuant to which
      biocon sa transferred all of its rights interests and obligations in insulin analogs ipr to biocon sdn bhd consequent to this transfer bsa recorded
      a gain of  1150 mn net of tax  78 mn

biocon fz  llc uae
biocon fz llc is a wholly owned subsidiary of the company based in dubai incorporated in june 2015 biocon fz llc was established as a marketing entity
for pharmaceutical products to target markets in the middle east and gcc during the year ended march 31 2017 biocon fz llc earned  1328 mn as
revenue and reported a net loss of  21 mn

biocon academy india
biocon academy spearheads biocons csr initiatives in the technical  professional education segment the academy was established as a centre of
excellence for advanced learning in biosciences in 2014 biocon academy leverages rich industry experience of biocon and subject matter expertise of
international education partners such as keck graduate institute of claremont california usa the academy is dedicated exclusively to industry oriented
biosciences education the programs offered by the academy aim to empower the biotechnology and engineering graduates with advanced learning and
industrial proficiency through jobskills development essential to build a promising career in the biotech industry

management discussion and analysis
in terms of the provisions of regulation 34 of sebi listing obligations and disclosure requirements regulations 2015 sebi lodr the managements
discussion and analysis is set out in this annual report

corporate governance
your company is committed to maintain the highest standards of corporate governance we believe sound corporate governance is critical to enhance and
retain investor trust our disclosures seek to attain the best practices in corporate governance as prevalent globally we have implemented several best
corporate governance practices in the company to enhance longterm shareholder value and respect minority rights in all our business decisions corporate
governance report for fy 201617 forms part of this annual report

the requisite certificate from the auditors of the company confirming compliance with the conditions of corporate governance as stipulated under sebi
lodr is annexed to the corporate governance report

business responsibility report
the business responsibility report brr of your company for the year 201617 forms part of this annual report as required under regulation 342f of
the sebi listing obligations and disclosure requirements regulations 2015

employee stock option plan esop
nomination and remuneration committee of the board inter alia administers and monitors the companys employees stock option plan plan in accordance
with sebi share based employee benefits regulations 2014 sbeb regulations the plan is implemented through biocon india limited employees welfare
trust esop trust

during the year ended march 31 2017 a total of 499689 shares were transferred from the esop trust to the eligible employees under the companys
prevailing esop plan as at march 31 2017 the esop trust held 3529870 equity shares of the company during the year ended march 31 2017 there
has been no material change in the companys existing plan and the plan is in compliance with sbeb regulations information as required under sbeb
regulations read with sebi circular circfdpolicy cell22015 dated june 16 2015 have been uploaded on the companys website and can be accessed
at the weblink httpwwwbioconcombiocon_invrelation_annualreportsaspsublinkfinance

the applicable disclosures as stipulated under the sbeb regulations as on march 31 2017 is appended herewith as annexure 3 to the boards report
the company has received a certificate from the statutory auditors that the scheme has been implemented in accordance with sbeb regulations and the
resolutions passed by the shareholders the certificate would be placed at the agm for inspection by the members




96       ahead of the curve  annual report 2017

                                                                                                                                         biocon limited



deposits
your company has not accepted any deposit and as such no amount of principal and interest were outstanding as of the balance sheet date

loans guarantees or investments
details of loans guarantees and investments covered under the provisions of section 186 of the companies act 2013 form part of the notes to the financial
statements

policy on directors appointment and remuneration
the companys current policy is to have an appropriate mix of executive and independent directors to maintain the independence of the board and separate
its functions of governance and management as on march 31 2017 the board consists of 10 directors majority of them being independent directors
besides the chairperson and managing director who is a promoter the board comprises of vice chairman who is a wholetime director a ceo  joint
managing director a non executive director and 6 independent directors the board periodically evaluates the need for change in its composition and size
the policy of the company on directors appointment and remuneration including criteria for determining qualifications positive attributes independence
of a director and other matters as required under subsection 3 of section 178 of the companies act 2013 are formulated by the nomination and
remuneration committee the policy of the company on directors appointment and remuneration is appended herewith as annexure 4 to the boards
report

board diversity
a diverse board enables efficient functioning through differences in perspective and skill it also fosters differentiated thought processes at the back
of varied industrial and management expertise gender knowledge and geographical background the board recognises the importance of a diverse
composition and has adopted a board diversity policy which sets out the approach to diversity the policy is available at the weblink httpwwwbiocon
comdocspolicydocument_boarddiversitypdf

declaration by independent directors
the company has received necessary declaration from each independent director under section 1497 of the companies act 2013 that heshe meets the
criteria of independence laid down in section 1496 of the companies act 2013 and regulation 25 of sebi lodr

board evaluation
pursuant to the provisions of the companies act 2013 and regulation 19 of sebi lodr the board has carried out the annual performance evaluation of
its own performance the directors individually as well as the evaluation of the working of its various committees a structured questionnaire was prepared
after taking into consideration inputs received from the directors covering various aspects of the boards functioning such as adequacy of the composition
of the board and its committees board culture execution and performance of specific duties obligations independence governance ethics and values
adherence to corporate governance norms interpersonal relationships attendance and contribution at meetings etc

a separate exercise was carried out to evaluate the performance of individual directors including the chairperson of the board who were evaluated on
parameters such as participation and contribution commitment including guidance provided to the senior management outside of board  committee
meetings effective deployment of knowledge and expertise effective management of relationship with various stakeholders independence of behaviour
and judgment etc the performance evaluation of the independent directors were carried out by the entire board the performance evaluation of the
chairperson  managing director was carried out by the independent directors the evaluation process has been explained in the corporate governance
report the board reviewed the evaluation results as collated by the nomination and remuneration committee

appointment of directors and key managerial personnel
the members at the 38th agm held on june 30 2016 appointed mr m damodaran as an independent director for a period of three consecutive years for a
term upto the conclusion of 41st agm of the company in the calendar year 2019 the members at the said agm also appointed dr arun s chandavarkar ceo
 joint managing director as a director liable to retire by rotation we thank the members for their support in confirming the above mentioned appointments

the board on the recommendation of the nomination and remuneration committee appointed mr rajiv balakrishnan as the company secretary and
compliance officer effective january 24 2017 in place of mr kiran kumar g who relinquished his post as the company secretary of the company to
pursue other interests within the group the board places on record its appreciation for the services rendered by mr kiran kumar g during his tenure as the
company secretary

retirement and reappointment
as per the provisions of section 1526 of companies act 2013 prof ravi mazumdar retires by rotation at the ensuing agm and being eligible seeks re
appointment the board recommends his reappointment

the current term of appointment of mr russell walls ms mary harney and mr daniel bradbury independent directors of the company shall come to an end
at the ensuing agm based on the outcome of the performance evaluation the nomination and remuneration committee has recommended to continue the
term of appointment of the above independent directors and nominated to the board reappointment of mr russell walls ms mary harney and mr daniel
bradbury as independent directors for an additional term of five consecutive years the company has received declarations from all the three independent
directors confirming that they meet with the criteria of independence as prescribed under subsection 6 of section 149 of the companies act 2013 and
regulation 25 of sebi lodr the company has also received requisite notices in writing from members proposing mr russell walls ms mary harney and mr




                                                                                                                             boards reports           97

daniel bradbury as independent directors of the company

the board recommends the re appointment of mr russell walls ms mary harney and mr daniel bradbury as independent directors

committees of the board
currently the board has four committees audit and risk committee nomination and remuneration committee corporate social responsibility committee
and stakeholders relationship committee as required under the provisions of section 177 8 of the companies act 2013 the composition of the audit
committee is disclosed as under

mr russell walls chairman mr daniel m bradbury dr jeremy m levin and mr m damodaran

a detailed note on the composition of the board and other committees is provided in the corporate governance report section of this annual report

meetings of the board
the meetings of the board are scheduled at regular intervals to decide and discuss on business performance policies strategies and other matters of
significance the schedule of the meetings are circulated in advance to ensure proper planning and effective participation in meetings in certain exigencies
decisions of the board are also accorded through circulation

the board during the financial year 201617 met four times the maximum interval between any two meetings did not exceed 120 days as prescribed in
the companies act 2013 detailed information regarding the meetings of the board are included in the report on corporate governance which forms part
of the boards report

related party contracts or arrangements
all transactions entered into with related parties as defined under companies act 2013 during the year were in the ordinary course of business and on an
arms length basis the company has formulated a policy on materiality of related party transactions and the process of dealing with such transactions
which are in line with the provisions of the companies act 2013 and sebi lodr the same is also available on the weblink httpwwwbioconcomdocs
policydocument_relatedpartytransaction_2015pdf

prior omnibus approval from the audit and risk committee are obtained for transactions which are repetitive and also normal in nature further disclosures
on related party contracts and arrangements are made to the audit and risk committee and the board on a quarterly basis

during the year under review there were no material related party transactions under regulation 23 4 of sebi lodr entered into by the company which
necessitates approval of shareholders particulars of contracts or arrangements with related parties referred to in section 188 1 of the companies act
2013 in the prescribed form aoc  2 is appended herewith as annexure 5 to the boards report

credit ratings
crisil and icra continued to reaffirm their rating of aa stable and a1 for various banking facilities throughout the year enabling your company to
avail facilities from banks at attractive rates indicating a very strong degree of safety for timely payment of financial obligations

conservation of energy technology absorption foreign exchange earnings  outgo
the particulars as prescribed under subsection 3m of section 134 of the companies act 2013 read with the companies accounts rules 2014 is
appended herewith as annexure 6 to the boards report

auditors
statutory auditors

messrs b s r  co llp chartered accountants icai registration no 101248ww100022 were appointed as the statutory auditors of the company to hold
office from the conclusion of the 38th agm held on june 30 2016 until the conclusion of the 43rd agm of the company to be held in the calendar year 2021
subject to ratification of their appointment by the members at every agm

as required under the provisions of section 1391 of the companies act 2013 the company has received a written consent from b s r  co llp chartered
accountants to their appointment and a certificate to the effect that their appointment if made would be in accordance with the companies act 2013 and
the rules framed thereunder and that they satisfy the criteria provided in section 141 of the companies act 2013

the members are requested to ratify the appointment of the statutory auditors at the ensuing agm

the auditors report on the financial statements of the company for the year ending march 31 2017 is unmodified ie it does not contain any qualification
reservation or adverse remark the auditors report is enclosed with the financial statements forming part of the annual report

cost auditors

the board of directors on the recommendation of the audit and risk committee appointed messrs rao  murthy cost accountants firm registration
number 000065 as the cost auditors of the company for the fy 201718 under section 148 of the companies act 2013 messrs rao  murthy cost
accountants have confirmed that their appointment is within the limits of section 1413 g of the companies act 2013 and have also certified that they
are free from any disqualifications specified under section 1413 and proviso to section 1483 read with section 1414 of the companies act 2013

the audit and risk committee has also received a certificate from the cost auditors certifying their independence and arms length relationship with the
company



98        ahead of the curve  annual report 2017

                                                                                                                                            biocon limited



as per the provisions of the companies act 2013 the remuneration payable to the cost auditors is required to be placed before the members in a general
meeting for their ratification accordingly a resolution seeking members ratification for the remuneration payable to messrs rao  murthy cost accountants
is included in the notice convening the 39th agm

secretarial auditors

pursuant to the provisions of section 204 of the companies act 2013 and rules thereunder ms sreedharan  co practicing company secretaries was
appointed to conduct the secretarial audit of the company for the fy 201617 the secretarial audit report for fy 201617 is appended herewith as annexure
7 to the boards report the secretarial audit report does not contain any qualification reservation or adverse remark

the board has appointed mr m damodaran of ms damodaran  associates practising company secretaries as secretarial auditor of the company for the
financial year 201718

risk management policy
the company has put in place an enterprise wide risk management framework with an object of timely identification of risks assessment and evaluation of
the same in line with overall business objectives and define adequate mitigation strategy on a quarterly basis the audit and risk committee reviews critical
risks on a rotation basis in line with the mitigation progress effectiveness and its impact on overall risk exposure of the company all the critical risk areas
are covered at least once a year annually all critical risk areas identified are reevaluated

internal financial control
the company has laid down certain guidelines processes and structures which enable implementation of appropriate internal financial controls across the
organisation such internal financial controls encompasses policies and procedures adopted by the company for ensuring the orderly and efficient conduct
of business including adherence to its policies safeguarding of its assets prevention and detection of frauds and errors the accuracy and completeness
of accounting records and the timely preparation of reliable financial information these include control processes both on manual and it applications
including the erp applications wherein the transactions are approved and recorded appropriate review and control mechanisms are built in place to ensure
that such control systems are adequate and are operating effectively

because of the inherent limitations of internal financial controls including the possibility of collusion or improper management override of controls material
misstatements in financial reporting due to error or fraud may occur and not be detected also evaluation of the internal financial controls are subject to
the risk that the internal financial control may become inadequate because of changes in conditions or that the compliance with the policies or procedures
may deteriorate

the company has in all material respects an adequate internal financial controls system and such internal financial controls were operating effectively
based on the internal control criteria established by the company considering the essential components of internal control stated in the guidance note on
audit of internal control over financial reporting issued by the institute of chartered accountants of india

vigil mechanism
the vigil mechanism as envisaged in the companies act 2013 the rules prescribed thereunder and sebi lodr is implemented through the companys
whistle blower policy to enable the directors employees and all stakeholders of the company to report genuine concerns to provide for adequate
safeguards against victimisation of persons who use such mechanism and make provision for direct access to the chairman of the audit and risk committee

whistle blower policy of your company is available on the companys website and can be accessed at the weblinkhttpwwwbioconcomdocsbiocon_
group_integrity_whistle_blower_policypdf

directors responsibility statement
pursuant to the requirement under section 134 3 c of the companies act 2013 your directors confirm that

a   in the preparation of the annual accounts the applicable accounting standards had been followed along with proper explanation relating to material
      departures

b   they have selected such accounting policies and applied them consistently and made judgements and estimates that are reasonable and prudent so
      as to give a true and fair view of the state of affairs of the company at the end of the financial year and of the profit and loss of the company for that
      period

c   they have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the act for
      safeguarding the assets of the company and for preventing and detecting fraud and other irregularities

d   they have prepared the annual accounts on a going concern basis

e   they have laid down internal financial controls based on internal controls framework established by the company which were adequate and are
      operating effectively and

f   they have devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating
      effectively

particulars of employees
the statement containing particulars in terms of section 197 12 of the companies act 2013 read with rule 51 of the companies appointment and
remuneration of managerial personnel rules 2014 forms part of this report and is appended herewith as annexure 8 to the boards report



                                                                                                                                boards reports           99

the statement containing particulars in terms of section 19712 of the companies act 2013 read with rule 52 and 53 of the companies appointment
and remuneration of managerial personnel rules 2014 forms part of this report

considering the first proviso to section 1361 of the companies act 2013 the annual report excluding the aforesaid information is being sent to the
members of the company and others entitled thereto the said information is available for inspection at the registered office of the company during
business hours on working days of the company up to the date of the ensuing annual general meeting any shareholder interested in obtaining a copy
thereof may write to the company secretary in this regard

corporate social responsibility csr
at biocon csr has been an integral part of our business since its inception with the incorporation of biocon foundation in 2004 the company formally
structured its csr activity today the company span its csr efforts through biocon foundation biocon academy and some partnership programs with like
minded private organizations and government the company promotes social and economic inclusion for the marginalized communities with its integrated
system focussing largely in the following areas

health care services the company firmly believes that the use of technology can make healthcare delivery in rural areas more efficient and therefore we
have developed an integrated and holistic healthcare delivery service which seeks to address critical gaps in the delivery of healthcare in rural india our
efforts are targeted at enabling last mile reach of preventive and primary health services in rural areas

education while the company projects address experiential learning in basic maths computer skills and language skills of the underserved young people
in rural areas it also imparts advanced training necessary and skills required for gainful employment in the biopharma sector to young graduates through
biocon academy

promote art  culture india has a rich heritage of art and culture across the land which needs to be preserved and promoted our various forms of music and
dance style of paintings and sculptures have intrigued many across the globe yet a large pool of our artistes have not gained enough recognition biocon
foundation believes in creating a platform to promote art  culture encourage artists and share this knowledge with the marginalized communities through
various initiatives to help them develop a keen sense of appreciating fine arts

safety of women and children biocon believes that the safety of women and children is the collective responsibility of society the company provides safe
transport for pregnant women to come to primary health centres for ante natal checkups and for children attending our aata paata wadi it also provides
vehicles for the police to support their work in managing the safety of citizens

gender equality gender equality and equity is basic human right and your company works towards this in all its communities the company works towards
gender equality by providing vocational skills and assisting with employment opportunities the company counsel mentor and protect young women at
risk from sexual trafficking and assist women and girls with life skills coaching and employment opportunities

rural development the company is working to build townships schools sanitation and water supply systems that can fulfil the basic needs of underprivileged
rural and urban communities the company has adopted a township in north karnataka and is also providing support infrastructure including a school safe
drinking water a health centre and community hall in the village the company has installed solar lights rain water harvesting systems and household and
community toilets to enable clean sanitation facilities for the rural communities

in compliance with the provisions of section 135 of the companies act 2013 the board has formed a corporate social responsibility committee which
monitors and oversees various csr initiatives and activities of the company the csr committee comprises of ms mary harney chairperson dr vijay
kuchroo and prof ravi mazumdar

a detailed report regarding corporate social responsibility is appended herewith as annexure 9 to the boards report

sexual harassment of women at workplace prevention prohibition and redressal act 2013
the company has in place an antisexual harassment policy in line with the requirements of the sexual harassment of women at workplace prevention
prohibition and redressal act 2013 internal complaints committee icc has been set up to redress complaints received regarding sexual harassment
all employees permanent contractual temporary trainees are covered under this policy the policy is gender neutral during the year under review
7 complaints with allegations of sexual harassment were filed all of which were disposedoff as per the provisions of sexual harassment of women at
workplace prevention prohibition and redressal act 2013

significant and material orders
there are no significant and material orders passed during the year by the regulators courts or tribunals impacting the going concern status and companys
operations in the future

statutory disclosures
none of the directors of your company are disqualified as per the provisions of section 1642 of the companies act 2013 your directors have made
necessary disclosures as required under various provisions of the act and sebi lodr

material changes and commitments
no material changes and commitments affecting the financial position of the company have occurred between march 31 2017 and the date of this report




100       ahead of the curve  annual report 2017

                                                                                                                                    biocon limited



change in nature of business
there has been no change in the nature of business of the company your company continues to be a pioneer biopharmaceutical company engaged in
manufacturing active pharmaceutical ingredients and formulations including biosimilar drugs for diabetics oncology and autoimmune diseases with sales
in markets across the globe

extract of annual return
in accordance with the provisions of section 1343 a of the companies act 2013 an extract of the annual return in the prescribed format is appended
herewith as annexure 10 to the boards report

acknowledgement
we place on record our appreciation for the committed services by every member of the biocon family globally whose contribution was significant to the
growth and success of the company we would like to thank all our clients partners vendors investors bankers and other business associates for their
continued support and encouragement during the year

we also thank the government of india and malaysia government of karnataka government of telangana ministry of information technology and
biotechnology ministry of commerce and industry ministry of finance department of scientific and industrial research ministry of corporate affairs
customs and excise departments income tax department csez ltu bengaluru and all other regulatory agencies for their assistance and cooperation
during the year and look forward to their continued support in the future

                                                                                                                          for and on behalf of the board


bengaluru                                                                                                                      kiran mazumdar shaw
april 27 2017                                                                                                         chairperson  managing director




                                                  this space has been intentionally left blank




                                                                                                                         boards reports          101

                                          annexure 1 statement containing salient features of the financial statement of




102 
                                          subsidiaries associate companies joint ventures
                                          pursuant to first proviso to subsection 3 of section 129 of the companies act 2013 read with rule 5 of companies accounts rules 2014  aoc1

                                                                                                                                                                                                                                                                                                         in  million
                                          part a  subsidiaries
                                          sl   name of the subsidiary                  date since subsidiary reporting      reporting     share         reserves        total    total liabilities investments turnover profit loss                provision    profit for the      proposed  of
                                          no                                           was acquired         period         currency     capital     surplus other     assets    excl capital  excluding in               before                         for            year       dividend shareholding by
                                                                                        incorporated                                                         equity                      reserves subsidiaries             taxation                   taxation                                 the company
                                          1     syngene international limited india    november 18 1993      apr  mar                     2000         12131       27738            13607                5404       12716             3465         592              2873             200 7354
                                          2     biocon research limited india          may 28 2008           apr  mar                        1              403        2773            2369                            1657              391         270                661               10000
                                          3     biocon academy india                   december 03 2013      apr  mar                        1                          16                 15                                                                                             10000
                                          4     biocon pharma limited india            october 31 2014       apr  mar                      121               10        1761            1630                              60                  9           4                   5               10000
                                          5     biocon sa switzerland                  april 21 2008         apr  mar     usd                 6            4430        5422              986                            1336              762           78                 684               10000
                                          6     biocon biologics limited uk            march 02 2016         apr  mar     usd              4342           113        6446            2217                            1826             189                          189               10000
                                          7     biocon sdn bhd malaysia                january 19 2011       apr  mar     usd              3543             12     21856            18325                             998                  5                              5               refer note 4
                                          8     biocon pharma inc us                   july 27 2015          jan  dec     usd                91              98         38                 45                                             98                            98              refer note 5
                                          9     biocon fz llc uae                      june 16 2015          apr  mar     aed                 3              18        658               673                            1328              21                            21              10000




ahead of the curve  annual report 2017
                                          10    biocon biologics india limited india   june 08 2016          apr  mar                 1                           1                                                                                                                      refer note 6
                                                exchange rate considered in the case of foreign subsidiaries  1 usd  6481 1 aed  1765


                                          part b  associates  joint ventures
                                          statement pursuant to section 1293 of the companies act 2013 related to associate companies and joint ventures
                                          sl   name of joint venture                   date on which the     latest        share of joint venture held by the               description of how there        reason why the             net worth attributable to        profit for the year
                                          no                                           joint venture was     audited       company on the year end                         is significant influence        joint venture is not       share holding as per latest
                                                                                        associatedacquired   balance       number        amount of            extent                                       consolidated               audited balance sheet          considered    not
                                                                                                              sheet date    of shares    investments in        of                                                                                                    in            considered in
                                                                                                                                         joint venture         holding                                                                                               consolidation consolidation
                                                                                                                                                               
                                          1     neobiocon uae                          april 29 2007        march 31      147000     422 mn                49          by way of control of more       na                         422 mn                            163 mn              
                                                                                                              2017                                                          than twenty percent of
                                                                                                                                                                            total share capital
                                          notes

                                          1 none of the subsidiaries have proposed dividends as at march 31 2017 except syngene international limited
                                          2 biocon research limited holds 093 of equity stake in syngene international limited
                                          3 biocon pharma limited and biocon pharma inc are yet to commence commercial operations as at march 31 2017
                                          4 biocon biologics limited uk holds 100 of equity stake in biocon sdn bhd malaysia the reporting currency of biocon sdn bhd is myr however usd is disclosed since it is the functional currency
                                          5 biocon pharma limited india holds 100 of equity stake in biocon pharma inc us
                                          6 biocon biologics india limited india has pending share application money from biocon biologics limited uk

                                          for and on behalf of the board


                                          kiran mazumdarshaw                                            arun s chandavarkar                                     siddharth mittal                                                                      rajiv balakrishnan
                                          chairperson  managing director                                ceo  joint managing director                            president  finance  chief financial officer                                         company secretary

                                          bengaluru
                                          april 27 2017

                                                                                                                                         biocon limited




annexure 2  dividend distribution policy
pursuant to regulation 43a of sebi listing obligations and disclosure requirements regulations 2015

the dividend distribution policy the policy establishes the principles to ascertain amounts that can be distributed to equity shareholders as dividend by
the company as well as enable the company strike balance between payout and retained earnings in order to address future needs of the company the
policy shall come into force for accounting periods beginning from april 01 2016

preamble

the profits earned by the company may either be retained in business or used for acquisitions expansion or diversification or it can be distributed to the
shareholders as dividend through this policy the company would endeavor to maintain a consistent approach to dividend payout plans by reconciling
between all these needs

the company currently has only one class of shares  ordinary equity shares therefore dividend if declared will be distributed amongst all shareholders
based on their shareholding on the record date dividends will generally be recommended by the board once a year after the announcement of the full year
results and before the annual general meeting agm of the shareholders as may be permitted by the companies act the board may also declare interim
dividends as may be permitted by the companies act

the company has had a consistent dividend policy that balances the objective of appropriately rewarding shareholders through dividends and to support
the future growth the company would ensure to strike the right balance between the quantum of dividend paid and amount of profits retained in the
business for various purposes

as in the past subject to the provisions of the applicable law the companys dividend payout will be determined based on available financial resources
investment requirements and taking into account optimal shareholder return the board of directors will refer to the policy while declaring recommending
dividends on behalf of the company

the company shall comply with the provisions of section 123 of companies act 2013 pertaining to recommendation declaration  payment of dividend

category of dividends

the companies act provides for two forms of dividend  final  interim

a      final dividend

        final dividend is paid once in a financial year after the annual accounts are prepared the board of directors of the company has the power to
        recommend the payment of final dividend to the shareholders in a general meeting

b      interim dividend

        interim dividend may be declared by the board of directors one or more times in a financial year as may be deemed fit by the board the board of
        directors of the company would declare an interim dividend as and when considered appropriate in line with this policy normally the board could
        consider declaring an interim dividend after finalization of quarterly or half yearly financial results

        the board at its discretion may additionally recommend a special dividend under certain circumstances such as extraordinary profits from sale of
        investments etc

factors to be considered while declaring dividend

while determining the nature and quantum of the dividend payout the board would take into account the following factors

internal factors

i      profitable growth of the company and specifically profits earned during the financial year as compared with

        a    previous years and

        b    internal budgets

ii     cash flow position of the company

iii    accumulated reserves

iv     earnings stability

v      future cash requirements for organic growthexpansion andor for inorganic growth

vi     brand acquisitions

vii    current and future leverage and under exceptional circumstances the amount of contingent liabilities

viii   deployment of funds in short term marketable investments

ix     long term investments

x      capital expenditures



                                                                                                                             boards reports           103

external factors

i      business cycles

ii     economic environment

iii    cost of external financing

iv     applicable taxes including tax on dividend

v      industry outlook for the future years

vi     inflation rate and

vii    changes in the government policies industry specific rulings  regulatory provisions

apart from the above the board also considers past dividend history while determining the rate of dividend

the board may consider not declaring dividend or may recommend a lower payout for a given financial year after analyzing the prospective opportunities
and threats or in the event of challenging circumstances such as regulatory and financial environment in such events the board will provide rationale in
the annual report

the retained earnings of the company may be used in any of the following ways

i      capital expenditure for working capital

ii     organic and or inorganic growth

iii    investment in new business es andor additional investment in existing business es

iv     declaration of dividend

v      capitalisation of shares

vi     buy back of shares

vii    general corporate purposes including contingencies

viii   correcting the capital structure

ix     any other permitted usage as per the companies act 2013

policy review

this policy will be reviewed periodically by the board and amended as appropriate any changes or revisions to the policy will be communicated to
shareholders in a timely manner

the policy will be available on the companys website and disclosed in the companys annual report




                                                      this space has been intentionally left blank




104        ahead of the curve  annual report 2017

                                                                                                                                                biocon limited




annexure 3  disclosure with respect to employees stock option
plan of the company
a summary of status of esop

 sl   particulars
 no
 1     date of shareholders approval                                          september 27 2001
 2     total number of options approved under esos                             11423820
 3     vesting requirements
 4     exercise price or pricing formula                                       refer note 31 of the standalone financial statements
 5     maximum term of options granted
 6     source of shares primary secondary or combination                    combination
 7     variation in terms of options                                           no variation
 8     method used to account for esos  intrinsic or fair value
                                                                               refer note 31 of the standalone financial statements
 9     the impact on the profits and eps of the company

number of options approved under esop 2000 is adjusted for subdivision of face value of equity shares in fy 200102 and fy 200304 and issue of bonus
shares in fy 200304 and fy 200809

b option movement during the year 201617

 sl   particulars                                                 grant iv         grant v      grant vi     grant vii   grant viii         grant ix      grant x
 no
 1     number of options outstanding at the beginning                3500         791875     1185839    1275500         312500                            
       of the period
 2     number of options granted during the year                                                95000      200000          55000       472500       255000
 3     number of options forfeited  lapsed during the               1000          74625        61600      238500         105000          5000       51250
       year
 4     number of options vested during the year                                   215889      260338        26250          28250                            
 5     number of options exercised during the year                   2500         221388      258001        16800           1000                            
 6     number of shares arising as a result of exercise              2500         221388      258001        16800           1000                            
       of options
 7     money realized by exercise of options inr if                                                                                                      
       scheme is implemented directly by the company
 8     loan repaid by the trust during the year from                                                                                                        
       exercise price received
 9     number of options outstanding at the end of the                            495862      961238     1220200         261500       467500       203750
       year
 10    number of options exercisable at the end of the                            135175      125026         9450          16750                            
       year
 11    weightedaverage exercise prices of options                                    357           471          482            460               496         392
       outstanding at the end of year
 12    weightedaverage fair values of options granted                                             156          251            149               617         442

c options granted to the employees of the company during the year

a    options granted to senior managerial personnel during the year

 sl   name of the employee                               designation                                                grant       no of options       exercise price
 no                                                                                                                                    granted
 1     suresh subramanian                                 senior vice president                                    grant ix               25000              467
 2     prasad deshpande                                   vice president                                           grant x                20000              415
 3     paul vazhayil thomas                               vice president                                           grant x                20000              415
 4     sandeep nilkanth athalye                           senior vice president                                    grant ix               25000              566

b    any other employee who received a grant during the year options amounting to 5 or more of option granted during the year  nil

c    identified employees who were granted options during the year equal to or exceeding 1 of the issued capital excluding outstanding warrants and
       conversions of the company at the time of grant  nil




                                                                                                                                  boards reports             105

d    description of the method and significant assumptions used during the year to estimate the fair value of options including the following information

1       weightedaverage values of share price exercise price expected volatility
        expected option life expected dividends the riskfree interest rate and any
        other inputs to the model
2       method used and the assumptions made to incorporate the effects of                   refer note 31 of the standalone financial statements
        expected early exercise
3       how expected volatility was determined including an explanation of the
        extent to which expected volatility was based on historical volatility
4       whether and how any other features of the option grant were incorporated             none
        into the measurement of fair value such as a market condition

                                                                                                                            for and on behalf of the board



bengaluru                                                                                                                          kiran mazumdarshaw
april 27 2017                                                                                                           chairperson  managing director




                                                     this space has been intentionally left blank




106       ahead of the curve  annual report 2017

                                                                                                                                     biocon limited




annexure 4  policy on directors appointment and remuneration
the policy on appointment and remuneration of directors and key management personnel provides an underlying basis and guide for human resource
management thereby aligning plans for strategic growth of the company the policy is pursuant to section 1784 of the companies act 2013 and
regulation 19 of sebi listing obligations and disclosure requirements regulations 2015

a brief summary of the policy in relation to the objective appointment criteria remuneration and general matters as administered by the nomination and
remuneration committee are reproduced herewith 

background

section i

the key objectives of the committee  policy would be

     to guide the board in relation to appointment retention and removal of directors key managerial personnel and senior management

     to evaluate the performance of the members of the board and provide necessary report to the board for further evaluation of the board

     to recommend to the board on remuneration payable to the directors and key managerial personnel

     to retain motivate and promote talent and to ensure long term sustainability of talented managerial persons and create competitive advantage

     to devise a policy on board diversity

     to develop a succession plan for the board and to regularly review the plan

composition and meetings

the board has constituted a nomination and remuneration committee nrc in line with the requirements of the companies act 2013 which oversees the
functions related to appointment and remuneration of directors key managerial personnel and senior management personnel

the terms of composition and requirements as to the meeting of the committee are as below

     the committee shall consist of minimum of 3 nonexecutive directors and atleast one half of the composition shall be independent

     minimum two 2 members shall constitute a quorum for the committee meeting

     nrc shall meet atleast twice in a year

     membership of the committee shall be disclosed in the annual report

definition

act means the companies act 2013 and rules framed thereunder as amended from time to time

board means board of directors of the company

committee means the nomination and remuneration committee

directors mean directors of the company

key managerial personnel means chief executive officer and managing director wholetime director chief financial officer company secretary and such
other officer as may be prescribed under the act

senior management means personnel of the company who are members of its core management team excluding the board of directors including functional
heads

section ii

this section covers the duties of the committee in relation to various matters and recommendations to be made by the committee to the board

duties and role of committee

matters to be dealt with perused and recommended to the board by the committee shall include 

     formulating the criteria for determining qualifications positive attributes and independence of a director

     identifying persons who are qualified to become director and persons who may be appointed in key managerial positions in accordance with the
      criteria laid down in this policy

     recommending to the board appointment and removal of director key managerial personnel and senior management personnel

specifically the duties include

a nomination matters

     determining the appropriate size diversity and composition of the board



                                                                                                                         boards reports          107

      setting a formal and transparent procedure for selecting new directors for appointment to the board

      ensuring that there is an appropriate induction in place for new directors and reviewing its effectiveness

      identifying and recommending directors who are to be put forward for retirement by rotation

      developing a succession plan for the board and senior management and regularly reviewing the plan

      evaluating the performance of the board members and senior management in the context of the companys performance industry benchmarks and
       compliance

      making recommendations to the board concerning any matters relating to the continuation in office of any director at any time including the
       suspension or termination of service of an executive director as an employee of the company subject to the provisions of the law and their service
       contract

      recommend necessary changes to the board in line with board diversity policy

      considering any other matters as may be requested by the board

b remuneration matters

      considering and determining the remuneration policy based on performance with a reasonable and sufficient need to attract retain and motivate
       members of the board

      to approve the remuneration of key managerial personnel of the company by maintaining a balance between fixed and incentive pay reflecting short
       and long term performance objectives appropriate to the working of the company and its growth strategy

      to manage and administer the employee stock option plans of the company

      to consider any other matters as may be requested by the board

section iii

this section covers the policy for appointment term and retirement of directors and key managerial personnel by the committee

appointment criteria and qualifications

      the committee shall identify and ascertain the integrity qualification expertise and experience of the person for appointment as director key
       managerial personnel and recommend to the board hisher appointment

      a person should possess adequate qualification expertise and experience for the position heshe is considered for appointment the committee has
       discretion to decide whether qualification expertise and experience possessed by a person is sufficientsatisfactory for the concerned position

      the company shall not appoint any person as wholetime director who has attained the age of seventy years provided that the term of the person
       holding this position may be extended beyond the age of seventy years with the approval of shareholders by passing a special resolution based on
       the explanatory statement annexed to the notice for such motion indicating the justification for extension of appointment beyond seventy years

termtenure

      managing directorwholetime director the company shall appoint or reappoint any person as its executive chairman managing director or
       executive director for a term not exceeding such term as may be specified under the act no reappointment shall be made earlier than one year
       before the expiry of term and which shall be done with the approval of the shareholders of the company

      independent director an independent director shall hold office for a term up to five consecutive years on the board of the company and will
       be eligible for reappointment on passing of a special resolution by the company and disclosure of such appointment in the boards report no
       independent director shall hold office for more than two consecutive terms but such independent director shall be eligible for appointment after
       expiry of three years of ceasing to become an independent director provided that an independent director shall not during the said period of three
       years be appointed in or be associated with the company in any other capacity either directly or indirectly

evaluation

the committee shall carry out evaluation of performance of every director at regular intervals and at least on an annual basis

removal

due to reasons for any disqualification mentioned in the act or under any other applicable act rules and regulations thereunder the committee may
recommend to the board with reasons recorded in writing removal of a director or key managerial personnel subject to the provisions and compliance of
the said act rules and regulations

retirement

the director and key managerial personnel shall retire as per the applicable provisions of the act and the prevailing policy of the company the board will
have the discretion to retain the director or key managerial personnel in the same position remuneration or otherwise even after attaining the retirement
age for the benefit of the company




108          ahead of the curve  annual report 2017

                                                                                                                                           biocon limited



section iv

this section of the policy covers provisions relating to the remuneration for the wholetime director key managerial personnel and senior management
personnel

general

        the remuneration to the wholetime director and key managerial personnel will be determined by the committee and recommended to the board
         for approval wherever required the remuneration  compensation  commission etc shall be subject to approval of the shareholders of the company
         and central government

        the remuneration and commission including increments recommended to be paid to the wholetime director shall be in accordance with the
         percentage  slabs conditions laid down as per the provisions of the act these would be subject to approval of the shareholders of the company

remuneration to wholetime  executive  managing director and key managerial personnel

a       fixed pay the wholetime director  managing director shall be eligible for a monthly remuneration as may be approved by the board on the
         recommendation of the committee the breakup of the pay scale and quantum of perquisites including employers contribution to provident fund
         pension scheme medical expenses club fees etc shall be decided and approved by the board and approved by the shareholders and central
         government wherever required the committee shall approve the remuneration for the key managerial personnel

b       minimum remuneration if in any financial year the company has no profits or its profits are inadequate the company shall pay remuneration to its
         wholetime director in accordance with the provisions of schedule v of the act and if it is not able to comply with such provisions with the previous
         approval of the central government

c       longterm rewards the longterm rewards are linked to contribution to the performance of the company based on relative position of the personnel
         in the organisation these rewards could be in the form  nature of stock options and are based on level of employees and their criticality

d       provisions for excess remuneration if any wholetime director draws or receives directly or indirectly by way of remuneration any such sums in
         excess of the limits prescribed under the act or without the prior sanction of the central government where required he  she shall refund such sums
         to the company and until such sum is refunded hold it in trust for the company the company shall not waive recovery of such sum refundable to it
         unless permitted by the central government

remuneration to non executive  independent director

a       remuneration  commission the remuneration  commission shall be fixed as per the limits mentioned in the act subject to approval from the
         shareholders as applicable

b       sitting fees the non executive  independent director shall receive remuneration by way of fees for attending meetings of board or committee
         thereof provided that the amount of such fees shall not exceed such amount as may be prescribed by the central government from time to time

c       stock options an independent director shall not be entitled to any stock option of the company

the remuneration structure for independent directors per meeting of the board  committee effective april 1 2014 is as follows 

    particulars                                                                                                                   currency           amount
    board sitting fees                                                                                                                 inr           100000
    board remuneration                                                                                                                 us             5000
    travel allowance for overseas directorsnon us                                                                                    us             3000
    travel allowance for overseas directors us                                                                                       us             4000
    chairperson of audit and risk committee                                                                                           us             6000
    chairperson of other committees                                                                                                    us             2000
    members of audit and risk committee                                                                                               us             3000
    members of other committees                                                                                                        us             1000

 revised from us  5000 to us  6000 with effect from january 21 2016
 revised from us  2000 to us  3000 with effect from january 21 2016

amendments and updates

the nomination and remuneration committee periodically shall review this policy and may recommend amendments to this policy from time to time
as it deems appropriate which shall be in accordance with the provisions of the companies act 2013 in case of any modifications amendments or
inconsistencies with the act the provisions of the act and the rules made thereunder would prevail over the policy

                                                                                                                                for and on behalf of the board



bengaluru                                                                                                                              kiran mazumdarshaw
april 27 2017                                                                                                               chairperson  managing director




                                                                                                                               boards reports           109

annexure 5  particulars of contractsarrangements made with
related parties
pursuant to clause h of subsection 3 of section 134 of the act and rule 82 of the companies accounts rules 2014  aoc  2

form for disclosure of particulars of contractsarrangements entered into by the company with related parties referred to in subsection 1 of section 188
of the companies act 2013 including certain arms length transactions under third proviso thereto

1     details of contracts or arrangements or transactions not at arms length basis

 sl    particulars                                                                                                          details
 no
 a     names of the related party and nature of relationship
 b     nature of contractsarrangementstransactions
 c     duration of the contractsarrangementstransactions
                                                                                                            not applicable since there were no contracts
 d     salient terms of the contracts or arrangements or transactions including the value if any
                                                                                                            or arrangements or transactions entered into
 e     justification for entering into such contracts or arrangements or transactions
                                                                                                            by the company during the year ended march
 f     dates of approval by the board if any
                                                                                                            31 2017 which were not at arms length basis
 g     amount paid as advances if any
 h     date on which the special resolution was passed in general meeting as required under first
        proviso to section 188

2     details of material contracts or arrangements or transactions at arms length basis

 sl    particulars                                                                                                          details
 no
 a     names of the related party and nature of relationship
 b     nature of contractsarrangementstransactions                                                       not applicable since there were no material
 c     duration of the contractsarrangementstransactions                                                 contracts or arrangements or transactions
 d     salient terms of the contracts or arrangements or transactions including the value if any          entered into by the company during the year
 e     dates of approval by the board if any                                                            ended march 31 2017
 f     amount paid as advances if any

                                                                                                                             for and on behalf of the board



bengaluru                                                                                                                           kiran mazumdarshaw
april 27 2017                                                                                                            chairperson  managing director




                                                     this space has been intentionally left blank




110       ahead of the curve  annual report 2017

                                                                                                                                       biocon limited




annexure 6  conservation of energy technology absorption
foreign exchange earnings and outgo
particulars pursuant to section 1343 m of the companies act 2013 read with rule 83 of the companies accounts rules 2014

a     conservation of energy

i     the steps taken or impact on conservation        power consumption for fy17 was 179 mn units as against 161 mn units in fy16 on account of
       of energy                                        increased consumption of 11 yoy while the unit consumption increased total energy cost reduced
                                                        by 6  1456 mn in fy17 from  1551 mn in fy16 the reduction in overall energy cost was
                                                        attributable to procurement of power from alternate sources
ii    the steps taken by the company for               the company has started procuring wind power from october 2016 total wind power procured in
       utilizing alternate source of energy             fy17 is  43 mn units and corresponding reduction in c02 emission is approx 35000 tons
iii   the capital investment on energy                  93 mn
       conservation equipments

sl     power and fuel consumption details
                                                                                                                                   fy 17                fy 16
no
1       electricity
a       purchased
        million units                                                                                                               168                  145
        total amount in  mn                                                                                                        930                  894
        rate  unit                                                                                                               55                   62
b       captive generation
        hsd quantity kl                                                                                                           3300                4674
       million units                                                                                                                  11                   16
       units  litre                                                                                                                 34                   34
       cost  litre                                                                                                              343                 418
       generation cost rate  unit                                                                                               99                 124
2      steam
a      furnace oil
       quantity kl                                                                                                             15302                 14262
       total amount  mn                                                                                                          413                  463
       average rate                                                                                                                 270                 324

sl    energy conservation measures                                                                    investment          energy saved per annum
no                                                                                                        mn           units           amount  mn
1      conversion of conventional motors with energy efficient motors
2      conversion of cfl lights into energy efficient led lights
                                                                                                          93            950000                54
3      installation of energy efficient brine chiller
4      optimisation of hvac system at brc

continuous monitoring of high energy consumption areasequipment and taking appropriate corrective measures as and when required resulted in energy
saving and maintained marginal increment in power consumption as against production growth

b     technology absorption

i     the efforts made towards technology absorption
ii    the benefits derived like product improvement cost reduction product development or import
       substitution
iii   in case of imported technology imported during the last three years reckoned from the beginning              no technology was imported by the
       of the financial year                                                                                        company during the year
       a the details of technology imported
       b the year of import
       c whether the technology been fully absorbed
       d if not fully absorbed areas where absorption has not taken place and the reasons thereof




iv    the expenditure incurred on research and development rd                                                    detailed disclosure on rd are
                                                                                                                     provided below




                                                                                                                           boards reports               111

research and development

specific areas in which rd work has been carried out by the company

1    development of synthetic and fermentation based generic small molecules for antiinfective oncology cardiovascular nephrology and
      transplantation segments

2    formulation development for abbreviated new drug applications andas

3    generation of intellectual property development  process patents for manufacture of key generic small molecules and biotherapeutics

4    clinical development pertaining to novel programs

benefits derived as a result of rd activities

1    global presence in supply of fermentation based small molecules to the generic industry in regulated markets

2    rich pipeline of generic small molecules catering to varied therapeutic areas

3    internationally competitive prices and product quality

4    established intellectual property with 1286 patents pct applications filed in indian and international markets the company has been granted 1053
      patents in various jurisdictions

5    safe and environment friendly processes

6    first anda molecule approval is received

future plan of action

1    strategic collaborations for increased speed and cost competitiveness in drug discovery

2    inhouse rd scale up of generic formulations

3    collaborate with global academia and industry to build value  visibility to the portfolio


expenditure incurred on research  development
                                                                                                                                              in  million
                                                                                                                                 fy 17             fy 16
 a     capital                                                                                                                   250                 35
 b     recurring                                                                                                               1461              1480
        total                                                                                                                   1711              1515
        less recharge                                                                                                              4              48
        net rd expenses                                                                                                        1707              1467

c    foreign exchange earnings and outgo
                                                                                                                                              in  million
 foreign exchange earned and used during the year                                                                               fy17              fy16
 gross earnings                                                                                                                12988            11614
 outflow                                                                                                                        7899              8182
 net foreign exchange earnings                                                                                                  5090              3432



                                                                                                                           for and on behalf of the board



bengaluru                                                                                                                         kiran mazumdarshaw
april 27 2017                                                                                                          chairperson  managing director




112       ahead of the curve  annual report 2017

                                                                                                                                        biocon limited




annexure 7  secretarial audit report for the financial year ended
march 31 2017
pursuant to sub section 1 of section 204 of the companies act 2013 and rule 9 of the companies appointment and remuneration of managerial
personnel rules 2014

to
the members
biocon limited
bengaluru

we have conducted the secretarial audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by biocon
limited hereinafter called the company secretarial audit was conducted in a manner that provided us a reasonable basis for evaluating the corporate
conductsstatutory compliances and expressing our opinion thereon

based on our verification of the companys books papers minute books forms and returns filed and other records maintained by the company and also the
information provided by the company its officers agents and authorized representatives during the conduct of secretarial audit we hereby report that in
our opinion the company has during the financial year ended on march 31 2017 the audit period complied with the statutory provisions listed hereunder
and also that the company has proper boardprocesses and compliancemechanism in place to the extent in the manner and subject to the reporting made
hereinafter

we have examined the books papers minute books forms and returns filed and other records maintained by the company during the audit period according
to the provisions of

i     the companies act 2013 the act and the rules made thereunder

ii    the securities contracts regulation act 1956 scra and the rules made thereunder

iii   the depositories act 1996 and the regulations and byelaws framed thereunder

iv    foreign exchange management act 1999 and the rules and regulations made thereunder to the extent of foreign direct investment overseas direct
        investment and external commercial borrowings

v     the following regulations and guidelines prescribed under the securities and exchange board of india act 1992 sebi act

        a    the securities and exchange board of india substantial acquisition of shares and takeovers regulations 2011

        b    the securities and exchange board of india prohibition of insider trading regulations 2015

        c    the securities and exchange board of india issue of capital and disclosure requirements regulations 2009 not applicable to the company
              during the audit period

        d    the securities and exchange board of india share based employee benefits regulations 2014

        e    the securities and exchange board of india issue and listing of debt securities regulations 2008 not applicable to the company during the
              audit period

        f    the securities and exchange board of india registrars to an issue and share transfer agents regulations 1993 regarding the companies act
              and dealing with client

        g    the securities and exchange board of india delisting of equity shares regulations 2009 and not applicable to the company during the audit
              period

        h    the securities and exchange board of india buyback of securities regulations 1998 not applicable to the company during the audit period

        i    securities and exchange board of india listing obligations and disclosure requirements regulations 2015

vi    other laws applicable specifically to the company namely

        a    drugs and cosmetics act 1940

        b    bio medical waste management  handling rules 1998

        c    ich guidelinesthis is the base on which us fda eu guidelines etc are created on

        d    ucpmp currently voluntary  however proposed to be made mandatory

        e    national biodiversity act 2002

        f    drugs  magical remediesobjectionable advertisements rules 1955

        g    narcotic drugs and psychotropic substance act




                                                                                                                            boards reports           113

we have also examined compliance with the applicable clauses of the following

a    secretarial standards issued by the institute of company secretaries of india on meetings of the board of directors and general meeting

b    listing agreements entered into by the company with bse limited and national stock exchange of india limited

during the period under review the company has complied with the provisions of the act rules regulations guidelines standards etc mentioned above

we have not examined compliance with applicable financial laws like direct and indirect tax laws since the same have been subject to review by statutory
financial audit and other designated professionals

we further report that

the board of directors of the company is duly constituted with proper balance of executive directors nonexecutive directors and independent directors
the changes in the composition of the board of directors that took place during the period under review were carried out in compliance with the provisions
of the act

adequate notice is given to all directors to schedule the board meetings agenda and detailed notes on agenda were sent at least seven days in advance and
a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation
at the meeting

as per the minutes of the meetings duly recorded and signed by the chairman the decisions of the board were unanimous and no dissenting views have
been recorded

we further report that based on the review of the compliance reports certificates of the chief executive officer ceo of the company which were taken on
record by the board of directors there are adequate systems and processes in the company commensurate with the size and operations of the company to
monitor and ensure compliance with applicable laws rules regulations and guidelines

we further report that during the audit period there was no event  action having a major bearing on the companys affairs in pursuance of the above
referred laws rules regulations guidelines etc



                                                                                                                       for v sreedharan  associates
                                                                                                                                    company secretaries

                                                                                                                                     pradeep b kulkarni
bengaluru                                                                                                                                        partner
april 24 2017                                                                                                                    fcs 7260 cp no 7835




                                                   this space has been intentionally left blank




114       ahead of the curve  annual report 2017

                                                                                                                                       biocon limited




annexure 8  particulars of remuneration
details pertaining to remuneration as required under section 19712 read with rule 51 of companies appointment and remuneration of managerial
personnel rules 2014

sl    name of the directorkey managerial personnel and      remuneration of director           percentage increase in      ratio of the remuneration
no    designation                                             key managerial personnel            remuneration of each           of each director to the
                                                                for the year ended march       directorcfocs in the fy     median remuneration of the
                                                                                31 2017                       201617                        employees
                                                                                million
1      ms kiran mazumdar shaw                                                       2037                           27                              498
       chairperson  managing director
2      mr john shaw                                                                 1723                            10                             421
       vice chairman
3      mr arun chandavarkar                                                         3304                             7                             808
       ceo  joint managing director
4      ms mary harney                                                               281                            14                              69
       independent director
5      mr russell walls                                                             375                             5                              92
       independent director
6      mr daniel m bradbury                                                         221                             0                              54
       independent director
7      dr jeremy m levin                                                            322                            24                              79
       independent director
8      dr vijay kumar kuchroo                                                       214                            13                              52
       independent director
9      mr m damodaran                                                              195                              na                             48
       independent director
10     mr siddharth mittal                                                          1965                            25                               na
       chief financial officer
11     mr rajiv balakrishnan                                                       077                              na                              na
       company secretary
12     mr kiran kumar                                                               655                             7                               na
       company secretary

mr rajiv balakrishnan was appointed as the company secretary effective january 24 2017 in place of mr kiran kumar g who relinquished the post on
december 15 2016 and hence their remuneration is disclosed only for the period of them holding the title

note remuneration of the independent directors is excluding sitting fees the above remuneration does not include perquisite value on account of stock
options exercised during the year

i      percentage increase  decrease in median the median remuneration of employees increased from  369820 to  408871 representing an
       remuneration of employees in the financial increase of 11 while computing the increase in median remuneration the employees considered
       year                                       are employees as at march 31 2017 and as at march 31 2016
ii     number of permanent employees on the there were 4832 permanent employees as at march 31 2017
       rolls of the company

iii    average percentile increase in salaries of   the average increase in employee remuneration other than managerial personnel was 178
       employees other than managerial personnel    which has been marginally higher than that for managerial personnel the increase in managerial
       and its comparison with the percentile       remuneration is in line with the measures to attract and retain the best talent the company also uses
       increase in managerial remuneration and      a mix of fixed variable and esop based compensation on a midtolong term basis to align middle
       justification thereof                        and senior management compensation to enhance shareholder values

it is hereby affirmed that the remuneration paid for the financial year 201617 was as per the policy for remuneration of the directors key managerial
personnel and other employees

                                                                                                                            for and on behalf of the board



bengaluru                                                                                                                         kiran mazumdarshaw
april 27 2017                                                                                                          chairperson  managing director




                                                                                                                            boards reports          115

annexure 9  annual report on corporate social responsibility
activities for the financial year 201617
pursuant to the provisions of section 135 of the companies act 2013

biocon believes in making a difference to the lives of millions of people who are underprivileged it promotes social and economic inclusion by ensuring that
marginalized communities have equal access to health care services educational opportunities and proper civic infrastructure

your companys csr activities are implemented through

        biocon foundation  works towards the development and implementation of healthcare education and infrastructure projects for the marginalized
         sections of society

        biocon academy aims to address the skill deficit in the biotechnology space

        external partners partner with reliable csr players who work towards the development of society

the csr vision of the company is

        to promote social and economic inclusion by ensuring that marginalized communities have equal access to healthcare services educational
         opportunities and proper civic infrastructure

        to create a globally competitive biotech ecosystem in india through skill development

        to bridge the gap of gender disparity in education healthcare and employment

        to create a platform for promoting the rich art  culture of the country and sensitizing the communities to appreciate fine arts

please refer httpwwwbioconcombiocon_csr_about_policyasp for more details related to the companys csr policy

csr committee

the csr committee of our board provides oversight of csr policy and monitors execution of various activities to meet the set csr objectives

the members of the csr committee are

a       ms mary harney chairperson

b       dr vijay kumar kuchroo

c       prof ravi mazumdar

financial details

the provisions pertaining to corporate social responsibility as prescribed under section 135 of the companies act 2013 are applicable to the company a
summary of the financial details of the company are as follows 

    particulars                                                                                                                                 in  million
    average net profit before tax of the company for last three financial years                                                                       4501
    prescribed csr expenditure 2 of the average net profit as computed above                                                                          90
    details of csr spent during the financial year 201617
     total amount to be spent for the financial year                                                                                                     90
     total amount spent                                                                                                                                  90
    amount unspent if any                                                                                                                               nil




116          ahead of the curve  annual report 2017

                                                                                                                                       biocon limited



the details of the amount spent during the financial year is detailed below

                                                                                                                                              in  million

sl    csr project  program     sector                     location of project program      amount        amount     cumulative amount spent
no    name                                                 district  state                 outlay         spent         spend direct through
                                                                                             budget        on the      up to the external agency
                                                                                                         projects or     reporting
                                                                                                          programs          period
i    expenditure on projects  programs
1      ary primary               healthcare and medical     karnataka  at nine arogya          1276         1264         1264   biocon foundation
       healthcare clinics        facilities                 raksha yojana primary
                                                            healthcare outpatient clinics
2      cancer screening          healthcare and medical     various districts in karnataka       343          298          298   biocon foundation
       program                   facilities
3      ehealth  rajasthan  healthcare and medical        rajasthan  karnataka               1274         1513         1513 direct and biocon
       karnataka              facilities                                                                                          foundation
4      project one               clean drinking water and   bengaluru huskur karnataka        130          076          076   biocon foundation
                                 rain water harvesting
5     lake development          rural development          hebbagudi bengaluru                406          240          240 biocon foundation
       project                                              karnataka
6      rural development         rural development          karnataka                            913          849          849   biocon foundation
       project
7      international school      improving quality of       hyderabad telangana                 325          325          325   biocon foundation
       of business               education
8      grant to ngo              healthcare and medical     karnataka telengana                 487          427          427   biocon foundation
                                 facilities
9      biotechnology training improving quality of          bengaluru karnataka                3487         3093         3093   biocon academy
                              education
10     contribution to biocon funding of activities         bengaluru karnataka                              337          337 biocon foundation
       foundation             under the approved csr
                              programmes
ii   administrative expenses
1      all projects excluding    office expenses            bengaluru karnataka                 363          582          582   biocon foundation
       sl no 10 above
                                                                                                9004         9004         9004

responsibility statement

we hereby confirm that the implementation of the policy and monitoring of the csr projects and activities is in compliance with csr objectives and csr
policy of the company



                                                                                                          for and on behalf of the board

bengaluru                                                                              kiran mazumdarshaw                  mary harney
april 27 2017                                                                         chairperson  managing director      chairperson  csr committee




                                                                                                                           boards reports            117

annexure 10  extract of annual return as on the financial year
ended on march 31 2017
pursuant to section 923 of the companies act 2013 and rule 121 of the companies management and administration rules 2014 form mgt09
i     registration and other details

 1     cin                                                                              l24234ka1978plc003417
 2     registration date                                                                november 29 1978
 3     name of the company                                                              biocon limited
 4     category  subcategory of the company                                           category  company limited by shares
                                                                                         sub category  indian non government company
 5     address of the registered office and contact details                             20th km hosur road electronic city
                                                                                         bengaluru 560 100
                                                                                         contact  tel 91 80 2808 2808
                                                                                         email  cosecretarybioconcom
 6     whether listed company                                                           yes
 7     name address and contact details of registrar and transfer agent if any        karvy computershare private limited
                                                                                         plot 3132 karvy selenium tower b gachibowli financial district
                                                                                         nanakramguda hyderabad  500 032
                                                                                         contact  tel 91 40 67161500
                                                                                         email  einwardriskarvycom

ii    principal business activities of the company
 sl    name and description of main products  services                    nic code of the product service            to total turnover of the company
 no
 1      manufacture of pharmaceuticals medicinal chemical and                                 21                                    10000
        botanical products

iii   particulars of holding subsidiary and associate companies

 sl    name and address of the company         cingln                             holdingsubsidiary             of shares held            applicable
 no                                                                                                                                           section
 1      syngene international limited           l85110ka1993plc014937                    subsidiary                  7354                    287
 2      biocon research limited                 u73100ka2008plc046583                    subsidiary                    100                     287
 3      biocon pharma limited                   u24232ka2014plc077036                    subsidiary                    100                     287
 4      biocon biologics india limited          u24119ka2016flc093936                    subsidiary                    100                     287
 5      biocon academy                          u80301ka2013npl072272                    subsidiary                    100                     287
 6      biocon sa                               na                                       subsidiary                    100                     287
 7      biocon sdn bhd                         na                                       subsidiary                    100                     287
 8      biocon biologics limited                na                                       subsidiary                    100                     287
 9      biocon pharma inc                       na                                       subsidiary                    100                     287
 10     biocon fz llc                           na                                       subsidiary                    100                     287
 11     neo biocon fz llc                       na                                        associate                    49                         26

including 093 held by biocon research limited
iv    share holding pattern equity share capital breakup as percentage of total equity
1     categorywise shareholding

 category      category of shareholder        no of shares held at the beginning of the year          no of shares held at the end of the year         
 code                                                          31032016                                            31032017                       change
                                                  demat        physical         total      of           demat       physical         total      of during
                                                                                          total                                                 total   the
                                                                                         shares                                                shares  year
 a           promoter and promoter
               group
 1           indian
 a           individualhuf                 79838266                   79838266        3992       79766766                  79766766      3988       004
 b           central govtstate govts                                                                                                               
 c           bodies corporate                                                                                                                         
 d           financial institutionsbanks                                                                                                             
 e           others                                                                                                                                   
               subtotal a1                 79838266                   79838266        3992       79766766                  79766766      3988       004


118          ahead of the curve  annual report 2017

                                                                                                                                         biocon limited



category   category of shareholder        no of shares held at the beginning of the year         no of shares held at the end of the year         
code                                                       31032016                                           31032017                       change
                                              demat       physical          total     of          demat       physical          total      of during
                                                                                     total                                                 total   the
                                                                                    shares                                                shares  year
2        foreign
a        individuals nrisforeign        2058986                   2058986       103        2058986                   2058986        103    000
           individuals
b        bodies corporate               39535194                   39535194      1977       39535194                  39535194       1977    000
c        institutions                                                                                                                       
d        qualified foreign investor                                                                                                         
e        others                                                                                                                             
           subtotal a2                 41594180                   41594180      2080       41594180                  41594180       2080    000
           total aa1a2              121432446                 121432446      6072       121360946                121360946       6068    004
b        public shareholding
1        institutions
a        mutual fundsuti                 5647569                   5647569       282        4296869                   4296869        215    068
b        financial institutionsbanks     5044830                   5044830       252        2429062                   2429062        121    131
c        central governmentstate                                                                                                           
           governments
d        venture capital funds                                                                                                              
e        insurance companies                                                                                                                
f        foreign institutional          27264626                   27264626      1363       35427957                  35427957       1771    408
           investors
g        foreign venture capital                                                                                                            
           investors
h        qualified foreign investor                                                                                                         
i        others                                                                                                                             
           subtotal b1                 37957025                   37957025      1898       42153888                  42153888       2108    210
2        noninstitutions
a        bodies corporate                 2889920                   2889920       144        4099910                   4099910        205    060
b        individuals
           i individuals holding
           nominal share capital upto
            1 lakh                       15649334         23468      15672802       784       13860069        24064      13884133        694   089
           ii individuals holding
           nominal share capital in
           excess of  1 lakh             11291220                   11291220       565        8184669                   8184669        409    155
c        others
           clearing members                  138067                    138067       007         127359                    127359        006    001
           foreign nationals                 459818       289902        749720       037         450818       264434        715252        036    002
           non resident indians             1358428       172394       1530822       077        1296201       172394       1468595        073    003
           nri nonrepatriation                                                               193072                    193072        010    010
           employees esop trust             3876828                   3876828       194        3529870                   3529870        176   017
           trusts                           4461150                   4461150       223        4282306                   4282306        214    009
d        qualified foreign investor                                                                                                         
           subtotal b2                 40124765        485764     40610529       2031       36024274       460892      36485166       1824   206
           total bb1b2              78081790        485764      78567554      3928       78178162       460892      78639054       3932    004
           total ab                   199514236       485764     200000000 10000           199539108      460892     200000000 10000            
c        shares held by custodians                                                                                                          
           for gdrs  adrs
           grand total abc           199514236       485764     200000000 10000           199539108      460892     200000000 10000            




                                                                                                                          boards reports          119

2    shareholding of promoters

sl     shareholders name                  shareholding at the beginning of the year              shareholding at the end of the year              change in
no                                     no of shares    of total          of shares         no of shares        of total    of shares        shareholding
                                                        shares of the      pledged                                shares       pledged            during the
                                                        company            encumbered to                           of the       encumbered to          year
                                                                           total shares                            company      total shares
1       kiran mazumdarshaw                79287564                3964                         79287564             3964                                     
2       glentec international limited      39535194                1977                         39535194             1977                                     
3       john shaw                           1407558                 070                          1407558               070                                    
4       ravi rasandra mazumdar               565014                 028                            565014              028                                    
5       yamini r mazumdar                    550702                 028                003         479202              024               003            004
6       dev mazumdar                           86414                004                             86414              004                                    
        total                            121432446                 6072                003     121360946             6068                003            004

3    change in promoters shareholding

sl     particulars                                               shareholding at the beginning of the year          cumulative shareholding during the year
no                                                                     no of shares      of total shares of              no of shares     of total shares of
                                                                                                the company                                        the company
1      kiran mazumdarshaw
        at the beginning of the year                                       79287564                      3964                  79287564                   3964
        increase decrease in shareholding during the year                                                                                                     
        at the end of the year                                                                                                79287564                   3964
2      glentec international
        at the beginning of the year                                       39535194                      1977                  39535194                   1977
        increase decrease in shareholding during the year                                                                                                     
        at the end of the year                                                                                                39535194                   1977
3      john shaw
        at the beginning of the year                                        1407558                       070                   1407558                    070
        increase decrease in shareholding during the year                                                                                                     
        at the end of the year                                                                                                 1407558                    070
4      ravi rasendra mazumdar
        at the beginning of the year                                         565014                       028                    565014                    028
        increase decrease in shareholding during the year                                                                                                     
        at the end of the year                                                                                                  565014                    028
5      yamini r mazumdar
        at the beginning of the year                                         550702                       028                    550702                    028
        increase decrease in shareholding during the year                   71500                      004                    479202                    024
        at the end of the year                                                                                                  479202                    024
6      dev mazumdar
        at the beginning of the year                                           86414                      004                     86414                    004
        increase decrease in shareholding during the year                                                                                                     
        at the end of the year                                                                                                   86414                    004




120       ahead of the curve  annual report 2017

                                                                                                                               biocon limited



4    shareholding pattern of top ten shareholders other than director promoter and holders of gdrs and adrs

1     franklin templeton investment funds
                                increase or decrease         shareholding at the beginning of      increase     cumulative shareholding during
                                reasons                            the year 01042016             decrease in        the year 31032017
                                                                 no of shares        of total    shareholding      no of shares       of total
                                                                                  shares of the                                     shares of the
                                                                                     company                                           company
at the beginning of the year                                        6048588               302                         6048588              302
01042016
22042016                      decreasesold                                                            96956        5951632              298
03062016                      decreasesold                                                           192686        5758946              288
10062016                      decreasesold                                                           423500        5335446              267
17062016                      decreasesold                                                            58283        5277163              264
30062016                      decreasesold                                                           127000        5150163              258
01072016                      decreasesold                                                            84500        5065663              253
08072016                      decreasesold                                                            65242        5000421              250
15072016                      decreasesold                                                             2500        4997921              250
29072016                      decreasesold                                                           122546        4875375              244
05082016                      decreasesold                                                            23657        4851718              243
12082016                      decreasesold                                                           343618        4508100              225
19082016                      decreasesold                                                           286717        4221383              211
26082016                      decreasesold                                                           112407        4108976              205
21102016                      decreasesold                                                           142584        3966392              198
02122016                      decreasesold                                                           141260        3825132              191
 09122016                     decreasesold                                                            76233        3748899              187
 16122016                     decreasesold                                                            55560        3693339              185
 23122016                     decreasesold                                                            76136        3617203              181
 06012017                     decreasesold                                                           144345        3472858              174
 13012017                     decreasesold                                                            44856        3428002              171
 03032017                     decreasesold                                                             7293        3420709              171
 at the end of the year                                                                                                3420709              171
 31032017


 2    oppenheimer developing markets fund

                                increase or decrease         shareholding at the beginning of      increase     cumulative shareholding during
                                reasons                            the year 01042016             decrease in        the year 31032017
                                                                 no of shares        of total    shareholding      no of shares       of total
                                                                                  shares of the                                     shares of the
                                                                                     company                                           company
 at the beginning of the year                                               0             000                                0             000
 01042016
 21102016                     increasebought                                                          438196         438196              022
 28102016                     increasebought                                                          358524         796720              040
 04112016                     increasebought                                                          438395        1235115              062
 11112016                     increasebought                                                          892326        2127441              106
 18112016                     increasebought                                                          212682        2340123              117
 25112016                     increasebought                                                          490655        2830778              142
 02122016                     increasebought                                                          454232        3285010              164
 09122016                     increasebought                                                          392417        3677427              184
 16122016                     increasebought                                                          318685        3996112              200
 23122016                     increasebought                                                           34166        4030278              202
 13012017                     increasebought                                                          272033        4302311              215
 03022017                     increasebought                                                           80450        4382761              219
 at the end of the year                                                                                                4382761              219
 31032017




                                                                                                                    boards reports         121

3      life insurance corporation of india

                               increase or decrease   shareholding at the beginning of      increase    cumulative shareholding during
                               reasons                      the year 01042016             decrease in       the year 31032017
                                                         no of shares         of total    shareholding     no of shares       of total
                                                                           shares of the                                    shares of the
                                                                              company                                          company
at the beginning of the year                                 3707822               185                        3707822              185
01042016
08042016                     decreasesold                                                     25000        3682822              184
22042016                     decreasesold                                                    137355        3545467              177
29042016                     decreasesold                                                    556571        2988896              149
06052016                     decreasesold                                                    472117        2516779              126
13052016                     decreasesold                                                    459591        2057188              103
20052016                     decreasesold                                                    110654        1946534              097
27052016                     decreasesold                                                     76818        1869716              093
10062016                     decreasesold                                                     15000        1854716              093
17062016                     decreasesold                                                     20000        1834716              092
24062016                     decreasesold                                                     29775        1804941              090
08072016                     decreasesold                                                     55561        1749380              087
09092016                     decreasesold                                                     12640        1736740              087
at the end of the year                                                                                         1736740              087
31032017


4      templeton developing markets trust

                               increase or decrease   shareholding at the beginning of      increase    cumulative shareholding during
                               reasons                      the year 01042016             decrease in       the year 31032017
                                                         no of shares         of total    shareholding     no of shares       of total
                                                                           shares of the                                    shares of the
                                                                              company                                          company
at the beginning of the year                                 2497396               125                        2497396              125
01042016
03062016                     decreasesold                                                     33500        2463896              123
10062016                     decreasesold                                                    147500        2316396              116
17062016                     decreasesold                                                     89322        2227074              111
30062016                     decreasesold                                                    152000        2075074              104
01072016                     decreasesold                                                      5000        2070074              104
08072016                     decreasesold                                                      7500        2062574              103
15072016                     decreasesold                                                      5500        2057074              103
29072016                     decreasesold                                                    313500        1743574              087
05082016                     decreasesold                                                     61007        1682567              084
21102016                     decreasesold                                                    306219        1376348              069
13012017                     decreasesold                                                     58727        1317621              066
03032017                     decreasesold                                                     15200        1302421              065
at the end of the year                                                                                         1302421              065
31032017




122       ahead of the curve  annual report 2017

                                                                                                                       biocon limited



5    reliance capital trustee co ltd ac reliancepharm

                               increase or decrease   shareholding at the beginning of      increase    cumulative shareholding during
                               reasons                      the year 01042016             decrease in       the year 31032017
                                                           no of shares       of total    shareholding     no of shares       of total
                                                                           shares of the                                    shares of the
                                                                              company                                          company
at the beginning of the year                                  2452018              123                        2452018              123
01042016
15042016                     decreasesold                                                     18700        2433318              122
22042016                     decreasesold                                                     13200        2420118              121
06052016                     decreasesold                                                    107800        2312318              116
27052016                     decreasesold                                                    100000        2212318              111
17062016                     increasebought                                                    19800        2232118              112
24062016                     decreasesold                                                     13200        2218918              111
30062016                     decreasesold                                                      6600        2212318              111
08072016                     decreasesold                                                     15000        2197318              110
15072016                     decreasesold                                                    385000        1812318              091
22072016                     increasebought                                                    20900        1833218              092
22072016                     decreasesold                                                    600000        1233218              062
29072016                     decreasesold                                                     33000        1200218              060
05082016                     increasebought                                                    58300        1258518              063
19082016                     increasebought                                                    15400        1273918              064
26082016                     increasebought                                                   166100        1440018              072
02092016                     increasebought                                                    99000        1539018              077
09092016                     decreasesold                                                      6600        1532418              077
16092016                     decreasesold                                                     50600        1481818              074
23092016                     decreasesold                                                      1100        1480718              074
07102016                     decreasesold                                                     11000        1469718              073
14102016                     decreasesold                                                    100000        1369718              068
21102016                     decreasesold                                                    167200        1202518              060
28102016                     increasebought                                                    19800        1222318              061
28102016                     decreasesold                                                    200000        1022318              051
04112016                     decreasesold                                                    101100         921218              046
11112016                     decreasesold                                                    321218         600000              030
02122016                     increasebought                                                    11000         611000              031
09122016                     decreasesold                                                     11000         600000              030
24022017                     increasebought                                                     3000         603000              030
03032017                     increasebought                                                   153600         756600              038
03032017                     decreasesold                                                    505673         250927              013
10032017                     increasebought                                                   199800         450727              023
10032017                     decreasesold                                                     94327         356400              018
17032017                     decreasesold                                                     21600         334800              017
31032017                     decreasesold                                                      3000         331800              017
at the end of the year                                                                                          331800              017
31032017

6    murali krishnan k n

                               increase or decrease   shareholding at the beginning of      increase    cumulative shareholding during
                               reasons                      the year 01042016             decrease in       the year 31032017
                                                           no of shares       of total    shareholding     no of shares       of total
                                                                           shares of the                                    shares of the
                                                                              company                                          company
at the beginning of the year                                  2120342              106                        2120342              106
01042016
17032017                     increasebought                                                 2100342         4220684              211
17032017                     decreasesold                                                   2100342        2120342              106
31032017                     decreasesold                                                   2000000         120342              006
at the end of the year                                                                                          120342              006
31032017


                                                                                                            boards reports         123

7      swiss finance corporation mauritius limited

                               increase or decrease    shareholding at the beginning of      increase    cumulative shareholding during
                               reasons                       the year 01042016             decrease in       the year 31032017
                                                          no of shares         of total    shareholding     no of shares       of total
                                                                            shares of the                                    shares of the
                                                                               company                                          company
at the beginning of the year                                  1961900               098                        1961900              098
01042016
08042016                     increasebought                                                     58479        2020379              101
15042016                     increasebought                                                    101774        2122153              106
22042016                     increasebought                                                     51493        2173646              109
29042016                     increasebought                                                     40535        2214181              111
06052016                     decreasesold                                                     148435        2065746              103
13052016                     increasebought                                                    161199        2226945              111
20052016                     increasebought                                                     33501        2260446              113
27052016                     increasebought                                                     24099        2284545              114
03062016                     increasebought                                                     38500        2323045              116
10062016                     increasebought                                                     88768        2411813              121
17062016                     increasebought                                                    221212        2633025              132
24062016                     increasebought                                                     47731        2680756              134
30062016                     decreasesold                                                     137026        2543730              127
08072016                     decreasesold                                                       1566        2542164              127
15072016                     increasebought                                                      4400        2546564              127
22072016                     increasebought                                                      5500        2552064              128
29072016                     decreasesold                                                     257577        2294487              115
05082016                     increasebought                                                     85518        2380005              119
12082016                     increasebought                                                     25097        2405102              120
19082016                     increasebought                                                     11100        2416202              121
26082016                     decreasesold                                                     670411        1745791              087
02092016                     increasebought                                                      3906        1749697              087
09092016                     decreasesold                                                     160668        1589029              079
16092016                     decreasesold                                                     289555        1299474              065
23092016                     increasebought                                                     39600        1339074              067
30092016                     decreasesold                                                      84690        1254384              063
07102016                     decreasesold                                                      86840        1167544              058
14102016                     decreasesold                                                     134893        1032651              052
21102016                     decreasesold                                                      48206         984445              049
28102016                     increasebought                                                     38500        1022945              051
04112016                     decreasesold                                                       2200        1020745              051
11112016                     decreasesold                                                     222793         797952              040
18112016                     decreasesold                                                      27069         770883              039
25112016                     decreasesold                                                      22782         748101              037
02122016                     increasebought                                                      9524         757625              038
16122016                     decreasesold                                                      38718         718907              036
23122016                     decreasesold                                                      51793         667114              033
30122016                     increasebought                                                     19800         686914              034
06012017                     increasebought                                                    110000         796914              040
13012017                     decreasesold                                                      51540         745374              037
20012017                     decreasesold                                                      37819         707555              035
27012017                     decreasesold                                                      16174         691381              035
10022017                     decreasesold                                                       3600         687781              034
17022017                     decreasesold                                                       2400         685381              034
24022017                     increasebought                                                      8431         693812              035
17032017                     increasebought                                                      4800         698612              035
24032017                     increasebought                                                      5400         704012              035
31032017                     increasebought                                                       600         704612              035
at the end of the year                                                                                           704612              035
31032017




124       ahead of the curve  annual report 2017

                                                                                                                       biocon limited



8    national westminster bank plc as trustee of the jupiter india fund

                               increase or decrease   shareholding at the beginning of      increase    cumulative shareholding during
                               reasons                      the year 01042016             decrease in       the year 31032017
                                                         no of shares         of total    shareholding     no of shares       of total
                                                                           shares of the                                    shares of the
                                                                              company                                          company
at the beginning of the year                                        0              000                               0             000
01042016
29072016                     increasebought                                                   835019         835019              042
05082016                     increasebought                                                   114981         950000              048
23122016                     increasebought                                                   182173        1132173              057
27012017                     increasebought                                                    58608        1190781              060
03022017                     increasebought                                                   250889        1441670              072
10022017                     increasebought                                                   288099        1729769              086
31032017                     increasebought                                                    40618        1770387              089
at the end of the year                                                                                         1770387              089
31032017


9    icici prudential equity arbitrage fund

                               increase or decrease   shareholding at the beginning of      increase    cumulative shareholding during
                               reasons                      the year 01042016             decrease in       the year 31032017
                                                         no of shares         of total    shareholding     no of shares       of total
                                                                           shares of the                                    shares of the
                                                                              company                                          company
at the beginning of the year                                  149600               007                         149600              007
01042016
22042016                     increasebought                                                    96800         246400              012
22042016                     decreasesold                                                     96800         149600              007
06052016                     decreasesold                                                     19800         129800              006
13052016                     decreasesold                                                      7700         122100              006
03062016                     decreasesold                                                     62700           59400             003
30062016                     increasebought                                                   163681         223081              011
01072016                     increasebought                                                    66713         289794              014
08072016                     increasebought                                                    90745         380539              019
15072016                     increasebought                                                   370244         750783              038
12082016                     increasebought                                                   698550        1449333              072
19082016                     increasebought                                                    58866        1508199              075
16092016                     increasebought                                                   102603        1610802              081
30092016                     decreasesold                                                     59400        1551402              078
07102016                     increasebought                                                     2200        1553602              078
14102016                     increasebought                                                    41800        1595402              080
28102016                     increasebought                                                    95700        1691102              085
28102016                     decreasesold                                                     74863        1616239              081
25112016                     decreasesold                                                      9900        1606339              080
02122016                     increasebought                                                   196112        1802451              090
23122016                     decreasesold                                                    129800        1672651              084
13012017                     increasebought                                                   119400        1792051              090
13012017                     decreasesold                                                    146744        1645307              082
27012017                     decreasesold                                                     11039        1634268              082
10022017                     decreasesold                                                     46804        1587464              079
03032017                     decreasesold                                                     66486        1520978              076
at the end of the year                                                                                         1520978              076
31032017




                                                                                                            boards reports         125

10     credit suisse singapore limited

                               increase or decrease   shareholding at the beginning of      increase     cumulative shareholding during
                               reasons                      the year 01042016             decrease in        the year 31032017
                                                         no of shares         of total    shareholding      no of shares       of total
                                                                           shares of the                                     shares of the
                                                                              company                                           company
at the beginning of the year                                  316163               016
01042016
08042016                     decreasesold                                                      6009          310154              016
15042016                     increasebought                                                    85091          395245              020
22042016                     increasebought                                                   261762          657007              033
29042016                     decreasesold                                                     22577          634430              032
06052016                     increasebought                                                   138726          773156              039
13052016                     increasebought                                                   311973         1085129              054
20052016                     increasebought                                                   121447         1206576              060
27052016                     increasebought                                                   111098         1317674              066
03062016                     increasebought                                                    90779         1408453              070
10062016                     increasebought                                                    55576         1464029              073
17062016                     increasebought                                                    31847         1495876              075
24062016                     increasebought                                                     9314         1505190              075
30062016                     decreasesold                                                      1537         1503653              075
01072016                     decreasesold                                                      1100         1502553              075
08072016                     increasebought                                                    59475         1562028              078
15072016                     increasebought                                                     2828         1564856              078
29072016                     increasebought                                                    24157         1589013              079
05082016                     increasebought                                                    54963         1643976              082
12082016                     increasebought                                                    58931         1702907              085
19082016                     increasebought                                                    18775         1721682              086
26082016                     decreasesold                                                     19200         1702482              085
02092016                     increasebought                                                    63125         1765607              088
09092016                     decreasesold                                                     26887         1738720              087
16092016                     decreasesold                                                        230        1738490              087
23092016                     increasebought                                                    29902         1768392              088
30092016                     decreasesold                                                     10682         1757710              088
07102016                     decreasesold                                                     31406         1726304              086
14102016                     decreasesold                                                     18160         1708144              085
21102016                     decreasesold                                                     15332         1692812              085
28102016                     decreasesold                                                      1100         1691712              085
04112016                     decreasesold                                                         43        1691669              085
18112016                     decreasesold                                                     11000         1680669              084
25112016                     decreasesold                                                     33000         1647669              082
02122016                     increasebought                                                    19602         1667271              083
09122016                     increasebought                                                    15988         1683259              084
16122016                     decreasesold                                                     21728         1661531              083
23122016                     decreasesold                                                    257447         1404084              070
30122016                     decreasesold                                                     35700         1368384              068
06012017                     increasebought                                                   120800         1489184              074
13012017                     increasebought                                                   100344         1589528              079
20012017                     decreasesold                                                     61682         1527846              076
27012017                     decreasesold                                                     35735         1492111              075
03022017                     increasebought                                                    10439         1502550              075
10022017                     decreasesold                                                     70800         1431750              072
10032017                     decreasesold                                                        300        1431450              072
17032017                     increasebought                                                    41392         1472842              074
31032017                     increasebought                                                    12850         1485692              074
at the end of the year                                                                                          1485692              074
31032017




126       ahead of the curve  annual report 2017

                                                                                                                                          biocon limited



v shareholding of directors and key managerial personnel

sl    for each of the directors and kmp                                 shareholding at the beginning of             cumulative shareholding during the
no                                                                                 the year                                        year
                                                                       no of shares           of total shares       no of shares        of total share
                                                                                              of the company                              of the company
1      kiran mazumdarshaw
       at the beginning of the year                                           79287564                    3964              79287564                 3964
       increase decrease in shareholding during the year                                                        
       at the end of the year                                                                                              79287564                 3964
2      john shaw
       at the beginning of the year                                            1407558                     070               1407558                  070
       increase decrease in shareholding during the year                                                        
       at the end of the year                                                                                               1407558                  070
3      arun suresh chandavarkar
       at the beginning of the year                                            2200000                     110               2200000                  110
       increase decrease in shareholding during the year                                                        
       at the end of the year                                                                                               2200000                  110
4      ravi rasendra mazumdar
       at the beginning of the year                                              565014                    028                565014                  028
       increase decrease in shareholding during the year                                                        
       at the end of the year                                                                                                565014                  028
5      siddharth mittal
       at the beginning of the year                                                                                                                       
       increase decrease in shareholding during the year                          7750                    000                   7750                 000
       at the end of the year                                                                                                   7750                 000
6      rajiv balakrishnan
       at the beginning of the year                                                                                                                       
       increase decrease in shareholding during the year                                                                                                 
       at the end of the year                                                                                                                             
7      kiran kumar g
       at the beginning of the year                                                                                                                       
       increase decrease in shareholding during the year                                                                                                 
       at the end of the year                                                                                                                             

5     indebtedness

indebtedness of the company including interest outstandingaccrued but not due for payment

                                                                                                                                                 in  million

                                                                           secured loans      unsecured loans                  deposits               total
                                                                               excluding                                                      indebtedness
                                                                                deposits
indebtedness at the beginning of the financial year

i principal amount                                                                1328                  2367                                      3696

ii interest due but not paid                                                                                                                             

iii interest accrued but not due                                                                                                                         
total iiiiii                                                                   1328                  2367                                      3696
change in indebtedness during the financial year

  addition                                                                                               501                                        501

  reduction                                                                            32                2830                                      2862
net change                                                                             32             2329                                    2361
indebtedness at the end of the financial year

i principal amount                                                                1296                     39                                      1335

ii interest due but not paid                                                                                                                             

iii interest accrued but not due                                                                                                                         
total iiiiii                                                                   1296                     39                                      1335



                                                                                                                             boards reports           127

6    remuneration of directors and key managerial personnel

a    remuneration to managing director wholetime director andor manager

                                                                                                                                                       in  million

sl     particulars of remuneration                                                                                                                 total amount
                                                                                              name of mdwtd manager
no
1      gross salary                                                              kiran mazumdar       john shaw           arun s
                                                                                    shaw cmd           wtd          chandavarkar
                                                                                                                        ceo  jt md
        a salary as per provisions contained in section 171 of the                     2034              1720               3301                    7055
            incometax act 1961

        b value of perquisites us 172 incometax act 1961                             003               003                003                      009

        c profits in lieu of salary under section 173 income tax act 1961                                                                               
2      stock option                                                                                                            330                          
3      sweat equity                                                                                                                                          
4      commission                                                                                                                                            

         as  of profit

         others specify

        others please specify
5      total a                                                                          2037              1723               3634                    7394
        ceiling as per the act                                                                                                                            54487

 the amount indicates perquisite value of stock options exercised during the year

b remuneration to other directors

                                                                                                                                                       in  million

sl     particulars of remuneration                                                       name of directors                                                total
no                                                                                                                                                      amount
1      independent directors                                  russell      daniel m     jeremy m mary harney           vijay k   damodaran
                                                                walls       bradbury         levin                     kuchroo
         fee for attending boardcommittee                      040             040        040         040           030               040            230
          meetings

         commission                                             375             221        322         281           214               195          1608

         others please specify
        total 1                                                415             261        362         321           244               235          1838
2      other nonexecutive directors                    ravi mazumdar

         fee for attending board committee                      040                                                                                        040
          meetings

         commission

         others please specify
        total 2                                                040                                                                                        040
        total b12                                                                                                                                    1878
        total managerial remuneration ab                                                                                                                8942
        overall ceiling as per the act                                                                                                                     5449




128       ahead of the curve  annual report 2017

                                                                                                                                         biocon limited



c remuneration to key managerial personnel other than mdmanagerwholetime director

                                                                                                                                                    in  million

sl     particulars                                                                                             key managerial personnel
no                                                                                           chief financial officer    company secretary               total
1       gross salary
        a salary as per provisions contained in section 171 of the incometax act 1961                   1962                     729            2691
        b value of perquisites us 172 incometax act 1961                                                003                     003             006
        c profits in lieu of salary under section 173 incometax act 1961
2       stock option                                                                                           631                                     631
3       sweat equity                                                                                                                                        
 4      commission                                                                                                                                          
         as  of profit
         others specify
 5      others please specify
        total                                                                                                 2596                     732            3328

 the amount indicates perquisite value of stock options exercised during the year

note

1      remuneration of ceo is not included above since he is joint managing director and his details are already included in section a above

2      remuneration of company secretary includes remuneration paid during the year to both mr kiran kumar g and mr rajiv balakrishnan for the period
        of them holding the title

7      penalties punishment compounding of offences

there were no material penaltiespunishmentcompounding of offences for the year ended march 31 2017

                                                                                                                              for and on behalf of the board

bengaluru                                                                                                                            kiran mazumdarshaw
april 27 2017                                                                                                             chairperson  managing director




                                                     this space has been intentionally left blank




                                                                                                                             boards reports             129

management discussion and analysis
the global life science industry has fared well amidst the past economic downturns in light of todays volatile marketplace which is faced with economic
political and social challenges this industry is faced with reformdriven pricing pressures and increased demand for value in innovation significant global
unmet needs aided by favourable demographic trends make it likely that this industry would enjoy long term growth driven by the recent wave of
innovative therapies approved by regulators reports suggest that the global drug spending could reach 11 trillion by 2022

globally spending on healthcare correlates well with general economic strength of a country given the high contribution of the usa russia brazil and
china in global growth of healthcare spending coupled with pricing pressures in the united states and the unstable economic conditions in large emerging
markets have led to a slowdown in the global marketplace strict measures taken by the governments with regards to health care budgets and or reductions
in out ofpocket expenditures in these countries have impacted the spending aging populations rise of chronic diseases and the introduction of innovative
and frequently expensive treatments eg for cancer and hepatitis c are some of the main factors which would continue to drive growth in health care
spending however many countries have taken steps to contain health care costs that includes price control valuebased pricing and reimbursement along
with progeneric and probiosimilar policies companies are responding to the current changing market dynamics and are trying to position themselves for
continued growth through portfolio transformation mergers and acquisitions ma costcutting sharpened focus on highperforming therapeutic areas
tas and on key geographic markets

global biologics market continues to grow
growth of the pharmaceutical companies is driven by specialty products with a focus on personalized medicine which includes biologic drugs with
increased number of biologics being approved as compared to nonbiologics synthetic molecules in recent times antibody drugs have become an
increasingly significant component of the therapeutic landscape antibodies exhibit very high specificity and selectivity reducing risks of offtarget toxicity
typical for synthetic molecules and enabling personalized treatments of the top 15 pharma drugs by sales in 2016 10 drugs were biologics figure 1

figure 1 biologics comprised 10 of top 15 drugs by revenue in 2016

sl     drug                                                                     sponsor                                      biologic yn       sales 2016
no
1       humira adalimumab                                                     abbvie                                              y                161
2       harvoni ledipasvir 90 mgsofosbuvir 400 mg                            gilead sciences                                     n                 91
3       enbrel etanercept                                                     amgen pfizer                                       y                 89
4       rituxan rituximab mabthera                                           roche genentech  biogen                          y                 86
5       remicade infliximab                                                   johnson  johnson  merck                           y                 78
6       revlimid lenalidomide                                                 celgene                                             n                 69
7       avastin bevacizumab                                                   roche genentech                                   y                 68
8       herceptin trastuzumab                                                 roche genentech                                   y                 68
9       lantus insulin glargine                                               sanofi                                              y                 61
10      prevnar 13  pneumococcal 13valent conjugate vaccine                    pfizer                                              y                 57
11      xarelto rivaroxaban                                                     bayer johnson  johnson                            n                 54
12      eylea aflibercept                                                       bayerregeneron                                     y                 50
13      lyricapregabalin                                                        pfizer                                              n                 49
14      neulasta pegfilgrastim                                                  amgen  kyowa hakko kirin                           y                 47
15      advairfluticasone  salmeterol                                          glaxosmithkline                                     n                 43

source genetic engineering  biotechnology news wwwgenengnewscom

driven by recent advances that have created much excitement in the industry eg nivolumab pembrolizumab atezolizumab ocrelizumab oncology
remains the most sought after therapeutic area followed by immunotherapy expanding waistlines across the globe will continue to see growth in the
segment of antidiabetic drugs and attract more research dollars over the past several years biologics have made many new ground breaking treatments
possible and gained significant traction in the pharmaceutical industry as novel biologic blockbusters have continued to enter the market companies are
increasingly focusing on narrow patient populations characterized by large unmet needs and easier market access estimates by evaluate pharma indicate
that sales of biotechnology products which stood at over 165 billion in revenue in 2013 are likely to go up to 337 billion by 2022 and comprise nearly
29 of the pharmaceutical market

the above mentioned growth trends are expected to be offset by increased demand for generic drugs and biosimilars who defines biosimilars as a
biotherapeutic product which is similar in terms of quality safety and efficacy to the already licensed reference biotherapeutic product given the high
costs of biologic treatments in the coming years lower cost biosimilars should be instrumental in expanding access to populations who need these therapies
but are unable to afford and have access to them analysts expect the worldwide biosimilars market to reach between 25 billion to 35 billion by 2020

access and affordability of biological drugs
the cost for access to advanced biologic therapies are paid for by different channels across the globe from reimbursed markets that have a welldefined
insurance payment mechanism to government funded healthcare to cash based outofpocket markets the access of patients to biologic treatments have
been defined accordingly




130       ahead of the curve  annual report 2017

                                                                                                                                                 biocon limited



the developed markets success is led by the united states where reimbursement is widely available through private insurance or medicare federal health
insurance program for people who are 65 or older and certain others followed by the eu even in the developed markets access to biologics is not uniform
often patients struggle to cope up with the cost of continued therapy in emerging markets biologics penetration has been suboptimal given the varied
nature of payment mechanisms for drug coverage governments of emerging market countries are trending towards adoption of universal healthcare
to promote wellbeing of their citizens and reduce outofpocket costs drugs provided may include biologics like human insulin which are available at
competitive prices but seldom include expensive drugs to treat cancer and chronic inflammatory conditions hence access to biologics by patients might be
severely limited in these markets as governments are unable to afford higher priced branded biologic therapies

biosimilars landscape
biologics development is long complex and expensive resulting in patients and payers buying drugs at a very high cost this has resulted in a large unmet
need for more affordable alternatives in form of biosimilars to be made available to patients in different parts of the world

to negate the effects of high pricing of drugs we have seen an increase in biosimilar development activity globally developed markets have been a focus
area for most biologics manufacturers while emerging markets may not have attracted the level of attention the developed markets have incurred in
biosimilar environment these markets are poised to drive long term growth companies would require specific strategies to be successful in this segment
the key to success will vary based on the market chosen although each countrys environment is unique there are similarities in trends across the developed
and emerging markets

given the need for significant investments of both capital and time required for biosimilar development companies need to build the right conditions for
success to be able to a get a fair return on those investments

figure 2 biosimilar landscape  summary of crosscountry analysis

                                      access to              regulatory        payer assessment            prescriber               patient            biosimilars
                                      affordable            environment           and access               acceptance             acceptance            presence
          variables                    biologics             presence of an      engagement and            willingness to        patient attitude       number of
    ranked by importance        physical and financial     abbreviated or       advocacy from         prescribe biosimilar   towards biosimilars       approved
                                    ability to receive     dedicated pathway    payers in favour of        vs reference                             biosimilars in the
                                        biologics                                   biosimilars              molecule                                     market

                       us            large access          in development              low                     low                    low                  05
developed             eu5            large access            established              high                   medium                medium                  10
                     japan           large access            established            medium                     low                    low                  10
                     brazil          poor access             established              high                   medium                medium                  05
                     russia          fragmented            in development              low                     low                 medium                  05
brics                india           poor access             established               low                   medium                medium                  10
                     china           poor access           in development           medium                   medium                   low                  05
                  south africa       poor access             established              high                     high                medium                  05
                    mexico           fragmented              established              high                     low                 medium                  05
                   indonesia         poor access                  no                medium                   medium                   low                  05
mist
                  south korea        fragmented              established              high                   medium                medium                  10
                     turkey          fragmented              established               low                   medium                medium                  610

source deloitte winning with biosimilars opportunities in global markets

developed markets  as per deloitte the greatest biosimilar presence today figure 2 is seen in the developed markets led by the adoption seen in the
eu countries markets such as the us eu5 and japan provide growth opportunities for biosimilars aided by the availability of better defined regulatory
requirements for registration of biosimilar products and payers that are pushing to contain costs

as witnessed in the eu markets the adoption of biosimilars has been largely payerdriven figure 2 given the need to contain public health expenditures
market uptake of these products has been varied across the eu with early physician scepticism and low patient awareness in certain markets especially in
southern europe with payers which include governments in many instances proactively promoting the use of biosimilars through education of patients
and encouraging doctors to use lower cost alternatives to branded biologics biosimilar manufacturers have tasted success the recent success of infliximab
in eu more specifically the penetration levels seen in nordic countries 90 is a good example pricing discounts have varied based on the level of
penetration achieved in various markets with discounts of 2530 seen in eu5 countries these discounts may be higher in eastern europe given the higher
unmet need due to lack of sophisticated reimbursement mechanisms in nordic countries where governments have promoted the use of biosimilars we
have witnessed much steeper discounts compared to either eu5 or eastern europe this is an outcome of government tenders with guaranteed volumes and
physicians willingness to switch patients from the branded biologics to biosimilars

in japan the government is pushing doctors and incentivising pharmacies to increase use of generics and biosimilars to treat its aging population thereby
helping control spiralling drug costs japan has traditionally been a branded market so the process of adoption has been slow but encouraging from a long
term perspective

the united states market has been behind the rest of the world in adoption of biosimilars there are still areas of regulatory policy which are evolving some
points include 1 standards for interchangeability and pharmaceutical substitution 2 extrapolation of indications and 3 traceability of pharmacovigilance
reports through naming conventions that permit differentiation of products recent commentary and actions at the payer and regulatory levels and
increased political noise around drug pricing is very encouraging towards acceptance of biosimilars there are currently two biosimilars and one generic
insulin glargine commercially available in the us biosimilar filgrastim has achieved success having been launched in the market in sep15 while biosimilar



                                                                                                      management discussion and analysis                          131

infliximab was launched in nov16 initial reports suggest that generic insulin glargine launched in dec16 has also been well accepted price discounts for
the launched products are suggested to be in the range of 1520 given that providing rebates to secure formulary access is common in the us one would
expect net discounts to be higher

given the high costs of development and long developmental times there are inherent risks developers face these includes change in standard of care
delays due to potential intellectual property lawsuits and commercial challenges to establish mainstream use of these drugs therefore commercial strategies
for formulary placement physician education and increased patient awareness coupled with smart navigation of the intellectual property landscape will be
needed by companies to be successful in the developed markets most notably us in the coming years as analyst reports suggest the pace of adoption
may surprise the industry once there are a few advanced biosimilars from the current wave approved and marketed in the united states

emerging markets  while most companies would want to have presence in the developed markets a considerable opportunity exists in emerging markets
for biosimilars these markets are characterized by poor physical and financial access to current highpriced branded biologics and provide favourable long
term growth opportunities to biosimilar companies figure 2 in addition to favourable macroeconomic factors such as improving gross domestic product
gdp growth rates coupled with a growing middle class and increasing healthcare spending there is strong focus on containing costs and increasing
treatment access physicians would increase prescription rates if lower priced biosimilar alternatives were available further many of these countries have
biosimilar approval pathways in place or are finalizing guidelines in many cases the intellectual property landscape in these markets is less troublesome for
biosimilar sponsors as compared to developed markets historically emerging markets have seen very high penetration of generic drugs and similar trends
could apply to biosimilars as well signalling strong growth attainable for biosimilar manufacturers over the course of the next few years

each market would require a tailored approach due to regional country and local complexities the key to success would involve choosing the right markets
with right therapeutic areas which provide the greatest impact on the local population keeping prices competitive to secure broad access and partnering
with local companies to overcome local resource and knowledge gap getting access to local commercial capabilities distribution networks and distinctive
understanding of local stakeholders including prescribing physicians figure 3 therefore biosimilar players would have to grow sales albeit at a lower
margin than the developed markets among an increasing affluent and health conscious population

figure 3 key themes in emerging markets




                                                                               governments are pushing
                                                                              for the development of their
                       patients cannot                                         domestic pharmaceutical
                      afford and do not                                                industries
                     have access to high
                       priced biologics
                                                     there is shifting
                                                   disease profile from
                                                  infectious diseases to                                     physcians are the key
                                                 more chronic conditions                                  influencers and deciders of
                                                  better treated by large                               patient therapy and often make
                                                   molecule therapies                                   decisions on brand vs generic 
                                                                                                        biosimilars based on perceived
                                                                                                                  ability to pay




source deloitte winning with biosimilars opportunities in global markets

conclusion regulatory framework governing requirements for biosimilar development continues to evolve globally requirement of large and expensive
phase 3 trials which are currently mandated in many geographies could be waived if biosimilar sponsors are able to demonstrate biosimilarity and address
regulatory concerns around residual risk using bioassays limited population pharmacokineticpharmacodynamics pkpd phase 1 trials and technologically
sophisticated analytical tools for characterization

we have seen this in eu guidance for future development of insulin products globally as and when this process becomes mainstream and includes more
complex drugs like monoclonal antibodies it would help reduce cost and time associated with biosimilar development benefitting patients and healthcare
systems  the macros are too favourable to ignore to support the requirements of biosimilars as effective tools to bring down healthcare costs and provide
increased access to biologic therapies however risks cannot be ignored in this highly fluid environment it would require utmost focus and dedication
perseverance and access to large pool of capital to make the most of this opportunity which would play out over the next five years for the current set of
molecules under development

indian pharmaceutical industry
the indian pharmaceutical industry has seen steady growth over the last decade backed by increased exports and an expanding indian pharma market
ipm indian companies have revenues coming in from the sale of intermediates active pharmaceutical ingredients api and formulations in various global
markets these include developed markets like us europe and japan and semi developed markets across the world major indian pharma companies are now
global players in generics vaccines and biosimilars and some of them are now generating more than half of their sales outside the country the ipm is highly



132       ahead of the curve  annual report 2017

                                                                                                                                          biocon limited



fragmented with over 20000 players sales are dominated by branded generics with top 10 players which include both indian as well as multinational firms
accounting for over 40 of the market value

in the past few years indian companies have grown tremendously capitalizing on major blockbusters losing patent protection and paving way for generics
especially in the us market by volume indian companies supply about 20 of global generics however every passing year has left fewer patented drug
opportunities for the indian companies to launch new products the market is moving from plain vanilla drugs to more complex formulations and delivery
systems thus indian pharma companies have stepped up rd efforts in newer areas the companies are spending more to establish niche product
portfolios for future growth respiratory dermatology biosimilars and sterile injectable product development have been some of the major areas in focus
regulatory challenges especially from the us fda has impacted many players including some who are major players in the us market resulting in lower
growth in the last two years this has been further complicated by the debate on drug pricing which has impacted the sentiment around the industry

economic growth and increase in disposable income in india has resulted in greater affordability and consumption of healthcare services in general
particularly generic medicines there is a growing burden on account of noncommunicable diseases and some infectious diseases in india lifestyle
diseases such as diabetes cardiovascular disease and stroke in india have become a public health challenge who estimates that these diseases with
mostly preventable risk factors account for 60 of all deaths and significant morbidity in india this should continue to increase the per capita consumption
of medicines in the country

however access to and quality of healthcare services is not equal in the country resulting in inequitable outcomes in some instances it has led to
catastrophic expenditures for families and has been one of the major contributors to families discontinuing treatment after being thrust into poverty both
central and state governments in india are taking steps to address the problem the recent national health policy nhp 2017 lays out a plan towards
achieving universal health coverage in india the policy aims at achieving universal health coverage and delivering quality health care services to all at
affordable cost it recommends prioritizing the role of the government in shaping health systems in all its dimensions the roadmap of the nhp is predicated
on public spending 25 of gdp in a phased manner and provisioning of a public healthcare system that is comprehensive integrated and accessible to
all it seeks to promote quality of care focus on emerging diseases and investment in promotive and preventive healthcare the policy is patient centric and
quality driven and addresses health security and promotes make in india for drugs and devices with private players as strategic partners

the cro space
contract research organizations cros provide support to the pharmaceutical biotechnology and related industries through outsourced research and
development services that span drug discovery preclinical research clinical research clinical trial management commercialization and pharmacovigilance

as the life science industry has evolved and matured companies are dedicating their resources and efforts to particular areas of the value chain and have
developed outsourcing relationships to perform other functions incremental outsourcing of additional processes to qualified contract research organizations
cros has brought cost efficiency to the process improved quality control and speed to market with increased spending on drug development the
industry is now outsourcing an increasing quantum of services to competitive vendors strong underlying pharmaceutical demand coupled with increasing
complexity and regulatory burden have created a favourable environment for cros it has helped to change the dynamics between the pharmaceutical
biotechnology industry and the cro from purely a client  vendor relationship to that of strategic partnership companies are trying to consolidate and
simplify their supply chains by concentrating sourcing among a select number of multiservice vendors

there is increased outsourcing of manufacturing services to cros to moderate manufacturing costs by outsourcing to lowcost global destinations like
india india has emerged as one of the leading economical quality pharmaceutical manufacturing hub for a number of global players outsourcing to
india offers significant benefits over mature pharmaceutical hubs in north america and europe india has become increasingly important in the global
pharmaceutical supply chain and hence incentivising the engagement of indian pharmaceutical players in research and related manufacture has resulted in
contract research and manufacturing services crams emerging as one of the fastest growing segments in the country

opportunities and prospects

the outsourcing of cro discovery services in 2016 is estimated at usd 178 bn this estimate exclude clinical research and contract manufacturing
outsourcing this number is estimated to grow to usd 29 bn by 2022 source iq4i report with increased outsourcing to efficient and low cost cro hubs
especially in india and china compared to the european and american counterparts asiapacific is therefore expected to be the fastest growing region in
the drug discovery outsourcing market in this time period




                                                    this space has been intentionally left blank




                                                                                                 management discussion and analysis                     133

company review
biocon utilises its core capabilities in fermentation technology and high end rd skills for manufacturing biopharmaceuticals across small molecule apis
and large molecule biologics the company currently has front end presence in india and uae where it sells novel and branded small molecule biologic
products through its field force it also addresses its customers rd requirements through various services provided through its publically listed research
services arm syngene international the company is organized into the following reporting segments

a    small molecule apis  generic formulations

b    biologics  biosimilars insulins mabs  other biologics  novel biologics

c    branded formulations currently india  uae

d    research services syngene

a detailed analysis of our business segments is indicated hereunder

small molecule segment apis and generic formulations

the small molecule segment comprises apis as well generic formulations revenues in this segment are currently derived from sale of api to third parties this
segment has had a successful track record of regulatory audits both by developed as well as the emerging market regulators in this segment we leverage our
strengths in manufacturing products that have high degree of complexity in most cases using fermentation as the preferred route these include production of
various statin api various immunosuppressant api and api contract manufacturing for innovators in the fermentation space we are working towards entering
the oncology space in the very near future through investments towards enhancing our development and manufacturing capabilities

key api product portfolio 

a    statin basket simvastatin pravastatin atorvastatin rosuvastatin  fluvastatin
b    immunosuppressant basket tacrolimus sirolimus everolimus mycophenolate mofetil mmf  mycophenolate sodium mpa
c    other key products orlistat fidaxomicin

we are leading suppliers of the above products to leading companies and estimate that our global market share ranges from 15 to as high as 50 for
the top10 molecules in our api portfolio most of these products are manufactured via fermentation process a core strength of biocon we have been
supplying our customers with high quality products over many years which have resulted in multiyear associations with our clients enabling high global
market shares for biocon in the api space

to diversify and address the needs of the changing landscape given the limited number of fermentation based api available as a generic opportunity
we decided to move up the value chain and ventured into generic formulations focusing on the following diseases segments  metabolics oncology
immunology and auto immune indications our strategy is to have a vertically integrated business model and currently have a nascent pipeline of products
with a couple of approved dossiers for the us and eu markets we are working on a niche portfolio of products which are complex and expected to have
limited competition we aim to leverage our strengths acquired in characterization and manufacturing of complex proteins to this business hence we would
be targeting select opportunities that would fit our selection criteria and where we can be vertically integrated we believe this could add value to our api
business and help sustain long term growth in this segment

the work on the greenfield generic oral solid dosage facility which would be a key component of our vertical integration efforts is in full swing the facility
is expected to be commissioned in fy18 we propose to use this facility primarily for potent products

currently this segment of our business contributes to significant revenues 40 in fy17 and profits for the company cash generated from this business
has helped fund our early biosimilar foray into global markets operationally fy17 has been a good year for the small molecules segment with a growth of
12 as compared to fy16 this growth was driven to a large extent by supplies of rosuvastatin api to our customers targeting the us generics market on
the generic formulations side we received approval for our rosuvastatin calcium anda from the usfda eu approval for the same was received in fy16

biologics segment biosimilars  novel biologics

biocon has been ahead of the curve in india by focussing early on innovation especially in the area of biologic drugs we have made significant investments
in building capability in science and technology courtesy to a highly talented team of scientists novel process engineering of drug substance and drug
product predictive toxicology adaptive clinical trial designs and data analytics the outcome of these efforts has been innovative products which include
antibodies like biomabegfr nimotuzumab for treatment of head and neck cancer and alzumab itolizumab for treating psoriasis in addition these
capabilities have also enabled approval of canmab an affordable trastuzumab biosimilar for treating her2 breast cancer very large scale development
of insulins insugen and insulin analogs basalog and device systems insupen made available to the global patient population

biocons biologics segment comprises of its pipeline of 10 biosimilar molecules that includes human insulininsulin analogues monoclonal antibodies and
other biologics apart from a pipeline of novel biologic products the focus in this segment is on drugs that help patients fight diabetes cancer and auto
immune diseases and inflammation

in the future the segment has been identified by management as a significant growth driver for the company being an early starter among its peers in india
and now having experience of developing manufacturing and selling some of these products in many markets globally the company is confident of making
its mark at the global scene once it enters the developed markets with its portfolio of products

in the year under review we built upon the success in fy16 with multiple clinical and regulatory milestones being met by this business segment segment
revenues grew 43 over fy16 to 5793 mn



134       ahead of the curve  annual report 2017

                                                                                                                                           biocon limited



biosimilars
biocon possesses one of the largest global biosimilars portfolios spanning human insulininsulin analogues monoclonal antibodies and other biologics with
an addressable market size of usd 61 bn of the 10 disclosed molecules in our pipeline nine molecules are being developed in partnership with mylan
a global generics major the strategic partnership between biocon and mylan represents biocons strength in biologics development and manufacturing as
well as mylans regulatory and commercial strengths globally

we received the first developed market approval for our insulin glargine product in japan in partnership with fujifilm pharma in fy16 our partner fujifilm
pharma ffp launched the product in japan on 15th july 2016 the feedback for our product has been very positive with our device being appreciated for
the ease of use the market for insulin glargine in japan is small if compared with the percentage of insulin glargine sales globally however the success of
getting the product approved in the first pass and now selling the product in the japanese market reinforces our internal belief that we are well positioned
to address the insulin glargine opportunity in other developed markets through our partnership with mylan

our proposed biosimilar trastuzumab and pegfilgrastim were accepted and are under review by the united states food  drugs administration usfda and the
europeans medicines agency ema ema is also reviewing our proposed biosimilar insulin glargine which is targeted at the eu market we expect to receive
marketing approval decisions for some of these molecules in the second half of fy18 while the filing for generic insulin glargine with the usfda is expected
in early fy18 our proposed biosimilar adalimumab for which the global clinical trial is now complete

we completed the emerging market targeted indian clinical trial for our proposed biosimilar bevacizumab and filed for marketing authorization with the
indian health regulator in fy17 the global phase 3 trial for bevacizumab was also initiated in late fy17
work on our recombinant human insulin rhi product targeted at the us market and two other global programs for insulin analogs insulin aspart insulin
lispro continues
the table below summarizes the status of our global biosimilar portfolio as on march 31 2017
table status of biocons global biosimilar portfolio
category                                     molecule                           status
regular acting insulin                       recombinant human insulin          preclinical us market marketed in emerging markets
long acting insulin                          insulin glargine                   filed in eu australia  canada us filing in h1 fy18 marketed in japan
                                                                                since jul16  emerging markets
rapid acting insulin analog                  insulin aspart                     preclinical
rapid acting insulin analog                  insulin lispro                     preclinical
cancer                                       trastuzumab                        filed in us eu marketed in emerging markets
neutropenia                                  pegfilgrastim                      filed in us eu canada australia emerging markets
autoimmune                                  adalimumab                         global phase 3 completed
cancer                                       bevacizumab                        indiaemerging markets phase 3 complete global phase 3 commenced
neutropenia                                  filgrastim                         early development
autoimmune                                  etanercept                         early development

biocon achieved the significant commercialization milestone of its first overseas facility in malaysia when our subsidiary biocon sdn bhd malaysia was
awarded a myr 300 million  4600 million three year contract for supplying rhi cartridges and reusable insulin pens under the malaysian governments
offtake agreement ota initiative from its large scale biopharmaceutical facility in johor malaysia the ota seeks to encourage local manufacturing of new
pharmaceutical products thus lowering the countrys reliance on imports and also enhancing the exports potential biocons rhi is malaysias first locally
manufactured biosimilar biologic product approved by the national pharmaceutical regulatory authority npra malaysia for commercial sales in the country

apart from the japanese and malaysia milestone under our insulins portfolio we saw an increase in licensing income in fy17 the income is to a great
extent a result of our successful partnership outcomes for trastuzumab in several of the large emerging markets once our local partners receive regulatory
approvals in their markets we expect it would result in a more meaningfully contribution from trastuzumab sales in this segment in fy18 and beyond from
some larger emerging markets given the high unmet need for this drug we see biosimilar trastuzumab as a very meaningful opportunity not only in the
developed markets but also in emerging markets from a developed markets stand point our partner mylan entered into a settlement agreement with
genentech and la hoffman roche related to intellectual property around trastuzumab this removes legal uncertainties related to the timing of launch of
this product in various markets around the world

the ability to address market demand by creating capacity reducing cost and increasing operational efficiency will be a key differentiator for the success of
our biosimilar forays in developed as well as emerging markets biocon has been building manufacturing capacity in a phased manner to fulfil market demand
for its portfolio products our malaysia insulins plant started commercial operation in fy17 while we plan to further augment our biologics manufacturing
capacity for monoclonal antibodies in line with the launch and ramp up of supplies of our products across the globe we expect to break ground on a new
monoclonal antibody facility in bengaluru in fy18 this facility will be built in two phases over a period of three to four years an expansion of our malaysian
insulin plant malaysia phase 2 will also be considered in due course in line with movement of portfolio of molecules insulin lispro insulin aspart in the
clinic and regulatory and commercial outcomes for our insulin glargine product in the eu and us markets

the company continues to work towards augmenting its portfolio with more biosimilar candidates under development names undisclosed where market
formation is expected in the next decade current efforts are focused on executing on our partnered pipeline which is expected to be commercialized over
the next few years

novel biologics
biocons novel biologics portfolio is comprised of therapeutics that aims at treating diabetes immunooncology and autoimmune inflammatory diseases
these therapeutics span across a broad range of platforms including recombinant proteins monoclonal antibodies mabs novel fusion mabs and small
interfering rna sirna



                                                                                                  management discussion and analysis                     135

in the field of diabetes biocons lead program is insulin tregopil a phase 2 ready firstinclass oral prandial insulin molecule for postprandial glycaemic
control in january 2016 biocon announced successful results from phase 1 studies which were concluded in fy16 these studies established the target
product profile of this molecule that includes food effects drugdrug interaction and pkpd profile these data provide the basis for our rd group to
continue development of this program in both type 1  type 2 diabetes patient populations for type 2 diabetes patients in india  a pivotal phase 3 study
is expected to start in fy18 likewise for type 1 diabetes patient population  a multiple ascending dose study is planned in fy18 these combined studies
in different diabetic populations will form the foundation of a broad global program envisioned for insulin tregopil

in autoimmuneinflammatory diseases itolizumab is a humanized monoclonal cd6 antibody approved in india for psorasis in fy17 a bridging phase 1
pk and safety study in normal healthy volunteers was initiated in australia to evaluate the pharmacokinetics of a subcutaneous route of administration
of itolizumab in comparison to intravenous route for which the company has marketing approval in india stage 1 dosing has been completed in which
the subcutaneous route administration shows very good bioavailability of the drug we plan to initiate the stage 2 dosing shortly biocon is the first global
company to biologically and clinically validate cd6 as a target for autoimmune diseases

qpi1007 a novel sirna molecule to treat nonarteritic ischemic optic neuropathy naion based on quark pharmas sirna technology platform is in
licensed for india and related markets qpi  1007 continues to make good progress following the initiation of pivotal global phase 23 studies by our
partner quark pharma the study which was initiated in fy17 in the us now includes patients randomized in india too

in immunooncology biocons lead program fmab2 is in preclinical development  a fusion protein of efgr mab tgf rii ecd this fusion antibody works
on the concept of preferentially delivering immune modulators to tumour site enhancing efficacy and delivering larger doses of tgf to the tumour micro
environment ind for this molecule is planned for fy18 and is currently ready with pharmacology and mechanism of action moa established in invitro and
invivo tumour models it provides us with a potentially broad clinical opportunity in multiple tumour types

we also have a 2nd generation humanized antibody targeting cd20 for which the path to ind has been mapped out and we plan to advance this asset in
neuroinflammatory diseases for eg multiple sclerosis

biocons focus on innovation for global markets continues to be strengthened via increasing the depth and emphasis on our inhouse research capabilities
 including access to novel ip therapeutic modalities invivo and invitro models toxicology studies early regulatory filings academic collaborations etc in
development  broader global advancement of our novel programs assets will likely be driven via external collaborations to further fund the larger studies
required to bring these to market and realize the full value of our innovations

branded formulations
biocon branded formulations business focuses on regional markets and is currently operational in india and the uae we have a clear strategy focused
around leveraging our strengths in biologics and differentiated products in chronic therapeutic areas such as metabolics diabetes cardiovascular
oncotherapeutics immunotherapy inflammation autoimmune nephrology dialysis transplants and specialty we provide worldclass quality products
for thousands of patients in india and uae

the performance of the india business continued to be sluggish in fy17 increased competition from low priced biosimilar mabs introduction of price caps
in some key brands by the government and loss of a key inlicensed oncology brand abraxane which was withdrawn by the licensor from the india and uae
markets impacted growth we are working to overcome these challenges by modernising our tomarket approach focussed execution expanding our reach
to adjacent markets like sri lanka and by making organizational changes

during the year under review the company has worked on portfolio consolidation focused targeting and segmenting of operating markets and targeted
licensing strategy in focus therapy areas repurposing of resources to high growth segments of the market is anticipated to drive growth in fy18 the idea
is to increase our reach with the key opinion leaders kol through augmented methods and having a digital strategy to communicate and detail we have
also flattened the organization structure brought in outside talent rolled out an attractive reward recognition and career path in branded formulations india
in key areas the objective is quicker decision making with the aim of taking our current execution a notch higher to ultimately deliver superior results for
the company through these changes we hope to deliver on higher growth from this segment in fy18 and beyond

in fy17 branded formulation segment grew 24 to  5489 mn as compared to the previous year attributable to the growth in our uae business biocon is
one of the strongest companies in india in the insulins space with 12 and 16 prescription share in human insulins and glargine market respectively
source cmarc our oncology products novel biosimilars command high market shares in the respective categories top 10 brands contribute 74 of
sales of our india business and grew 1 in fy17 over the previous year primarily due to impact of price controls on key brands like insugen and tacrograf
the insulins franchise grew 4 in fy17 to  1589 mn

our uae branded business is supported by 27 brands and its sales are well diversified across a portfolio of products top 10 brands contribute 73 of sales
and grew 9 in fy17 as compared to fy16 biocon brands are ranked in top 3 in their respective therapy segments in the uae market

research services syngene
our subsidiary syngene biocon has 745 shareholding is one of the leading india based cro offering a suite of integrated endtoend drug discovery
and development services for the novel molecular entities nmes to hundreds of clients including startup companies large pharma biotech agrochemical
chemical nutrition and animal health companies in the us europe and asia pacific including japan

includes 093 held by biocon research limited

syngene is amongst one of the few listed drug discovery and development companies globally to offer a onestop solutions for organisations looking to
optimize their rd expenditures right from the foundation of conducting discovery from hit to candidate selection development including preclinical
and clinical studies analytical and bioanalytical evaluation formulation development and stability studies to pilot manufacturing scaleup preclinical
and clinical supplies under one roof its service offering in discovery and development cover multiple domains across small molecules large molecules



136       ahead of the curve  annual report 2017

                                                                                                                                           biocon limited



antibodydrugs conjugates adc and oligonucleotides unlike traditional business models these services are offered through flexible time engagement
models that are customized to the clients requirements these engagement ranges from a fulltime equivalent fte to a feeforservice ffs model or
a combination of both based on client requirements

with over 3100 scientists and a laboratory base of 132 million square feet it currently services over 290 clients ranging from multinational corporations
to startups including eight of the top ten global pharma companies based on their rd spend besides a number of multiyear contracts syngene has five
longduration multidisciplinary partnerships each with a dedicated research centre with bristolmeyers squibb co bms amgen research and development
center sarc abbott laboratories singapore pte ltd abbott herbalife nutrition company and baxter international inc baxter

during the year under review syngenes revenues grew 7 to  11604 mn driven by business momentum across is three verticals  discovery services
dedicated centres and development and manufacturing services

some notable achievement during the year includes

1    commissioning of the first phase of the syngene research centre

2    set up of a stateofthe art viral testing facility

3    commissioning of an integrated multidisciplinary drug discovery and development centre for amgen syngene amgen research and development
      centre with the capacity to staff more than 100 highly qualified scientists

4    acquisition of strand life science assets related to systems biology heptox and pharma bioinformatics services

5    signing of a strategic partnership with herbalife nutrition a global nutrition company to set up their first dedicated nutrition research and development
      lab in india and

6    commissioning phase i of a new formulation facility capable of manufacturing clinical or commercial supplies of small volume niche technology
      products and complies with regulatory requirements of the usfda emea and other authorities

in december 2017 there was a fire accident at one of syngenes research facilities in bangalore this facility which includes office and lab space made up
approximately 20 of its total revenues the fire was caused due to a chemical reaction that was being conducted at the facility there was no injury or loss
of life as a part of its business continuity plan most of the client related projects were redeployed to other labs and enhanced shift working was introduced
to minimize the impact on revenues

the long term structural story of the business is robust as syngene continues its investments to expand its service offerings and building capacities in the
near term investments include forward integration into commercialscale manufacturing of nmes with a proven track record and an effective combination
of scientific talent global accredited systems rd infrastructure and continued focus on protection of clients intellectual property syngene remains well
positioned to benefit from the expected growth in the cro industry

operational performance

the year 2017 was an eventful one for the company not only did we made a lot of clinical progress in diverse pipeline of products but also delivered better
financial performance as a group overview of the financial performance of the company is given on the next page which forms part of the mda

resource review

employees
employees represent the cornerstone of our success we believe that good employee culture translates individual performance into success for all our
shareholders

in light of our steady growth and ambitious plans attracting grooming and retaining talent is of utmost importance a detailed discussion on human capital
is provided in our human resources section of the annual report

as a group we employ over 9200 people including 500 individuals outside india

ipr
one of our key focus areas is the creation of intellectual property ip which generates not only a competitive advantage but also creates the potential for
exponential and enduring value

patents
the ip portfolio of the biocon group of companies comprises 1286 patent applications and 1053 patents granted in various jurisdictions

trade marks
biocon limiteds ip portfolio comprises 833 trade mark applications of which 555 are registered trademarks in different classes and various jurisdictions
across the world

designs
biocon limiteds ip portfolio consists of four design applications of which three designs are registered




                                                                                                  management discussion and analysis                     137

financial performance  an overview
from april 1 2016 the company adopted the new indian accounting standards commonly referred to as ind as based on ifrs principles the displayed
financials have been classified based on the new accounting standards and previous years numbers fy16 have been restated to reflect these changes

consolidated balance sheet
the following table highlights the consolidated balance sheet as on march 31 2017 fy17 and march 31 2016 fy16

                                                                                                                             table 1 all figures in  million

particulars                                                                                                   fy17                  fy16            change
assets
noncurrent assets
tangible and intangible assets                                                                             44651                  39887              12
 investment in associates and a joint venture                                                                  422                   259               63
 financial assets                                                                                            2747                   872              215
 assets for current tax net                                                                                  895                   852                 5
 deferred tax assets net                                                                                   1975                   715              176
 other noncurrent assets                                                                                    2775                  2287              21
                                                                                                           53465                  44872              19
current assets
inventories                                                                                                  6353                  5424              17
financial assets                                                                                            32535                 33633               3
other current assets                                                                                         1589                   652              144
                                                                                                           40477                  39709                2
total                                                                                                      93942                  84581              11


equity and liabilities
equity
equity share capital                                                                                         1000                  1000               0
other equity                                                                                               47377                  39338              20
noncontrolling interests                                                                                    3761                  2658              41
                                                                                                           52138                  42996              21
noncurrent liabilities
financial liabilities                                                                                      21145                  20918                1
provisions and other noncurrent liabilities                                                                 3876                  4010               3
                                                                                                           25021                  24928                0
current liabilities
financial liabilities                                                                                       11693                 12154               4
income tax liability net                                                                                     964                   965                 0
provisions and other current liabilities                                                                     4126                  3538              17
                                                                                                           16783                  16657                1
total                                                                                                      93942                  84581              11

noncurrent assets
noncurrent assets grew 19 primarily due to investments in tangible assets for the malaysian facility research services syngene and intangible
capitalisation pertaining to product development expenses also we have continued to invest in research service business facilities investments in long
term securities and mat credit have also contributed to an increase in noncurrent financial assets

equity share capital
we have an equity share capital that comprises of 200000000 equity shares having a face value of  5 each there was no change in the equity capital of
the company during the year

other equity

other equity majorly comprises of share premium treasury shares retained earnings and other reserves the total other equity of the company increased by
20 in fy17 as compared to fy16 due to profit accumulation during the year net of dividend distribution

noncontrolling interests

the profit attributable to minority shareholders increased 41 in fy17 attributable to accumulation of profits of current year




138       ahead of the curve  annual report 2017

                                                                                                                                        biocon limited



noncurrent liabilities

there is no major movement in the noncurrent liabilities in fy17 as compared to fy16 there was an increase in termloan obtained by biocon sdn bhd
which is offset by reduction in derivative liability and release of deferred revenues

working capital current assets less current liabilities

working capital as at march 31 2017 stood at  23694 mn up by 3 as compared to fy16 which is in line with volume of operations

consolidated statement of profit and loss
the following table highlights key components of the statement of profit and loss for the fiscal years ended march 31 2017 fy17 and march 31 2016
fy16

                                                                                                                           table 2 all figures in  million

particulars                                                                                                    fy17              fy16             change
total revenue                                                                                                40787            34602                18
expenses
cost of materials consumed                                                                                   14466            12904                12
excise duty                                                                                                     305               336                 9
employee benefit expenses                                                                                     7470              6101               22
depreciation and amortisation expenses                                                                        2772              2487               11
finance costs                                                                                                   260               293               11
other expenses                                                                                                8463              8111                4
subtotal                                                                                                    33736            30232                12
less recovery of product development costs from codevelopment partners net                               1283           1320                3
total expenses                                                                                               32453            28912                12
share of profit of joint venture                                                                                163               217               25
profit before tax and exceptional item                                                                        8497              5907               44
exceptional item                                                                                                                1606             100
profit before tax                                                                                             8497              7513               13
tax expense                                                                                                   1538              1299               18
tax on exceptional item                                                                                            78             123               37
profit after tax                                                                                              6881              6091               13
noncontrolling interest                                                                                        760               587                29
profit for the year                                                                                           6121              5504               11
other comprehensive income attributable to shareholders                                                         764                58          1417
total comprehensive income attributable to shareholders                                                       6885              5446               26

revenue

during the year under review revenues grew 18 on a consolidated basis from  34602 mn to  40787 mn the small molecules segment grew by
12 driven by strong sales of rosuvastatin and immunosuppressants the biologics segment achieved an annual growth of 43 year on year the major
contributors to the growth were insulins sales from malaysia and trastuzumab sales to emerging markets including strong outlicencing opportunities also
the branded formulations segment showed a growth of 24 resulting in a total revenue of  5489 mn as against  4409 mn in previous fiscal due to
deconsolidation of joint venture in uae on a likeforlike basis however this segment was down marginally contract research segment syngene reported
a turnover of  11604 mn reflecting an annual growth of 7

the total revenue composition for fy17 and fy16 is detailed below

                                                                                                                                                    table 3

                                                                                       fy17                fy16                fy17                  fy16
particulars
                                                                                       mn               mn                                   
small molecule                                                                       16330              14546                   40                    42
biologics                                                                              5793               4046                  14                    12
branded formulations                                                                   5489               4409                  13                    13
research services                                                                    11604              10809                   29                    31
revenue from operations                                                              39216              33810
other income                                                                           1571                 792                    4                    2
total revenue                                                                        40787              34602

cost of materials consumed

the material costs comprised of raw materials packing materials traded goods and change in inventories in fy17 material costs as a percentage of our
overall revenue from operations remained consistent with fy16



                                                                                               management discussion and analysis                    139

employee benefit expenses

our employee benefit expenses comprise the following items

     salaries wages allowances and bonuses
     contributions to provident fund
     contributions towards gratuity provisions
     amortisation of employees stock compensation expenses
     welfare expenses including employee insurance schemes

these expenses increased 22 in fy17 driven largely by increased employee strength and annual increments

research and development expenses

the net rd expenditure for fy17 reduced 3 to  2662 mn  2742 mn in fy16 this amount in the profit and loss account represented 9 of revenue
exsyngene as compared to 11 in the previous year we capitalized  1357 mn taking gross rd spend to  4019 mn for the year compared to  4267
mn in fy16 the decrease in rd expenses was on account of reduced spends in anda development programs whereas the expenditure on inhouse novel
programs increased 38 in fy17 we estimate rd spends to remain in the range of 1215 of revenues exsyngene in the coming years

depreciation and amortization

during this fiscal depreciation and amortization increased to  2772 mn from  2487 mn in fy16 new facilities in the research arm have resulted in
additional depreciation for the current year

finance costs

the finance cost for fy17 is  260 mn which was contributed through use of foreign currency borrowings to address routine operations the total finance
cost for fy17 is reduced by  33 mn there has been an increase in interest costs on term loan as new terms have been obtained during the fy17 however
in fy17 exchange difference considered as borrowing costs remained nil as against  67 mn in fy16

exceptional items net

a    during the year ended march 31 2017 biocon sa bsa and biocon sdn bhd biocon malaysia have entered into an assignment and license
      agreement pursuant to which bsa transferred all of its rights interests and obligations in insulin analogs ipr to biocon malaysia consequent to this
      transfer bsa recorded a net gain in its standalone books which is offered to tax under the swiss tax laws the above restructuring did not have any
      impact on consolidated financial statements except for a tax cost of  78 mn representing the tax payable by bsa locally which has been included
      within income tax expenses for the year ended march 31 2017

the exceptional items during the previous year comprised the following

a    consequent to an agreement with a customer which resulted in changes to the nature of the groups future obligations on the rhinsulin program
      deferred revenue of  2684 mn relating to the program has been recognized as income in the consolidated financial results for the year ended march
      31 2016 and has been disclosed under exceptional items

b    pursuant to the uncertainty in respect of the ability of the group to license a product for development and commercialization in certain territories
      biocon sa recorded an impairment of the carrying value of the intangible asset amounting to  1078 mn the impairment has been recognized as an
      exceptional item in the consolidated financial results for the year ended march 31 2016

c    the gain arising from sale of equity shares in respect of syngene net of related expenses and cost of equity shares amounting to  962 mn has been
      accounted as an exceptional gain in the standalone financial results for the year ended march 31 2016

d    during the year ended march 31 2016 the company sold its investment in the equity shares of biocon malaysia a wholly owned subsidiary to biocon
      biologics limited uk another wholly owned subsidiary of the company for a sum of  811 mn gain arising from such sale of equity shares net of
      cost of such equity shares amounting to  99 mn is recorded as an exceptional item in the standalone financial results consequential tax of  21 mn
      is recorded on such gain

tax expenses

tax expenses for the fiscal stood at  1538 mn in comparison to  1299 mn in fy16 the increase is on account of higher profits in comparison with previous
year

other comprehensive income

other comprehensive income includes remeasurement gainslosses on defined benefit plans and gainlosses on hedging instrument cash flow hedges the
increase in the current year is primarily on account of gain on hedging instruments amounting to  871 mn net of taxes arising from research business of
the group




140       ahead of the curve  annual report 2017

                                                                                                                                           biocon limited



risks threats and concerns
risk is a potential event or nonevent the occurrence or nonoccurrence of which can adversely affect the objectives or strategy of the company

the global pharma industry bears a striking resemblance with the financial services industry of a decade ago the industry landscape is affected by product
safety and quality issues intellectual property tangles inappropriate marketing practices and corruption thereby leading to penalties product recalls brand
loss and revenue loss the regulatory landscape of the international pharma industry is complex and dynamic the primary industry driver is patient health
and safety even as regulatory approach to patient protection can vary from market to market besides there are factors of rapid change increased scrutiny
sophisticated riskmonitoring techniques and coordination across agencies and regions in such a context it is imperative to respond with a holistic risk
mitigation framework

the company has carved a niche on the back of its steadfastness in conducting business in accordance with all applicable laws and regulations as well
as a manner consistent with core organizational values our established risk management framework addresses strategic operational legal financial and
compliance risks which are inherent to the pharma business and impact our strategic goals risk management coupled with a robust internal control
framework helps the company to emphasize qualitative consistency employee safety and longterm sustainability

the global pharma business is marked by a variety of risks pharmaceutical companies struggle to globally enforce ip protection particularly in some
emerging markets enhanced regulatory scrutiny is set against a backdrop of increasing patient advocacy social media and affiliate marketing programmes
the digitisation and proliferation of electronic medical records networked medical devices mobile health applications cloudbased technologies and
datasharing among industry stakeholders have increased the complexity in managing information assets particularly protected health information and
intellectual property the success of new products in the global pharmaceutical industry will more than offset global pricing pressures supporting an outlook
change from stable to positive for the industry

although the comprehensive eradication of risks associated with our business of the company is unfeasible constant efforts are made to mitigate their
adverse impact the company has implemented a precise methodology entailing the timely identification analysis and assessment of risks and their
potential consequences formulation of specific mitigation strategies and seamless execution an enterprisewide risk evaluation and validation process is
conducted regularly and reviewed by a risk management committee and board of directors

the government investor and the public demand transparency in life science companies covering aspects like product commercialisation executive pay
financial information accuracy manufacturing processes and clinical trial quality several highprofile incidents particularly in emerging markets have
enhanced the need for more transparency other key developments comprise the indian governments plans to involve the private sector in rd across
vaccines drugs and pharmaceuticals on the brighter side drug approval processes have been simplified by the authorities and approval times for new
facilities drastically reduced the onus will be on the company to capitalise on these opportunities while protecting itself from risks

in addition to the above other key risks relating to our current operations include human capital risk such as loss of key personnel timely non replenishment
of critical vacant roles concentration or reliance on third party sole suppliers or service providers including regional supplier reliance risk arising out of
codevelopment arrangements disruption of operations from natural disasters risk arising out of strategic projects foreign exchange fluctuations changing
global political and regulatory landscape change in company strategy etc

internal controls
the company is responsible for establishing and maintaining adequate and effective internal controls and the preparation and presentation of the financial
statements including assertions on the internal financial controls in accordance with broader criteria established by the company

a robust comprehensive internal control system is a prerequisite for an organisation to function ethically and in commensuration with its abilities and
objectives we have established a strong internal control system for the company which is comprised of policies guidelines and procedures adopted by
the company to ensure the orderly and efficient business conduct including adherence to policies asset safeguarding fraud cum error prevention and
detection accounting records accuracy and completeness and the timely preparation and presentation of reliable financial information

this internal control system is aimed at providing assurance of our operational effectiveness and efficiency compliance with laws and regulations asset
safeguarding and reliability of financial and management reporting

the company is staffed by experienced qualified professionals who play an important role in designing implementing maintaining and monitoring the
internal control environment

an independent firm of chartered accountants perform periodic internal audits to provide a reasonable assurance of internal control effectiveness and
advice on industrywide best practices the audit committee consisting of independent directors reviews important issues raised by the internal and
statutory auditors on a regular basis and status of rectification measures to ensure that risks are mitigated appropriately on a timely basis

outlook

fiscal 201617 was an exciting year for biocon it marked the beginning of a new growth journey for the company led by our biologics segment coupled with
the commencement of insulin glargine product sales in japan this was followed by initiation of commercial supplies of recombinant human insulin from
our malaysian insulin facility progress of our global biosimilar pipeline continued with multiple filings across various developed markets while syngene
continued to make investments to expand its capacities and service offerings taking everything into consideration the beginning of a new growth journey
has provided a good visibility to us to deliver long term growth to all our shareholders




                                                                                                  management discussion and analysis                     141

corporate governance report
i    companys philosophy on code of governance
biocon believes that good corporate governance emerges from the application of best management practices and compliance with the laws coupled with
the highest standards of integrity transparency accountability and ethics in all business matters

biocon also believes that sound corporate governance is critical to enhance and retain investor trust hence biocons business policies are based on ethical
conduct health safety and a commitment to building long term sustainable relationships with relevant stakeholders the company continues to strengthen
its governance principles to generate long term value for its stakeholders on sustainable basis thus ensuring ethical and responsible leadership both at the
board and management levels

at biocon we also consider it as our inherent responsibility to disclose timely and accurate information regarding our financials and performance as well as
the leadership and governance of the company all bioconites are committed to a balanced corporate governance system which provides the framework for
attaining the companys objectives encompassing practically every sphere of management from action plans and internal controls to corporate disclosure

your company is not only in compliance with the requirements stipulated under sebi listing obligations and disclosure requirements regulations 2015
sebi lodr with regard to corporate governance but is also committed to sound corporate governance principles  practices and constantly strives to
adopt emerging best corporate governance practices being followed worldwide

a report on compliance with the corporate governance provisions as prescribed under the sebi lodr is given below

ii   board of directors
the composition of the board of your company is in conformity with regulation 17 of sebi lodr the chairperson  managing director of your company
though a professional director in her individual capacity is a promoter the number of independent directors is more than onehalf of the total number of
directors on the board of your company

ms kiran mazumdar shaw chairperson  managing director mr john shaw vice chairman and dr arun s chandavarkar chief executive officer and
joint managing director are the executive directors of your company prof ravi mazumdar is a non  executive non independent director the remaining
directors on the board of your company comprises six independent directors as on march 31 2017 and are renowned professionals drawn from diverse
fields possessing requisite qualifications and experience in general corporate management finance banking insurance economics science technology and
other allied fields which enable them to contribute effectively to your company and enhance the quality of boards decision making process

the board being aware of its fiduciary responsibilities recognizes its responsibilities towards all stakeholders to uphold highest standards in all matters
concerning the company it has empowered responsible persons to implement its broad policies guidelines and has set up adequate review processes
the board provides strategic guidance on the affairs of the company the independent directors provide independent and objective judgement on matters
placed before them

the companys day to day affairs are managed by the chairperson vice  chairman and ceo assisted by a competent management team under the overall
supervision of the board the companys commitment to ethical and lawful business conduct is a fundamental shared value of the board senior management
and all its employees the board is committed to representing the long term interests of the stakeholders and in providing effective governance over the
companys affairs and exercise reasonable business judgment on the affairs of the company

the directors are elected based on their qualification and experience in varied fields at the time of induction of a director a formal invitation to join the
board is sent out and a directors handbook comprising a compendium of the role powers and duties to be performed is given to the new director the
independent directors annually provide a certificate of independence in accordance with the applicable laws which is taken on record by the board all
board members are encouraged to meet and interact with the management board members are invited at key meetings of senior management for strategic
guidance and advice

a    composition of the board

the board of your company comprises of ten directors as on march 31 2017 the names and categories of directors the number of directorships and
committee positions held by them in the companies are given below none of the director is a director in more than 10 public limited companies as
specified in section 165 of the companies act 2013 the act or act as an independent director in more than 7 listed companies or 3 listed companies in
case heshe serves as a wholetime director in any listed company as specified in regulation 25 of sebi lodr further none of the directors on the board
is a member of more than 10 committees and chairman of more than 5 committees as specified in regulation 26 of sebi lodr across all the indian public
limited companies in which heshe is a director




142       ahead of the curve  annual report 2017

                                                                                                                                                   biocon limited



 name of the director                            category                       directors               total number of directorships committee chairmanships
                                                                                identification                and memberships of public limited companies
                                                                                number                                    as on march 31 2017
                                                                                                          directorships           committee          committee
                                                                                                                                 chairmanships      memberships
 ms kiran mazumdarshaw                        promoter  executive           00347229                          8                                         
 mr john shaw                                  promoter  executive           00347250                          4                                         
 dr arun s chandavarkar                         executive                      01596180                          4                                        2
 prof ravi mazumdar                            promoter  nonexecutive       00109213                          1                                        1
 mr russell walls                               independent                    03528496                          5                    4                    2
 ms mary harney                                 independent                    05321964                          1                                         
 mr daniel m bradbury                           independent                    06599933                          2                    1                    2
 dr vijay k kuchroo                             independent                    07071727                          3                                        1
 dr jeremy m levin                              independent                    07071720                          1                                        1
 mr m damodaran                                 independent                    02106990                          5                    2                    5

excludes private limited companies foreign companies companies registered under section 8 of the act and government bodies
 includes additional directorships and directorship in biocon limited
 committees considered are audit committee and stakeholders relationship committee including that of biocon limited
ms kiran mazumdar shaw chairperson and managing director is the spouse of mr john shaw vice chairman and wholetime director and sister of prof ravi mazumdar non
executive director

b     board procedure

detailed agenda is sent to each director at least 7 days in advance of board and committee meetings all material information is incorporated in the agenda
for facilitating meaningful and focused discussions at the meeting where it is not practicable to attach any document to the agenda the same is tabled
at the meeting with specific reference to this effect in the agenda in special and exceptional circumstances additional or supplementary items on the
agenda are permitted to enable the board to discharge its responsibilities effectively the chairperson presents during every board meeting the overall
performance of the company

the board reviews strategy and business plans annual operating and capital expenditure budgets investment and exposure limits compliance reports of all
laws applicable to the company as well as steps taken by the company to rectify instances of noncompliances if any the board also reviews major legal
issues minutes of meeting of various committees of the board and subsidiary companies significant transactions and arrangements entered into by the
subsidiary companies adoption of financial results transactions pertaining to purchase or disposal of properties major accounting provisions and writeoffs
corporate restructuring details of any joint ventures or collaboration agreement material default in financial obligations if any fatal or serious accidents
any material effluent or pollution problems transactions that involve substantial payment towards goodwill brand equity or intellectual property any issue
that involves possible public or product liability claims of substantial nature including judgement or order which may have passed strictures on the conduct
of your company quarterly details of foreign exchange exposures and the steps taken by management to limit the risks of adverse exchange rate movement
and information on recruitment of senior officers just below the board level and key managerial personnel

the company secretary records minutes of proceedings of each board and committee meetings draft minutes are circulated to board committee members
within 15 days from the meeting for their comments directors communicate their comments if any in writing on the draft minutes within seven days from
the date of circulation the minutes are entered in the minutes book within 30 days from the conclusion of the meeting and signed by the chairperson at
the subsequent meeting

the guidelines for board and committee meetings facilitate an effective post meeting followup review and reporting process for decisions taken by the
board and committees thereof important decisions taken at board committee meetings are communicated promptly to the concerned departments
divisions actiontaken report on decisionsminutes of the previous meetings is placed at the succeeding meeting of the board committee for noting

apart from board members and the company secretary the board and committee meetings are also attended by the chief financial officer and wherever
required by the heads of various corporate functions

c     number of board meetings attendance of the directors at meetings of the board and at the annual general meeting agm

during the year april 01 2016 to march 31 2017 four board meetings were held on the following dates  april 26 2016 july 21 2016 october 20 2016
and january 24 2017 the board met at least once in every calendar quarter and the gap between two meetings did not exceed one hundred and twenty
days these meetings were well attended the 38th agm of your company was held on june 30 2016




                                                                                                                      corporate governance report                 143

the attendance of the directors at these meetings were as under

 directors                                                       no of board meetings held         no of board meetings        attendance at the 38th agm
                                                                      during fy 1617                      attended
 ms kiran mazumdarshaw                                                       4                               4                              yes
 mr john shaw                                                                 4                               4                              yes
 dr arun s chandavarkar                                                       4                               4                              yes
 prof ravi mazumdar                                                           4                               4                               no
 mr russell walls                                                             4                               4                              yes
 ms mary harney                                                               4                               4                               no
 mr daniel m bradbury                                                         4                               4                               no
 dr vijay k kuchroo                                                           4                               3                               no
 dr jeremy m levin                                                            4                               4                               no
 mr m damodaran                                                               4                               4                              yes

d     shareholding of nonexecutive directors

the details of companys shares held by non  executive directors as on march 31 2017 are as below

 directors                                                                                         no of shares held as on march 31 2017
 prof ravi mazumdar                                                                                               565014
 mr russell walls                                                                                                    nil
 ms mary harney                                                                                                      nil
 mr daniel m bradbury                                                                                                nil
 dr vijay k kuchroo                                                                                                  nil
 dr jeremy m levin                                                                                                   nil
 mr m damodaran                                                                                                      nil

joint holding with spouse

e     meeting of independent directors

the independent directors of your company met once during the year without the presence of nonindependent directors and members of the management
the meeting was conducted in an informal and flexible manner to enable the independent directors to inter alia discuss matters pertaining to review
of performance of non independent directors and the board as a whole review the performance of the chairperson of the company after taking into
account the views of the executive and nonexecutive directors assess the quality quantity and timeliness of flow of information between the company
management and the board that is necessary for the board to effectively and reasonably perform their duties

f     details of familiarisation programme imparted to independent directors

during the year the independent directors were apprised at frequent intervals on the industry trends business model and the overview of the company and
its operations by the senior management team further various business unit heads made presentations to the independent directors at periodic intervals
on the performance and future strategy of their respective business units the independent directors were also regularly appraised of all regulatory and
policy changes including their roles rights and responsibilities presentations on internal control over financial reporting operational control over financial
reporting prevention of insider trading regulations sebi lodr framework for related party transactions etc were made to the board members during the
year

the companys familiarisation policy and the details of programmes attended and hours spent by the independent directors during the financial year 2016
17 is available on the companys website httpwwwbioconcomdocsfamiliarisation_programme_fy1617pdf

iii   committees of the board
the board has constituted various committees to focus on specific areas and to make informed decisions within their authority each committee is directed
by its charter which outlines their scope roles responsibilities and powers all the decisions and recommendations of the committee are placed before the
board for their approval the companys guidelines relating to board meetings are applicable to committee meetings as far as practicable each committee
has the authority to engage outside experts advisors and counsels to the extent it considers appropriate to assist in its functions senior officers functional
heads of company are invited to present various details called for by the committee at its meeting

the various committees of the board are as under

 audit and risk committee

 nomination and remuneration committee

 stakeholders relationship committee

 corporate social responsibility committee




144         ahead of the curve  annual report 2017

                                                                                                                                          biocon limited



a     audit and risk committee

i     brief description of terms of reference

the powers role and terms of reference of the audit and risk committee are in line with the provisions of section 177 of the act and part c of schedule ii of
sebi lodr the audit and risk committee discharges such duties and functions generally indicated under regulation 18 of sebi lodr companies act 2013
and such other functions as may be specifically assigned to it by the board from time to time

the company has put in place an enterprise wide risk management framework which is overseen by the audit and risk committee this holistic approach
provides the assurance that to the best of its capabilities the company and all its business units identify assess and mitigate risks that could materially
impact its performance in achieving the stated objectives the committee ensures that the company is taking appropriate measures to achieve prudent
balance between risk and reward in both ongoing and new business activities reviews strategic decisions of the company and on regular basis reviews
the companys portfolio of risks considering it against the companys risk appetite the committee also recommend changes as appropriate to the risk
management technique andor associated frameworks processes and practices of the company

ii    composition

the following directors are the members of the committee

1     mr russell walls chairman

2     mr daniel m bradbury

3     dr jeremy m levin

4     mr m damodaran

all the members of the committee are independent directors the committee members possess sound knowledge of accounts finance audit governance
and legal matters

senior staff from the accounts finance department and representatives of statutory and internal auditors attend all audit and risk committee meetings
the company secretary acts as the secretary to the committee the chairman of the audit and risk committee mr russell walls was present at the last
annual general meeting held on june 30 2016

iii   meeting and attendance during the year

during the year the committee met 4 times on april 26 2016 july 21 2016 october 20 2016 and january 24 2017

the attendance at the meetings is as under

 members                                                                                         no of meetings
                                                                            held                                              attended
 mr russell walls                                                            4                                                   4
 mr daniel m bradbury                                                        4                                                   3
 dr jeremy m levin                                                           4                                                   4
 mr m damodaran                                                             4                                                   3

mr m damodaran was appointed as a member of audit and risk committee at the board meeting held on april 26 2016

the committee as a good governance practice also meets the external auditors internal auditors and the chief financial officer of the company in private
to know their independent opinion on the performance of the company

b     stakeholders relationship committee

i     brief description of terms of reference

the terms of reference of the stakeholders relationship committee are in line with the provisions of section 178 of the act and part d of schedule ii of
sebi lodr

the stakeholders relationship committee is primarily responsible for redressal of shareholders  investors  security holders grievances including
complaints related to transfer of shares nonreceipt of declared dividends annual reports etc

ii    composition

the following directors are the members of the committee

1     mr daniel m bradbury chairman

2     mr russell walls

3     prof ravi mazumdar

all the members of the committee are nonexecutive directors and majority are independent mr rajiv balakrishnan company secretary is the compliance
officer of the company




                                                                                                           corporate governance report                  145

iii   meeting and attendance during the year

during the year the committee met 4 times on april 26 2016 july 21 2016 october 20 2016 and january 24 2017 the attendance at the meetings is
as under

 members                                                                                         no of meetings
                                                                            held                                              attended
 mr daniel m bradbury                                                        4                                                   3
 mr russell walls                                                            4                                                   4
 prof ravi mazumdar                                                          4                                                   4

during the year 103 complaints were received and resolved to the satisfaction of investors as on march 31 2017 there are no outstanding complaints from
the investors the quarterly statement on investor complaints received and disposed of are filed with stock exchanges within 21 days from the end of each
quarter and the statement filed is also placed before the subsequent meeting of board of directors

c     corporate social responsibility committee

i     brief description of terms of reference

the terms of reference of the committee are in line with the provisions of section 135 of the act

the committees prime responsibility is to assist the board in discharging its social responsibilities by way of formulating monitoring and implementing a
framework in line with the corporate social responsibility policy of the company

ii    composition

the following directors are the members of the committee

1     ms mary harney chairperson

2     dr vijay k kuchroo

3     prof ravi mazumdar

all the members of the committee are nonexecutive directors and majority independent

iii   meeting and attendance during the year

during the year the committee met twice on april 26 2016 and october 20 2016 the attendance at the meeting is as under

 members                                                                                         no of meetings
                                                                            held                                              attended
 ms mary harney                                                              2                                                   2
 dr vijay k kuchroo                                                          2                                                   2
 prof ravi mazumdar                                                          2                                                   2

d     nomination and remuneration committee

i     brief description of terms of reference

the terms of reference of the nomination and remuneration committee are in line with the provisions of section 178 of the act and part d of schedule ii
of sebi lodr

the nomination and remuneration committee has been vested with the authority to inter alia recommend nominations for board membership develop and
recommend policies with respect to composition of the board commensurate with the size nature of the business and operations of the company establish
criteria for selection of board members with respect to competencies qualifications experience track record integrity devise appropriate succession plans
and determine overall compensation policies of the company

the scope of the committee also includes review of market practices and decide on remuneration packages to the executive directors lay down performance
parameters for the chairperson  managing director the executive directors senior management key managerial personnel etc and review the same

in addition to the above the committees role includes identifying persons who may be appointed in senior management in accordance with the criteria laid
down recommending to the board their appointment and removal

the committee also formulates the criteria for determining qualifications positive attributes and independence of a director and recommends to the board
periodically policies relating to the remuneration of the directors key managerial personnel and other employees

the committee also carries out a separate exercise to evaluate the performance of individual directors feedback is sought by way of structured
questionnaires covering various aspects of the boards functioning such as adequacy of the composition of the board and its committees board culture
execution and performance of specific duties obligations and governance performance evaluation is carried out based on the responses received from the
directors




146       ahead of the curve  annual report 2017

                                                                                                                                         biocon limited



the performance evaluation of independent directors were based on various criteria including experience and expertise independent judgment ethics and
values adherence to corporate governance norms interpersonal relationships attendance and contribution at meetings etc

ii    composition

the following directors are the members of the committee

1     ms mary harney chairperson

2     dr vijay k kuchroo

3     prof ravi mazumdar

4     ms kiran mazumdar shaw

majority of the members of the committee are nonexecutive directors and half of the committee composition consist of independent directors

iii   meeting and attendance during the year

during the year the committee met thrice on april 26 2016 october 20 2016 and january 24 2017 the attendance at the meetings is as under

 members                                                                                        no of meetings
                                                                            held                                             attended
 ms mary harney                                                             3                                                    3
 dr vijay k kuchroo                                                         3                                                    3
 prof ravi mazumdar                                                         3                                                   3
 ms kiran mazumdar shaw                                                    3                                                   1

ms kiran mazumdar shaw was appointed as a member of nomination and remuneration committee at the board meeting held on april 27 2017

  attended as an invitee

iv    remuneration of directors
a     remuneration policy

your company has a welldefined policy for remuneration of the directors key managerial personnel and other employees this policy is furnished as
annexure iii to the boards report

the elements of remuneration package of executive directors includes fixed and variable salary performance bonus contribution to provident fund
superannuation gratuity perquisites and allowances reimbursement of expenses etc as applicable to the employees of the company the executive
directors are employees of the company and are subject to service conditions as per the company policy which is two months notice period or such period
as mutually agreed there is no separate provision for payment of severance fees to executive directors non  executive directors independent directors
are paid remuneration in the form of commission apart from sitting fees and are not subject to any notice period and severance fees

b     remuneration to nonexecutive directors

pursuant to the approval granted by the shareholders of the company at the 35th agm held on 26th july 2013 the independent directors are paid commission
upto a maximum of 1 of the net profits of the company for each financial year as computed in the manner laid down in the act

subject to the above limits the independent directors are eligible for commission as outlined below for participation in various meetings and meeting the
various performance parameterscriteria including but not restricted to participation and contribution by a director commitment guidance provided to the
senior management outside of board committee meetings effective deployment of knowledge and expertise effective management of relationship with
various stakeholders independence of behaviour and judgment etc as set out by the nomination and remuneration committee

 sl   particulars                                                                                                                      amount in usd
 no
 1     commission for attending each board meeting                                                                                           5000
 2     commission for attending each audit and risk committee meeting as                                      chairman                       6000
                                                                                                              member                         3000
 3     commission for attending each nomination and remuneration committee meeting as                         chairman                       2000
                                                                                                              member                         1000
 4     commission for attending each corporate social responsibility committee meeting as                     chairman                       2000
                                                                                                              member                         1000

besides the above commission foreign independent directors are paid travel allowances of usd 4000 in case of travel from united states and usd 3000 in
case of travel from any other country for attending the meetings the non executive directors are paid a consolidated sitting fees of  100000 for attending
the board and committee meetings the company also reimburses the outofpocket expenses incurred by the directors for attending the meetings

the non  executive directors bring with them significant professional expertise and rich experience across a wide spectrum of functional areas such as
marketing technology corporate strategy legal finance and other corporate functions the company seeks their expert advice on various matters in science




                                                                                                          corporate governance report                  147

technology legal and governance matters there were no pecuniary relationship or transactions of nonexecutive directors vis avis the company during
the financial year 201617

c      remuneration to executive directors

the shareholders at their 37th agm appointed ms kiran mazumdar shaw as the chairman  managing director for a period of five years effective april 01
2015 on certain terms and conditions including her remuneration subject to a limit of 5 of net profit of the company the remuneration includes fixed and
variable salary performance bonus contribution to provident fund superannuation gratuity perquisites and allowances reimbursement of expenses etc
as applicable to the employees of the company

mr john shaw was appointed as a whole time director and designated as vice  chairman of the company by the shareholders at their 32nd agm on certain
terms and conditions including his remuneration comprising of fixed and variable salary performance bonus contribution to provident fund superannuation
gratuity perquisites and allowances reimbursement of expenses etc as applicable to the employees of the company further the shareholders at their 35th
agm increased the remuneration of mr john shaw subject to a limit of 5 of net profits of the company

dr arun s chandavarkar was appointed as the ceo  joint managing director for a period of five years effective april 24 2014 by the shareholders at their
36th agm on certain terms and conditions including his remuneration comprising of fixed and variable salary performance bonus contribution to provident
fund superannuation gratuity perquisites and allowances reimbursement of expenses etc as applicable to the employees of the company

the details of remuneration paid to each of the directors during the year ended march 31 2017 are given below
                                                                                                                                          amount in  million

 directors                                            salary and perquisites                                    others
                                      fixed pay  bonus       perquisites     retiral benefits       commission           sitting fees                  total
 ms kiran mazumdar shaw                          194                003                098                                                        2041
 mr john shaw                                    172                003                                                                           1723
 dr arun s chandavarkar                         317                003                127                                                        3300
 prof ravi mazumdar                                                                                                            04                   04
 mr russell walls                                                                                         375                  04                  379
 ms mary harney                                                                                           281                  04                  285
 mr daniel m bradbury                                                                                     221                  04                  225
 dr vijay k kuchroo                                                                                       214                  03                  217
 dr jeremy m levin                                                                                        322                  04                  326
 mr m damodaran                                                                                           195                  04                  199

 perquisites valued as per income  tax act 1961
dr arun s chandavarkar was granted 76500 restricted stock units rsus of companys subsidiary syngene international limited in april 2015 at nil
exercise price which doesnt form part of his remuneration shown above rsus shall vest over a period of 4 years from the date of grant during the year
201617 7650 rsus were exercised by dr arun s chandavarkar

no options under the companys esop plan were granted to executive  nonexecutive directors during the financial year 201617

v      general body meetings
a      annual general meetings

the date time location of annual general meetings held during last three years and the special resolutions passed there at are as follows

 year                date and time    venue                                                  special resolution passed
 201314             july 25 2014   tyler jacks auditorium biocon research centre        1approval for enhancement of borrowing limits and creation
                     330 pm        plot no 3 biocon sez bommasandra jigani link road   of charge
                                      bengaluru  560 099
 201415             july 24 2015   tyler jacks auditorium biocon research centre        1 amendment in articles of association of the company
                     330 pm        plot no 3 biocon sez bommasandra jigani link road   2 implementation of esop plan through esop trust
                                      bengaluru  560 099                                    3 acquisition of shares by esop trust from secondary
                                                                                             market
 20152016           june 30 2016   tyler jacks auditorium biocon research centre        1 appointment of statutory auditor
                     400 pm        plot no 3 biocon sez bommasandra jigani link road   2 approval of new grants under the companys esop plan
                                      bengaluru  560 099

i      special resolutions passed through postal ballot

no special resolution was passed through postal ballot during fy 201617 the board at its meeting held on april 27 2017 proposes to seek approval
of shareholders by special resolution for increasing the authorised share capital of the company and consequent amendment to the memorandum of
association by way of postal ballot none of the business proposed to be transacted at the ensuing agm requires passing of special resolution through
postal ballot




148         ahead of the curve  annual report 2017

                                                                                                                                           biocon limited



ii    procedure for postal ballot

in compliance with the provisions of sections 108 and 110 of the act read with applicable rules the company provides electronic voting evoting facility
to all its members the company engages the services of karvy computershare private limited karvy for the purpose of providing evoting facility to all its
members the members have the option to vote either by physical ballot or through evoting the company dispatches the postal ballot notices and forms
along with postage prepaid business reply envelopes to its members whose names appear on the register of members  list of beneficiaries as on a cutoff
date the postal ballot notice is sent to members in electronic form to the email addresses registered with their depository participants in case of electronic
shareholding and to the registered addresses of the members in case of physical shareholding the company also publishes a notice in the newspaper
declaring the details of completion of dispatch and other requirements as mandated under the act and applicable rules

voting rights are reckoned on the paidup value of the shares registered in the names of the members as on the cutoff date members desiring to exercise
their votes by physical postal ballot forms are requested to return the forms duly completed and signed to the scrutinizer on or before the close of the
voting period members desiring to exercise their votes by electronic mode are requested to vote before close of business hours on the last date of evoting

the scrutinizer submits his report to the chairman after the completion of scrutiny and the consolidated results of the voting by postal ballot are then
announced by the chairman  any director of the company company secretary the results are also displayed on the company website wwwbioconcom
besides being communicated to the stock exchanges depository and registrar and share transfer agent the date of declaration of postal ballot result shall
be the date on which the resolution would be deemed to have been passed if approved by the requisite majority

b     means of communication

i     quarterly results

the quarterly financial results are published in financial express and vijayavani kannada edition and are also displayed on the companys website www
bioconcom

ii    news releases presentations

official news  press releases are sent to the stock exchanges and are displayed on the companys website wwwbioconcom

iii   presentations to institutional investors  analysts

presentations are made to institutional investors and financial analysts on the quarterly financial results of the company these presentations are also
uploaded on the companys website wwwbioconcom and are sent to stock exchanges the schedule of meetings with institutional investors financial
analysts are intimated in advance to the stock exchanges and disclosed on the companys website

iv    website

the companys website wwwbioconcom contains a separate dedicated section investors where shareholders information is available the information
such as press releases notice of board meeting outcome of board meeting  revision in credit rating clippings of newspaper publications etc are uploaded
on the website the companys annual report is also uploaded on the website in a userfriendly and downloadable form

v     nse electronic application processing system neaps

neaps is a webbased application designed by nse for corporates all periodical compliance filings like shareholding pattern corporate governance report
media releases etc are filed electronically on neaps

vi    bse corporate compliance  listing centre listing centre

bses listing centre is a webbased application designed for corporates all periodical compliance filings like shareholding pattern corporate governance
report media releases etc are filed electronically on the listing centre

vii   sebi complaints redress system scores

the investor complaints are processed in a centralized webbased complaints redressal system centralized database of all complaints received online
upload of action taken reports atrs by company and online viewing by investors of actions taken on the complaint and its current status are updated
resolved electronically in the sebi scores system

vi    general shareholders information
a     company registration details

the company is registered in the state of karnataka india the corporate identity number cin allotted to the company by the ministry of corporate affairs
mca is l24234ka1978plc003417




                                                                                                            corporate governance report                  149

b    annual general meeting

 date and time                                                           friday july 28 2017 at 400 pm
 venue                                                                   tyler jacks auditorium biocon research centre
                                                                         plot no 3 biocon sez bommasandra jigani link road
                                                                         bengaluru  560 099


 financial year                                                          april 01 march 31
 dividend payment date                                                   creditdispatch of dividend warrants if approved at the members meeting
                                                                         would be made on or after july 28 2017 but before august 4 2017
 dates of book closure                                                   saturday july 22 2017 to friday july 28 2017 both days inclusive
 financial results calendar for 20172018
 q1  fy 18                                                              july 27 2017
 q2  fy 18                                                              october 26 2017
 q3  fy 18                                                              january 24 2018
 q4  fy 18                                                              april 26 2018
 the above dates are tentative
 listed on stock exchanges                                               national stock exchange of india limited
                                                                         exchange plaza bandrakurla complex bandra e
                                                                         mumbai  400 051
                                                                         bse limited
                                                                         p j towers dalal street mumbai  400 001
 stock codesymbol                                                       nse  biocon  bse  532523
 international securities identification number                          ine 376g01013
 payment of annual listing fees to stock exchanges                       paid

i    market price data during 201617

the monthly high low closing prices and volume of shares of the company from april 1 2016 to march 31 2017 are given below

 months                                           bse                                                               nse
                              high price             low price   volume of equity              high price             low price       volume of equity
                                                                          shares                                                               shares
 apr16                            58950               48245          2560625                 58990                  48215           22005012
 may16                            72135               58200          2208773                 72180                  58340           21269893
 jun16                            76600               68900          1691858                 76500                  68815           18200909
 jul16                            83730               68900          4073823                 83720                  68895           36117642
 aug16                            92350               76700          4043362                 92400                  81080           32982382
 sep16                            98800               87530          2303143                 98475                  87135           18928591
 oct16                        102000                 89500          2021224               102000                  89490           22441085
 nov16                            94685               80350          1304937                 93690                  80440           17164695
 dec16                            99205               88210          1361276                 99000                  88170           15784030
 jan17                        105205                 93050          2107061               105175                  92925           19298822
 feb17                        114420                 99510            955671              114380                  99510             9817612
 mar17                        116185              101500           1003262               116290               101755            12725905

ii   performance in comparison with broad based indices

the chart below shows performance of the companys share price in comparison to broad based indices such as bse sensex and nse nifty the biocon
management cautions that the stock price movement shown in the graph below should not be considered indicative of potential future stock price
performance




150       ahead of the curve  annual report 2017

                                                                                                                                                      biocon limited



                                          biocon  bse sensex share price movement from april 1 2016 to march 31 2017


            250


            200


            150


            100


             50


              0
                             6




                                                                 6




                                                                                                    6



                                                                                                                 16




                                                                                                                                                  7
                                                                            16




                                                                                                                                        7
                  6




                                                                                        6
                                          6




                                                                                                                               7
                                                     6
                           1




                                                               1




                                                                                                     1




                                                                                                                                                1
                                                                                                                                        1
                  r1




                                                                                      t1
                                       1




                                                                                                                           1
                                                   1




                                                                                                  v



                                                                                                               c
                                                                          p
                         ay




                                                                g




                                                                                                                                              ar
                                                                                                                                      b
                                        n




                                                                                                                             n
                                                     l
               ap




                                                                                    oc



                                                                                                no



                                                                                                             de
                                                  ju



                                                             au



                                                                         se




                                                                                                                                   fe
                                     ju




                                                                                                                          ja




                                                                                                                                             m
                        m




                                                1




                                                                                                                        1
                                   1
             1




                                                                                   1




                                                                                                                                   1
                                                                       1




                                                                                                                                             1
                                                                                                            1
                                                                                               1
                                                           1
                        1




                                                                      biocon bse                         sensex close


note share price of biocon limited and bse sensex have been indexed to 100 on april 1 2016

                                          biocon  s  p nifty share price movement from april 1 2016 to march 31 2017


            250


            200


            150


            100


             50


              0
                             6




                                                                 6




                                                                                                    6



                                                                                                                 16




                                                                                                                                                  7
                                                                            16




                                                                                                                                        7
                  6




                                                                                        6
                                        16




                                                                                                                            17
                                                     6
                           1




                                                               1




                                                                                                     1




                                                                                                                                                1
                                                                                                                                        1
                  r1




                                                                                      t1
                                                   l1




                                                                                                  v



                                                                                                               c
                                                                          p
                                      n




                                                                                                                          n
                         ay




                                                                g




                                                                                                                                              ar
                                                                                                                                      b
               ap




                                                                                    oc



                                                                                                no



                                                                                                             de
                                                  ju



                                                             au



                                                                         se




                                                                                                                                   fe
                                     ju




                                                                                                                          ja




                                                                                                                                             m
                        m




                                                1




                                                                                                                        1
                                   1
             1




                                                                                   1




                                                                                                                                   1
                                                                       1




                                                                                                                                             1
                                                                                                            1
                                                                                               1
                                                           1
                        1




                                                                      biocon nse                         nifty close


note share price of biocon limited and nse nifty have been indexed to 100 on april 1 2016

iii   share transfer system

share transfers are processed and share certificates duly endorsed are returned within a period of fifteen days from the date of receipt subject to documents
being valid and complete in all respects the stakeholders relationship committee has delegated the authority for approving transfer transmission etc of
the companys securities to the share transfer committee consisting of ms kiran mazumdar shaw chairperson  managing director and mr john shaw
vice chairman  wholetime director of the company a summary of transfertransmission of securities of the company so approved by the share transfer
committee is placed at every stakeholders relationship committee meeting the company obtains from a company secretary in practice halfyearly
certificate of compliance with the share transfer formalities as required under sebi lodr and files a copy of the said certificate with the stock exchanges

iv    dematerialization of shares and liquidity

9977  of the equity shares of the company are in electronic form as on march 31 2017 trading in equity shares of the company is permitted only in
dematerialized form the companys equity shares are actively traded on both nse and bse substantial increase in daily trading activity of the companys
equity shares was witnessed during fy 201617 as compared to fy 2015 16




                                                                                                                          corporate governance report           151

v       distribution of shareholding category wise as on march 31 2017 is as under

 category                                                                                                           no of shares                to equity
 promoters indian  foreign                                                                                       121360946                         6068
 foreign institutional investors                                                                                     35427957                         1771
 mutual funds banks ifis                                                                                            6725931                          336
 nris  foreign nationals                                                                                             2376919                          119
 corporate bodies                                                                                                     4099910                          205
 trusts                                                                                                               7812176                          391
 indian public  others                                                                                              22196161                         1110
 total                                                                                                              200000000                        10000

vi      distribution of shareholding by number of shares as on march 31 2017 is as under

 category                                                 no of holders                to holders                no of shares                 to equity
 1           1000                                                98420                       9768                  9145919                          457
 1001        2000                                                  1029                       102                  1543058                          077
 2001        3000                                                   343                        034                    872209                         044
 3001        4000                                                   179                        018                    648380                         032
 4001        5000                                                   132                        013                    622874                         031
 5001        10000                                                  247                        025                  1845984                          092
 10001        20000                                                 131                        013                  1904957                          095
 20001        30000                                                  53                        005                  1355012                          068
 30001        40000                                                  19                        002                    641159                         032
 40001        50000                                                  30                        003                  1330520                          067
 50001       100000                                                  62                        006                  4400966                          220
 100001 and above                                                    116                        012               175688962                         8784
 total                                                          100761                      10000               200000000                        10000

vii     outstanding adrsgdrswarrants or any convertible instruments conversion date and likely impact on equity

the company has not issued any adrsgdrs warrants or any convertible instruments

viii    commodity price risk or foreign exchange risk and hedging activities

the input pricing risk is managed through appropriate long term rate contracts and constant evaluation of alternate support sources for key raw materials
company has an approved foreign exchange risk management policy and accordingly during the year ended march 31 2017 the company has managed
the foreign exchange risk and hedged to the extent considered necessary the details of foreign currency exposure and hedging are disclosed in note 39 of
standalone financial statements

ix      plant locations

 1                                       2                                      3                                      4
 20th km hosur road                    biocon park                            plot 213215                           plot no 2
 electronics city po                   plot no 2 3 4 and 5                 ida phaseii pashamylaram             road no 21 jn pharma city ida
 bengaluru  560 100                     bommasandra  jigani link road         medak district  502307                parvada vishakapatnam 531021
                                         bengaluru  560 099                    andhra pradesh india

x       address for correspondence

 financial disclosure                                                           media  corporate communications
 mr siddharth mittal                                                           ms seema ahuja
 president  finance  chief financial officer                                  head  corporate communications
 tel 91 80  2808 2808                                                         tel 91 80  2808 2808
 email id siddharthmittalbioconcom                                         email id seemaahujabioconcom
 investor relations institutional investors  research analysts               registrar and share transfer agents
 mr saurabh paliwal                                                            karvy computershare private limited
 head  investor relations                                                      unit biocon limited
 tel 91 80  2808 2808                                                         plot 3132 karvy selenium tower b gachibowli financial district
 email id investorrelationsbioconcom                                       nanakramguda hyderabad  500 032
                                                                                email id einwardriskarvycom
 corporate governance  compliance                                              registered office
 mr rajiv balakrishnan                                                         biocon limited
 company secretary and compliance officer                                       20th k m hosur road
 tel 91 80  2808 2808                                                         electronics city po bengaluru  560 100
 email id cosecretarybioconcom


152          ahead of the curve  annual report 2017

                                                                                                                                          biocon limited



your company has also designated cosecretarybioconcom as an exclusive email id for the purpose of investor servicing and registering complaints which
has been displayed on the companys website

c      other disclosures

i      materially significant related party transactions

during the financial year 201617 there were no materially significant transactions or arrangements entered into between the company and its promoters
management directors or their relatives subsidiaries etc that may have potential conflict with the interests of the company at large your company has
formulated a policy on dealing with related party transactions which specify the manner of entering into related party transactions this policy has also been
posted on the website of the company and can be accessed through web link httpwwwbioconcomdocspolicydocument_relatedpartytransaction_2015
pdf

ii     details of noncompliance

during the last three years there were no instances of noncompliance by the company related to the capital markets and no penalty or strictures were
imposed on the company by the stock exchanges or sebi or any statutory authorities the company has also complied with the requirements of corporate
governance report of paras 2 to 10 mentioned in part c of schedule v of sebi lodr and disclosed necessary information as specified in regulation 17
to 27 and regulation 462 b to i as appropriately in the annual report

iii    vigil mechanism and whistle blower policy

the vigil mechanism as envisaged in the act and the rules prescribed thereunder and sebi lodr is implemented through the companys whistle blower
policy to provide for adequate safeguards against victimisation of persons who use such mechanism and make provision for direct access to the chairperson
of the audit committee the address of the chairman of the audit and risk committee has been given in the policy for the employees directors vendors
suppliers or other stakeholders associated with the company to report any matters of concern whistle blower policy of the company is available on the
website of the company and can be accessed through the web link httpwwwbioconcomdocsbiocon_group_integrity_whistle_blower_policypdf

iv     compliance with nonmandatory requirements

apart from complying with the mandatory requirements prescribed by sebi listing obligations and disclosure requirements regulations 2015 the
company has complied with a few nonmandatory requirements such as

       during the year under review there is no audit qualification in your companys financial statements your company continues to adopt best practices
        to ensure regime of unqualified financial statements

       the post of chairperson  managing director and chief executive officer are separately held

       the internal auditors report directly to the audit and risk committee

v      material subsidiary

all the companys subsidiaries are board managed with their respective boards having the rights and obligations to manage such companies in the best
interest of their stakeholders the audit and risk committee reviews the financial statements in particular investments made by the unlisted subsidiary
companies minutes of the board meetings of unlisted subsidiary companies are placed and reviewed periodically by the companys board a statement
containing all significant transactions and arrangements entered into by unlisted subsidiary companies is placed before the companys board periodically
your company has formulated a policy for determining material subsidiaries as defined in regulation 16 of sebi lodr this policy is also posted on the
website of the company and can be accessed through web link httpwwwbioconcomdocspolicydocument_materialsubsidiarypdf

vi     disclosures with respect to demat suspense account unclaimed suspense account

the company does not have any securities in the demat suspense accountunclaimed suspense account

vii    code of conduct

the code of conduct the code for board members and senior management personnel as adopted by the board is a comprehensive code applicable to
directors and senior management personnel the code lays down in detail the standards of business conduct ethics and strict governance norms for the
board and senior management personnel a copy of the code has been put on the companys website wwwbioconcomthe code has been circulated to
directors and senior management personnel and its compliance is affirmed by them annually a declaration signed by the companys chief executive officer
to this effect is published in this report

viii   code for prevention of insider trading practices

the company had formulated a comprehensive code of conduct for prevention of insider trading for its designated persons in compliance with securities
and exchange board of india prohibition of insider trading regulations 2015 as amended from time to time the directors officers designated persons
and other connected persons of the company are governed by the code

ix     disclosure by senior management personnel

the senior management of your company have made disclosures to the board confirming that there are no material financial and commercial transactions
where they have personal interest that may have a potential conflict of interest with the company at large




                                                                                                           corporate governance report                  153

x    ceocfo certification

the chief executive officer ceo and chief financial officer cfo of the company have furnished to the board the requisite compliance certificate under
regulation 178 of sebi lodr for the financial year ended march 31 2017

declaration on code of conduct

biocon group is committed to conducting its business in accordance with the applicable laws rules and regulations and with highest standards of business
ethics the company has adopted a code of ethics and business conduct which is applicable to all directors officers and employees

i hereby certify that the board members and senior management personnel of the company have affirmed compliance with the code of ethics and business
conduct for the year 201617



                                                                                                                                      for biocon limited

                                                                                                                                                    sd
bengaluru                                                                                                                         dr arun s chandavarkar
april 27 2017                                                                                                                     chief executive officer




                                                   this space has been intentionally left blank




154      ahead of the curve  annual report 2017

                                                                                                                                         biocon limited




auditors certificate on corporate governance
to
the members of biocon limited

we have examined the compliance of conditions of corporate governance by biocon limited for the year ended 31 march 2017 as per regulations 17 to 27
clauses b to i of regulation 462 and paragraphs c d and e of schedule v of securities and exchange board of india listing obligations and disclosure
requirements regulations 2015 listing regulations

managements responsibility

the companys management is responsible for compliance of conditions of corporate governance requirements as stipulated under the listing regulations
this responsibility includes the design implementation and maintenance of corporate governance process relevant to the compliance of the conditions
responsibility also includes collecting collating and validating data and designing implementing and monitoring of corporate governance process suitable
for ensuring compliance with the above mentioned listing regulations

auditors responsibility

pursuant to the requirements of the above mentioned listing regulations our examination was limited to procedures and implementation thereof adopted
by the company for ensuring the compliance of the conditions of the corporate governance it is neither an audit nor an expression of opinion on the
financial statements of the company

we conducted our examination of the corporate governance compliance by the company as per the guidance note on reports or certificates for special
purposes revised 2016 issued by the institute of chartered accountants of india icai the guidance note requires that we comply with the ethical
requirements of the code of ethics issued by the icai

we have complied with the relevant applicable requirements of the standard on quality control sqc 1 quality control for firms that perform audits and
reviews of historical financial information and other assurance and related services engagements

opinion

in our opinion and to the best of our information and according to the explanations given to us we certify that the company has complied with the
conditions of corporate governance as per regulations 17 to 27 clause b to i of regulation 462 and paragraph c d and e of schedule v of the listing
regulations as applicable

we state that such compliance is neither an assurance as to the future viability of the company nor the efficiency or effectiveness with which the management
has conducted the affairs of the company

restriction on use

this certificate has been solely issued for the purpose of complying with the aforesaid regulations and may not be suitable for any other purpose
accordingly we do not accept or assume any liability or duty of care for any other purpose or to any other person to whom this report is shown or into whose
hands it may come save where expressly agreed by our prior consent in writing

for b s r  co llp
chartered accountants
firm registration number 101248ww100022



s sethuraman
partner
membership number 203491

place bengaluru
date 27 april 2017




                                                                                                          corporate governance report                  155

business responsibility report
pursuant to regulation 342f of the securities and exchange board of india listing obligations and disclosure requirements regulations 2015

section a general information about the company
1     corporate identity number cin of the company  l24234ka1978plc003417

2     name of the company biocon limited

3     registered address 20th km hosur road electronic city bangalore  560100

4     website  wwwbioconcom

5     email id  cosecretarybioconcom

6     financial year reported 01042016 to 31032017

7      sectors that the company is engaged in industrial activity codewise

 industrial group                    description
 021                                 manufacture of pharmaceuticals medicinal chemical and botanical products

as per national industrial classification  ministry of statistics and programme implementation

8     list three key productsservices that the company manufacturesprovides as in balance sheet

i     statins

ii    immunosuppressants

iii   insulin

9     total number of locations where business activity is undertaken by the company

a number of international locations 5 united states of america switzerland united kingdom malaysia and dubai

b number of national locations 3 manufacturing locations bengaluru hyderabad and vishakhapatnam  marketing offices in india

10    markets served by the company  localstatenationalinternational

in addition to serving indian markets the company has global footprints and serves markets of 120 countries

section b financial details of the company
1     paid up capital   1000 million

2     total turnover   27172 million

3     total profit after taxes  5193 million

4     total spending on corporate social responsibility csr as percentage of profit after tax  2

5     list of activities in which expenditure in 4 above has been incurred refer annexure 9 of the boards report on csr activities

section c other details
1     does the company have any subsidiary company companies  yes the company has 10 subsidiaries as on march 31 2017

2     do the subsidiary companycompanies participate in the br initiatives of the parent company if yes then indicate the number of such subsidiary
       companys 

       yes the companys subsidiary biocon academy participates in the br initiatives of the company

3     do any other entityentities eg suppliers distributors etc that the company does business with participate in the br initiatives of the company
       if yes then indicate the percentage of such entityentities less than 30 3060 more than 60 

as per corporate risk governance process suppliers and distributors work closely with supply chain on several risk mitigation programs including business
continuity plans geographic risk mitigation reducing environmental burden by using recycled solvents and training user teams inside the company to
manage product functioning and related hazards products where specific product handling and usage procedures set by suppliers are required to be
followed




156        ahead of the curve  annual report 2017

                                                                                                                                      biocon limited



section d br information
1     details of directordirectors responsible for br

       a   details of the directordirectors responsible for implementation of the br policypolicies

             i       din number  01596180

             ii      name  dr arun s chandavarkar

             iii     designation  ceo and joint managing director

       b   details of the br head

 no    particulars                                          details
 1      din number if applicable                           01596180
 2      name                                                 dr arun s chandavarkar
 3      designation                                          ceo and joint managing director
 4      telephone number                                     080  2808 2808
 5      email  id                                           arunchandavarkarbioconcom

2     principlewise as per nvgs br policypolicies

       p1 businesses should conduct and govern themselves with ethics transparency and accountability

       p2 businesses should provide goods and services that are safe and contribute to sustainability throughout their life cycle

       p3 businesses should promote the wellbeing of all employees

       p4 businesses should respect the interests of and be responsive towards all stakeholders especially those who are disadvantaged vulnerable and
       marginalized

       p5 businesses should respect and promote human rights

       p6 businesses should respect protect and make efforts to restore the environment

       p7 businesses when engaged in influencing public and regulatory policy should do so in a responsible manner

       p8 businesses should support inclusive growth and equitable development

       p9 businesses should engage with and provide value to their customers and consumers in a responsible manner




                                                       this space has been intentionally left blank




                                                                                                         business responsibility report            157

                                                a   details of compliance reply in yn




158 
                                          no    questions                                   p1          p2             p3            p4            p5                p6               p7                p8                        p9
                                                                                          ethics      product       wellbeing responsiveness    respect        environmental        public        support inclusive        engagement with
                                                                                       transparency responsibility      of     to stakeholders   human          responsibility       policy            growth                  customers
                                                                                                                     employees                    rights                           advocacy
                                          1      do you have a policy policies for         y            y              y            y             y                 y                n                  y                        y
                                          2      has the policy being formulated in          y            y              y            y             y                 y                n                  y                        y
                                                 consultation with the relevant
                                                 stakeholders
                                          3      does the policy conform to any              y            y              y            n             y                 y                n                  y                        y
                                                 national  international standards
                                                 if
                                                 yes specify 50 words
                                          4      has the policy being approved by            y            y              y            y             y                 y                n                  y                        y
                                                 the board
                                                 is yes has it been signed by md
                                                 owner ceo appropriate board
                                                 director
                                          5      does the company have a                     y            y              y            n             y                 y                n                  y                        y
                                                 specified committee of the board




ahead of the curve  annual report 2017
                                                 director official to oversee the
                                                 implementation of the policy
                                          6      indicate the link for the policy to refer to the         y           refer to       y           refer to    httpwwwbiocon       n         httpwwwbiocon     httpwwwbioconcom
                                                 be viewed online                   table below                     the table                   the table   combiocon_aboutus_                  combiocon_csr_       biocon_invrelation_cor_
                                                                                                                       below                       below         ehspolicyasp                    about_policyasp      codeaspsublinkgover
                                          7      has the policy been formally                y            y              y            y             y                 y                n                  y                        y
                                                 communicated to all relevant
                                                 internal
                                                 and external stakeholders
                                          8      does the company have inhouse              y              y            y            y             y                 y                n                  y                        y
                                                 structure to implement the policy                  policy being
                                                 policies                                             uploaded
                                                                                                        in local
                                                                                                       intranet
                                          9      does the company have a                     y            y              y            y             y                 y                n                  y                        y
                                                 grievance redressal mechanism
                                                 related to the policy policies to
                                                 address stakeholders grievances
                                                 related to the policy policies
                                          10     has the company carried out                 y            y              y            n             y                 y                n                  n                        y
                                                 independent audit evaluation of
                                                 the working of this policy by an
                                                 internal or external agency

                                          note 1 the company doesnt have a formal all stakeholder responsiveness policy however specific stakeholder engagement policies exist like biocon communications policy and social media policy for
                                          internal and external stakeholders which also outlines the issue management and crisis communications sop it has been companys practice to upload all policies on biospace the intranet site for the
                                          information and implementation by the internal stakeholders

                                          note 2 public policy advocacy is yet to be formulated however the company plays a strong role in public policy advocacy through regular engagement with specific external stakeholders including
                                          industry associations government bodies and regulatory departments

                                                                                                                                          biocon limited



principle 1 businesses should conduct and      principle 3 businesses should promote the                principle 5 businesses should respect and
govern themselves with ethics transparency and wellbeing of all employees                                promote human rights
accountability
code of conduct                                       code of conduct                                     code of conduct
standing orders                                       employment policy
                                                      standing orders

it has been companys practice to upload all policies on the intranet site for information and implementation by the internal stakeholders however code of
conduct integrity policy which is applicable to both internal and external stakeholders are available on the companys website wwwbioconcom

3      governance related to br
        i    indicate the frequency with which the board of directors committee of the board or ceo meet to assess the br performance of the company
              within 3 months 36 months annually more than 1 year

              corporate social responsibility committee of the board meets at an interval of six months to assess the br performance of the company

        ii   does the company publish a br or a sustainability report what is the hyperlink for viewing this report how frequently it is published 

              this maiden br report is being published annually as part of the companys annual report in compliance with the provisions of sebi listing
              obligations and disclosure requirements regulations 2015

              the hyperlink for viewing the report is httpwwwbioconcombiocon_invrelation_annualreportsaspsublinkfinance

section e principle  wise performance
principle 1 businesses should conduct and govern themselves with ethics transparency and accountability

1      does the policy relating to ethics bribery and corruption cover only the company yes no does it extend to the groupjoint ventures suppliers
        contractorsngos others

        no it extends to groupjoint venturescontractors etc

2      how many stakeholder complaints have been received in the past financial year and what percentage was satisfactorily resolved by the management
        if so provide details thereof in about 50 words or so

closed                                                                        1
pending management review                                                     1
yet to commence investigation                                               2
total                                                                         4

received during end of march 2017

company has a hotline for whistle blowing and any other concerns to be voiced any complaints received are addressed accordingly by authorized officials

principle 2 businesses should provide goods and services that are safe and contribute to sustainability throughout their life cycle

1      list up to 3 of your products or services whose design has incorporated social or environmental concerns risks andor opportunities

             anticholesterol agents

             human insulin

             immunosuppresants

2      for each such product provide the following details in respect of resource use energy water raw material etc per unit of productoptional

        a   reduction during sourcingproduction distribution achieved since the previous year throughout the value chain

              biocon believes that behaviours and practices throughout the value chain should contribute to sustainability our company prefers to enter
              into long term commitments with those suppliers who fulfil their responsibility towards society as well as environment initiatives are taken to
              improve awareness about legal compliances to enhance ecofriendly efficiencies and packaginglogistics improvements at the suppliers end
              supplier and transporter meets are held on a periodical basis where the company engages and encourages them to undertake sustainable
              practices across supply chain company drives its distribution plan using an erp enterprise resource planning system to optimize freight cost
              our approach is to add value in such a manner that not only are our products affordable and accessible but our practices are also sustainable
              and equitable

              along with spreading wellness through our products we also work for the welfare of the neighbourhood economy by sourcing local material
              and labour wherever possible local sourcing is also an environmentally sustainable option as decrease in logistics significantly reduces the
              carbon footprint




                                                                                                          business responsibility report                159

     b    reduction during usage by consumers energy water has been achieved since the previous year

            the company manufactures and distributes at its world class manufacturing facilities a wide range of small molecules biosimilars and
            fermentation based products with a diverse product portfolio and complex production processes calculating our environmental performance
            per product poses unique challenges however the company has taken several measures to reduce the consumption of energy and water biocon
            has adopted principles of natural resource conservation reuse reduce recycle waste minimization and renewable energy all manufacturing
            units are certified for ohsas 18001 and iso 14001 standards

            the waste generated in the companys operations is either recycled or disposed of in a responsible way in line with legal requirements all
            manufacturing facilities are zero discharge facilities and 100 of wastewater is recycled and reused back in the process or utilities water
            consumption forms an important part of our agenda at all our manufacturing units across india efforts are continuously underway to reduce
            our fresh water consumption

3   does the company have procedures in place for sustainable sourcing including transportation if yes what percentage of your inputs was sourced
     sustainably also provide details thereof in about 50 words or so

     yes the company has formulated an operating procedure to approve vendors materials are procured from approved vendors both local and
     international the quality assurance team of the company conducts periodic audit of the vendors especially those who supply key materials on
     various parameters towards evaluating business sustainability our integrated scm function which encompasses multiple products verticals and
     manufacturing locations revolves around meticulous planning smart sourcing and disciplined monitoring some of the initiatives in place for
     sustainable sourcing are as below

     a     sourcing  vendor consolidation

            i     we believe that for strategic suppliers in the interest of business its best to have minimum touchpoints at multiple levels this helps
                   in driving a common corporate message across without it having to fly through multiple channels towards this sourcing strategies have
                   been consolidated for all plants at our bengaluru headquarters we strive to achieve a balance between the benefits of centralization
                   and decentralization

            ii    consolidating vendors also helps us in keeping transactions to a minimum thereby minimizing operational loads consolidating
                   requirements also helps in better planning and effective negotiations

     b     green supply chain

            i     biocon has made tremendous strides in moving from animalorigin to recombinant supply base for some of our key product portfolio
                   which includes insulins we believe this has contributed significantly to our environment friendly initiatives apart from being a social
                   cause in itself

            ii    sourcing team at biocon focus on use of green solvents which are nonpetrochemicals based eg ethanol for majority of our business
                   units thereby reducing the dependency on nonrenewable forms of energy

            iii   deployment of professional and regulatory compliant logistics providers helps in consolidating solvents deliveries which further helps
                   in achieving reduction in fuel cost per unit of solvent consumed at biocon

     c     periodic vendor evaluation

            i     all suppliers small medium and large are periodically evaluated on the basis of the supply performance matrices used to evaluate
                   include otif ontime infull deliveries  number of quality complaints

            ii    we conduct monthly reviews for each supply chain function to address issues with suppliers

            iii   we have also entrusted vendor evaluation to 3rd party international agencies like dun  bradstreet

4   has the company taken any steps to procure goods and services from local  small producers including communities surrounding their place of
     work

     if yes what steps have been taken to improve their capacity and capability of local and small vendors

     yes biocon has always strived to work and develop small and medium enterprises around its area of operation the company procures a considerable
     part of its goods and avails services from local and small vendors particularly those located around its manufacturing locations 1520 of our total
     supplier base are small and medium enterprises there is also a strong corporate directive of develop sourcing capabilities locally this enables us in
     achieving multiple benefits like

     a     shorter turnaround times for delivery

     b     quicker resolution of issues pertaining to material quality

     c     contribute to the local economy thereby enhancing sustainability of our operations

     besides we also help in long term capacity planning for such vendors by sharing forecasts for upto 12 months




160       ahead of the curve  annual report 2017

                                                                                                                                           biocon limited



5    does the company have a mechanism to recycle products and waste if yes what is the percentage of recycling of products and waste separately
      as 5 510 10 also provide details thereof in about 50 words or so

      yes a mechanism for recycling products as well as waste is in place in the company since the company is a zero liquid discharge facility 100 of
      wastewater is recycled and reused back in the process or utilities stp treated water is used for gardening in company premises thereby reducing
      usage of fresh water our hyderabad unit has managed to reduce their water consumption by around 30 100 of the used solvents is recovered
      a part of it is reused internally to reduce usage of fresh solvent and the rest is sent to recycling through our authorized recyclers efforts are made
      to further strengthen the recovery processes in a biologics b small molecules and c cross functional projects to drive further reduction in utilities
      and solvents through novel technology platforms which will help in making significant progress towards long term reduction in consumption of fresh
      solvents

principle 3 businesses should promote the wellbeing of all employees

company is committed to promote diversity in work place recognize the right to be heard and provide equal opportunity to all employees regardless of race
colour religion age gender sexual orientation national origin disability and other factors as may be covered in local labour laws no child labour unpaid
or any form of involuntary labour is encouraged employees have the right to work in an environment free from any form of discrimination which can be
considered harassing coercive or disruptive particularly behaviour that tantamount to sexual harassment

company ensures providing a safe healthy and clean working environment for all its employees employees are provided with transport and canteen
facilities at subsidised prices employee engagement activities are conducted regularly to maintain a healthy work environment comprehensive health
checkup is mandatory for all employees annually

company ensures timely and fair payment of wages in accordance to all applicable laws and standards wellbeing of all employees is a priority to the
company and all necessary steps are taken to ensure the same

2     i      please indicate the total number of employees                                                                                            4278
       ii    please indicate the total number of employees hired on temporarycontractualcasual basis                                                1466
       iii   please indicate the number of permanent women employees                                                                                    505
       iv    please indicate the number of permanent employees with disabilities                                                                           5

3     do you have an employee association that is recognized by management                                                  no
4     what percentage of your permanent employees is members of this recognized employee association                        na
5     please indicate the number of complaints relating to child labour forced labour involuntary labour sexual           child labour  nil
       harassment in the last financial year and pending as on the end of the financial year                                forced labour  nil
                                                                                                                              involuntary labour  nil
                                                                                                                              sexual harassmentsh  7
                                                                                                                              sh pending closure  3

        received in mar 2017

6    what percentage of your under mentioned employees were given safety  skill upgradation training in the last year

                                                                                                                          skill upgradation             safety
 permanent employees                                                                                                                  74                59
 permanent women employees                                                                                                            98                77
 casualtemporarycontractual employees                                                                                                 2              100
 employees with disabilities                                                                                                          67                83


principle 4 businesses should respect the interests of and be responsive towards all stakeholders especially those who are disadvantaged vulnerable
and marginalized

1    has the company mapped its internal and external stakeholders yesno

      yes the stakeholders have been mapped and the key categories are as below

      i       government and regulatory authorities

      ii      employees

      iii     customers

      iv      local community

      v       investors and shareholders

      vi      suppliers




                                                                                                           business responsibility report                161

2    out of the above has the company identified the disadvantaged vulnerable  marginalized stakeholders

      yes the company has identified the disadvantaged and marginalized stakeholders biocon foundation  the csr arm works with marginalized
      and underserved communities to promote social and economic inclusion by ensuring that these marginalized communities have equal access to
      healthcare services and educational opportunities

3    are there any special initiatives taken by the company to engage with the disadvantaged vulnerable and marginalized stakeholders if so provide
      details thereof in about 50 words or so

      biocons csr initiative has a vision to promote social and economic inclusion by ensuring that marginalised communities have equal access to
      healthcare services and educational opportunities

      healthcare

      we have focused on primary healthcare by establishing e laj smart clinics to ensure that rural poor have access to efficient health management
      via competent clinical care generic medicines and standard diagnostic tests we also provide services for early detection and prevention of non
      communicable diseases like cancers diabetes and hypertension the primary objective of the program is to eliminate health disparities among the
      poor address social determinants of health develop care pathways educate and disseminate information on health and wellbeing

      education

      since education holds the key to progress biocon has made concentrated efforts to empower rural indian youth aiming to provide computer
      aided learning extracurricular activities life skills education and english language skills for rural children the foundation has spearheaded several
      education programs such as chinnara ganitha which seeks to strengthen the learning of basic maths concepts aata paata wadi an afterschool
      resource center for children from local government schools kelsa an initiative that tries to inexpensively reach out to lowincome staff in biocons
      campuses

      community development

      the foundation also provides support for infrastructure in some of the villages like a community centre primary health clinic proper sanitation and
      safe drinking water rain water harvesting facilities water purification system etc more importantly biocon has built a new village to resettle villagers
      of mangalgudda in north karnataka which was washed away in floods a few years ago

      the companys efforts were directed at constructing 400 new houses equipped with toilets and solar lights for each house

principle 5 businesses should respect and promote human rights

1    does the policy of the company on human rights cover only the company or extend to the groupjoint ventures suppliers contractors ngos
      others

      no it extends to groupjoint ventures contractors etc

2    how many stakeholder complaints have been received in the past financial year and what percent was satisfactorily resolved by the management

        received during the financial year 201617                                                                                                             2
        resolved during the financial year 201617                                                                                                             2
        percentage satisfactorily resolved                                                                                                                100

principle 6 business should respect protect and make efforts to restore the environment

1    does the policy related to principle 6 cover only the company or extends to the groupjoint ventures suppliers contractorsngosothers

      yes biocon has a well defined environment health  safety policy in place to motivate employees so as to minimize environmental impacts and to
      prevent injuries and ill health at workplace it covers all our internal and external stakeholders and extends to the group joint ventures suppliers
      contractors and other stakeholders like ngos who work with us the policy is communicated to all our stakeholders to ensure that they are in
      compliance with the policy

      adherence to ehs policy is emphasized to all stake holders by the top management as well as through appropriate communications within the
      company

2    does the company have strategies initiatives to address global environmental issues such as climate change global warming etc yn if yes
      please give hyperlink for webpage etc

      yes commitment pertaining to global warming climate change and biodiversity is clearly stressed in the companys ehs policy relevant projects and
      initiatives are in place

      hyperlink for the webpage httpwwwbioconcombiocon_aboutus_ehspolicyasp

3    does the company identify and assess potential environmental risks yn

      yes aspect impact identification methodology is in place to assess and identify environmental risks for all the activities new projects and any
      modifications




162       ahead of the curve  annual report 2017

                                                                                                                                         biocon limited



4    does the company have any project related to clean development mechanism if so provide details thereof in about 50 words or so also if yes
      whether any environmental compliance report is filed

      as on date the company does not have any project registered with clean development mechanism cdm but the company has various projects
      related to clean technology and we strive to identify cdm potential in all of our projects some of the projects in line with cdm methodologies in our
      company are

             switching over to piped natural gas to fuel boilers instead of conventional fossil fuels thus reducing our ghg emissions

             usage of biogas generated by our effluent treatment unit anaerobic digesters as a cofuel in boilers

             usage of solar energy for water heating and lighting purposes

             35 of our power requirements is sourced from wind energy

      currently we are exploring opportunities of registering a cdm project in the near future

5    has the company undertaken any other initiatives on  clean technology energy efficiency renewable energy etc yn if yes please give hyperlink
      for web page etc

      yes few of the energy efficiency clean technology and renewable energy projects implemented at our sites are

      i      installation of energy efficient centrifugal air compressors

      ii     installation of led lighting to replace fluorescent lamps

      iii    power trading through indian energy exchange

      iv     installation of energy efficient air blower motors

      v      reduction in co2 emissions by using png piped natural gas for steam generation

      vi     35 of our power requirements is sourced from wind energy

      vii    installation of solar powered lighting

      viii   installation of waste steam recovery system

      intranetlink httpsbionetinbioconcomceehsirbp_layouts15wopiframe2aspxsourcedocceehsirbpmanagement_review_report
      mrm 20report0620mrm2020160220mrm2020pdfpdfactiondefault

6    are the emissionswaste generated by the company within the permissible limits given by cpcbspcb for the financial year being reported

      yes air emissions and waste generated by the company are well within the permissible limits prescribed by the environmental regulators and
      reported for the last financial year

7    number of show causelegal notices received from cpcbspcb which are pending ie not resolved to satisfaction as on end of financial year

      there were no show causelegal notices received from cpcbspcb which are pending as at the end of financial year 1617

principle 7 businesses when engaged in influencing public and regulatory policy should do so in a responsible manner

1    is your company a member of any trade and chamber or association if yes name only those major ones that your business deals with

      cii idma kdpma karnataka chamber of commerce

2    have you advocatedlobbied through above associations for the advancement or improvement of public good yesno if yes specify the broad areas
      drop box governance and administration economic reforms inclusive development policies energy security water food security sustainable
      business principles others

      as a pioneering biotechnology company biocon engages with various stakeholders including various government departments to facilitate progressive
      and pragmatic policies that can address the daunting healthcare challenges of the country biocons cmd kiran mazumdar shaw is a biotech pioneer
      and well regarded globally she is passionate about enabling affordable healthcare and therefore contributes selflessly towards creating an enabling
      ecosystem that promotes science encourages startups and enables access to affordable universal healthcare biocons ceo is also the chairperson
      of the national cii committee on biotechnology which engages with the government to enable creation of an optimal biotech ecosystem

principle 8 businesses should support inclusive growth and equitable development

1    does the company have specified programmesinitiativesprojects in pursuit of the policy related to principle 8 if yes details thereof

      biocon believes that its corporate social responsibility lies in creating a comprehensive and integrated ecosystem that can deliver affordable and
      effective healthcare to the less privileged among indias rural and urban population we also support education initiatives that can impart better
      learning to the underprivileged students in rural schools and empower communities by providing proper infrastructure for self  sustained villages
      with health centres community centres schools sanitation water and source of light




                                                                                                         business responsibility report               163

      we understand that our csr efforts must be collaborative concentrated and comprehensive it must integrate private and public sector participation
      permeate social strata and expand its radius to reach the grassroots level  the poorest and the underserved citizens

primary healthcare service through elaj 

based on the core principles of integrated healthcare services biocon foundation has introduced elaj smart clinics across karnataka and rajasthan each
clinic has state of the art diagnostic equipment clinic and patient management software along with doctors technicians the eclinics provide access to
preventive and primary healthcare supported with robust screening and early detection programs digital record of patients case file on the elaj electronic
medical record system the multi parameter monitor mpm in the clinic collects the following vitals  blood pressure temperature random blood sugar
spo2 pulse rate height and weight

preventive healthcare 

biocon foundations primary healthcare program is well supported by our population based screening programmes and specialist clinics

early detection and prevention of oral cancer  mhealth program

eighty percent of the burden of oral cancer occurs in lowresource settings due to delayed presentation a community approach to ensure last mile reach
is critical to making this program impactful biocon foundation introduced the mhealth approach mobile health to connect specialists to remote rural
populations implemented since 2011 this program has reached around 20000 people individually  obtained risk profile and images of the lesions
electronically this program has empowered community health workers who are capable of identifying oral lesions  monitoring high risk groups biocon is
now running several pilots with the government of karnataka gok facilitate integration with the government screening programs

detection and prevention of cervical cancer screening

the high incidence of cervical cancer among indian women is a growing public health concern

biocon foundation has addressed this since may 2013 by developing a comprehensive program which not only looks towards preventive mechanisms but
also provides support services through free screening and subsidized treatment

the program focuses on

a    community information and education

b    conducting monthly screening services that includes pap smear pelvic breast and bimanual examination

c    effective followup and referral for further diagnosis andor treatment services at our tertiary care centres

breast cancer screening

biocon foundation has introduced a hand held device called intelligent breast exam ibe in order to conduct breast screening in its field practice areas it is
designed for geographies where most cancer cases are detected at a later stage or where there is limited no access to early detection of breast cancer the
device has an accuracy to detect clinically relevant breast lesions that is higher than 85 this device can be easily used by any healthworker or doctor its
a pain free process without radiation this device has helped the health worker conduct house to house breast cancer screening

diabetes and hypertension

we have built and successfully executed a multipronged holistic strategy to manage non communicable diseases with a focus on diabetes and hypertension
health promotion and prevention strategies are conducted in the communities to encourage healthy life styles and reduce the incidence of integrated risk
factors in addition we have incorporated psychosocial counselling to meet the emotional social and mental health needs of patients we conduct early
diagnosis through a combination of periodic and opportunistic screening of communities and provide handholding and referrals as and when required

balaspandana  management of malnutrition

this program supports the governments anganwadis by ensuring that children with severe acute malnutrition sam children receive regular health check
ups prescribed medicines and nutritional supplements this program has reached 1 25 000 malnourished children under the age of 5 years in bagalkot
district in karnataka

education

the company spearheaded several education programs such as chinnara ganitha which seeks to strengthen the learning of basic maths concepts aata
paata wadi an afterschool resource centre for children from local government schools kelsa an initiative that provides access to internet connected
computers and encourages informal selfpaced learning this program is run for support staff in the company

community development

community and school sanitation

in line with the swachh bharat mission and swachh vidyalaya program we have constructed toilets in 5 government primary schools  3 in anekal taluk near
bangalore and 2 in badami in bagalkot district we have also built 1000 plus household toilets in anekal and bagalkot districts in karnataka




164         ahead of the curve  annual report 2017

                                                                                                                                             biocon limited



project one

project one is a community drinking water initiative through this program we have installed water purification systems with ro and uv technology which
provide potable drinking water to the communities we serve the system has a capacity of purifying 500 litres of water in one hour and can provide drinking
water to communities of 5000 members we have installed these community water points in 3 locations

biocon nagar

biocon nagar is a village that consists of 411 houses that were built by biocon foundation for the mangalgudda community that was displaced by the floods
of 2009 each house has solar lights and an independent toilet the foundation has built a clinic for the community which provides medical consultation
medicines and diagnostic tests a school and community centre are also being built

girls hostel

biocon foundation in collaboration with shri vr deshpande memorial trust has established a ladies hostel for the economically weaker sections of the
society in haliyal north karnataka the hostel has dormitories with provision for 65 women young girls from surrounding and distant villages come to
haliyal to learn vocational skills this hostel provides safe and free accommodation for them

biocon academy

we have established biocon academy a centre for excellence of advanced learning in applied bio sciences this platform provides industry oriented training
programs and makes students industry ready

2    are the programmesprojects undertaken through inhouse teamown foundationexternal ngogovernment structuresany other organization

      the csr initiatives are primarily implemented in house and grants are provided for ngos that are doing impactful work

      the foundation has carried out these programs in the domain of healthcare education and community development for the past 12 years we also
      support ngos with small grants to implement projects

3    have you done any impact assessment of your initiative

      impact assessments are conducted continuously for some programs and at intervals for other programs

               the primary healthcare program is monitored and assessed on a continuous basis through live dashboards below is a snapshot of information
                from the dashboard

               annual patient footfall recorded is more than 100000 across 14 clinics 8 biocon foundation clinics 5 government of rajasthan primary
                health centres and 1 government of karnataka primary health centre disease profiles in each community is populated by the dashboard this
                helps with public health planning and developing better public health policies a listing of patients suffering from diseases can also be made
                available to facilitate follow up

               control rates of non communicable diseases ncds compliance with medications progress of illnesses can be monitored and patients can be
                counselled frequently

               effective follow up and referrals for patients visiting the clinic is possible the clinics have created a complete care pathway to address health
                concerns of the community

               accuracy of elaj data and data presentation through elaj dashboard for project evaluation are also impact indicators for the project

4    what is your companys direct contribution to community development projects amount in inr and the details of the projects undertaken

      refer annexure 8 of boards report on corporate social responsibility

5    have you taken steps to ensure that this community development initiative is successfully adopted by the community please explain in 50 words or
      so

      yes the steps taken to ensure that the programs are successfully adopted by the community can be illustrated with a few examples 

               increase in patient footfall in all the clinics show that the community is using our services we have tried to strengthen preventive and primary
                health services to reduce the burden on larger tertiary centres and reduce the number of in patients

               regular awareness and sensitization programs are conducted for the beneficiaries by a dedicated team of health workers  the last mile reach in
                the community we use iec material to train and educate our health workers and to create awareness amongst our beneficiaries about diseases
                and screening programs doctors consultation lab tests and medicines are provided at subsidized cost

               for noncommunicable diseases health promotion and prevention strategies are conducted in the communities to encourage healthy life styles
                and reduce the incidence of integrated risk factors

               we have introduced diabetes educator and counsellor who helps the patients with key selfcare points about diet exercise and drug compliance
                for optimal management of blood sugars

               behaviour change education is given to care givers of malnourished children health camps and regular growth monitoring of under nourished
                children has facilitated an upward growth trend in these children




                                                                                                             business responsibility report                 165

             rigorous training for care givers of malnourished children providing nutritional supplements and growth monitoring of under nourished
              children in health camps have reduced outliers

             cancer screening in low resource settings and quality care and referral has encouraged more individuals to participate in the screening process

             follow up and referrals as and when required have increased the patient footfall in our clinics

             training on operation and maintenance of school sanitation units have helped in maintaining the toilet facilities

             introducing a subscription mechanism for drinking water for project one has helped the community maintain the water purification system

principle 9 businesses should engage with and provide value to their customers and consumers in a responsible manner

1    what percentage of customer complaintsconsumer cases are pending as on the end of financial year

      there are no customer complaintsconsumer cases pending as on the end of financial year

2    does the company display product information on the product label over and above what is mandated as per local laws yesnonaremarks
      additional information

      no since the companys products are biopharmaceuticals only product information that is approved by the regulatory authorities is displayed on the
      product label

3    is there any case filed by any stakeholder against the company regarding unfair trade practices irresponsible advertising andor anticompetitive
      behaviour during the last five years and pending as on end of financial year if so provide details thereof in about 50 words or so

      nil

4    did your company carry out any consumer survey consumer satisfaction trends

      no however company is in process of conducting a formal survey for the financial year 201718




                                                     this space has been intentionally left blank




166         ahead of the curve  annual report 2017

                                                                                                                                         biocon limited




independent auditors report
to the members of biocon limited

report on the standalone indian accounting standards ind as financial statements
we have audited the accompanying standalone ind as financial statements of biocon limited the company which comprise the balance sheet as at
31march 2017 the statement of profit and loss including other comprehensive income the statement of cash flows and the statement of changes in equity
for the year then ended and a summary of the significant accounting policies and other explanatory information herein after referred to as standalone ind
as financial statements

managements responsibility for the standalone ind as financial statements
the companys board of directors is responsible for the matters stated in section 1345 of the companies act 2013 the act with respect to the
preparation of these standalone ind as financial statements that give a true and fair view of the financial position financial performance including other
comprehensive income cash flows and changes in equity of the company in accordance with the accounting principles generally accepted in india including
the ind as prescribed under section 133 of the act read with relevant rules issued thereunder

this responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the act for safeguarding the assets of the
company and for preventing and detecting frauds and other irregularities selection and application of appropriate accounting policies making judgments
and estimates that are reasonable and prudent and design implementation and maintenance of adequate internal financial controls that were operating
effectively for ensuring the accuracy and completeness of the accounting records relevant to the preparation and presentation of the standalone ind as
financial statements that give a true and fair view and are free from material misstatement whether due to fraud or error

auditors responsibility
our responsibility is to express an opinion on these standalone ind as financial statements based on our audit

we have taken into account the provisions of the act the accounting and auditing standards and matters which are required to be included in the audit
report under the provisions of the act and the rules made thereunder

we conducted our audit in accordance with the standards on auditing specified under section 14310 of the act those standards require that we comply
with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the standalone ind as financial statements are
free from material misstatement

an audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the standalone ind as financial statements the
procedures selected depend on the auditors judgment including the assessment of the risks of material misstatement of the standalone ind as financial
statements whether due to fraud or error in making those risk assessments the auditor considers internal financial control relevant to the companys
preparation of the standalone ind as financial statements that give a true and fair view in order to design audit procedures that are appropriate in the
circumstances an audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates
made by the companys directors as well as evaluating the overall presentation of the standalone ind as financial statements

we believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the standalone ind as financial
statements

opinion
in our opinion and to the best of our information and according to the explanations given to us the aforesaid standalone ind as financial statements give
the information required by the act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted
in india including the ind as of the financial position of the company as at 31 march 2017 and its financial performance including other comprehensive
income its cash flows and the changes in equity for the year ended on that date

other matters
the comparative financial information of the company for the year ended 31 march 2016 and the transition date opening balance sheet as at 1 april
2015 included in these standalone ind as financial statements are based on the previously issued statutory financial statements prepared in accordance
with the companies accounting standards rules 2006 audited by the predecessor auditor whose report for the year ended 31 march 2016 and
31 march 2015 dated 26 april 2016 and 29 april 2015 respectively expressed an unmodified opinion on those standalone financial statements as adjusted
for the differences in the accounting principles adopted by the company on transition to the ind as which have been audited by us

our opinion is not modified in respect of this matter

report on other legal and regulatory requirements
1    as required by the companies auditors report order 2016 the order issued by the central government of india in terms of section 14311 of
      the act we give in annexure a a statement on the matters specified in the paragraph 3 and 4 of the order

2    as required by section 1433 of the act we report that

      a    we have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the
             purposes of our audit




                                                                                                                            financial report           167

      b    in our opinion proper books of account as required by law have been kept by the company so far as it appears from our examination of those
             books

      c    the balance sheet the statement of profit and loss the statement of cash flows and statement of changes in equity dealt with by this report are
             in agreement with the books of account

      d    in our opinion the aforesaid standalone ind as financial statements comply with the indian accounting standards specified under section 133
             of the act read with relevant rules issued thereunder

      e    on the basis of the written representations received from the directors as on 31 march 2017 taken on record by the board of directors none of
             the directors is disqualified as on 31 march 2017 from being appointed as a director in terms of section 1642 of the act

      f    with respect to the adequacy of the internal financial controls over financial reporting of the company and the operating effectiveness of such
             controls refer to our separate report in annexure b and

      g    with respect to the other matters to be included in the auditors report in accordance with rule 11 of the companies audit and auditors rules
             2014 in our opinion and to the best of our information and according to the explanations given to us

             i     the company has disclosed the impact of pending litigations on its financial position in its standalone ind as financial statements refer
                    note 36 to the standalone ind as financial statements

             ii    provision has been made in the financial statements as required under the applicable law or accounting standards for the material
                    foreseeable losses if any on longterm contracts including derivative contracts refer note 39 to the standalone ind as financial
                    statements

             iii   there has been no delay in transferring amounts required to be transferred to the investor education and protection fund by the
                    company and

             iv    the company has provided requisite disclosures in its standalone ind as financial statements as to holdings as well as dealings in
                    specified bank notes during the period from 8 november 2016 to 30 december 2016 based on audit procedures and relying on the
                    management representation we report that the disclosures are in accordance with books of account maintained by the company and as
                    produced to us by the management refer note 37 to the standalone ind as financial statements



for b s r  co llp
chartered accountants
firm registration number 101248ww100022



s sethuraman
partner
membership number 203491

place bengaluru
date 27 april 2017




168        ahead of the curve  annual report 2017

                                                                                                                                              biocon limited




annexure  a to the independent auditors report
the annexure referred to in independent auditors report to the members of the company on the standalone ind as financial statements of biocon limited
for the year ended 31 march 2017 we report that

i     a   the company has maintained proper records showing full particulars including quantitative details and situation of property plant and
              equipment

        b   the company has a regular programme of physical verification of its property plant and equipment by which all property plant and equipment
              are verified in a phased manner over a period of three years in our opinion this periodicity of physical verification is reasonable having regard
              to the size of the company and the nature of its assets in accordance with this programme certain property plant and equipment were verified
              during the year and no material discrepancies were noticed on such verification

        c   according to the information and explanations given to us and basis our examination of the records of the company the title deeds of
              immovable properties are held in the name of the company except for one immovable property amounting to  35 million as at 31 march 2017
              for which the company is in the process of obtaining registration

ii    inventories apart from goods in transit and inventories lying with outside parties have been physically verified by the management during the year
        and the discrepancies noticed on such verification between the physical stock and book records were not material in our opinion the frequency of
        such verification is reasonable inventories lying with outside parties has been substantially confirmed by them as at the yearend and no material
        discrepancies were noticed in respect of such confirmations

iii   the company has granted loan to a company covered in the register maintained under section 189 of the companies act 2013 the act

        a   in our opinion the rate of interest and other terms and conditions on which the loan had been granted to the company listed in the register
              maintained under section 189 of the act was not prima facie prejudicial to the interest of the company

        b   in the case of the loan granted covered in the register maintained under section 189 of the act the borrower has been regular in the payment
              of the principal and interest as stipulated

        c   there are no overdue amounts in respect of the loan granted to a company covered in the register maintained under section 189 of the act

iv    in our opinion and according to the information and explanations given to us the company has complied with the provisions of section 185 and 186
        of the act with respect to the loans given investments made and guarantees and securities given

v     the company has not accepted any deposits from the public

vi    we have broadly reviewed the books of accounts maintained by the company pursuant to the companies cost records and audit rules 2014 as
        amended prescribed by the central government under section 148 of the act and are of the opinion that prima facie the prescribed accounts and
        records have been made and maintained however we have not made a detailed examination of such records

vii   a   according to the information and explanations given to us and on the basis of our examination of the records of the company amounts
              deducted accrued in the books of account in respect of undisputed statutory dues including provident fund employees state insurance
              incometax sales tax value added tax duty of customs excise duty service tax cess and other material statutory dues have been regularly
              deposited during the year with the appropriate authorities

              according to the information and explanations given to us no undisputed amounts payable in respect of provident fund employees state
              insurance income tax sales tax value added tax duty of customs excise duty service tax cess and other material statutory dues were in arrears
              as at 31 march 2017 for a period of more than six months from the date they became payable

        b   according to the information and explanations given to us there are no dues of income tax sales tax value added tax service tax duty of customs
              duty of excise which have not been deposited with the appropriate authorities on account of any disputes other than the following dues

               name of the statute        nature of dues               amount      amount paid period to which the amount            forum where dispute is
                                                                      disputed    under protest relates                              pending
                                                                  in million     in million
               incometax act 1961       income tax                         4                 4 199697                             supreme court
               incometax act 1961       income tax                    1207                111 200910 201213  201314          commissioner appeals
               incometax act 1961       income tax                    1053                117 200809 201011  201112 income tax appellate
                                                                                                                             tribunal itat
               incometax act 1961       income tax                         4                 4 199798                             high court
               finance act 1994          service tax                       54                   march 2010                  commissioner appeals
                                                                                                  april 2009 to march 2013
                                                                                                  march 2009 to december 2011
                                                                                                  july 2009 to march 2013
               finance act 1994          service tax                       91                   may 2006 to september 2010 customs excise and
                                                                                                  october 2010 to march 2011 service tax appellate
                                                                                                  march 2006 to march 2010   tribunal cestat
                                                                                                  200708



                                                                                                                                 financial report           169

               name of the statute       nature of dues             amount      amount paid period to which the amount         forum where dispute is
                                                                   disputed    under protest relates                           pending
                                                               in million     in million
               finance act 1994         service tax                      1                 january 2009 to may 2012         additional commissioner
                                                                                             june 2010 to june 2012
               finance act 1994         service tax                     11                 april 2014 to march 2015          principal commissioner
                                                                                                                               ltu
               value added tax act      value added tax                  1                 200607                           commissioner appeals
               2005
               the central excise act   excise duty                   361               53 april 2005 to march 2008           cestat
               1944                                                                         200607 to 200809
                                                                                            200910 to 201213
               the central excise act   excise duty                      1                 200910 to 201213                commissioner appeals
               1944
               the central excise act   excise duty                     15                 200708 to 201112                commissioner appeals
               1944                                                                          september 2013 to october
                                                                                             2013
               the customs act 1962     customs duty                     4                3 1994 till 2008                    cestat
               the customs act 1962     customs duty                     4                4 2005 till 2011                    commissioner appeals

viii in our opinion and according to the information and explanations given to us the company has not defaulted in repayment of dues to banks financial
       institutions or government the company did not have any borrowings during the year by way of debentures

ix    according to the information and explanations given to us the company has not raised any money by way of public issue or further public offer
        including debt instruments during the year the term loans raised by the company have been applied for the purpose for which they were raised

x     according to the information and explanations given to us no fraud by the company or on the company by its officers or employees has been noticed
        or reported during the year

xi    according to the information and explanations given to us and based on our examination of the records of the company the company has paid
        provided for managerial remuneration in accordance with the requisite approvals as per provisions of section 197 read with schedule v to the act

xii   in our opinion and according to the information and explanations given to us the company is not a nidhi company

xiii according to the information and explanations given to us and based on our examination of the records of the company transactions with the
       related parties are in compliance with sections 177 and 188 of the act where applicable and details of such transactions have been disclosed in the
       standalone ind as financial statements as required by the applicable accounting standards

xiv according to the information and explanations given to us and based on our examination of the records of the company the company has
      not made any preferential allotment or private placement of shares or fully or partly convertible debentures during the year accordingly
      para 3 xiv of the order is not applicable

xv    according to the information and explanations given to us and based on our examination of the records of the company the company has not entered
        into noncash transactions with directors or persons connected with him

xvi according to the information and explanations given to us the company is not required to be registered under section 45ia of the reserve bank of
      india act 1934



for b s r  co llp
chartered accountants
firm registration number 101248ww100022



s sethuraman
partner
membership number 203491

place bengaluru
date 27 april 2017




170        ahead of the curve  annual report 2017

                                                                                                                                             biocon limited




annexure  b to the independent auditors report of even date on
the standalone financial statements of biocon limited
report on the internal financial controls under clause i of subsection 3 of section 143 of the companies act 2013 the act

we have audited the internal financial controls over financial reporting of biocon limited the company as of 31 march 2017 in conjunction with our audit
of the standalone ind as financial statements of the company for the year ended on that date

managements responsibility for internal financial controls
the companys management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting
criteria established by the company considering the essential components of internal control stated in the guidance note on audit of internal financial
controls over financial reporting guidance note issued by the institute of chartered accountants of india icai these responsibilities include the design
implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of
its business including adherence to companys policies the safeguarding of its assets the prevention and detection of frauds and errors the accuracy and
completeness of the accounting records and the timely preparation of reliable financial information as required under the companies act 2013

auditors responsibility
our responsibility is to express an opinion on the companys internal financial controls over financial reporting based on our audit we conducted our audit
in accordance with the guidance note on audit of internal financial controls over financial reporting the guidance note and the standards on auditing
issued by icai and deemed to be prescribed under section 14310 of the companies act 2013 to the extent applicable to an audit of internal financial
controls both applicable to an audit of internal financial controls and both issued by the institute of chartered accountants of india those standards
and the guidance note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether
adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects

our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting
and their operating effectiveness our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial
controls over financial reporting assessing the risk that a material weakness exists and testing and evaluating the design and operating effectiveness of
internal control based on the assessed risk the procedures selected depend on the auditors judgment including the assessment of the risks of material
misstatement of the financial statements whether due to fraud or error

we believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the companys internal
financial controls system over financial reporting

meaning of internal financial controls over financial reporting
a companys internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial
reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles a companys
internal financial control over financial reporting includes those policies and procedures that 1 pertain to the maintenance of records that in reasonable
detail accurately and fairly reflect the transactions and dispositions of the assets of the company 2 provide reasonable assurance that transactions
are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles and that receipts
and expenditures of the company are being made only in accordance with authorisations of management and directors of the company and 3 provide
reasonable assurance regarding prevention or timely detection of unauthorised acquisition use or disposition of the companys assets that could have a
material effect on the ind as financial statements

inherent limitations of internal financial controls over financial reporting
because of the inherent limitations of internal financial controls over financial reporting including the possibility of collusion or improper management
override of controls material misstatements due to error or fraud may occur and not be detected also projections of any evaluation of the internal financial
controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate
because of changes in conditions or that the degree of compliance with the policies or procedures may deteriorate

opinion
in our opinion the company has in all material respects an adequate internal financial controls system over financial reporting and such internal financial
controls over financial reporting were operating effectively as at 31 march 2017 based on the internal control over financial reporting criteria established
by the company considering the essential components of internal control stated in the guidance note on audit of internal financial controls over financial
reporting issued by the institute of chartered accountants of india

for b s r  co llp
chartered accountants
firm registration number 101248ww100022

s sethuraman
partner
membership number 203491

place bengaluru
date 27 april 2017


                                                                                                                                financial report           171

balance sheet as at march 31 2017
all amounts are in indian rupees million except share data and per share data unless otherwise stated
                                                                                             note     march 31 2017      march 31 2016    april 01 2015
assets
noncurrent assets
property plant and equipment                                                                3                8649               8596              8527
capital workinprogress                                                                     3                2408               1723                576
investment property                                                                          4                  439                 439                459
intangible assets                                                                            5                  292                 342                156
financial assets
i    investments                                                                          6                33635              32106            32492
ii   loans                                                                                7                 1923               1584             2447
iii other financial assets                                                               8a                 243                 670               373
incometax asset net                                                                                          414                 428               415
deferred tax asset net                                                                   18                 1054                                    
other noncurrent assets                                                                   9a               1847               1382             1471
total noncurrent assets                                                                                     50904              47270            46916
current assets
inventories                                                                                 10                5396               5046              4359
financial assets
i    investments                                                                         11                 5247               5983             1018
ii   trade receivables                                                                   12                 7982               5038             5033
iii cash and cash equivalents                                                            13                 3416               2903             3219
iv bank balances other than iii above                                                  13                   413               3527             3383
v    other financial assets                                                              8b                 983                 990               607
other current assets                                                                       9b                 348                 224               194
total current assets                                                                                         23785              23711            17813
total                                                                                                        74689              70981            64729

equity and liabilities
equity
equity share capital                                                                       14a              1000               1000             1000
other equity                                                                                                 64411              58966            56341
total equity                                                                                                 65411              59966            57341
noncurrent liabilities
financial liabilities
i    borrowings                                                                           15                1324               1365                114
ii   other financial liabilities                                                         16a                  2                   7                  6
provisions                                                                                 17a                133                  95                  
deferred tax liability net                                                                18                                       9                282
other noncurrent liabilities                                                              19a                767                 913                905
total noncurrent liabilities                                                                                 2226               2389              1307
current liabilities
financial liabilities
i    borrowings                                                                           20                                   2255               561
ii   trade payables                                                                       21                4505               3944             3008
iii other financial liabilities                                                          16b                663                 910             1385
provisions                                                                                 17b                320                 285               325
incometax liability net                                                                                      777                 729               584
other current liabilities                                                                  19b                787                 503               218
total current liabilities                                                                                     7052               8626             6081
total                                                                                                        74689              70981            64729
the accompanying notes are an integral part of the standalone financial statements
as per our report of even date attached
for b s r  co llp                                                                         for and on behalf of the board of directors of biocon limited
chartered accountants
firm registration number 101248ww100022
s sethuraman                                                                                kiran mazumdarshaw               arun chandavarkar
partner                                                                                     managing director                 joint managing director  ceo
membership no 203491                                                                      din 00347229                     din 01596180
                                                                                            siddharth mittal                  rajiv balakrishnan
                                                                                            president  finance  chief       company secretary
                                                                                            financial officer                 membership no f6326
bengaluru                                                                                   bengaluru
april 27 2017                                                                              april 27 2017


172       ahead of the curve  annual report 2017

                                                                                                                                         biocon limited




statement of profit and loss for the year ended march 31 2017
all amounts are in indian rupees million except share data and per share data unless otherwise stated
                                                                                                               note            year ended       year ended
                                                                                                                           march 31 2017   march 31 2016
income
revenue from operations                                                                                         22                26184             23354
other income                                                                                                    23                   988              1731
total income                                                                                                                      27172             25085


expenses
cost of raw materials and packing materials consumed                                                            24                 9915              9479
purchases of traded goods                                                                                                            902                760
changes in inventories of traded goods finished goods and workinprogress                                     25                 465              364
excise duty                                                                                                                          305                336
employee benefits expense                                                                                       26                 3650              3219
finance costs                                                                                                   27                    38                  19
depreciation and amortisation expense                                                                           28                 1506              1397
other expenses                                                                                                  29                 5963              5754
                                                                                                                                  21814             20600
less recovery of product development costs from codevelopment partners net                                  30                    4               48
total expenses                                                                                                                    21810             20552

profit before tax and exceptional item                                                                                              5362             4533

exceptional items net                                                                                          33                                   1061
profit before tax                                                                                                                   5362             5594
tax expense                                                                                                     35
current tax                                                                                                                        1269              2175
less mat credit entitlement                                                                                                      1172                 
deferred tax                                                                                                                          72              267
total tax expense                                                                                                                    169              1908

profit for the year                                                                                                                 5193             3686
other comprehensive income expense
i items that will not be reclassified subsequently to profit or loss
remeasurement on defined benefit plans                                                                                              27               16
income tax effect                                                                                                                       9                  6
                                                                                                                                     18               10
ii items that will be reclassified subsequently to profit or loss
effective portion of gainslosses on hedging instrument in cash flow hedges                                                        149                   
income tax effect                                                                                                                    47                  
                                                                                                                                     102                   
other comprehensive income expense for the year net of taxes                                                                       84               10
total comprehensive income for the year                                                                                             5277             3676
earnings per share                                                                                              32
basic in                                                                                                                         2645             1878
diluted in                                                                                                                       2627             1876
the accompanying notes are an integral part of the standalone financial statements
as per our report of even date attached
for b s r  co llp                                                                          for and on behalf of the board of directors of biocon limited
chartered accountants
firm registration number 101248ww100022
s sethuraman                                                                                 kiran mazumdarshaw               arun chandavarkar
partner                                                                                      managing director                 joint managing director  ceo
membership no 203491                                                                       din 00347229                     din 01596180
                                                                                             siddharth mittal                  rajiv balakrishnan
                                                                                             president  finance  chief       company secretary
                                                                                             financial officer                 membership no f6326
bengaluru                                                                                    bengaluru
april 27 2017                                                                               april 27 2017



                                                                                                                             financial report          173

statement of changes in equity for the year ended march 31 2017
all amounts are in indian rupees million except share data and per share data unless otherwise stated

a equity share capital           march 31    march 31
                                       2017         2016
opening balance                        1000        1000
changes in equity share capital                         
closing balance                        1000        1000


b other equity
particulars                       securities revaluation general retained      sez re              share     treasury cash flow    other items total
                                   premium       reserve reserve earnings investment                based       shares  hedging        of other other
                                    reserve                                   reserve            payment                reserves comprehensive equity
                                                                                                  reserve                               income
balance at april 01 2015              2788             9    3458    50180                        328        427                           5 56341
profit for the year                                                  3686                                                                     3686
other comprehensive income                                                                                                            10     10
net of tax
transactions recorded directly
in equity
dividend including dividend                                         1107                                                                 1107
distribution tax
purchase of treasury shares                                                                                150                              150
share based payment                                                                              107                                            107
exercise of share options                                               99                                                                       99
balance at march 31 2016              2788             9   3458     52858                        435        577                         5 58966
profit for the year                                                  5193                                                                     5193
other comprehensive income                                                                                             102              18      84
net of tax
transactions recorded directly
in equity
share based payment                                                                              125                                            125
purchase of treasury shares                                                                                150                              150
transfer to special economic                                          162          162                                                            
zone sez reinvestment
reserve
transfer from sez reinvestment                                        162         162                                                            
reserve on utilization
exercise of share options                 120                           193                      120                                            193
balance at march 31 2017              2908             9   3458     58244                        440        727        102              23 64411

the accompanying notes are an integral part of the standalone financial statements
as per our report of even date attached

for b s r  co llp                                                                            for and on behalf of the board of directors of biocon limited
chartered accountants
firm registration number 101248ww100022
s sethuraman                                                                                   kiran mazumdarshaw            arun chandavarkar
partner                                                                                        managing director              joint managing director  ceo
membership no 203491                                                                         din 00347229                  din 01596180
                                                                                               siddharth mittal               rajiv balakrishnan
                                                                                               president  finance  chief    company secretary
                                                                                               financial officer              membership no f6326
bengaluru                                                                                      bengaluru
april 27 2017                                                                                 april 27 2017




174       ahead of the curve  annual report 2017

                                                                                                                         biocon limited




statement of cash flows for the year ended march 31 2017
all amounts are in indian rupees million except share data and per share data unless otherwise stated
                                                                                                            march 31 2017   march 31 2016
i     cash flows from operating activities
      profit for the year                                                                                           5193            3686
      adjustments to reconcile profit for the year to net cash flows
      depreciation and amortisation expense                                                                         1506            1397
      unrealised foreign exchange gainloss                                                                         213               55
      sharebased compensation expense                                                                                125              107
      provisionreversal of provision for doubtful debts                                                             16              43
      bad debts written off                                                                                                             8
      interest expense                                                                                                 38               19
      interest income                                                                                                669            727
      net gain on financial assets measured at fair value through profit or loss                                      69                
      dividend income                                                                                                 13            618
      net gain on sale of investments                                                                                 39          1077
      tax expense                                                                                                     169            1908
      operating profit before working capital changes                                                               6470            4715


      movements in working capital
      decreaseincrease in inventories                                                                             350            687
      decreaseincrease in trade receivables                                                                     3077            165
      decreaseincrease in other assets                                                                            736          1123
      increasedecrease in trade payable other liabilities and provisions                                          758            1397
      cash generated from operations                                                                                3065            4137
      direct taxes paid net of refunds                                                                           1207          2052
      net cash flow generated from operating activities                                                             1858            2085


ii    cash flows from investing activities
      purchase of tangible assets                                                                                  2276          2202
      acquisition of intangible assets                                                                                31            232
      proceeds from sale of fixed assets                                                                                2                7
      loan given to subsidiaries                                                                                     957          1979
      recovery of loans from subsidiaries                                                                           1162            3707
      purchase of investments                                                                                     28008         34350
      proceeds from sale of investments                                                                            25007           35254
      investment in bank deposits and inter corporate deposits                                                     3250          6944
      redemptionmaturity of bank deposits and inter corporate deposits                                             8679            2395
      interest received                                                                                               763              515
      dividend received                                                                                                13              618
      net cash flow generated fromused in investing activities                                                   1104           3211


iii   cash flows from financing activities
      purchase of treasury shares                                                                                    150            150
      proceeds from exercise of share options                                                                         193               99
      proceeds from longterm borrowings                                                                                            1324
      repayment of longterm borrowings                                                                               75            140
      proceedsrepayment of shortterm borrowings net                                                          2312           1716
      dividend paid on equity shares including tax thereon                                                                         2107
      interest paid                                                                                                   39             12
      net cash flow generated fromused in financing activities                                                  2383             730




                                                                                                              financial report        175

statement of cash flows for the year ended march 31 2017 contd
all amounts are in indian rupees million except share data and per share data unless otherwise stated
                                                                                                                           march 31 2017    march 31 2016
iv    net increasedecrease in cash and cash equivalents i  ii  iii                                                            579              396


v     effect of exchange differences on cash and cash equivalents held in foreign currency                                            64               78


vi    cash and cash equivalents at the beginning of the year                                                                        2901             3219


vii   cash and cash equivalents at the end of the year iv  v  vi                                                                3416             2901


      reconciliation of cash and cash equivalents as per statement of cash flow
      cash and cash equivalents note 13
         balances with banks  on current accounts                                                                                  3410             2653
                                on unpaid dividend accounts                                                                           6                10
         deposits with original maturity of less than 3 months                                                                                         240
                                                                                                                                    3416             2903
      bank overdraftscash credits note 20                                                                                                            2
      balance as per statement of cash flows                                                                                        3416             2901
       the company can utilize these balances only towards settlement of the respective unpaid dividend liabilities
the accompanying notes are an integral part of the standalone financial statements
as per our report of even date attached

for b s r  co llp                                                                          for and on behalf of the board of directors of biocon limited
chartered accountants
firm registration number 101248ww100022
s sethuraman                                                                                 kiran mazumdarshaw               arun chandavarkar
partner                                                                                      managing director                 joint managing director  ceo
membership no 203491                                                                       din 00347229                     din 01596180
                                                                                             siddharth mittal                  rajiv balakrishnan
                                                                                             president  finance  chief       company secretary
                                                                                             financial officer                 membership no f6326
bengaluru                                                                                    bengaluru
april 27 2017                                                                               april 27 2017




                                                   this space has been intentionally left blank




176      ahead of the curve  annual report 2017

                                                                                                                                          biocon limited




notes to the standalone financial statements                                                            for the year ended march 31 2017
all amounts are in indian rupees million except share data and per share data unless otherwise stated

1    company overview
11   reporting entity
      biocon limited biocon or the company is engaged in the manufacture of biotechnology products and research services the company is a public
      limited company incorporated and domiciled in india and has its registered office in bengaluru karnataka india the companys shares are listed on
      the bombay stock exchange bse and the national stock exchange nse in india
12   basis of preparation of financial statements
      a    statement of compliance
            the standalone financial statements have been prepared in accordance with indian accounting standards ind as as per the companies indian
            accounting standards rules 2015 notified under section 133 of companies act 2013 the act and other relevant provisions of the act
            the companys standalone financial statements up to and for the year ended march 31 2016 were prepared in accordance with the companies
            accounting standards rules 2006 notified under section 133 of the act read together with paragraph 7 of the companies accounts rules
            2014 previous gaap
            as these are the companys first standalone financial statements prepared in accordance with indian accounting standards ind as ind as 101
            firsttime adoption of indian accounting standards has been applied an explanation of how the transition to ind as has affected the previously
            reported financial position financial performance and cash flows of the company is provided in note 41
            these standalone financial statements have been prepared for the company as a going concern on the basis of relevant ind as that are effective
            at the companys annual reporting date march 31 2017 these standalone financial statements were authorised for issuance by the companys
            board of directors on april 27 2017
            details of the companys accounting policies are included in note 2
      b    functional and presentation currency
            these standalone financial statements are presented in indian rupees inr which is also the functional currency of the company all amounts
            have been roundedoff to the nearest million unless otherwise indicated
      c    basis of measurement
            these standalone financial statements have been prepared on the historical cost basis except for the following items
                 certain financial assets and liabilities including derivative instruments are measured at fair value
                 net defined benefit assetsliability are measured at fair value of plan assets less present value of defined benefit obligations
      d    use of estimates and judgements
            the preparation of the financial statements in conformity with ind as requires management to make estimates judgements and assumptions
            these estimates judgements and assumptions affect the application of accounting policies and the reported amounts of assets and liabilities
            the disclosures of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses
            during the period accounting estimates could change from period to period actual results could differ from those estimates appropriate
            changes in estimates are made as management becomes aware of changes in circumstances surrounding the estimates changes in estimates
            are reflected in the financial statements in the period in which changes are made and if material their effects are disclosed in the notes to the
            standalone financial statements
            judgements
            information about judgements made in applying accounting policies that have the most significant effects on the amounts recognised in the
            financial statements is included in the following notes
                 note 12b               assessment of functional currency
                 note 2a and 39          financial instruments
                 note 2b 2c and 2d  useful lives of property plant and equipment intangible assets and investment property
                 note 38                   assets and obligations relating to employee benefits
                 note 31                   share based payments and
                 note 2l and 35          provision for income taxes and related tax contingencies and evaluation of recoverability of deferred tax
                                             assets
13   assumptions and estimation uncertainties
      information about assumptions and estimation uncertainties that have a significant risk of resulting in a material adjustment in the year ending march
      31 2018 is included in the following notes
           note 18 and 35  recognition of deferred tax assets availability of future taxable profit against which tax losses carried forward can be used
           note 39  impairment of financial assets and
           note 17 and 36  recognition and measurement of provisions and contingencies key assumptions about the likelihood and magnitude of an
            outflow of resources


                                                                                                                             financial report             177

14   measurement of fair values
      a number of the companys accounting policies and disclosures require the measurement of fair values for both financial and nonfinancial assets
      and liabilities
      fair values are categorised into different levels in a fair value hierarchy based on the inputs used in the valuation techniques as follows
            level 1 quoted prices unadjusted in active markets for identical assets or liabilities
            level 2 inputs other than quoted prices included in level 1 that are observable for the asset or liability either directly ie as prices or
             indirectly ie derived from prices
            level 3 inputs for the asset or liability that are not based on observable market data unobservable inputs
      when measuring the fair value of an asset or a liability the company uses observable market data as far as possible if the inputs used to measure the
      fair value of an asset or a liability fall into different levels of the fair value hierarchy then the fair value measurement is categorised in its entirety in
      the same level of the fair value hierarchy as the lowest level input that is significant to the entire measurement
      the company recognises transfers between levels of the fair value hierarchy at the end of the reporting period during which the change has occurred
      further information about the assumptions made in measuring fair values is included in the following notes
            note 31               share based payment arrangements
            note 4                investment property and
            note 2a and 39      financial instruments

2    significant accounting policies
a    financial instruments
      i     recognition and initial measurement
             trade receivables and debt securities issued are initially recognised when they are originated all other financial assets and financial liabilities
             are initially recognised when the company becomes a party to the contractual provisions of the instrument
             a financial asset or financial liability is initially measured at fair value plus for an item not at fair value through profit and loss fvtpl transaction
             costs that are directly attributable to its acquisition or issue
      ii    classification and subsequent measurement
             financial assets
             on initial recognition a financial asset is classified as measured at
                   amortised cost
                   fvoci  debt investment
                   fvoci  equity investment or
                   fvtpl
             financial assets are not reclassified subsequent to their initial recognition except if and in the period the company changes its business model
             for managing financial assets
             a financial asset is measured at amortised cost if it meets both of the following conditions and is not designated as at fvtpl
                   the asset is held within a business model whose objective is to hold assets to collect contractual cash flows and
                   the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest
                    on the principal amount outstanding
             a debt investment is measured at fvoci if it meets both of the following conditions and is not designated as at fvtpl
                   the asset is held within a business model whose objective is achieved by both collecting contractual cash flows and selling financial
                    assets and
                   the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest
                    on the principal amount outstanding
             on initial recognition of an equity investment that is not held for trading the company may irrevocably elect to present subsequent changes in
             the investments fair value in oci designated as fvoci  equity investment this election is made on an investment by investment basis
             all financial assets not classified as measured at amortised cost or fvoci as described above are measured at fvtpl this includes all derivative
             financial assets on initial recognition the company may irrevocably designate a financial asset that otherwise meets the requirements to be
             measured at amortised cost or at fvoci as at fvtpl if doing so eliminates or significantly reduces an accounting mismatch that would otherwise
             arise




178        ahead of the curve  annual report 2017

                                                                                                                                          biocon limited



       financial assets subsequent measurement and gains and losses

       financial assets at fvtpl                        these assets are subsequently measured at fair value net gains and losses including any
                                                        interest or dividend income are recognised in statement of profit and loss however see note
                                                        39 for derivatives designated as hedging instruments
       financial assets at amortised cost               these assets are subsequently measured at amortised cost using the effective interest method
                                                        the amortised cost is reduced by impairment losses interest income foreign exchange gains
                                                        and losses and impairment are recognised in statement of profit and loss any gain or loss on
                                                        derecognition is recognised in statement of profit and loss
       debt investments at fvoci                        these assets are subsequently measured at fair value interest income under the effective
                                                        interest method foreign exchange gains and losses and impairment are recognised in statement
                                                        of profit and loss other net gains and losses are recognised in oci on derecognition gains and
                                                        losses accumulated in oci are reclassified to statement of profit and loss
       equity investments at fvoci                      these assets are subsequently measured at fair value dividends are recognised as income in
                                                        statement of profit and loss unless the dividend clearly represents a recovery of part of the cost
                                                        of the investment other net gains and losses are recognised in oci and are not reclassified to
                                                        statement of profit and loss
       financial liabilities classification subsequent measurement and gains and losses
       financial liabilities are classified as measured at amortised cost or fvtpl a financial liability is classified as at fvtpl if it is classified as held
       for trading or it is a derivative or it is designated as such on initial recognition financial liabilities at fvtpl are measured at fair value and
       net gains and losses including any interest expense are recognised in statement of profit and loss other financial liabilities are subsequently
       measured at amortised cost using the effective interest method interest expense and foreign exchange gains and losses are recognised in
       statement of profit and loss any gain or loss on derecognition is also recognised in statement of profit and loss
iii   derecognition
       financial assets
       the company derecognises a financial asset when the contractual rights to the cash flows from the financial asset expire or it transfers the
       rights to receive the contractual cash flows in a transaction in which substantially all of the risks and rewards of ownership of the financial asset
       are transferred or in which the company neither transfers nor retains substantially all of the risks and rewards of ownership and does not retain
       control of the financial asset
       if the company enters into transactions whereby it transfers assets recognised on its balance sheet but retains either all or substantially all of
       the risks and rewards of the transferred assets the transferred assets are not derecognised
       financial liabilities
       the company derecognises a financial liability when its contractual obligations are discharged or cancelled or expire
       the company also derecognises a financial liability when its terms are modified and the cash flows under the modified terms are substantially
       different in this case a new financial liability based on the modified terms is recognised at fair value the difference between the carrying
       amount of the financial liability extinguished and the new financial liability with modified terms is recognised in statement of profit and loss
iv    offsetting
       financial assets and financial liabilities are offset and the net amount presented in the balance sheet when and only when the company
       currently has a legally enforceable right to set off the amounts and it intends either to settle them on a net basis or to realise the asset and
       settle the liability simultaneously
v     derivative financial instruments and hedge accounting
       the company holds derivative financial instruments to hedge its foreign currency and interest rate risk exposures embedded derivatives are
       separated from the host contract and accounted for separately if the host contract is not a financial asset and certain criteria are met
       derivatives are initially measured at fair value subsequent to initial recognition derivatives are measured at fair value and changes therein are
       generally recognised in statement of profit and loss
       the company designates certain derivatives as hedging instruments to hedge the variability in cash flows associated with highly probable
       forecast transactions arising from changes in foreign exchange rates and interest rates
       at inception of designated hedging relationships the company documents the risk management objective and strategy for undertaking the
       hedge the company also documents the economic relationship between the hedged item and the hedging instrument including whether the
       changes in cash flows of the hedged item and hedging instrument are expected to offset each other
       cash flow hedges
       when a derivative is designated as a cash flow hedging instrument the effective portion of changes in the fair value of the derivative is
       recognised in oci and accumulated in other equity under effective portion of cash flow hedges the effective portion of changes in the fair
       value of the derivative that is recognised in oci is limited to the cumulative change in fair value of the hedged item determined on a present
       value basis from inception of the hedge any ineffective portion of changes in the fair value of the derivative is recognised immediately in
       statement of profit and loss
       if a hedge no longer meets the criteria for hedge accounting or the hedging instrument is sold expires is terminated or is exercised then hedge
       accounting is discontinued prospectively when hedge accounting for cash flow hedges is discontinued the amount that has been accumulated


                                                                                                                             financial report            179

             in other equity remains there until for a hedge of a transaction resulting in recognition of a nonfinancial item it is included in the nonfinancial
             items cost on its initial recognition or for other cash flow hedges it is reclassified to profit and loss in the same period or periods as the hedged
             expected future cash flows affect profit and loss
             if the hedged future cash flows are no longer expected to occur then the amounts that have been accumulated in other equity are immediately
             reclassified to statement of profit and loss
     vi     treasury shares
             the company has created an employee welfare trust ewt for providing sharebased payment to its employees own equity instruments that
             are reacquired treasury shares are recognised at cost and deducted from equity when the treasury shares are issued to the employees by ewt
             the amount received is recognised as an increase in equity and the resultant gain loss is transferred to from securities premium
     vii    cash and cash equivalents
             cash and cash equivalent in the balance sheet comprise cash at banks and on hand and shortterm deposits with an original maturity of three
             months or less which are subject to an insignificant risk of changes in value for the purpose of the statement of cash flows cash and cash
             equivalents consist of cash and shortterm deposits as defined above net of outstanding bank overdrafts as they are considered an integral
             part of the companys cash management
             cash dividend to equity holders
             the company recognises a liability to make cash to equity holders when the distribution is authorised and the distribution is no longer at the
             discretion of the company as per the corporate laws in india a distribution is authorised when it is approved by the shareholders a corresponding
             amount is recognised directly in equity interim dividends are recorded as a liability on the date of declaration by the companys board of directors
b      property plant and equipment
     i      recognition and measurement
             items of property plant and equipment are measured at cost less accumulated depreciation and accumulated impairment losses if any the
             cost of a selfconstructed item of property plant and equipment comprises the cost of materials and direct labor any other costs directly
             attributable to bringing the item to working condition for its intended use and estimated costs of dismantling and removing the item and
             restoring the site on which it is located
             if significant parts of an item of property plant and equipment have different useful lives then they are accounted for as separate items major
             components of property plant and equipment
             any gain or loss on disposal of an item of property plant and equipment is recognised in statement of profit and loss
             subsequent expenditure is capitalised only if it is probable that the future economic benefits associated with the expenditure will flow to the
             company
     ii     depreciation
             depreciation is calculated on cost of items of property plant and equipment less their estimated residual values over their estimated useful
             lives using the straightline method assets acquired under finance leases are depreciated over the shorter of the lease term and their useful
             lives unless it is reasonably certain that the company will obtain ownership by the end of the lease term freehold land is not depreciated
             the estimated useful lives of items of property plant and equipment for the current and comparative periods are as follows

              asset                                                                                     management estimate          useful life as per schedule ii
                                                                                                                  of useful life
              building                                                                                                 25 years                           30 years
              roads                                                                                                     5 years                            5 years
              plant and equipment including electrical installation and lab equipment                              911 years                         820 years
              computers and servers                                                                                     3 years                          36 years
              office equipment                                                                                          5 years                            5 years
              research and development equipment                                                                        9 years                         510 years
              furniture and fixtures                                                                                    6 years                           10 years
              vehicles                                                                                                  6 years                         610 years
              leasehold improvements                                                                    5 years or lease period
                                                                                                            whichever is lower
             depreciation method useful lives and residual values are reviewed at each financial yearend and adjusted if appropriate based on technical
             evaluation and consequent advice the management believes that its estimates of useful lives as given above best represent the period over
             which management expects to use these assets
             depreciation on additions disposals is provided on a prorata basis ie from upto the date on which asset is ready for use disposed of
c   intangible assets
     internally generated research and development
     expenditure on research activities is recognised in statement of profit and loss as incurred
     development expenditure is capitalised as part of the cost of the resulting intangible asset only if the expenditure can be measured reliably the
     product or process is technically and commercially feasible future economic benefits are probable and the company intends to and has sufficient




180        ahead of the curve  annual report 2017

                                                                                                                                              biocon limited



     resources to complete development and to use or sell the asset otherwise it is recognised in statement of profit and loss as incurred subsequent to
     initial recognition the asset is measured at cost less accumulated amortisation and any accumulated impairment losses
     others
     other intangible assets are initially measured at cost subsequently such intangible assets are measured at cost less accumulated amortization and
     any accumulated impairment losses
     i    subsequent expenditure
           subsequent expenditure is capitalised only when it increases the future economic benefits embodied in the specific asset to which it relates all
           other expenditure including expenditure on internally generated goodwill and brands is recognised in statement of profit and loss as incurred
     ii   amortisation
           goodwill is not amortised and is tested for impairment annually
           other intangible assets are amortised on a straight line basis over the estimated useful life as follows
                  computer software                                                                       35 years
                  marketing and manufacturing rights                                                      510 years
                  customer related intangibles                                                            5 years
           amortisation method useful lives and residual values are reviewed at the end of each financial year and adjusted if appropriate
d   investment property
     investment property is property held either to earn rental income or for capital appreciation or for both but not for sale in the ordinary course
     of business use in the production or supply of goods or services or for administrative purposes upon initial recognition an investment property
     is measured at cost subsequent to initial recognition investment property is measured at cost less accumulated depreciation and accumulated
     impairment losses if any
     based on technical evaluation and consequent advice the management believes a period of 25 years as representing the best estimate of the period
     over which investment properties which are quite similar are expected to be used accordingly the company depreciates investment properties over
     a period of 25 years on a straightline basis the useful life estimate of 25 years is different from the indicative useful life of relevant type of buildings
     mentioned in part c of schedule ii to the act ie 30 years
     any gain or loss on disposal of an investment property is recognised in statement of profit and loss
e   business combination
     in accordance with ind as 103 business combinations the company accounts for business combinations after acquisition date using the acquisition
     method when control is transferred to the company see note 42 the cost of an acquisition is measured at the fair value of the assets given equity
     instruments issued and liabilities incurred or assumed at the date of exchange the cost of acquisition also includes the fair value of any contingent
     consideration and deferred consideration if any any goodwill that arises is tested annually for impairment any gain on a bargain purchase is recognised
     in oci and accumulated in equity as capital reserve if there exists clear evidence of the underlying reasons for classifying the business combination as
     resulting in a bargain purchase otherwise the gain is recognised directly in equity as capital reserve transaction costs are expensed as incurred
f   inventories
     inventories are measured at the lower of cost and net realisable value the cost of inventories is based on the firstin firstout formula and includes
     expenditure incurred in acquiring the inventories production or conversion costs and other costs incurred in bringing them to their present location
     and condition in the case of manufactured inventories and workinprogress cost includes an appropriate share of fixed production overheads based
     on normal operating capacity
     net realisable value is the estimated selling price in the ordinary course of business less the estimated costs of completion and selling expenses the
     net realisable value of workinprogress is determined with reference to the selling prices of related finished products
     raw materials components and other supplies held for use in the production of finished products are not written down below cost except in cases
     where material prices have declined and it is estimated that the cost of the finished products will exceed their net realisable value
     the comparison of cost and net realisable value is made on an itembyitem basis
g   impairment
     i    impairment of financial assets
           in accordance with ind as 109 the company applies expected credit loss ecl model for measurement and recognition of impairment loss
           on following
                  financial assets measured at amortised cost and
                  financial assets measured at fvoci debt investments
           loss allowance for trade receivables with no significant financing component is measured at an amount equal to lifetime expected credit losses
           for all other financial assets ecl are measured at an amount equal to the 12month ecl unless there has been a significant increase in credit
           risk from initial recognition in which case those are measured at lifetime ecl
           loss allowance for financial assets measured at amortised cost are deducted from gross carrying amount of the assets for debt securities at
           fvoci the loss allowance is charged to statement of profit and loss and is recognised in oci




                                                                                                                                financial report            181

     ii     impairment of nonfinancial assets
             the company assess at each reporting date whether there is any indication that the carrying amount may not be recoverable if any such
             indication exists then the assets recoverable amount is estimated and an impairment loss is recognised if the carrying amount of an asset or
             cgu exceeds its estimated recoverable amount in the statement of profit and loss
             goodwill is tested annually for impairment for the purpose of impairment testing goodwill arising from a business combination is allocated to
             cgus or groups of cgus that are expected to benefit from the synergies of the combination
             the companys nonfinancial assets inventories and deferred tax assets are reviewed at each reporting date to determine whether there is any
             indication of impairment if any such indication exists then the assets recoverable amount is estimated for impairment testing assets that
             do not generate independent cash inflows are grouped together into cashgenerating units cgus each cgu represents the smallest group of
             assets that generates cash inflows that are largely independent of the cash inflows of other assets or cgus
             impairment loss recognised in respect of a cgu is allocated first to reduce the carrying amount of any goodwill allocated to the cgu and then
             to reduce the carrying amounts of the other assets of the cgu or groups of cgus on a pro rata basis
             an impairment loss in respect of goodwill is not subsequently reversed in respect of other assets for which impairment loss has been recognised
             in prior periods the company reviews at each reporting date whether there is any indication that the loss has decreased or no longer exists
             an impairment loss is reversed if there has been a change in the estimates used to determine the recoverable amount such a reversal is made
             only to the extent that the assets carrying amount does not exceed the carrying amount that would have been determined net of depreciation
             or amortisation if no impairment loss had been recognised
h   employee benefits
     i      gratuity
             the company provides for gratuity a defined benefit plan the gratuity plan covering the eligible employees of the company the gratuity
             plan provides a lumpsum payment to vested employees at retirement death incapacitation or termination of employment of an amount
             based on the respective employees salary and the tenure of the employment with the company
             liability with regard to the gratuity plan are determined by actuarial valuation performed by an independent actuary at each balance sheet date using
             the projected unit credit method the defined benefit plan is administered by a trust formed for this purpose through the company gratuity scheme
             the company recognises the net obligation of a defined benefit plan as a liability in its balance sheet gains or losses through remeasurement of
             the net defined benefit liability are recognised in other comprehensive income and are not reclassified to profit and loss in the subsequent periods
             the actual return of the portfolio of plan assets in excess of the yields computed by applying the discount rate used to measure the defined benefit
             obligation is recognised in other comprehensive income the effect of any plan amendments are recognised in the statement of profit and loss
     ii     provident fund
             eligible employees of the company receive benefits from provident fund which is a defined contribution plan both the eligible employees
             and the company make monthly contributions to the government administered provident fund scheme equal to a specified percentage of the
             eligible employees salary amounts collected under the provident fund plan are deposited with in a government administered provident fund
             the company has no further obligation to the plan beyond its monthly contributions
     iii    compensated absences
             the company has a policy on compensated absences which are both accumulating and nonaccumulating in nature the expected cost of
             accumulating compensated absences is determined by actuarial valuation performed by an independent actuary at each balance sheet date
             using the projected unit credit method on the additional amount expected to be paidavailed as a result of the unused entitlement that has
             accumulated at the balance sheet date expense on nonaccumulating compensated absences is recognised is the period in which the absences
             occur
     iv     sharebased compensation
             the grant date fair value of equity settled sharebased payment awards granted to employees is recognised as an employee expense with a
             corresponding increase in equity over the period that the employees unconditionally become entitled to the awards the amount recognised
             as expense is based on the estimate of the number of awards for which the related service and nonmarket vesting conditions are expected
             to be met such that the amount ultimately recognised as an expense is based on the number of awards that do meet the related service and
             nonmarket vesting conditions at the vesting date
i   provisions other than for employee benefits
     a provision is recognised if as a result of a past event the company has a present legal or constructive obligation that can be estimated reliably and
     it is probable that an outflow of economic benefits will be required to settle the obligation provisions are determined by discounting the expected
     future cash flows representing the best estimate of the expenditure required to settle the present obligation at the balance sheet date at a pre
     tax rate that reflects current market assessments of the time value of money and the risks specific to the liability the unwinding of the discount is
     recognised as finance cost expected future operating losses are not provided for
     onerous contracts
     a contract is considered to be onerous when the expected economic benefits to be derived by the company from the contract are lower than the
     unavoidable cost of meeting its obligations under the contract the provision for an onerous contract is measured at the present value of the lower of
     the expected cost of terminating the contract and the expected net cost of continuing with the contract before such a provision is made the company
     recognises any impairment loss on the assets associated with that contract
j   revenue
     i      sale of goods
             revenue is recognised when the significant risks and rewards of ownership have been transferred to the buyer recovery of the consideration
             is probable the associated costs and possible return of goods can be estimate reliably there is no continuing management involvement with


182        ahead of the curve  annual report 2017

                                                                                                                                             biocon limited



            the goods and the amount of revenue can be measured reliably the timing of transfers of risks and rewards varies depending on the individual
            terms of sale revenue from the sale of goods includes excise duty and is measured at the fair value of the consideration received or receivable
            net of returns sales tax and applicable trade discounts and allowances
     ii    milestone payments and out licensing arrangements
            the company enters into certain dossier sales licensing and supply arrangements that in certain instances include certain performance
            obligations based on an evaluation of whether or not these obligations are inconsequential or perfunctory we recognise or defer the upfront
            payments received under these arrangements the deferred revenue is recognised in the standalone statement of operations in the period in
            which we complete our remaining performance obligations
            these arrangements typically also consist of subsequent payments dependent on achieving certain milestones in accordance with the terms
            prescribed in the agreement milestone payments which are contingent on achieving certain clinical milestones are recognised as revenues
            either on achievement of such milestones if the milestones are considered substantive or over the period we have continuing performance
            obligations if the milestones are not considered substantive if milestone payments are creditable against future royalty payments the
            milestones are deferred and released over the period in which the royalties are anticipated to be paid
     iii   sales return allowances
            the company accounts for sales return by recording an allowance for sales return concurrent with the recognition of revenue at the time of a
            product sale the allowance is based on companys estimate of expected sales returns the estimate of sales return is determined primarily by
            the companys historical experience in the markets in which the company operates
     iv    dividends
            dividend is recognised when the companys right to receive the payment is established which is generally when shareholders approve the dividend
     v     rental income
            rental income from investment property is recognised in statement of profit and loss on a straightline basis over the term of the lease except
            where the rentals are structured to increase in line with expected general inflation lease incentives granted are recognised as an integral part
            of the total rental income over the term of the lease
     vi    contribution received from customerscodevelopment partners towards plant and equipment
            contributions received from customerscodevelopment partners towards items of property plant and equipment which require an obligation to
            supply goods to the customer in the future are recognised as a credit to deferred revenue the contribution received is recognised as revenue from
            operations over the useful life of the assets the company capitalises the gross cost of these assets as the company controls these assets
k   government grants
     the company recognises government grants only when there is reasonable assurance that the conditions attached to them will be complied with and
     the grants will be received government grants received in relation to assets are presented as a reduction to the carrying amount of the related asset
     grants related to income are deducted in reporting the related expense
l   income taxes
     income tax comprises current and deferred income tax income tax expense is recognised in statement of profit and loss except to the extent that
     it relates to an item recognised directly in equity in which case it is recognised in other comprehensive income current income tax for current year
     and prior periods is recognised at the amount expected to be paid or recovered from the tax authorities using the tax rates and laws that have been
     enacted or substantively enacted by the balance sheet date
     deferred income tax assets and liabilities are recognised for all temporary differences arising between the tax bases of assets and liabilities and their
     carrying amounts in the financial statements except when
           taxable temporary differences arising on the initial recognition of goodwill
           temporary differences arising on the initial recognition of assets or liabilities in a transaction that is not a business combination and that affects
            neither accounting nor taxable profit or loss at the time of transaction
           temporary differences related to investments in subsidiaries associates and joint arrangements to the extent that the company is able to
            control the timing of the reversal of the temporary differences and it is probable that they will not reverse in the foreseeable future
     deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable that the related tax benefit will be
     realised
     deferred income tax assets and liabilities are measured using the tax rates and laws that have been enacted or substantively enacted by the balance
     sheet date and are expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled
     the effect of changes in tax rates on deferred income tax assets and liabilities is recognised as income or expense in the period that includes the
     enactment or substantive enactment date a deferred income tax assets is recognised to the extent it is probable that future taxable income will
     be available against which the deductible temporary timing differences and tax losses can be utilised the company offsets incometax assets and
     liabilities where it has a legally enforceable right to set off the recognised amounts and where it intends either to settle on a net basis or to realise
     the asset and settle the liability simultaneously
m   borrowing cost
     borrowing costs are interest and other costs including exchange differences relating to foreign currency borrowings to the extent that they are
     regarded as an adjustment to interest costs incurred in connection with the borrowing of funds borrowing costs directly attributable to acquisition
     or construction of an asset which necessarily take a substantial period of time to get ready for their intended use are capitalised as part of the cost of
     that asset other borrowing costs are recognised as an expense in the period in which they are incurred
n   earnings per share
     basic earnings per share is computed using the weighted average number of equity shares outstanding during the period adjusted for treasury shares
     held diluted earnings per share is computed using the weightedaverage number of equity and dilutive equivalent shares outstanding during the
     period using the treasury stock method for options and warrants except where the results would be antidilutive


                                                                                                                                financial report           183

3 property plant and equipment and capital workinprogress
                                      land     buildings       leasehold  plant and research and           furniture     vehicles        total       capital
                                                            improvements equipment development                  and                                 workin
                                                                                     equipments             fixtures                                progress
                                refer note                                   refer note                                                        refer note
                                        a                                          b                                                               e
gross carrying amount
at april 01 2015                      346         3440                 6        11973         1148          393            44      17350           576
additions                              130           381                            832            15            43            6       1407          2554
disposals                                                                         77                                    6        83       1407
at march 31 2016                      476         3821                 6        12728         1163          436            44      18674          1723
additions                                88           89                          1164            66            42           11       1460          2145
disposals                                            1                           10                        2          5        18       1460
at march 31 2017                      564         3909                 6        13882         1229          476            50      20116          2408

accumulated depreciation
at april 01 2015                                   879                 1         6966           745          215            17       8823               
depreciation for the year                           149                          1040            86            50            6       1331               
disposals                                                                         74                                    2        76              
at march 31 2016                                 1028                 1         7932           831          265            21      10078               
depreciation for the year                           158                          1109            78            54            6       1405               
disposals                                                                           9                       2          5        16              
at march 31 2017                                 1186                 1         9032           909          317            22      11467               

net carrying amount
at april 01 2015                      346         2561                 5         5007           403          178            27       8527           576
at march 31 2016                      476         2793                 5         4796           332          171            23       8596          1723
at march 31 2017                      564         2723                 5         4850           320          159            28       8649          2408
a     land includes land held on leasehold basis gross carrying amount  nil march 31 2016   236 net carrying amount  nil march 31 2016   236
b     plant and equipment include computers and office equipment
c     additions to property plant and equipment includes additions related to research and development amounting to  250 march 31 2016   35
d     during the year ended march 31 2016 the company had acquired the business of the pharmaceutical manufacturing unit of ms acacia lifesciences
        private limited located at vishakhapatnam with effect from october 01 2015 also refer note 42
e     capital workinprogress mainly comprises new biopharmaceutical manufacturing unit being constructed in india
f     for details of security on certain property plant and equipment refer note 15b




                                                     this space has been intentionally left blank




184        ahead of the curve  annual report 2017

                                                                                                                                          biocon limited



4 investment property
gross carrying amount
at april 01 2015                                                                                                                                      533
additions                                                                                                                                                 
at march 31 2016                                                                                                                                      533
additions                                                                                                                                               20
at march 31 2017                                                                                                                                      553


accumulated depreciation
at april 01 2015                                                                                                                                       74
depreciation for the year                                                                                                                               20
at march 31 2016                                                                                                                                       94
depreciation for the year                                                                                                                               20
at march 31 2017                                                                                                                                      114


net carrying amount
at april 01 2015                                                                                                                                      459
at march 31 2016                                                                                                                                      439
at march 31 2017                                                                                                                                      439
during the year the company has recognised rental income of  109 march 31 2016   107 and depreciation charge of  20 march 31 2016   20 in
the statement of profit and loss for investment property


the fair value of investment property as at march 31 2017 is  479 march 31 2016   495 april 1 2015   510


5 intangible assets
                                                                    intellectual         computer     marketing and              customer             total
                                                                 property rights          software    manufacturing                related
                                                                                                              rights           intangibles
                                                                                                      refer note a     refer note b
gross carrying amount
at april 01 2015                                                             81               163               193                                  437
additions                                                                                      54               101                    77             232
at march 31 2016                                                             81               218               294                    77             669
additions                                                                                      31                                                    31
at march 31 2017                                                             81               249               294                    77             700

accumulated amortisation
as at april 01 2015                                                          81                59               141                                  281
amortisation for the year                                                                      27                 12                    8              46
at march 31 2016                                                             81                86               153                     8             327
amortisation for the year                                                                      39                 27                   15              81
at march 31 2017                                                             81               125               180                    23             408

net carrying amount
at april 01 2015                                                                             104                 52                                 156
at march 31 2016                                                                             132               141                    69             342
at march 31 2017                                                                             124               114                    54             292
a   pursuant to an asset purchase agreement with a customer executed during the year ended march 31 2016 the company had acquired the marketing
      and manufacturing rights of a product for a sum of  101
b   also refer note 42 for acquisition of customer related intangible as part of business acquired from ms acacia lifesciences private limited




                                                                                                                             financial report          185

                                                                                                       march 31 2017   march 31 2016     april 01 2015
6 noncurrent investments
i quoted equity instruments
in subsidiary company at cost
syngene international limited  145217843 march 31 2016  145217843 april 01 2015  nil              27591            27591                   
equity shares of  10 each refer note 33
total quoted noncurrent investments                                                                          27591            27591                   
ii unquoted equity instruments
in subsidiary companies at cost
syngene international limited  nil march 31 2016  nil april 01 2015  167217843 equity                                                 31771
shares of  10 each refer note 33
biocon research limited  500000 march 31 2016  500000 april 01 2015  500000 equity                      1                  1                 1
shares of  1 each
biocon sa switzerland  100000 march 31 2016  100000 april 01 2015  100000 equity                       4                  4                 4
shares of chf 1 each
biocon sdn bhd malaysia  nil march 31 2016  nil april 01 2015  4853734 equity shares of                                               712
rm 10 each refer note 33
biocon fz llc uae  150 march 31 2016  150 april 01 2015  nil equity shares of aed 1000                   3                  3                  
each
biocon pharma limited  12050000 march 31 2016  5050000 april 01 2015  50000 equity                  121                51                  1
shares of  10 each
biocon biologics limited uk  47183101 march 31 2016  47183101 april 01 2015  nil                  4453             4453                   
equity shares of gbp 1 each
biocon academy  50000 march 31 2016  50000 april 01 2015  50000 equity shares of                       1                  1                 1
10 each
in joint venture company
neobiocon fz llc uae  147 march 31 2016  153 april 01 2015  153 equity shares of aed                      2                  2                 2
1000 each
in others
energon kn wind power private limited  38500 march 31 2016  nil april 01 2015  nil equity                 1                                    
shares of  10 each
less provision for decline other than temporary in the value of non current investments                        1                                 
total unquoted investments in equity instruments                                                               4585             4515            32492
iii unquoted preference shares
in associate company
iatrica inc usa  4285714 march 31 2016  4285714 april 01 2015  4285714 series a                  139               139               139
preferred stock at us 070 each par value us  000001 each
less provision for decline other than temporary in the value of noncurrent investments                      139             139             139
total unquoted investments in preference shares in associate company                                                                                  
others
vaccinex inc usa  2722014 march 31 2016  2722014 april 01 2015  2722014 series b1                186               186               186
preferred convertible stock at us 155 each par value us 0001 each
vaccinex inc usa  217972 march 31 2016  217972 april 01 2015  217972 series b2                       32                32                 32
preferred convertible stock at us 310 each par value us 0001 each
less provision for decline other than temporary in the value of noncurrent investments                      218             218             218
                                                                                                                                                      
energon kn wind power private limited  14666 march 31 2016  nil april 01 2015  nil                        1                                   
compulsorily convertible preference shares par value  100 each
less provision for decline other than temporary in the value of non current investments                        1                                   
                                                                                                                                                       
total unquoted investments in preference shares                                                                                                        
iv unquoted debentures or bonds
others
lic housing finance co ltd  700 march 31 2016  nil april 01 2015  nil 751 bonds at                    701                                    
1001120 each par value  1000000 each
hdfc ltd  75 march 31 2016  nil april 01 2015  nil 815 bonds at  10090700 each par                 758                                    
value  10000000 each
total unquoted investments in debentures or bonds                                                              1459                                    
total noncurrent investments                                                                                 33635            32106             32492
aggregate book value of quoted investments                                                                    27591            27591                   
aggregate market value of quoted investments                                                                  75622            55800                   
aggregate value of unquoted investments                                                                        6403             4872             32849
aggregate amount of impairment in value of investments                                                           359               357                 357
a the company has invested in national savings certificates unquoted which are not disclosed above since amounts are rounded off to rupees million


186      ahead of the curve  annual report 2017

                                                                                                                               biocon limited



                                                                                                march 31 2017   march 31 2016    april 01 2015
7 loans
unsecured considered good
      loans to subsidiaries refer note 34                                                             1923             1584            2447
                                                                                                        1923             1584            2447
loans to related parties comprise loans to the following subsidiaries
i   biocon research limited                                                                           1923             1455            2447
      maximum amount outstanding during the year                                                        1965             4799            3053
ii biocon pharma limited                                                                                                129                  
      maximum amount outstanding during the year                                                          260              179                  


8 other financial assets
a noncurrent
fair value of hedging instruments                                                                          14                16               26
interest accrued but not due                                                                                                26                 
deposits                                                                                                  179              173               166
other receivables from related parties refer note 34                                                     50              455               181
                                                                                                          243              670               373
b current
fair value of hedging instruments                                                                         128                23              143
interest accrued but not due                                                                              173              241                55
unbilled revenue                                                                                                                           108
other receivables from
  related parties refer note 34                                                                         670              705               285
  others                                                                                                   12                21               16
                                                                                                          983              990               607
9 other assets
a noncurrent
capital advances                                                                                          409              430               274
duty drawback receivable                                                                                  329              313               326
balances with statutorygovernment authorities                                                          1101              631               858
prepayments                                                                                                  8                8               13
                                                                                                        1847             1382            1471
b current
prepayments                                                                                               348              224               194
                                                                                                          348              224               194
10 inventories
raw materials including goodsinbond                                                                   988             1166              957
packing materials                                                                                         386              323               209
workinprogress                                                                                        2494             1569            1316
finished goods                                                                                          1305             1726            1628
traded goods                                                                                              223              262               249
                                                                                                        5396             5046            4359
 includes goods intransit  nil march 31 2016   151 april 01 2015   nil
writedown of inventories to net realisable value amounted to  3 march 31 2016   3 these were recognised as an expense during the year and
included in changes in inventories of traded goods finished goods and workinprogress in statement of profit and loss




                                                    this space has been intentionally left blank




                                                                                                                   financial report         187

                                                                                                       march 31 2017   march 31 2016   april 01 2015


11 current investments
unquoted
investment in mutual funds
birla sun life short term fund growth 14572296 units march 31 2016  nil units april 01                   907                                 
2015  nil units
dhfl pramerica banking  psu debt fund gr 6602593 units march 31 2016  nil units april                      93                                 
01 2015  nil units
axis liquid fund  daily dividend reinvestment nil units march 31 2016  nil units april 01                                                   98
2015  98005 units
dws banking  psu debt fund  weekly dividend reinvestment nil units march 31 2016                                            724                 
70409716 units april 01 2015  nil units
edelweiss banking  psu debt fund  regular plan growth 20407166 units march 31 2016  nil                   276                                 
units april 01 2015  nil units
hdfc liquid fund  daily dividend reinvestment nil units march 31 2016  nil units                                                            138
april 01 2015  13566785 units
hdfc medium term opportunities fund  regular plan  growth 27762046 units march 31 2016                     503                                 
 nil units april 01 2015  nil units
hdfc short term opportunities fund  regular plan  growth 22489571 units march 31 2016                     405                                 
nil units april 01 2015  nil units
idfc cash fund  daily dividend regular plan nil units march 31 2016  nil units april 01 2015                                               159
 158344 units
jp morgan banking  psu debt fund  weekly dividend reinvestment option nil units march 31                                     258                 
2016  24569495 units april 01 2015  nil units
reliance banking  psu debt fund weekly dividend plan nil units march 31 2016  46064513                                     465                 
units april 01 2015  nil units
reliance banking  psu debt fund  growth 72201894 units march 31 2016  nil units april                    851                                 
01 2015  nil units
reliance liquidity fund  daily dividend reinvestment option nil units march 31 2016  nil units                                              135
april 01 2015  135112 units
sbi premier liquid fund  regular plan  daily dividend nil units march 31 2016  73826 units                                 74                 
april 01 2015  nil units
tata fixed maturity plan series 47 scheme c  plan a  growth nil units march 31 2016  nil units                                             150
april 01 2015  15000000 units
tata liquid fund  plan a  daily dividend nil units march 31 2016  nil units april 01 2015                                                163
146580 units
uti  treasury advantage fund  institutional plan  daily dividend reinvestment 91862 units
march 31 2016  41818 units april 01 2015  175000 units                                                   92               42              175
                                                                                                               3127            1563            1018
in others
inter corporate deposits with financial institutions                                                           2120            4420                 
                                                                                                               5247            5983            1018
aggregate value of unquoted investments                                                                        5247            5983            1018




                                                       this space has been intentionally left blank




188        ahead of the curve  annual report 2017

                                                                                                                                   biocon limited



                                                                                                     march 31 2017   march 31 2016   april 01 2015
12 trade receivables
unsecured considered good also refer note 34                                                              7982            5038             5033
doubtful                                                                                                        58               42                85
                                                                                                             8040            5080             5118
allowance for credit loss                                                                                      58             42              85
                                                                                                             7982            5038             5033
the above includes
due from narayana hrudayalaya limited nhl formerly known as narayana hrudayalaya private                    4                8                 5
limited in which a director of the company is a member of board of directors of nhl
the companys exposure to credit and currency risks and loss allowances are disclosed in note 39


13 cash and bank balances
cash and cash equivalents
balances with banks
 on current accounts                                                                                         3410            2653             3213
 on unpaid dividend account                                                                                      6               10                 6
 deposits with original maturity of less than 3 months                                                                         240                  
total cash and cash equivalents                                                                              3416            2903             3219
other bank balances
 deposits with maturity of less than 12 months                                                                 410            3524             3380
 margin money deposit refer note a below                                                                     3                3                 3
total other bank balances                                                                                      413            3527             3383
                                                                                                             3829            6430             6602
a margin money deposits with carrying amount of  3 march 31 2016   3 april 01 2015   3 are subject to first charge against bank guarantees
    obtained
b the company has cash on hand which are not disclosed above since amounts are rounded off to rupees million




                                                     this space has been intentionally left blank




                                                                                                                        financial report         189

                                                                                                       march 31 2017     march 31 2016    april 01 2015
14a equity share capital
authorised
220000000 march 31 2016  220000000 april 01 2015  220000000
equity shares of  5 each march 31 2016   5 each april 01 2015   5 each                                1100             1100              1100
issued subscribed and fully paidup
200000000 march 31 2016  200000000 april 01 2015  200000000
equity shares of  5 each march 31 2016   5 each april 01 2015   5 each                                1000             1000              1000


i   reconciliation of the shares outstanding at the beginning and at the end of the reporting year
equity shares                                                                               march 31 2017                       march 31 2016
                                                                                                no           million               no           million
at the beginning of the year                                                          200000000               1000       200000000              1000
issued during the year                                                                                                                                 
outstanding at the end of the year                                                    200000000               1000       200000000              1000


ii termsrights attached to equity shares
the company has only one class of equity shares having a par value of  5 per share each holder of equity shares is entitled to one vote per share the
company declares and pays dividends in indian rupees the dividend proposed by the board of directors is subject to the approval of the shareholders
in the ensuing annual general meeting
in the event of liquidation of the company the holders of equity shares will be entitled to receive remaining assets of the company after distribution of
all preferential amounts if any the distribution will be in proportion to the number of equity shares held by the shareholders


iii details of shareholders holding more than 5 shares in the company
                                                                                            march 31 2017                       march 31 2016
                                                                                                no         holding                 no         holding
equity shares of  5 each fully paid
dr kiran mazumdarshaw                                                                 79287564            3964          79287564           3964
glentec international limited                                                          39535194            1977          39535194           1977
as per records of the company including its register of shareholdersmembers the above shareholding represents both legal and beneficial ownerships
of shares


iv shares reserved for issue under options
for details of shares reserved for issue under the employee stock option plan esop of the company refer note 31


14b other equity
securities premium reserve
securities premium is used to record the premium received on issue of shares it is utilised in accordance with the provisions of the companies act 2013
general reserve
general reserve is used from time to time to transfer profits from retained earnings for appropriation purposes
retained earnings
the amount that can be distributed by the company as dividends to its equity shareholders
sez reinvestment reserve
the sez reinvestment reserve has been created out of profit of eligible sez units in terms of the provisions of section 10aa1ii of the incometax act
1961 the reserve has been utilised for acquiring new plant and machinery for the purpose of its business in terms of section 10aa2 of the incometax
act 1961
share based payment reserve
the company has established various equity settled share based payment plans for certain categories of employees of the company also refer note 31
for further details on these plans
treasury shares
own equity instruments that are reacquired treasury shares are recognised at cost and deducted from equity
cash flow hedging reserves
the cash flow hedging reserve represents the cumulative effective portion of gains or losses net of taxes if any arising on changes in fair value of
designated portion of hedging instruments entered into for cash flow hedges




190       ahead of the curve  annual report 2017

                                                                                                                                              biocon limited



                                                                                                          march 31 2017      march 31 2016      april 01 2015
15 longterm borrowings
deferred sales tax liability unsecured refer note a below                                                                           65                195
loans from banks secured
term loan refer note b below                                                                                     1296              1326                    
other loans and advances unsecured
nmitli  csir loan refer note c below                                                                                1                  1                  1
financial assistance from dsir refer note d below                                                                    3                  6                 10
financial assistance from dst refer note e below                                                                    35                 42                 48
                                                                                                                     1335              1440                254
less amount disclosed under the head other current financial liabilities refer note 16b                         11               75              140
                                                                                                                     1324              1365                114
the above amount includes
secured borrowings                                                                                                   1296              1326                   
unsecured borrowings                                                                                                    39                114                254
amount disclosed under the head other current financial liabilities refer note 16b                               11               75              140
net amount                                                                                                           1324              1365                114


a on february 9 2000 the company obtained an order from the karnataka sales tax authority for allowing an interest free deferment of sales tax
    including turnover tax for a period upto 12 years with respect to sales from its hebbagodi manufacturing facility for an amount not exceeding  649
    this is an interest free liability the amount is repayable in 10 equal half yearly instalments of  65 each starting from february 2012 the loan was
    repaid during the year

b during the year ended march 31 2016 the company had obtained an external commercial borrowing facility of usd 20 million from a bank the term
    loan facility is secured by first priority paripassu charge on the plant and machinery of the proposed expanded facility line in the existing facility with
    a carrying amount of  1410 the longterm loan is repayable in 4 equal quarterly instalments of usd 5 million each commencing from december 31
    2018 and carries an interest rate of libor  095 pa during the year ended march 31 2016 the company had entered into interest rate swap to
    convert floating rate to fixed rate

c on march 31 2005 the company entered into an agreement with the council of scientific and industrial research csir for an unsecured loan of 3
    for carrying out part of the research and development project under the new millennium indian technology leadership initiative nmitli scheme the
    loan is repayable over 10 equal annual instalments of  03 starting from april 2009 and carry an interest rate of 3 pa

d on march 31 2009 the department of scientific and industrial research dsir sanctioned financial assistance for a sum of  17 to the company for
    part financing one of its research projects the assistance is repayable in the form of royalty payments for three years post commercialisation of the
    project in five equal annual instalments of  3 each starting from april 1 2013

e on august 25 2010 the department of science and technology dst under the drugs and pharmaceutical research programme dprp has
    sanctioned financial assistance for a sum of  70 to the company for financing one of its research projects the loan is repayable over 10 annual
    instalments of  7 each starting from july 1 2012 and carries an interest rate of 3 pa

f   in respect of the financial assistance received under the aforesaid programmes refer note c to e above the company is required to utilise the funds
      for the specified projects and is required to obtain prior approvals from the said authorities for disposal of assetsintellectual property rights acquired
      developed under the above programmes
the companys exposure to liquidity interest rate and currency risks are disclosed in note 39




                                                      this space has been intentionally left blank




                                                                                                                                 financial report           191

                                                                           march 31 2017   march 31 2016   april 01 2015
16 other financial liabilities
a noncurrent
fair value of hedging instruments                                                                      4                 
interest accrued but not due                                                           2                3                6
                                                                                       2                7                6
b current
current maturities of longterm borrowings refer note 15                            11               75              140
unpaid dividends                                                                       6               10                6
payables for capital goods                                                           646              748              239
interim dividend on equity shares                                                                                  1000
fair value of hedging instruments                                                                     77                 
                                                                                     663              910            1385


17 provisions
a noncurrent
provision for employee benefits
  gratuity refer note 38                                                           133               95                 
                                                                                     133               95                 
b current
provision for employee benefits
  gratuity refer note 38                                                            88               73              121
  compensated absences                                                                96               82               74
provision for sales return                                                           136              130              130
                                                                                     320              285              325


i movement in provisions                                                       gratuity    compensated       sales return
                                                                                                absences
opening balance                                                                      168               82              130
provision recognisedreversed during the year                                       53               14                6
closing balance                                                                      221               96              136


                                                                           march 31 2017   march 31 2016   april 01 2015
18 deferred tax liabilityassets net
deferred tax liability
property plant and equipment investment property and intangible assets             523              558              609
derivative asset                                                                      46                               48
gross deferred tax liability                                                         569              558              657
deferred tax assets
employee benefit obligations                                                         110               86               67
allowance for doubtful debts                                                          20               14               29
other disallowable expenses                                                          169              145               80
deferred revenue                                                                                     162               69
mat credit entitlement                                                             1194               22               22
derivative liability                                                                                   1                 
others                                                                               130              119              108
gross deferred tax assets                                                          1623              549              375
net deferred tax liabilityassets                                               1054               9              282

19 other liabilities
a noncurrent
deferred revenues                                                                    767              913              905
                                                                                     767              913              905
b current
deferred revenues                                                                    113              116               97
advances from customers                                                               82               58               32
book overdraft                                                                       501              252                 
statutory taxes and dues payable                                                      91               77               89
                                                                                     787              503              218


192      ahead of the curve  annual report 2017

                                                                                                                                           biocon limited



                                                                                                        march 31 2017      march 31 2016     april 01 2015
20 shortterm borrowings
from banksfinancial institutions
  packing credit foreign currency loan unsecured refer notes i ii and iii below                                           2253               561
  cash credit secured refer note iv below                                                                                          2                   
                                                                                                                                     2255               561
the above amount includes
  secured borrowings                                                                                                                     2                   
  unsecured borrowings                                                                                                               2253               561


i   during the year ended march 31 2016 the company had obtained unsecured foreign currency denominated loans of  597 usd 9 million april
      01 2015   nil usd nil carrying an interest rate of libor  020 pa from a bank the facility was repayable within 120 days from the date of its
      origination and has been repaid during the current year
ii during the year ended march 31 2016 the company had obtained unsecured foreign currency denominated loans of  1656 usd 25 million april
     01 2015   nil usd nil carrying an interest rate of libor  010 pa from a bank the facility was repayable within 180 days from the date of its
     origination and has been repaid during the current year
iii during the year ended march 31 2015 the company had obtained foreign currency denominated loan of  561 usd 9 million carrying an interest
      rate of libor  035 pa from a bank the facility was repayable within 180 days from the date of its origination and was repaid during the year
      ended march 31 2016
iv the company had working capital facilities with various banks carrying interest rate ranging from 97  13 pa these facilities were repayable on
     demand secured by paripassu first charge on inventories and trade receivables


                                                                                                        march 31 2017      march 31 2016     april 01 2015
21 trade payables
trade payables refer note a below and note 34                                                                  4505              3944             3008


a disclosure required under clause 22 of micro small and medium enterprise development
    msmed act 2006
      i   the principal amount and the interest due thereon remaining unpaid to any supplier as at
            the end of each year
            principal amount due to micro and small enterprises                                                      120               102                  77
            interest due on the above                                                                                  3                                    1
      ii the amount of interest paid by the buyer in terms of section 16 of the msmed act 2006                    328               317                312
           along with the amounts of the payment made to the supplier beyond the appointed day
           during each accounting year
      iii the amount of interest due and payable for the period of delay in making payment which                                                         
            has been paid but beyond appointed day during the year but without adding the interest
            specified under the msmed act 2006
      iv the amount of interest accrued and remaining unpaid at the end of each accounting year                                                          
      v the amount of further interest remaining due and payable even in the succeeding years                      31                 25                 23
          until such date when the interest dues as above are actually paid to the small enterprise
          for the purpose of disallowance as a deductible expenditure under section 23 of the
          msmed act 2006
the above disclosures are provided by the company based on the information available with the
company in respect of the registration status of its vendorssuppliers
b all trade payables are current the companys exposure to currency and liquidity risks related
    to trade payables is disclosed in note 39




                                                      this space has been intentionally left blank




                                                                                                                              financial report           193

                                                                                                                      march 31 2017   march 31 2016
22 revenue from operations
sale of products
  finished goods                                                                                                             22174           19861
  traded goods                                                                                                                1583            1679
sale of services
  licensing and development fees                                                                                                329               93
other operating revenue
  sale of process waste                                                                                                         127              129
  others refer note a below                                                                                               1971            1592
revenue from operations                                                                                                      26184           23354
a others include processing charges rentals and cross charge of power and other facilities by the sez developer
    sez unit of the company


23 other income
interest income on
  deposits with banks and financial institutions                                                                                523              397
  others                                                                                                                        146              330
dividend income from
  subsidiaries                                                                                                                                  487
  current investments                                                                                                            13              131
net gain on sale of current investments                                                                                          39               16
net gain on financial assets measured at fair value through profit or loss                                                       69                 
foreign exchange gain net                                                                                                                      160
other nonoperating income                                                                                                      198              210
                                                                                                                                988            1731
24 cost of raw materials and packing materials consumed
inventory at the beginning of the year                                                                                        1489            1166
add purchases                                                                                                                9800            9802
less inventory at the end of the year                                                                                       1374          1489
cost of raw materials and packing materials consumed                                                                          9915            9479


25 changes in inventories of traded goods finished goods and workinprogress
inventory at the beginning of the year
  traded goods                                                                                                                  262              249
  finished goods                                                                                                              1726            1628
  workinprogress                                                                                                            1569            1316
                                                                                                                              3557            3193
inventory at the end of the year
  traded goods                                                                                                                  223              262
  finished goods                                                                                                              1305            1726
  workinprogress                                                                                                            2494            1569
                                                                                                                              4022            3557
                                                                                                                               465            364
26 employee benefits expense
salaries wages and bonus                                                                                                     3091            2740
contribution to provident and other funds                                                                                       134              115
gratuity refer note 38                                                                                                         39               31
share based compensation expense refer note 31                                                                                125              107
staff welfare expenses                                                                                                          261              226
                                                                                                                              3650            3219
27 finance costs
interest expense on financial liability measured at amortised cost                                                               38                9
fair value changes on interest rate swap                                                                                                         10
                                                                                                                                 38               19




194       ahead of the curve  annual report 2017

                                                                                                                               biocon limited



                                                                                                                  march 31 2017   march 31 2016
28 depreciation and amortisation expense
depreciation of tangible assets refer note 3 and 4                                                                      1425            1351
amortisation of intangible assets refer note 5                                                                             81               46
                                                                                                                          1506            1397
29 other expenses
royalty and technical fees                                                                                                   36               56
rent                                                                                                                         16               17
communication expenses                                                                                                       38               40
travelling and conveyance                                                                                                   292              335
professional charges                                                                                                        257              383
payments to auditors refer note a below                                                                                   6                6
directors fees including commission                                                                                         19               20
power and fuel                                                                                                            1456            1551
insurance                                                                                                                    27               30
rates taxes and fees                                                                                                       197              180
lab consumables                                                                                                             327              373
repairs and maintenance
 plant and machinery                                                                                                        502              368
 buildings                                                                                                                  107               90
 others                                                                                                                     324              280
selling expenses
 freight outwards and clearing charges                                                                                      243              284
 sales promotion expenses                                                                                                   474              423
 commission and brokerage other than sole selling agents                                                                  247              253
bad debts written off                                                                                                                         8
provisionreversal for doubtful debts net                                                                                 16              43
foreign exchange fluctuation net                                                                                           239                 
printing and stationery                                                                                                      35               26
research and development expenses refer note 30                                                                           920              902
csr expenditure refer note 45                                                                                              90               81
miscellaneous expenses                                                                                                       95               91
                                                                                                                          5963            5754
a payments to auditors
as auditor
 statutory audit fee                                                                                                          3                3
 tax audit fee                                                                                                                1                1
 limited review                                                                                                               1                2
in other capacity
 other services certification fees refer note b below                                                                   1                 
reimbursement of outofpocket expenses refer note b below                                                                                 
                                                                                                                              6                6
 payments for the year ended march 31 2016 represents fees and reimbursements paid to the predecessor
auditor
b amounts are not presented since the amounts are rounded off to rupees million

30 research and development expenses
research and development expenses                                                                           a             920              902
other research and development expenses included in other heads of account
 salaries wages and bonus                                                                                                  201              182
 contribution to provident and other funds                                                                                    9                7
 staff welfare expenses                                                                                                       2                2
 lab consumables                                                                                                            324              373
 travelling and conveyance                                                                                                    4               14
 professional charges                                                                                                         1                 
                                                                                                            b             541              578
                                                                                                          ab           1461            1480
less recovery of product development costs from codevelopment partners net                                               4             48
                                                                                                                          1457            1432



                                                                                                                    financial report        195

31   employee stock compensation
a   biocon esop plan

      on september 27 2001 biocons board of directors approved the biocon employee stock option plan esop plan 2000 for the grant of stock
      options to the employees of the company and its subsidiariesjoint venture company the nomination and remuneration committee remuneration
      committee administers the plan through a trust established specifically for this purpose called the biocon india limited employee welfare trust
      esop trust

      the esop trust shall make additional purchase of equity shares of the company using the proceeds from the loan obtained from the company other
      cash inflows from allotment of shares to employees under the esop plan and shall subscribe when allotted to such number of shares as is necessary
      for transferring to the employees the esop trust may also receive shares from the promoters for the purpose of issuance to the employees under the
      esop plan the remuneration committee shall determine the exercise price which will not be less than the face value of the shares

      grant iv

      in july 2006 the company approved the grant of 3478200 options face value of shares   5 each to its employees under the existing esop plan
      2000 the options under this grant would vest to the employees as 25 35 and 40 of the total grant at the end of first second and third year
      from the date of grant for existing employees and at the end of 3rd 4th and 5th year from the date of grant for new employees exercise period is 3
      years for each grant the conditions for number of options granted include service terms and performance grade of the employees these options are
      exercisable at a discount of 20 to the market price of companys shares on the date of grant

      details of grant iv

        particulars                                                                        march 31 2017                              march 31 2016
                                                                                    number of              weighted               number of              weighted
                                                                                     options               average                 options               average
                                                                                                         exercise price                                exercise price
                                                                                                                                                         
        outstanding at the beginning of the year                                            3500                   231                61625                     187
        granted during the year                                                                                                                                      
        forfeited during the year                                                                                                                                    
        exercised during the year                                                           2500                   231                55250                     179
        expired during the year                                                             1000                   231                 2875                     154
        outstanding at the end of the year                                                                                            3500                     231
        exercisable at the end of the year                                                                                            3500                     231
        weighted average remaining contractual life in years                                                                          03                           
        range of exercise prices for outstanding options at the end of year                                                         231                            

      grant v

      in april 2008 the company approved the grant to its employees under the existing esop plan 2000 the options under this grant would vest to the
      employees as 25 35 and 40 of the total grant at the end of first second and third year from the date of grant for existing employees and at the
      end of 3rd 4th and 5th year from the date of grant for new employees exercise period is 3 years for each grant the conditions for number of options
      granted include service terms and performance grade of the employees these options are exercisable at the market price of companys shares on the
      date of grant

      details of grant v

        particulars                                                                         march 31 2017                              march 31 2016
                                                                                     number of             weighted               number of              weighted
                                                                                      options              average                 options               average
                                                                                                         exercise price                                exercise price
                                                                                                                                                         
        outstanding at the beginning of the year                                           791875                   343             1151975                     336
        granted during the year                                                                                                                                          
        forfeited during the year                                                           74625                   344              269087                      324
        exercised during the year                                                          221388                   307                91013                     303
        expired during the year                                                                                                                                          
        outstanding at the end of the year                                                 495862                   357              791875                      343
        exercisable at the end of the year                                                 135175                   312              220638                      310
        weighted average remaining contractual life in years                                  25                                          46                           
        range of exercise prices for outstanding options at the end of year            221471                                    197531                               




196       ahead of the curve  annual report 2017

                                                                                                                                  biocon limited



grant vi

in july 2014 the company approved the grant to its employees under the existing esop plan 2000 the options under this grant would vest to the
employees as 10 20 30 and 40 of the total grant at the end of first second third and fourth year from the date of grant respectively with an
exercise period ending one year from the end of last vesting the vesting conditions include service terms and performance grade of the employees
these options are exercisable at the closing market price of companys shares existing on the date preceding to the date of grant

particulars                                                                           march 31 2017                       march 31 2016
                                                                               number of          weighted           number of         weighted
                                                                                options           average             options          average
                                                                                                exercise price                       exercise price
                                                                                                                                       
outstanding at the beginning of the year                                           1185839               470          1346152               470
granted during the year                                                               95000               477                                       
forfeited during the year                                                             61600               470           160313                470
exercised during the year                                                           258001                471                                       
expired during the year                                                                                                                            
outstanding at the end of the year                                                  961238                471          1185839               470
exercisable at the end of the year                                                  125026                470           116750                470
weighted average remaining contractual life in years                                    23                                 33                    
weighted average fair value of options granted                                        156                                                        
range of exercise prices for outstanding options at the end of year              470493                                  470                     

grant vii

in july 2014 the company approved the grant to its employees under the existing esop plan 2000 the options under this grant would vest to the
employees as 10 20 30 and 40 of the total grant at the end of first second third and fourth year from the date of grant respectively with an
exercise period ending one year from the end of last vesting the vesting conditions include service terms and performance grade of the employees
these options are exercisable at the closing market price of companys shares existing on the date preceding to the date of grant

particulars                                                                           march 31 2017                       march 31 2016
                                                                               number of          weighted           number of         weighted
                                                                                options           average             options          average
                                                                                                exercise price                       exercise price
                                                                                                                                       
outstanding at the beginning of the year                                           1275500               461           293000                452
granted during the year                                                             200000                605          1077500               461
forfeited during the year                                                           238500                392             95000               472
exercised during the year                                                             16800               457                                       
expired during the year                                                                                                                            
outstanding at the end of the year                                                 1220200               482          1275500               461
exercisable at the end of the year                                                     9450               457                                       
weighted average remaining contractual life in years                                    52                                 60                    
weighted average fair value of options granted                                        251                                 185                     
range of exercise prices for outstanding options at the end of year              415741                             415518                      

grant viii

in july 2015 the company approved the grant to its employees under the existing esop plan 2000 the options under this grant would vest to the
employees as 10 20 30 and 40 of the total grant at the end of first second third and fourth year from the date of grant respectively with an
exercise period ending one year from the end of last vesting the vesting conditions include service terms and performance grade of the employees
these options are exercisable at the closing price as per national stock exchange as on the last day of the month preceding the month of first grant




                                             this space has been intentionally left blank




                                                                                                                     financial report           197

        particulars                                                                       march 31 2017                       march 31 2016
                                                                                   number of          weighted           number of         weighted
                                                                                    options           average             options          average
                                                                                                    exercise price                       exercise price
                                                                                                                                           
        outstanding at the beginning of the year                                        312500                459                                       
        granted during the year                                                           55000               457           312500                459
        forfeited during the year                                                       105000                457                                       
        exercised during the year                                                          1000               457                                       
        expired during the year                                                                                                                        
        outstanding at the end of the year                                              261500                460           312500                459
        exercisable at the end of the year                                                16750               457                                       
        weighted average remaining contractual life in years                                38                                 46                    
        weighted average fair value of options granted                                    149                                 154                     
        range of exercise prices for outstanding options at the end of year          457481                             457481                      

    grant ix

    in june 2016 the company approved the grant to its employees under the existing esop plan 2000 the options under this grant would vest to the
    employees as 10 20 30 and 40 of the total grant at the end of first second third and fourth year from the date of grant respectively with an
    exercise period ending one year from the end of last vesting the vesting conditions include service terms and performance grade of the employees
    these options are exercisable at 50 of the closing price as per national stock exchange as on the preceding day to the date of grant

        particulars                                                                       march 31 2017                       march 31 2016
                                                                                   number of          weighted           number of         weighted
                                                                                    options           average             options          average
                                                                                                    exercise price                       exercise price
                                                                                                                                           
        outstanding at the beginning of the year                                                                                                       
        granted during the year                                                          472500                495                                      
        forfeited during the year                                                          5000                467                                      
        exercised during the year                                                                                                                      
        expired during the year                                                                                                                        
        outstanding at the end of the year                                               467500                496                                      
        exercisable at the end of the year                                                                                                             
        weighted average remaining contractual life in years                                89                                                       
        weighted average fair value of options granted                                    617                                                        
        range of exercise prices for outstanding options at the end of year          415566                                                         

    grant x

    in june 2016 the company approved the grant to its employees under the existing esop plan 2000 the options under this grant would vest to the
    employees as 10 20 30 and 40 of the total grant at the end of first second third and fourth year from the date of grant respectively with an
    exercise period ending one year from the end of last vesting the vesting conditions include service terms and performance grade of the employees
    these options are exercisable at 50 of the closing price as per national stock exchange as on the preceding day to the date of grant

        particulars                                                                       march 31 2017                       march 31 2016
                                                                                   number of          weighted           number of         weighted
                                                                                    options           average             options          average
                                                                                                    exercise price                       exercise price
                                                                                                                                           
        outstanding at the beginning of the year                                                                                                       
        granted during the year                                                          255000                388                                      
        forfeited during the year                                                         51250                373                                      
        exercised during the year                                                                                                                      
        expired during the year                                                                                                                        
        outstanding at the end of the year                                               203750                392                                      
        exercisable at the end of the year                                                                                                             
        weighted average remaining contractual life in years                                43                                                       
        weighted average fair value of options granted                                    442                                                        
        range of exercise prices for outstanding options at the end of year          371467                                                         

    assumptions used in determination of the fair value of the stock options under the black scholes model are as follows



198       ahead of the curve  annual report 2017

                                                                                                                                           biocon limited



      particulars                                                                                                            march 31 2017    march 31 2016
      weighted average exercise price                                                                                           388605            459461
      expected volatility                                                                                                    295 to 334    29 to 345
      life of the options granted vesting and exercise period in years                                                             3065           3065
      average riskfree interest rate                                                                                                712             765
      expected dividend rate                                                                                                         110             110

      expected volatility is based on historical volatility of the market price of the companys publicly traded equity shares during the expected term of the
      option grant

b   rsu plan 2015

      on march 11 2015 biocons remuneration committee approved the biocon  restricted stock units rsus of syngene rsu plan 2015 for the grant
      of rsus to the employees of the company and its subsidiaries other than syngene the remuneration committee administers the plan through a trust
      established specifically for this purpose called the biocon limited employee welfare trust rsu trust for this purpose on march 31 2015 the
      company transferred 2000000 equity shares of syngene to rsu trust

      in april 2015 the company approved the grant to its employees under the rsu plan 2015 the rsus under this grant would vest to the employees
      as 10 20 30 and 40 of the total grant at the end of first second third and fourth year from the date of grant respectively with an exercise
      period ending one year from the end of last vesting the vesting conditions include service terms and performance grade of the employees exercise
      price of rsus will be nil

      particulars                                                                            march 31 2017                          march 31 2016
                                                                                       number of          weighted             number of         weighted
                                                                                         units            average                units           average
                                                                                                        exercise price                         exercise price
                                                                                                                                                 
      outstanding at the beginning of the year                                            1231803                                                           
      granted during the year                                                               193454                              1364148                     
      forfeited during the year                                                             117963                                132345                     
      exercised during the year                                                              10742                                                           
      expired during the year                                                                                                                                
      outstanding at the end of the year                                                  1296552                              1231803                     
      exercisable at the end of the year                                                     92320                                                           
      weighted average remaining contractual life in years                                     41                                    48                    
      weighted average fair value of options granted                                         468                                     162

      assumptions used in determination of the fair value of the stock options under the black scholes model are as follows

      particulars                                                                                                            march 31 2017    march 31 2016
      weighted average exercise price                                                                                                                       
      expected volatility                                                                                                    2992  4431          2992
      life of the options granted vesting and exercise period in years                                                             5065           5065
      average riskfree interest rate                                                                                                712             765
      expected dividend rate                                                                                                         030             030

      summary of movement in respect of the shares held by the esop trust is as follows

                                                                                                                             march 31 2017    march 31 2016
      opening balance                                                                                                             3876828        3674928
      add shares purchased by the esop trust                                                                                       152731           348163
      less shares exercised by employees                                                                                         499689         146263
      closing balance                                                                                                             3529870        3876828
      options granted and eligible for exercise at end of the year                                                                  286401           340888
      options granted but not eligible for exercise at end of the year                                                            3323649        3228326


      summary of movement in respect of equity shares of syngene held by the rsu trust is as follows
      opening balance                                                                                                             2000000        2000000
      less shares exercised by employees                                                                                           10742                    
      closing balance                                                                                                             1989258        2000000




                                                                                                                                financial report         199

32   earnings per share eps

                                                                                                                           march 31 2017      march 31 2016
        earnings
        profit for the year                                                                                                          5193             3686


        shares
        basic outstanding shares                                                                                              200000000        200000000
        less weighted average shares held with the esop trust                                                                 3702196        3697436
        weighted average shares used for computing basic eps                                                                  196297804        196302564


        add effect of dilutive options granted but not yet exercisednot yet eligible for exercise                              1376487           167870
        weighted average shares used for computing diluted eps                                                                197674291        196470434


        earnings per share
            basic in                                                                                                              2645             1878
            diluted in                                                                                                            2627             1876

33   exceptional items net

                                                                                                                           march 31 2017      march 31 2016
        gain on sale of shares in subsidiaries net refer note a and b below                                                                    1061
                                                                                                                                                       1061

      a       during the year ended march 31 2016 the company sold its investment in the equity shares of biocon sdn bhd a wholly owned subsidiary
                to biocon biologics limited uk for a sum of  811 gain arising from such sale of equity shares amounting to  99 net of cost of such equity
                shares is recorded as an exceptional gain in the standalone financial statements consequential tax of  21 is recorded on such gain

      b       during the year ended march 31 2016 syngene international limited syngene completed its initial public offering ipo through an offer
                for sale of 22000000 equity shares of  10 each by the company gain arising from such sale of equity shares net of related expenses and
                cost of equity shares amounting to  962 is recorded as an exceptional gain in the standalone financial statements consequential tax of
                 1042 is recorded on such gains is included within income tax expense

                mat credit on above transaction was not recorded in the previous year due to uncertainty of utilization during the current year pursuant to
                change in the income tax law and other business restructuring the company believes that it will be able to utilize the mat credit entitlement
                accordingly during the year ended march 31 2017 the company has recorded mat credit entitlement of  1042 which is included within
                income tax expense of the current year




                                                      this space has been intentionally left blank




200          ahead of the curve  annual report 2017

                   34   related party transactions
                         related parties where control exists and related parties with whom transactions have taken place during the year are listed below

                   sl    name of the related party       relationship                       description of transaction                                      april 1      balance           april 1      balance        balance
                   no                                                                                                                                      2016 to            as at        2015 to            as at          as at
                                                                                                                                                         march 31       march 31       march 31       march 31        april 1
                                                                                                                                                             2017            2017            2016            2016           2015
                                                                                                                                                          income       payable        income       payable     payable
                                                                                                                                                       expenses     receivable      expenses     receivable     receivable
                                                                                                                                                             other                           other
                                                                                                                                                      transactions                    transactions
                   a    remuneration paid to key management personnel refer note g below
                   1     kiran mazumdarshaw           chairperson  managing director salary and perquisites                                                  20                           16                             
                   2     john shaw                     vicechairman  director         salary and perquisites                                                 17                           16                             
                   3     arun chandavarkar             joint managing director  ceo    salary and perquisites                                                 33                           31                             
                   4     siddharth mittal              president  finance  chief      salary and perquisites                                                 20                           16                             
                                                       financial officer
                   5     kiran kumar                   company secretary                salary and perquisites                                                   7                           6                             
                                                       upto dec 15 2016
                   6     rajiv balakrishnan            company secretary                salary and perquisites                                                   1                                                          
                                                       wef jan 24 2017
                   b    others
                   7     syngene international limited subsidiary                       power and facility charges recovered refer note b below            466                            454                              
                                                                                        rent income refer note b below                                      47                             50                              
                                                                                        dividend income                                                                                      145                              
                                                                                        expenses incurred on behalf of the related party refer                 49                             58                              
                                                                                        note a below
                                                                                        sale of goodsother products                                             4                              4                             
                                                                                        research services received                                             89                         107                             
                                                                                        ipo expenses incurred on behalf of the company                                                       45                            
                                                                                        other receivables                                                                    125                             91            150
                                                                                        trade payables                                                                       53                           16           30
                                                                                        guarantee given on behalf of related party to customs                                148                            148            242
                                                                                         excise department ced
                                                                                        guarantee given by related party to ced on behalf of                                500                          500          500
                                                                                        the company
                   8     biocon research limited       whollyowned subsidiary          rent income refer note b below                                      42                             37                              
                                                                                        power and facility charges recovered refer note b below             63                             66                              
                                                                                        cross charges towards lab consumables and other                                                      673                              
                                                                                        expenses
                                                                                        research services received                                            243                                                         
                                                                                        sale of goods                                                             6                            40                            
                                                                                        other receivables                                                                      50                           431            181
                                                                                        royalty expense                                                         16                          27                           
                                                                                        interest on loans to related party                                     121                            316                            
                                                                                        expenses incurred on behalf of the related party                                                      26                            




financial report
                                                                                        refer note a below
                                                                                        trade payables                                                                       63                                           
                                                                                        loans to related party net                                            468          1923            992          1455          2447




 201
                                                                                                                                                                                                                                     biocon limited

                                          sl   name of the related party   relationship                 description of transaction                                      april 1      balance           april 1      balance        balance
                                          no                                                                                                                           2016 to            as at        2015 to            as at          as at




202 
                                                                                                                                                                     march 31       march 31       march 31       march 31        april 1
                                                                                                                                                                         2017            2017            2016            2016           2015
                                                                                                                                                                      income       payable        income       payable     payable
                                                                                                                                                                   expenses     receivable      expenses     receivable     receivable
                                                                                                                                                                         other                           other
                                                                                                                                                                  transactions                    transactions
                                          9    biocon sa                   whollyowned subsidiary      cross charges towards facility and other expenses                  197                             50                              
                                                                                                        expenses incurred by related party on behalf of the                25                                                           
                                                                                                        company
                                                                                                        trade receivable                                                                 157                                              
                                                                                                        other receivable                                                                                                 51             94
                                          10   biocon sdnbhd             whollyowned subsidiary of   expenses incurred on behalf of the related party refer               8                            15                              
                                                                           biocon biologics limited     note a below
                                                                                                        sale of goods                                                       64                             69                              
                                                                                                        purchase of goods                                                218                                                            
                                                                                                        other operating income                                                9                                                           
                                                                                                        guarantee income                                                    29                                                            
                                                                                                        trade payables                                                                  274                                             




ahead of the curve  annual report 2017
                                                                                                        trade receivables                                                                125                              81             30
                                                                                                        other receivables                                                                505                            560              41
                                                                                                        guarantee given by the company to banks on behalf of                          12330                         10760          8096
                                                                                                        related party loan facility
                                          11   neobiocon fz llc            jointventure                sale of goods                                                       39                             35                              
                                                                                                        dividend income                                                                                  342                              
                                                                                                        other receivables                                                                                                 3               
                                                                                                        trade receivables                                                                   2                             30             29
                                          12   glentec international       enterprise owned by key      rent expenses                                                                      1                            1            1
                                               limited                     management personnel
                                          13   biocon pharma limited       whollyowned subsidiary      investment in equity shares                                         70                             50                              
                                                                                                        expenses incurred on behalf of the related party refer               7                            21                              
                                                                                                        note a below
                                                                                                        interest on loans to related party                                    4                              4                             
                                                                                                        loans to related party net                                      129                            129            129                
                                                                                                        other receivables                                                                   5                             24               
                                                                                                        guarantee given by the company to banks on behalf of                           1296                          1362                
                                                                                                        related party loan facility
                                          14   biocon biologics limited    whollyowned subsidiary      investment in equity shares                                                                    4453                              
                                                                                                        sale of noncurrent investments  shares of biocon                                                811                              
                                                                                                        sdn bhd refer note 33
                                                                                                        sale of goods                                                      522                             73                              
                                                                                                        cross charges towards other expenses                             1093                                                             
                                                                                                        royalty expense                                                                                   5                             
                                                                                                        trade receivables                                                              1746                              71               
                                                                                                        trade payables                                                                     5                            5              

                   sl    name of the related party       relationship                        description of transaction                                     april 1      balance           april 1      balance        balance
                   no                                                                                                                                      2016 to            as at        2015 to            as at          as at
                                                                                                                                                         march 31       march 31       march 31       march 31        april 1
                                                                                                                                                             2017            2017            2016            2016           2015
                                                                                                                                                          income       payable        income       payable     payable
                                                                                                                                                       expenses     receivable      expenses     receivable     receivable
                                                                                                                                                             other                           other
                                                                                                                                                      transactions                    transactions
                   15    biocon fz llc                   whollyowned subsidiary             investment in equity shares                                                                        3                             
                                                                                             sale of goods                                                                                      1                             
                                                                                             trade receivables                                                                                                1               
                   16    biocon pharma inc               whollyowned subsidiary         of expenses incurred on behalf of the related party                    35                                                            
                                                         biocon pharma limited               other receivables                                                                 35                                             
                   17    biocon academy                  whollyowned subsidiary             csr expenditure                                                   30                           29                             
                   18    biocon foundation               trust in which key management csr expenditure                                                         60                           52                             
                                                         personnel are the board of
                                                         trustees
                   19    narayana hrudayalaya            enterprise in which a director sale of goods                                                           41                             51                              
                         limited formerly known as      of the company is a member of trade receivables                                                                        4                              8              5
                         narayana hrudayalaya private    board of directors
                         limited

                   a   expenses incurred on behalf of the related party include recharge of software license fees and amount paid on behalf to vendors
                   b   the companys sez developer division has entered into agreements to lease land and provide certain facilities such as power utilities etc to sez units of biocon research limited and syngene
                         international limited in respect of which the company recovers rent and facilities usage charges
                   c   the company has purchased consumables from mazumdar farms a proprietary firm of relative of director which are not disclosed above since the amounts are rounded off to rupees million
                   d   during the year there is no transaction with biocon india limited employees welfare trust trust in which key management personnel were the board of trustees
                   e   the above disclosures include related parties as per ind as 24 on related party disclosures and companies act 2013
                   f   the remuneration to key management personnel doesnt include the provisions made for gratuity and compensated absences as they are obtained on an actuarial basis for the company as a whole
                   g   share based compensation expense allocable to key management personnel is  5 march 31 2016   10 which is not included in the remuneration disclosed above
                   h   all transactions with these related parties are priced on an arms length basis and none of the balances are secured




                                                                                              this space has been intentionally left blank




financial report
 203
                                                                                                                                                                                                                                     biocon limited

35 tax expense
                                                                                                                             march 31 2017    march 31 2016
a     amount recognised in statement of profit and loss
        current tax                                                                                                                  1269             2175
        mat credit entitlement                                                                                                      1172                
        deferred tax expenseincome related to
          origination and reversal of temporary differences                                                                             72             267
        tax expense for the year                                                                                                       169             1908

b     reconciliation of effective tax rate
        profit before tax                                                                                                            5362             5594
        less exceptional items net                                                                                                                 1061
        profit before tax and exceptional items                                                                                      5362             4533
        tax at statutory income tax rate 3461 march 31 2016  3461                                                            1856             1569

        tax effects of amounts which are not deductibletaxable in calculating taxable income
        weighted deduction on research and development expenditure                                                                    520            432
        exempt income and other deductions                                                                                            254            372
        nondeductible expense                                                                                                          74                65
        tax on exceptional item                                                                                                     1042            1063
        basis difference that will reverse during the tax holiday period                                                                22                27
        others                                                                                                                          33               12
        income tax expense                                                                                                             169             1908

c     tax losses
        unused tax losses for which no deferred tax asset has been recognised                                                         238                 70
        potential tax impact                                                                                                           36                 11
        expiry date financial year                                                                                            202223 to           202223
                                                                                                                                  202324
d     recognised deferred tax assets and liabilities
        the following is the movement of deferred tax assetsliabilities presented in the balance sheet
        for the year ended                                                                  opening     recognised in           recognised           closing
        march 31 2017                                                                       balance     profit or loss              in oci          balance
        deferred tax liability
        property plant and equipment investment property and intangible assets                 558               35                                 523
        derivative assets                                                                                                             46                46
        gross deferred tax liability                                                             558               35                 46               569
        deferred tax assets
        defined benefit obligations                                                               86                 15                   9              110
        allowance for doubtful debts                                                              14                  6                                  20
        other disallowable expenses                                                              145                 24                                 169
        deferred revenue                                                                         162             162                                    
        mat credit entitlement                                                                    22             1172                                1194
        derivative liability                                                                        1                                   1               
        others                                                                                   119                 11                                 130
        gross deferred tax assets                                                                549             1066                    8            1623
                                                                                                  9            1101                 38            1054

        for the year ended                                                                    opening      recognised in        recognised           closing
        march 31 2016                                                                        balance       profit or loss           in oci          balance
        deferred tax liability
        property plant and equipment investment property and intangible assets                    609              51                               558
        derivative assets                                                                            48              48                                 
        gross deferred tax liability                                                                657              99                               558
        deferred tax assets
        defined benefit obligations                                                                   67              13                  6               86
        allowance for doubtful debts                                                                  29             15                                14
        other disallowable expenses                                                                   80              65                                145
        deferred revenue                                                                              69              93                                162
        mat credit entitlement                                                                        22                                                22
        derivative liability                                                                                          1                                   1
        others                                                                                       108              11                                119
        gross deferred tax assets                                                                    375             168                  6              549
                                                                                                   282             267                  6               9




204       ahead of the curve  annual report 2017

                                                                                                                                      biocon limited




36    contingent liabilities and commitments
       to the extent not provided for
                                                                                                       march 31 2017   march 31 2016    april 01 2015
i    contingent liabilities
a    claims against the company not acknowledged as debt                                                     2893            3041              1241
       the above includes
       i     direct taxation                                                                                 1950            2050               297
       ii    indirect taxation includes matters pertaining to disputes on central excise custom              550              594               552
               duty and service tax
       iii   other litigations                                                                                 393              397               392
       the company is involved in taxation and other disputes lawsuits proceedings etc including patent and commercial matters that arise from time to
       time in the ordinary course of business management is of the view that above claims are not tenable and will not have any material adverse effect
       on the companys financial position and results of operations
                                                                                                       march 31 2017   march 31 2016    april 01 2015
b    guarantees
       i     corporate guarantees given in favour of the central excise department in respect of
               certain performance obligations of the subsidiaries
                syngene international limited                                                                    148              148               242
       ii    corporate guarantees given in favour of banks towards loans obtained by subsidiaries
               stepdown subsidiaries
                biocon research limited                                                                                                           685
                biocon sdn bhd                                                                              12330           10760              8096
                biocon pharma limited                                                                          1296            1362                   
                                                                                                              13626           12122              8781
       iii   guarantees given by banks on behalf of the company for contractual obligations of                  18                18                63
               the company the necessary terms and conditions have been complied with and no
               liabilities have arisen
ii   commitments
a    estimated amount of contracts remaining to be executed on capital account and not
       provided for net of advances                                                                             401            1114               824
b    operating lease commitments
where the company is a lessee
i    vehicles
       the company has taken vehicles for certain employees under operating leases which expire
       over a period upto january 2020 gross rental expenses for the year aggregate to  16
       march 31 2016   16
       the committed lease rentals in future are as follows                                           march 31 2017   march 31 2016    april 01 2015
         not later than one year                                                                                  19                15                12
         later than one year and not later than five years                                                        22                26                24
c    as at march 31 2016 and 2015 the company had committed to provide financial support to
       biocon research limited with regard to the operations of such company


37    disclosure on specified bank notes sbns
during the year the company had specified bank notes or other denomination note as defined in the mca notification gsr 308e dated
march 30 2017 on the details of specified bank notes sbn held and transacted during the period from november 8 2016 to december 30 2016
the denomination wise sbns and other notes as per the notification is given below
                                                                                                                                            amount in 
particulars                                                                                                    sbns            other               total
                                                                                                                         denomination
                                                                                                                                notes
closing cash in hand as on november 8 2016                                                                  130500          148761           279261
 permitted receipts                                                                                                       604105           604105
 permitted payments                                                                                                      499419         499419
 amount deposited in banks                                                                               130500                         130500
closing cash in hand as on december 30 2016                                                                                 253447           253447
for the purposes of this clause the term specified bank notes shall have the same meaning provided in the notification of the government of india in
the ministry of finance department of economic affairs number so 3407e dated the november 8 2016




                                                                                                                          financial report          205

38 employee benefit plans
i     the company has a defined benefit gratuity plan as per the payment of gratuity act 1972 under this legislation employee who has completed five
        years of service is entitled to specific benefit the level of benefit provided depends on the employees length of service and salary at retirement
        termination age the gratuity plan is a funded plan and the company make contributions to a recognised fund in india
        based on the actuarial valuation obtained in this respect the following table sets out the status of the gratuity plan and the amounts recognised in
        the companys financial statements as at balance sheet date
                                                                                                         defined benefit        fair value of      net defined
                                                                                                               obligation        plan assets            benefit
                                                                                                                                               assetliability
        balance as on april 01 2016                                                                                  229                61              168
        current service cost                                                                                           27                                   27
        interest expenseincome                                                                                      17                  5               12
        amount recognised in statement of profit and loss                                                              44                 5                39
        remeasurements
        return on plan assets excluding amounts included in interest expenseincome                                                    2               2
        actuarial gainloss arising from
          demographic assumptions                                                                                       3                                 3
          financial assumptions                                                                                          9                                    9
          experience adjustment                                                                                        23                                   23
        amount recognised in other comprehensive income                                                                29                 2                27
        employers contribution                                                                                                          13              13
        benefits paid                                                                                                 23                 23                  
        balance as at march 31 2017                                                                                  279                58              221

        balance as on april 01 2015                                                                                  193               72               121
        current service cost                                                                                           23                                  23
        interest expenseincome                                                                                      15                 7                8
        amount recognised in statement of profit and loss                                                              38                7                31
        remeasurements
        return on plan assets excluding amounts included in interest expenseincome                                                   1                1
        actuarial gainloss arising from
          demographic assumptions                                                                                                                          
          financial assumptions                                                                                         5                                   5
          experience adjustment                                                                                        12                                  12
        amount recognised in other comprehensive income                                                                17                1                16
        employers contribution                                                                                                                             
        benefits paid                                                                                                 19                19                 
        balance as at march 31 2016                                                                                  229               61               168

                                                                                                          march 31 2017     march 31 2016     april 01 2015
        noncurrent                                                                                                  133                 95                  
        current                                                                                                       88                 73                121
                                                                                                                     221                168                121
ii    the assumptions used for gratuity valuation are as below
                                                                                                       march 31 2017 march 31 2016            april 01 2015
        interest rate                                                                                             69            75                    88
        discount rate                                                                                             69            75                    79
        expected return on plan assets                                                                            69            75                    79
        salary increase                                                                                           90            90                    90
        attrition rate                                                                                     14  30          7  26             7  26
        retirement age  years                                                                                       58              58                      58
        assumptions regarding future mortality experience are set in accordance with published statistics and mortality tables
        the weighted average duration of the defined benefit obligation was 8 years march 31 2016  8 years
        the defined benefit plan expose the company to actuarial risks such as longevity and interest rate risk

iii   sensitivity analysis
        the sensitivity of the defined benefit obligation to changes in the weighted principal assumptions are as below
        particulars                                                                             march 31 2017                       march 31 2016
                                                                                              increase           decrease           increase          decrease
        discount rate                                                                              13                14                 9                10
        salary increase                                                                             14               13                 10                 9
        attrition rate                                                                              2                 3                 1                 2
        sensitivity of significant actuarial assumptions is computed by varying one actuarial assumption used for the valuation of defined benefit obligation
        by one percentage keeping all other actuarial assumptions constant although the analysis does not take account of the full distribution of cash
        flows expected under the plan it does provide an approximation of the sensitivity of the assumption shown


206        ahead of the curve  annual report 2017

                                                                                                                                   biocon limited



      as of march 31 2017 and march 31 2016 the plan assets have been invested in insurer managed funds and the expected contribution to the fund
      during the year ending march 31 2018 is approximately  51 march 31 2017   73
      maturity profile of defined benefit obligation
      particulars                                                                                                                           million
      1st following year                                                                                                                         51
      2nd following year                                                                                                                         30
      3rd following year                                                                                                                         29
      4th following year                                                                                                                         39
      5th following year                                                                                                                         27
      years 6 to 10                                                                                                                             106


39    financial instruments fair value and risk managements
a     accounting classification and fair values
                                                        carrying amount                                            fair value
march 31 2017                                fvtpl     fvtoci     amortised          total       level 1       level 2         level 3        total
                                                                        cost
financial assets
noncurrent investments                                              1459         1459                                                      
loans                                                                1923         1923                                                      
current investments                           3127                   2120         5247          3127                                   3127
trade receivables                                                    7982         7982                                                      
cash and bank balances                                               3829         3829                                                      
other financial asset                                     142         1084         1226                        142                         142
                                              3127        142        18397        21666          3127          142                       3269
financial liabilities
borrowings                                                           1324         1324                                                      
trade payables                                                       4505         4505                                                      
other financial liabilities                                             665          665                                                      
                                                                     6494         6494                                                      


march 31 2016                               fvtpl      fvtoci     amortised          total       level 1       level 2         level 3        total
                                                                        cost
financial assets
loans                                                                1584         1584                                                      
current investments                           1563                   4420         5983          1563                                   1563
trade receivables                                                    5038         5038                                                      
cash and bank balances                                               6430         6430                                                      
other financial asset                                      39         1621         1660                          39                         39
                                              1563         39        19093        20695          1563            39                      1602
financial liabilities
borrowings                                                           3620         3620                                                      
trade payables                                                       3944         3944                                                      
other financial liabilities                        71       10            836          917                          81                         81
                                                   71       10         8400         8481                          81                         81


april 01 2015                               fvtpl      fvtoci     amortised          total       level 1       level 2         level 3        total
                                                                        cost
financial assets
loans                                                                2447         2447                                                      
current investments                           1018                                1018          1018                                   1018
trade receivables                                                    5033         5033                                                      
cash and bank balances                                               6602         6602                                                      
other financial asset                                     169            811          980                        169                         169
                                              1018        169        14893        16080          1018          169                       1187
financial liabilities
borrowings                                                              675          675                                                      
trade payables                                                       3008         3008                                                      
other financial liabilities                                          1391         1391                                                      
                                                                     5074         5074                                                      




                                                                                                                      financial report         207

b measurement of fair values
fair value of liquid mutual funds are based on quoted price derivative financial instruments are valued based on quoted prices for similar assets and
liabilities in active markets or inputs that are directly or indirectly observable in the market place

sensitivity analysis
for the fair values of forward contracts of foreign currencies reasonably possible changes at the reporting date to one of the significant observable inputs
holding other inputs constant would have the following effects

 significant observable inputs                                                                                march 31 2017                 march 31 2016
                                                                                                              profit or loss                profit or loss
                                                                                                             increase      decrease         increase       decrease
 spot rate of the foreign currency 1 movement                                                                 31              31              1             1
 interest rates 100 bps movement                                                                               38              38            27             27

c financial risk management

the company has exposure to the following risks arising from financial instruments
 credit risk
 liquidity risk
 market risk

risk management framework

the companys risk management is carried out by the treasury department under policies approved by the board of directors the board provides written
principles for overall risk management as well as policies covering specific areas such as foreign exchange risk interest rate risk credit risk use of derivative
and nonderivative financial instruments and investment of excess liquidity

i credit risk

credit risk is the risk that the counterparty will not meet its obligation under a financial instrument or customer contract leading to financial loss the credit
risk arises principally from its operating activities primarily trade receivables and from its financing activities including deposits with banks and financial
institutions and other financial instruments

customer credit risk is managed by each business unit subject to companys established policy procedures and control relating to customer credit risk
management the audit and risk management committee has established a credit policy under which each new customer is analysed individually for
creditworthiness before the companys standard payment and delivery terms and conditions are offered the companys review includes external ratings
where available and other publicly available financial information outstanding customer receivables are regularly monitored and any shipments to major
customers are generally covered by letters of credit or other forms of credit insurance

the company establishes an allowance for impairment that represents its estimate of expected losses in respect of trade and other receivables the
maximum exposure to credit risk as at reporting date is primarily from trade receivables amounting to  7982 march 31 2016   5038 april 01 2015 
 5033 the movement in allowance for impairment in respect of trade and other receivables during the year was as follows

 allowance for impairment                                                                                                        march 31 2017     march 31 2016
 opening balance                                                                                                                              42                  85
 impairment loss recognisedreversed                                                                                                        16                 43
 closing balance                                                                                                                              58                  42

no single customer accounted for more than 10 of the trade receivable as of march 31 2017 and 2016 there is no significant concentration of credit risk

credit risk on cash and cash equivalent and derivatives is limited as the company generally transacts with banks and financial institutions with high credit
ratings assigned by international and domestic credit rating agencies investments primarily include investment in liquid mutual fund units bonds and non
convertible debentures

ii liquidity risk

liquidity risk is the risk that the company will encounter difficulty in meeting the obligations associated with its financial liabilities that are settled by
delivering cash or another financial asset the companys approach to managing liquidity is to ensure as far as possible that it will have sufficient liquidity to
meet its liabilities when they are due under both normal and stressed conditions without incurring unacceptable losses or risking damage to the companys
reputation

the company believes that the working capital is sufficient to meet its current requirements accordingly no liquidity risk is perceived in addition the
company maintains the following line of credit

a cash credit facility from banks carrying interest rate ranging from 97  13 pa these facilities were repayable on demand and secured by paripassu
    charge on inventories and trade receivables

b unsecured foreign currency denominated loans from banks amounting to  nil march 31 2016   2253 carrying interest ranging from nil march 31
    2016  libor  010 to 020 pa the facilities are repayable within 180 days from its origination



208        ahead of the curve  annual report 2017

                                                                                                                                           biocon limited



the table below provides details regarding the undiscounted contractual maturities of significant financial liabilities as of march 31 2017

particulars                                                       less than 1 year          12 years          25 years         57 years             total
longterm borrowings                                                            11               655                669                              1335
shortterm borrowings                                                                                                                                   
trade payables                                                               4505                                                                 4505
other financial liabilities                                                    652                  2                                                 654
total                                                                        5168               657                669                              6494


the table below provides details regarding the undiscounted contractual maturities of significant financial liabilities as of march 31 2016
particulars                                                       less than 1 year          12 years          25 years         57 years             total
longterm borrowings                                                            75                 11             1347                   7           1440
shortterm borrowings                                                        2255                                                                 2255
trade payables                                                               3944                                                                 3944
other financial liabilities                                                    835                  7                                                 842
total                                                                        7109                 18             1347                   7           8481

the table below provides details regarding the undiscounted contractual maturities of significant financial liabilities as of april 01 2015

particulars                                                       less than 1 year          12 years          25 years         57 years             total
longterm borrowings                                                           140                 76                 24                14              254
shortterm borrowings                                                          561                                                                   561
trade payables                                                               3008                                                                 3008
other financial liabilities                                                  1245                  6                                               1251
total                                                                        4954                 82                 24                14            5074

iii market risk
market risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market prices such as foreign
exchange rates interest rates and equity prices
foreign currency risk
the company operates internationally and a major portion of the business is transacted in several currencies and consequently the company is exposed to
foreign exchange risk through operating and borrowing activities in foreign currency the company holds derivative instruments such as foreign exchange
forward interest rate swaps and option contracts to mitigate the risk of changes in exchange rates and foreign currency exposure
the currency profile of financial assets and financial liabilities as at march 31 2017 and march 31 2016 are as below

march 31 2017                                                                                   usd                eur             others              total
financial assets
loans                                                                                                                                                   
trade receivables                                                                               4916               259                               5175
cash and cash equivalents                                                                       2800               188                  19            3007
other noncurrent financial assets                                                                                                                      
other current financial assets                                                                    539                                                  539
financial liabilities
longterm borrowings                                                                          1296                                              1296
shortterm borrowings                                                                                                                                   
trade payables                                                                                  620               81                 4           705
other current financial liabilities                                                             154               99               30            283
net assetsliabilities                                                                        6185               267                15            6437

march 31 2016                                                                                   usd                eur             others              total
financial assets
loans                                                                                                                                                    
trade receivables                                                                               2696               222                               2918
cash and cash equivalents                                                                       2062               302                  14            2378
other noncurrent financial assets                                                                                                                       
other current financial assets                                                                    600                                                 600
financial liabilities
longterm borrowings                                                                          1326                                              1326
shortterm borrowings                                                                         2253                                              2253
trade payables                                                                                  951               86               10          1047
other current financial liabilities                                                             117                                   6           123
net assetsliabilities                                                                          711               438                  2           1147


                                                                                                                              financial report          209

sensitivity analysis

the sensitivity of profit or loss to changes in exchange rates arises mainly from foreign currency denominated financial instruments and the impact on other
components of equity arises from foreign exchange forwardoption contracts designated as cash flow hedges

particulars                                                                                impact on profit or loss                impact on other
                                                                                                                                 components of equity
                                                                                      march 31 2017     march 31 2016     march 31 2017     march 31 2016
usd sensitivity
inrusd  increase by 1                                                                           62                   7                31                     6
inrusd  decrease by 1                                                                          62                7               31                  6
eur sensitivity
inreur  increase by 1                                                                             3                  4                 3                     4
inreur  decrease by 1                                                                           3                4                3                  4

derivative financial instruments
the following table gives details in respect of outstanding foreign exchange forward and option contracts

particulars                                                                                                                 march 31 2017     march 31 2016
                                                                                                                                       in million
foreign exchange forward contracts to buy                                                                                                               usd 25
                                                                                                                                                     inr 1656
european style option contracts with periodical maturity dates                                                                      usd 44               usd 59
                                                                                                                                inr 2844           inr 3903
european style option contracts with periodical maturity dates                                                                       eur 6               eur 12
                                                                                                                                  inr 434            inr 899

cash flow and fair value interest rate risk

the companys main interest rate risk arises from longterm borrowings with variable rates which expose the company to cash flow interest rate risk during
the year ended march 31 2017 and march 31 2016 the companys borrowings at variable rate were mainly denominated in usd

a interest rate risk exposure

the exposure of the companys borrowing to interest rate changes at the end of the reporting period are as follows

particulars                                                                                              march 31 2017     march 31 2016      april 01 2015
variable rate borrowings                                                                                           1296              3579                  561
fixed rate borrowings                                                                                                 36                 45                   49
total borrowings                                                                                                   1332              3624                  610

b sensitivity

the company policy is to maintain most of its borrowings at fixed rate using interest rate swaps to achieve this when necessary they are therefore not
subject to interest rate risk as defined under ind as 107 since neither the carrying amount nor the future cash flows will fluctuate because of change in
market interest rates

40   capital management
the key objective of the companys capital management is to ensure that it maintains a stable capital structure with the focus on total equity to uphold
investor creditor and customer confidence and to ensure future development of its business the company focused on keeping strong total equity base
to ensure independence security as well as a high financial flexibility for potential future borrowings if required without impacting the risk profile of the
company

the companys goal is to continue to be able to return excess liquidity to shareholders by continuing to distribute annual dividends in future periods

the amount of future dividends of equity shares will be balanced with efforts to continue to maintain an adequate liquidity status

the capital structure as of march 31 2017 and 2016 was as follows
particulars                                                                                                                 march 31 2017     march 31 2016
total equity attributable to the equity shareholders of the company                                                                 65411               59966
as a percentage of total capital                                                                                                      98                   94
longterm borrowings                                                                                                                 1335                 1440
shortterm borrowings                                                                                                                                     2255
total borrowings                                                                                                                     1335                 3695
as a percentage of total capital                                                                                                        2                   6
total capital equity and borrowings                                                                                               66746               63661




210       ahead of the curve  annual report 2017

                                                                                                                                             biocon limited



41   firsttime adoption of ind as
these standalone financial statements have been prepared in accordance with the ind as for the purpose of transition from previous gaap to ind as the
company has followed the guidance prescribed under ind as 101  first time adoption of indian accounting standards ind as 101 with effect from april
01 2015 transition date

in preparing its ind as balance sheet as at april 1 2015 and in presenting the comparative information for the year ended march 31 2016 the group
has adjusted amounts reported previously in financial statements prepared in accordance with previous gaap this note explains how the transition from
previous gaap to ind as has affected the companys balance sheet financial performance

a optional exemptions availed and mandatory exceptions
in preparing these standalone financial statements the company has applied the below mentioned optional exemptions and mandatory exceptions

optional exemptions availed
1 deemed cost
investment in subsidiaries

as per ind as 101 the entity may elect to use the fair value of investment in subsidiaries at the date of transition as the deemed cost accordingly the
company has recognised the fair value of a subsidiary as the deemed cost at the date of transition

2 business combination
ind as 101 provides the option to apply ind as 103 business combinations prospectively from the transition date or from a specific date prior to the
transition date

the company has elected to apply ind as 103 prospectively to business combinations occurring after its transition date business combinations occurring
prior to the transition date has not been restated

3 share based payments
ind as 102 share based payment has not been applied to equity instruments in share based payment transactions that vested before april 1 2014 for cash
settled share based payment transactions the company has not applied ind as 102 to liabilities that were settled before april 1 2014

mandatory exemptions availed
1 estimates
as per ind as 101 an entitys estimates in accordance with ind as at the date of transition to ind as shall be consistent with estimates made for the same
date in accordance with the previous gaap unless there is objective evidence that those estimates were in error

the companys estimates under ind as are consistent with the above requirement key estimates considered in preparation of the financial statements that
were not required under the previous gaap are listed below

     fair valuation of financial instruments carried at fvtpl and or fvoci

     impairment of financial assets based on the expected credit loss model

     determination of the discounted value for financial instruments carried at amortised cost

2 classification and measurement of financial assets
ind as 101 requires an entity to assess classification of financial assets on the basis of facts and circumstances existing as on the date of transition further
the standard permits measurement of financial assets accounted at amortised cost based on facts and circumstances existing at the date of transition if
retrospective application is impracticable

accordingly the company has determined the classification of financial assets based on facts and circumstances that exist on the date of transition
measurement of the financial assets accounted at amortised cost has been done retrospectively except where the same is impracticable

3 hedge accounting
hedge accounting can only be applied prospectively from the transition date to transactions that satisfy the hedge accounting criteria in ind as 109
financial instruments at the date of transition hedging relationships cannot be designated retrospectively and the supporting documentation cannot be
created retrospectively as a result only hedging relationships that satisfied the hedge accounting criteria as on the date of transition are reflected as hedges
in the consolidated financial statements under ind as




                                                     this space has been intentionally left blank




                                                                                                                                financial report           211

b reconciliations
the following reconciliations provides the effect of transition to ind as from previous gaap in accordance with ind as 101  firsttime adoption of ind as

i reconciliation of equity as at april 01 2015

                                                                                                       previous gaap        adjustments              ind as
assets
noncurrent assets
property plant and equipment                                                                                   8986              459             8527
capital workinprogress                                                                                          576                                 576
investment property                                                                                                                 459               459
intangible assets                                                                                                 157                 1              156
financial assets
i investments                                                                                                   804            31688             32492
ii loans                                                                                                      2447                               2447
iii other financial assets                                                                                    1032              659               373
incometax asset net                                                                                            462                47              415
other noncurrent assets                                                                                        1465                  6             1471
total noncurrent assets                                                                                       15929            30987             46916
current assets
inventories                                                                                                     4063                296             4359
financial assets
i investments                                                                                                   843                175             1018
ii trade receivables                                                                                          5551              518             5033
iii cash and cash equivalents                                                                                 3159                 60             3219
iv bank balances other than iii above                                                                       3053                330             3383
v other financial assets                                                                                        494                113               607
other current assets                                                                                              196                 2              194
total current assets                                                                                           17359                454            17813
total                                                                                                          33288            31441             64729

equity and liabilities
equity
equity share capital                                                                                            1000                               1000
other equity                                                                                                   24844            31497             56341
total equity                                                                                                   25844            31497             57341
noncurrent liabilities
financial liabilities
i borrowings                                                                                                    114                                 114
ii other financial liabilities                                                                                     6                                   6
provisions                                                                                                                                              
deferred tax liability net                                                                                      326                44              282
other noncurrent liabilities                                                                                   1358              453               905
total noncurrent liabilities                                                                                   1804              497             1307
current liabilities
financial liabilities
i borrowings                                                                                                    561                                 561
ii trade payables                                                                                             3008                               3008
iii other financial liabilities                                                                               1385                               1385
provisions                                                                                                        195                130               325
incometax liability net                                                                                        273                311               584
other current liabilities                                                                                         218                                 218
total current liabilities                                                                                       5640                441             6081
total                                                                                                          33288            31441             64729




                                                    this space has been intentionally left blank




212         ahead of the curve  annual report 2017

                                                                                                                            biocon limited



ii reconciliation of equity as at march 31 2016

                                                                                                  previous gaap   adjustments        ind as
assets
noncurrent assets
property plant and equipment                                                                            9035          439         8596
capital workinprogress                                                                                 1723                       1723
investment property                                                                                                     439           439
intangible assets                                                                                          342                        342
financial assets
i investments                                                                                          4587        27519         32106
ii loans                                                                                               1584                       1584
iii other financial assets                                                                             1307          637          670
incometax asset net                                                                                     462           34          428
other noncurrent assets                                                                                 1384            2         1382
total noncurrent assets                                                                                20424        26846         47270
current assets
inventories                                                                                              4675           371          5046
financial assets
i investments                                                                                          5941            42          5983
ii trade receivables                                                                                   5731          693         5038
iii cash and cash equivalents                                                                          2860            43          2903
iv bank balances other than iii above                                                                3103           424          3527
v other financial assets                                                                                 990                        990
other current assets                                                                                       224                        224
total current assets                                                                                    23524           187         23711
total                                                                                                   43948        27033         70981

equity and liabilities
equity
equity share capital                                                                                     1000                       1000
other equity                                                                                            31885        27081         58966
total equity                                                                                            32885        27081         59966
noncurrent liabilities
financial liabilities
i borrowings                                                                                           1365                       1365
ii other financial liabilities                                                                             4             3             7
provisions                                                                                                  95                         95
deferred tax liability net                                                                               255          246            9
other noncurrent liabilities                                                                            1236          323          913
total noncurrent liabilities                                                                            2955          566         2389
current liabilities
financial liabilities
i borrowings                                                                                           2255                       2255
ii trade payables                                                                                      3943             1          3944
iii other financial liabilities                                                                          901             9           910
provisions                                                                                                 155           130           285
incometax liability net                                                                                 351           378           729
other current liabilities                                                                                  503                        503
total current liabilities                                                                                8108           518          8626
total                                                                                                   43948        27033         70981




                                                     this space has been intentionally left blank




                                                                                                                  financial report     213

iii reconciliation of statement of profit and loss for the year ended march 31 2016

                                                                                                  previous gaap   adjustments   ind as
income
revenue from operations                                                                                 23236           118    23354
other income                                                                                             1841          110    1731
total income                                                                                            25077             8    25085
expenses
cost of raw materials and packing materials consumed                                                     9478             1     9479
purchases of traded goods                                                                                  760                   760
changes in inventories of traded goods finished goods and workinprogress                               288          76    364
excise duty                                                                                                             336      336
employee benefits expense                                                                                3187            32     3219
finance costs                                                                                                9            10       19
other expenses                                                                                           5754                  5754
depreciation and amortisation expense                                                                    1310            87     1397
                                                                                                        20210           390    20600
less recovery of product development costs from codevelopment partners net                             48                  48
total expenses                                                                                          20162           390    20552
profit before tax and exceptional item                                                                   4915          382    4533
exceptional items net                                                                                   5230        4169    1061
profit before tax                                                                                       10145        4551    5594
tax expense
  current tax                                                                                            2128            47     2175
  deferred tax                                                                                             71         196    267
total tax expense                                                                                        2057          149    1908
profit for the year                                                                                      8088        4402    3686
other comprehensive incomeexpense
i     items that will not be reclassified subsequently to profit or loss
remeasurement on defined benefit plans                                                                                 16     16
income tax effect                                                                                                         6        6
                                                                                                                        10     10
ii    items that will be reclassified subsequently to profit or loss
effective portion of gainslosses on hedging instrument in cash flow hedges                                                      
income tax effect                                                                                                                  
                                                                                                                                   
other comprehensive incomeexpense for the year net of taxes                                                         10     10
total comprehensive income for the year                                                                  8088        4412    3676




                                                     this space has been intentionally left blank




214       ahead of the curve  annual report 2017

                                                                                                                                            biocon limited



iv reconciliation of total equity

                                                                                                              note          march 31 2016      april 01 2015
 equity under previous gaap attributable to shareholders of the company                                                              32885            25844
 adjustments
 difference on account of revenue recognition net of related costs                                             i                   802              571
 impact of derivative accounting                                                                                ii                     2              126
 consolidation of esop trust                                                                                   vii                    475               526
 fair valuation of investment in subsidiary on transition date                                                                       27519            31688
 other adjustments                                                                                             iii                     24                 14
 income tax on above adjustments and corrections for earlier years                                             iv                   133              286
 total adjustments                                                                                                                   27081            31497
 equity under ind as attributable to shareholders of the company                                                                     59966            57341


 v reconciliation of the net profit
 net profit reconciliation                                                                                    note                             march 31 2016
 net profit attributable to shareholders of the company as per previous gaap a                                                                         8088
 adjustments
 difference on account of revenue recognition net of related costs                                             i                                      230
 impact of derivative accounting                                                                                ii                                     130
 other adjustments                                                                                             iii                                       23
 income tax impact of above adjustments and corrections for earlier years                                      iv                                       150
 impact on profit on sale of syngene shares net of tax                                                         v                                    4169
 total adjustments b                                                                                                                                 4402
 profit for the year c ab                                                                                                                            3686
 other comprehensive income oci
 actuarial loss on defined benefit obligations  gratuity                                                      vi                                        10
 subtotal d                                                                                                                                            10
 total comprehensive income for the year c  d                                                                                                         3676

notes to reconciliation

i     difference on account of revenue recognition net of related costs is primarily due to difference in timing of revenue recognition under ind as as
        compared to previous gaap and deferral of licensing income on account of continuing obligations

ii    impact due to derivative accounting in accordance with ind as 109

iii   other adjustments on account of employee benefit expenses share based payments actuarial gainslosses mark to market adjustments on mutual
        funds and guarantee income

iv    represents income tax impact of ind as adjustments including corrections for earlier years

v     reduction in profit on sale of syngene shares is primarily on account of fair valuation of investment in syngene a subsidiary on the ind as transition
        date as deemed cost

vi    actuarial loss on defined benefit obligations gratuity taken to other comprehensive income under ind as as compared to the statement of profit and
        loss under previous gaap

vii   impact on consolidation of esop trust

42 business combination
during the year ended march 31 2016 the company acquired the business of pharmaceutical manufacturing unit of ms acacia lifesciences private
limited located at vishakhapatnam with effect from october 01 2015 on a going concern basis for a consideration of  531 paid in cash the transaction
was accounted under ind as 103 business combinations as a business combination with the purchase price being allocated to identifiable assets and
liabilities at fair value

following table presents the allocation of purchase price

 particulars                                                                                                                                          amount
 net tangible assets                                                                                                                                      454
 customer related intangibles                                                                                                                               77
 total purchase price                                                                                                                                     531




                                                                                                                               financial report           215

43     segmental information
in accordance with ind as 108  operating segments segment information has been provided in the consolidated financial statements of the company and
therefore no separate disclosure on segment information is given in these standalone financial statements

44     other notes
a     the company had entered into transactions of sale of products to a private company during the year ended march 31 2013 and 2012 amounting to
         28 and  17 respectively that required prior approval from central government under section 297 of the companies act 1956 these transactions
        entered into at prevailing market prices were approved by the board of directors of the company during the year ended march 31 2014 the
        company had filed application with the central government for approval of such transactions and for compounding of such noncompliance and same
        is pending with central government as at march 31 2017

b     the company has paid the dividend distribution tax of  nil march 31 2016   107 on interim dividend after reducing the amount of dividend
        received by the company from its subsidiaries

45     corporate social responsibility
as per section 135 of the companies act 2013 a company meeting the applicability threshold needs to spend at least 2 of its average net profit for the
immediately preceding three financial years on corporate social responsibility csr activities

a     gross amount required to be spent by the company during the year is  90 and

b     amount spent during the year on

 sl    particulars                                                                                             in cash      yet to be paid            total
 no                                                                                                                                in cash
 i    constructionacquisition of any asset                                                                                                            
 ii   on purposes other than i above                                                                             90                                 90

46     events after reporting period
a     on april 27 2017 the board of directors of the company approved issue of bonus shares in the proportion of 21 ie 2 two bonus equity shares of
         5 each for every 1 one fully paidup equity shares held as on the record date subject to the approval by the shareholders of the company through
        postal ballot

b     on april 27 2017 the board of directors of the company has proposed a final dividend of  3 per equity share on a prebonus share basis the
        proposed dividend is subject to the approval of the shareholders in the annual general meeting

as per our report of even date attached

for b s r  co llp                                                                            for and on behalf of the board of directors of biocon limited
chartered accountants
firm registration number 101248ww100022
s sethuraman                                                                                   kiran mazumdarshaw              arun chandavarkar
partner                                                                                        managing director                joint managing director  ceo
membership no 203491                                                                         din 00347229                    din 01596180
                                                                                               siddharth mittal                 rajiv balakrishnan
                                                                                               president  finance  chief      company secretary
                                                                                               financial officer                membership no f6326
bengaluru                                                                                      bengaluru
april 27 2017                                                                                 april 27 2017




216        ahead of the curve  annual report 2017

                                                                                                                      biocon limited  subsidiaries




independent auditors report
to the members of biocon limited

report on the consolidated indian accounting standards ind as financial statements
we have audited the accompanying consolidated ind as financial statements of biocon limited the holding company and its subsidiaries and a joint
venture collectively referred to as the company or the group which comprise the consolidated balance sheet as at 31 march 2017 the consolidated
statement of profit and loss including other comprehensive income the consolidated statement of cash flows and the consolidated statement of changes
in equity for the year then ended and a summary of the significant accounting policies and other explanatory information hereinafter referred to as the
consolidated ind as financial statements

managements responsibility for the consolidated ind as financial statements
the holding companys board of directors is responsible for the preparation of these consolidated ind as financial statements in terms of the requirements
of the companies act 2013 hereinafter referred to as the act that give a true and fair view of the consolidated financial position consolidated financial
performance including other comprehensive income consolidated cash flows and consolidated changes in equity of the group in accordance with the
accounting principles generally accepted in india including the ind as prescribed under section 133 of the act read with relevant rules issued thereunder

the respective board of directors of the companies included in the group are responsible for maintenance of adequate accounting records in accordance
with the provisions of the act for safeguarding the assets of the group and for preventing and detecting frauds and other irregularities the selection and
application of appropriate accounting policies making judgments and estimates that are reasonable and prudent and the design implementation and
maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records
relevant to the preparation and presentation of the consolidated ind as financial statements that give a true and fair view and are free from material
misstatement whether due to fraud or error which have been used for the purpose of preparation of the consolidated ind as financial statements by the
directors of the holding company as aforesaid

auditors responsibility
our responsibility is to express an opinion on these consolidated ind as financial statements based on our audit while conducting the audit we have taken
into account the provisions of the act the accounting and auditing standards and matters which are required to be included in the audit report under the
provisions of the act and the rules made thereunder

we conducted our audit in accordance with the standards on auditing specified under section 14310 of the act those standards require that we comply
with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the consolidated ind as financial statements are
free from material misstatement

an audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the consolidated ind as financial statements
the procedures selected depend on the auditors judgment including the assessment of the risks of material misstatement of the consolidated ind as
financial statements whether due to fraud or error in making those risk assessments the auditor considers internal financial control relevant to the holding
companys preparation of the consolidated ind as financial statements that give a true and fair view in order to design audit procedures that are appropriate
in the circumstances an audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting
estimates made by the holding companys board of directors as well as evaluating the overall presentation of the consolidated ind as financial statements

we believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion on the consolidated ind as financial
statements

opinion
in our opinion and to the best of our information and according to the explanations given to us and based on the consolidation of reports of the other
auditors on separate financial statements of a subsidiary and a joint venture of the group as noted below the aforesaid consolidated ind as financial
statements give the information required by the act in the manner so required and give a true and fair view in conformity with the accounting principles
generally accepted in india including the ind as of the consolidated financial position of the group as at 31 march 2017 and its consolidated financial
performance including other comprehensive income its consolidated cash flows and the consolidated changes in equity for the year then ended

other matters
a    the comparative financial information of the group for the year ended 31 march 2016 and the transition date opening balance sheet as at
      1 april 2015 included in these consolidated ind as financial statements are based on the previously issued statutory financial statements prepared
      in accordance with the companies accounting standards rules 2006 audited by the predecessor auditor whose report for the year ended
      31 march 2016 and 31 march 2015 dated 26 april 2016 and 29 april 2015 respectively expressed an unmodified opinion on those consolidated
      financial statements as adjusted for the differences in the accounting principles adopted by the company on transition to the ind as which have
      been audited by us

b    we did not audit the financial statements and financial information of a subsidiary and a joint venture both incorporated outside india included in the
      consolidated ind as financial statements of the group this subsidiary accounts for  5 million of net profit and  998 million of revenues for the year
      ended 31 march 2017 and  21856 million of total assets as at 31 march 2017 the consolidated ind as financial statements also include the groups
      share of net profit of  163 million for the year ended 31 march 2017 in respect of such joint venture the financial statements of the subsidiary
      and joint venture both incorporated outside india have been audited by the other auditors whose reports have been furnished to us our opinion on




                                                                                                                             financial report            217

      the consolidated ind as financial statements in so far as it relates to this subsidiary and joint venture is based on the aforesaid reports of the other
      auditors

      our opinion on the consolidated ind as financial statements and our report on other legal and regulatory requirements below is not modified in
      respect of the above matters with respect to our reliance on the work done and the reports of the other auditor

report on other legal and regulatory requirements
1    as required by section 1433 of the act based on our audit and on the consideration of the report of the other auditors on separate financial
      statements of the subsidiary company and a joint venture both incorporated outside india as noted in other matters paragraph we report to the
      extent applicable that

      a    we have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the
             purposes of our audit of the aforesaid consolidated ind as financial statements

      b    in our opinion proper books of account as required by law relating to preparation of the aforesaid consolidated ind as financial statements have
             been kept so far as it appears from our examination of those books and reports of other auditors

      c    the consolidated balance sheet the consolidated statement of profit and loss the consolidated statement of cash flows and consolidated
             statement of changes in equity dealt with by this report are in agreement with the relevant books of account maintained for the purpose of
             preparation of the consolidated ind as financial statements

      d    in our opinion the aforesaid consolidated ind as financial statements comply with the indian accounting standards prescribed under section
             133 of the act read with relevant rules issued thereunder

      e    on the basis of the written representations received from the directors of the group companies incorporated in india as on 31 march 2017 taken
             on record by the respective board of directors of the group companies incorporated in india none of the directors of the group companies
             incorporated in india is disqualified as on 31 march 2017 from being appointed as a director of that company in terms of section 1642 of the
             act

      f    with respect to the adequacy of the internal financial controls over financial reporting of the group and the operating effectiveness of such
             controls refer to our separate report in annexure a and

      g    with respect to the other matters to be included in the auditors report in accordance with rule 11 of the companies audit and auditors rules
             2014 in our opinion and to the best of our information and according to the explanations given to us and based on the consideration of the
             report of the other auditors on the separate financial statements and other financial information of the subsidiary company and a joint venture
             as noted in the other matters paragraph

             i     the consolidated ind as financial statements disclose the impact of pending litigations on the consolidated financial position of the
                    group refer note 35 to the consolidated ind as financial statements

             ii    provision has been made in the consolidated ind as financial statements as required under the applicable law or accounting standards
                    for the material foreseeable losses if any on longterm contracts including derivative contracts refer note 38 to the consolidated ind as
                    financial statements

             iii   there has been no delay in transferring amounts required to be transferred to the investor education and protection fund by the holding
                    company and its subsidiary companies incorporated in india and

             iv    the company has provided requisite disclosures in its consolidated ind as financial statements as to holdings as well as dealings in
                    specified bank notes during the period from 8 november 2016 to 30 december 2016 based on audit procedures and relying on the
                    management representation we report that the disclosures are in accordance with books of account maintained by the company and as
                    produced to us by the management refer note 33 to the consolidated ind as financial statements

for b s r  co llp
chartered accountants
firm registration number 101248ww100022



s sethuraman
partner
membership number 203491

place bengaluru
date 27 april 2017




218        ahead of the curve  annual report 2017

                                                                                                                      biocon limited  subsidiaries




annexure  a to the independent auditors report of even date on
the consolidated financial statements of biocon limited
report on the internal financial controls under clause i of subsection 3 of section 143 of the companies act 2013 the act

in conjunction with our audit of the consolidated ind as financial statements of the group as of and for the year ended 31 march 2017 we have audited
the internal financial controls over financial reporting of biocon limited the holding company and its subsidiary companies which are companies
incorporated in india as of that date

managements responsibility for internal financial controls
the respective board of directors of the holding company and its subsidiary companies which are companies incorporated in india are responsible for
establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the company considering
the essential components of internal control stated in the guidance note on audit of internal financial controls over financial reporting guidance note
issued by the institute of chartered accountants of india icai these responsibilities include the design implementation and maintenance of adequate
internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business including adherence to companys
policies the safeguarding of its assets the prevention and detection of frauds and errors the accuracy and completeness of the accounting records and the
timely preparation of reliable financial information as required under the companies act 2013

auditors responsibility
our responsibility is to express an opinion on the companys internal financial controls over financial reporting based on our audit we conducted our audit
in accordance with the guidance note on audit of internal financial controls over financial reporting the guidance note issued by icai and the standards
on auditing issued by icai and deemed to be prescribed under section 14310 of the companies act 2013 to the extent applicable to an audit of internal
financial controls both issued by the institute of chartered accountants of india those standards and the guidance note require that we comply with ethical
requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was
established and maintained and if such controls operated effectively in all material respects

our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting
and their operating effectiveness our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial
controls over financial reporting assessing the risk that a material weakness exists and testing and evaluating the design and operating effectiveness of
internal control based on the assessed risk the procedures selected depend on the auditors judgment including the assessment of the risks of material
misstatement of the ind as financial statements whether due to fraud or error

we believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the companys internal
financial controls system over financial reporting

meaning of internal financial controls over financial reporting
a companys internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial
reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles a companys
internal financial control over financial reporting includes those policies and procedures that 1 pertain to the maintenance of records that in reasonable
detail accurately and fairly reflect the transactions and dispositions of the assets of the company 2 provide reasonable assurance that transactions
are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles and that receipts
and expenditures of the company are being made only in accordance with authorisations of management and directors of the company and 3 provide
reasonable assurance regarding prevention or timely detection of unauthorised acquisition use or disposition of the companys assets that could have a
material effect on the ind as financial statements

inherent limitations of internal financial controls over financial reporting
because of the inherent limitations of internal financial controls over financial reporting including the possibility of collusion or improper management
override of controls material misstatements due to error or fraud may occur and not be detected also projections of any evaluation of the internal financial
controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate
because of changes in conditions or that the degree of compliance with the policies or procedures may deteriorate

opinion
in our opinion the holding company and its subsidiary companies which are companies incorporated in india have in all material respects an adequate
internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at
31 march 2017 based on the internal control over financial reporting criteria established by the company considering the essential components of internal
control stated in the guidance note on audit of internal financial controls over financial reporting issued by the icai

for b s r  co llp
chartered accountants
firm registration number 101248ww100022

s sethuraman
partner
membership number 203491

place bengaluru
date 27 april 2017


                                                                                                                             financial report            219

consolidated balance sheet as at march 31 2017
all amounts are in indian rupees million except share data and per share data unless otherwise stated
                                                                                             note    march 31 2017      march 31 2016    april 01 2015
assets
noncurrent assets
property plant and equipment                                                              3                35529              16811            15982
capital workinprogress                                                                   3                 5327              20597            15582
investment property                                                                        4                     8                   9                11
goodwill                                                                                   5                   264                 264               264
other intangible assets                                                                    5                   458                 408               228
intangible assets under development                                                        5                 3065               1798             1718
investment in associates and a joint venture                                              42c                422                 259               384
financial assets
i     investments                                                                         6                1458                                    
ii    derivative assets                                                                                    1092                 614               874
iii   other financial assets                                                             7a                197                 258               193
incometax assets net                                                                                        895                 852               890
deferred tax assets net                                                                   8                1975                 715               320
other noncurrent assets                                                                   9a              2775               2287             2123
total noncurrent assets                                                                                    53465              44872            38569
current assets
inventories                                                                                 10               6353                5424            4756
financial assets
i     investments                                                                         11              10650               8747             2478
ii    trade receivables                                                                   12               8832               7145             6833
iii   cash and cash equivalents                                                           13               7102               7613             4575
iv    other bank balances                                                                 13               3341               7773             4629
v     derivative assets                                                                                    1059                 511               350
vi    other financial assets                                                             7b              1551               1844               468
other current assets                                                                       9b              1589                 652               661
total current assets                                                                                        40477              39709            24750
total                                                                                                       93942              84581            63319
equity and liabilities
equity
equity share capital                                                                      14a              1000               1000             1000
other equity                                                                                                47377              39338            31622
equity attributable to owners of the company                                                                48377              40338            32622
noncontrolling interests                                                                 42b              3761               2658             1121
total equity                                                                                                52138              42996            33743
noncurrent liabilities
financial liabilities
i     borrowings                                                                          15              21082              20724             7671
ii    derivative liability                                                                                    61                 191               174
iii   other financial liabilities                                                       16a                  2                   3                 6
provisions                                                                                17a                360                 299               150
other noncurrent liabilities                                                             18a              3516               3711             5601
total noncurrent liabilities                                                                               25021              24928            13602
current liabilities
financial liabilities
i     borrowings                                                                          19                 972               3949             2610
ii    trade payables                                                                      20               7397               6098             4126
iii   derivative liability                                                                                    63                 143               128
iv    other financial liabilities                                                       16b              3261               1964             4416
provisions                                                                                17b                468                 374               398
income tax liability net                                                                                     964                 965               609
other current liabilities                                                                 18b              3658               3164             3687
total current liabilities                                                                                   16783              16657            15974
total                                                                                                       93942              84581            63319
the accompanying notes are an integral part of the consolidated financial statements
as per our report of even date attached

for b s r  co llp                                                                        for and on behalf of the board of directors of biocon limited
chartered accountants
firm registration number 101248ww100022
s sethuraman                                                                               kiran mazumdarshaw               arun chandavarkar
partner                                                                                    managing director                 joint managing director  ceo
membership no 203491                                                                     din 00347229                     din 01596180
                                                                                           siddharth mittal                  rajiv balakrishnan
                                                                                           president  finance  chief       company secretary
                                                                                           financial officer                 membership no f6326
bengaluru                                                                                  bengaluru
april 27 2017                                                                             april 27 2017



220      ahead of the curve  annual report 2017

                                                                                                                 biocon limited  subsidiaries




consolidated statement of profit and loss for the year ended march 31 2017
all amounts are in indian rupees million except share data and per share data unless otherwise stated
                                                                                                            note       year ended       year ended
                                                                                                                   march 31 2017   march 31 2016
income

revenue from operations                                                                                     21            39216           33810
other income                                                                                                22             1571              792
total income                                                                                                              40787           34602


expenses

cost of raw materials and packing materials consumed                                                        23            13224           12549
purchases of traded goods                                                                                                  1932              760
changes in inventories of traded goods finished goods and workinprogress                                 24              690            405
excise duty                                                                                                                  305              336
employee benefits expense                                                                                   25             7470            6101
finance costs                                                                                               26               260              293
depreciation and amortisation expense                                                                       27             2772            2487
other expenses                                                                                              28             8463            8111
                                                                                                                          33736           30232
less recovery of product development costs from codevelopment partners net                              29            1283          1320
total expenses                                                                                                            32453           28912
profit before tax share of profit of joint venture exceptional items and tax                                             8334            5690
share of profit of joint venture                                                                                             163              217
profit before tax and exceptional items                                                                                    8497            5907
exceptional items net                                                                                      32                             1606

profit before tax                                                                                                          8497            7513
tax expense                                                                                                 41
current tax                                                                                                                2082            1813
less mat credit entitlement                                                                                                369            166
deferred tax                                                                                                                 97            225
total tax expense                                                                                                          1616            1422

profit for the year                                                                                                        6881            6091




                                                    this space has been intentionally left blank




                                                                                                                      financial report       221

consolidated statement of profit and loss for the year ended march 31 2017 contd
all amounts are in indian rupees million except share data and per share data unless otherwise stated
                                                                                                              note            year ended       year ended
                                                                                                                          march 31 2017   march 31 2016
other comprehensive income
i items that will not be reclassified subsequently to profit or loss


remeasurement on defined benefit plans                                                                                             57               39
income tax effect                                                                                                                     15                 9
                                                                                                                                    42               30
ii items that may be reclassified subsequently to profit or loss
effective portion of gains losses on hedging instrument in cash flow hedges                                                     1293               21
income tax effect                                                                                                                  263                5
                                                                                                                                   1030               26
other comprehensive income expense for the year net of taxes                                                                    988                56

total comprehensive income for the year                                                                                            7869            6035

profit attributable to
shareholders of the company                                                                                                        6121            5504
noncontrolling interest                                                                                                            760                587
profit for the year                                                                                                                6881            6091

other comprehensive income expense attributable to
shareholders of the company                                                                                                         764                58
noncontrolling interest                                                                                                            224                  2
other comprehensive income expense for the year                                                                                  988                56
total comprehensive income attributable to
shareholders of the company                                                                                                        6885            5446
noncontrolling interest                                                                                                            984                589
total comprehensive income for the year                                                                                            7869            6035

earnings per share                                                                                             31
basic in                                                                                                                        3118            2804
diluted in                                                                                                                      3097            2801

the accompanying notes are an integral part of the consolidated financial statements

as per our report of even date attached

for b s r  co llp                                                                         for and on behalf of the board of directors of biocon limited
chartered accountants
firm registration number 101248ww100022
s sethuraman                                                                                kiran mazumdarshaw               arun chandavarkar
partner                                                                                     managing director                 joint managing director  ceo
membership no 203491                                                                      din 00347229                     din 01596180
                                                                                            siddharth mittal                  rajiv balakrishnan
                                                                                            president  finance  chief       company secretary
                                                                                            financial officer                 membership no f6326
bengaluru                                                                                   bengaluru
april 27 2017                                                                              april 27 2017




222       ahead of the curve  annual report 2017

                   consolidated statement of changes in equity for the year ended march 31 2017
                   all amounts are in indian rupees million except share data and per share data unless otherwise stated

                   a equity share capital           march 31     march 31
                                                          2017          2016
                   opening balance                        1000         1000
                   changes in equity share capital                          
                   closing balance                        1000         1000



                   b other equity
                   particulars                                                                           attributable to owners of the company                                                 non           total
                                                      securities revaluation capital general retained             sez re    share treasury    foreign cash flow other items of other total controlling
                                                       premium       reserve reserve reserve earnings         investment     based   shares   currency hedging       comprehensive other interests
                                                        reserve                                                   reserve payment           translation reserves              income equity
                                                                                                                           reserve             reserve
                   balance at april 01 2015              2788             9      801    3459    24054                     462    427      494                           18 31622       1121       32743


                   profit for the year                                                          5504                                                                          5504       587        6091
                   other comprehensive income                                                                                           163       32                 26      105         2          107
                   net of tax
                   transactions with owners
                   directly recorded in equity
                   dividend including dividend                                                 1148                                                                                   53      1201
                   distribution tax                                                                                                                                                    1148
                   share based payment                                                                                   186                                                    186                   186
                   gain on sale of shares in                                                    3160                                                                         3160       939        4099
                   subsidiary net of tax
                   refer note 32
                   purchase of treasury shares                                                                                 150                                          150                 150
                   exercise of share options                                                       99                     40                                                    59        62          121
                   balance at march 31 2016              2788             9      801    3459    31669                     608    577      657       32                 44 39338       2658       41996




financial report
 223
                                                                                                                                                                                                                        biocon limited  subsidiaries

                                          consolidated statement of changes in equity for the year ended march 31 2017 contd




224 
                                          all amounts are in indian rupees million except share data and per share data unless otherwise stated

                                          b other equity contd
                                          particulars                                                                             attributable to owners of the company                                                non           total
                                                                             securities revaluation capital general retained              sez re    share treasury    foreign cash flow other items of other total controlling
                                                                              premium       reserve reserve reserve earnings          investment     based   shares   currency hedging       comprehensive other interests
                                                                               reserve                                                    reserve payment           translation reserves              income equity
                                                                                                                                                   reserve             reserve
                                          balance at march 31 2016              2788             9      801    3459    31669                        608     577          657        32           44 39338     2658       41996
                                          profit for the year                                                          6121                                                                           6121      760        6881
                                          other comprehensive income                                                                                                  118       800            36    646       224         870
                                          net of tax
                                          transfer to special economic                                                  162            162                                                                                       
                                          zone sez reinvestment
                                          reserve
                                          transfer from sez reinvestment                                                162            162                                                                                      
                                          reserve on utilisation




ahead of the curve  annual report 2017
                                          transactions with owners
                                          directly recorded in equity
                                          share based payment                                                                                      266                                                  266                  266
                                          tax benefit related to gain on                                               1042                                                                           1042                1042
                                          sale of share in subsidiary
                                          refer note 32
                                          purchase of treasury shares                                                                                     150                                        150                150
                                          exercise of share options                 120                                   193                     199                                                   114       119         233
                                          balance as at march 31 2017           2908             9      801    3459    39025                        675     727          539        768            80 47377     3761       51138

                                          the accompanying notes are an integral part of the consolidated financial statements

                                          as per our report of even date attached

                                          for b s r  co llp                                                                           for and on behalf of the board of directors of biocon limited
                                          chartered accountants
                                          firm registration number 101248ww100022
                                          s sethuraman                                                                                  kiran mazumdarshaw               arun chandavarkar
                                          partner                                                                                       managing director                 joint managing director  ceo
                                          membership no 203491                                                                        din 00347229                     din 01596180
                                                                                                                                        siddharth mittal                  rajiv balakrishnan
                                                                                                                                        president  finance  chief       company secretary
                                                                                                                                        financial officer                 membership no f6326
                                          bengaluru                                                                                     bengaluru
                                          april 27 2017                                                                                april 27 2017

                                                                                                            biocon limited  subsidiaries




consolidated statement of cash flows for the year ended march 31 2017
all amounts are in indian rupees million except share data and per share data unless otherwise stated
                                                                                                               march 31 2017   march 31 2016
i      cash flows from operating activities
       profit for the year                                                                                             6881            6091
       adjustments to reconcile profit for the year to net cash flows
       depreciation and amortisation                                                                                   2772            2487
       tax expense                                                                                                     1616            1422
       unrealised foreign exchange gainloss                                                                           311               18
       sharebased compensation expense                                                                                  266              186
       provisionreversal of provision for doubtful debts                                                               34              47
       bad debts written off                                                                                               6                8
       interest expense                                                                                                  260              226
       interest income                                                                                                1115            428
       dividend income                                                                                                  156            191
       net gain on financial assets measured at fair value through profit or loss                                       132                
       net gain on sale of investments                                                                                   39             16
       proceeds from insurance company towards loss of tangible assets                                                   159                 
       share of profit of joint venture                                                                                 163            217
       exceptional items net                                                                                                         1606
       operating profit before working capital changes                                                                10700            7933


       movements in working capital
       decreaseincrease in inventories                                                                               929            668
       decreaseincrease in trade receivables                                                                       1883            654
       decreaseincrease in other assets                                                                            1125          2019
       increasedecrease in trade payable other liabilities and provisions                                          1667            1579
       cash generated from operations                                                                                  8430            6171
       direct taxes paid net of refunds                                                                             2030          2465
       net cash flow generated from operating activities                                                               6400            3706


ii     cash flows from investing activities
       purchase of tangible assets                                                                                    6084          6180
       acquisition of intangible assets                                                                               1537          1857
       proceeds from sale of fixed assets                                                                                  2                9
       purchase of investments                                                                                       38689         39668
       proceeds from sale of investments                                                                              33182           42964
       investment in bank deposits and inter corporate deposits                                                      17337         11190
       redemptionmaturity of bank deposits and inter corporate deposits                                              24083            3710
       interest received                                                                                               1239              262
       dividend received                                                                                                 156              533
       net cash flow generated fromused in investing activities                                                    4985         11417


iii    cash flows from financing activities
       purchase of treasury shares                                                                                      150            150
       proceeds from exercise of share options                                                                           193               99
       proceeds from longterm borrowings                                                                              2002           12620
       repayment of longterm borrowings                                                                                264            541
       proceeds repayment of shortterm borrowings net                                                           2970           1350
       dividend paid on equity shares including tax thereon                                                                           2201
       interest paid                                                                                                    586            501
       net cash flow generated fromused in financing activities                                                    1775          10676




                                                                                                                 financial report        225

consolidated statement of cash flows for the year ended march 31 2017 contd
all amounts are in indian rupees million except share data and per share data unless otherwise stated
                                                                                                                           march 31 2017    march 31 2016
iv      net increasedecrease in cash and cash equivalents i  ii  iii                                                         360            2965


v       effect of exchange differences on cash and cash equivalents held in foreign currency                                        113                35


vi      cash and cash equivalents at the beginning of the year                                                                      7575            4575


vii     cash and cash equivalents at the end of the year iv  v  vi                                                              7102            7575



reconciliation of cash and cash equivalents as per statement of cash flows
cash and cash equivalents note 13
balances with banks  on current accounts                                                                                           7096            7063
                       on unpaid dividend accounts                                                                                    6                10
deposits with original maturity of less than 3 months                                                                                                  540
                                                                                                                                    7102            7613
bank overdrafts cash credits note 19                                                                                                                38
balance as per statement of cash flows                                                                                              7102            7575


 the group can utilize these balances only towards settlement of the respective unpaid dividend liabilities                                              

the accompanying notes are an integral part of the consolidated financial statements


as per our report of even date attached
for b s r  co llp                                                                          for and on behalf of the board of directors of biocon limited
chartered accountants
firm registration number 101248ww100022
s sethuraman                                                                                 kiran mazumdarshaw               arun chandavarkar
partner                                                                                      managing director                 joint managing director  ceo
membership no 203491                                                                       din 00347229                     din 01596180
                                                                                             siddharth mittal                  rajiv balakrishnan
                                                                                             president  finance  chief       company secretary
                                                                                             financial officer                 membership no f6326
bengaluru                                                                                    bengaluru
april 27 2017                                                                               april 27 2017




                                                     this space has been intentionally left blank




226       ahead of the curve  annual report 2017

                                                                                                                         biocon limited  subsidiaries




notes to the consolidated financial statements for the year ended march 31 2017
all amounts are in indian rupees million except share data and per share data unless otherwise stated
1    company overview
11   reporting entity

      biocon limited biocon or the parent company or the company together with its subsidiaries joint venture and associates collectively the
      group is engaged in the manufacture of biotechnology products and research services the company is a public limited company incorporated and
      domiciled in india and has its registered office in bengaluru karnataka india the companys shares are listed on the bombay stock exchange bse
      and the national stock exchange nse in india

12   basis of preparation of financial statements

      a    statement of compliance

            the consolidated financial statements have been prepared in accordance with indian accounting standards ind as as per the companies indian
            accounting standards rules 2015 notified under section 133 of companies act 2013 the act and other relevant provisions of the act

            the groups consolidated financial statements up to and for the year ended march 31 2016 were prepared in accordance with the companies
            accounting standards rules 2006 notified under section 133 of the act read together with paragraph 7 of the companies accounts rules
            2014 previous gaap

            as these are the groups first consolidated financial statements prepared in accordance with indian accounting standards ind as ind as 101
            firsttime adoption of indian accounting standards has been applied an explanation of how the transition to ind as has affected the previously
            reported financial position financial performance and cash flows of the group is provided in note 40

            these consolidated financial statements have been prepared for the group as a going concern on the basis of relevant ind as that are effective at
            the companys annual reporting date march 31 2017 these consolidated financial statements were authorised for issuance by the companys
            board of directors on april 27 2017

            details of the groups accounting policies are included in note 2

      b    functional and presentation currency

            these consolidated financial statements are presented in indian rupees inr which is also the functional currency of the parent company all
            amounts have been roundedoff to the nearest million unless otherwise indicated in respect of subsidiaries and associates whose operations
            are selfcontained and integrated the functional currency has been determined to be the currency of the primary economic environment in
            which the entity operates

      c    basis of measurement

            these consolidated financial statements have been prepared on the historical cost basis except for the following items

                  certain financial assets and liabilities including derivative instruments are measured at fair value

                  net defined benefit assetsliability are measured at fair value of plan assets less present value of defined benefit obligations

      d    use of estimates and judgements

            the preparation of the financial statements in conformity with ind as requires management to make estimates judgements and assumptions
            these estimates judgements and assumptions affect the application of accounting policies and the reported amounts of assets and liabilities the
            disclosures of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the
            period accounting estimates could change from period to period actual results could differ from those estimates appropriate changes in estimates
            are made as management becomes aware of changes in circumstances surrounding the estimates changes in estimates are reflected in the financial
            statements in the period in which changes are made and if material their effects are disclosed in the notes to the consolidated financial statements

            judgements

            information about judgements made in applying accounting policies that have the most significant effects on the amounts recognised in the
            financial statements is included in the following notes

                  note 12b                  assessment of functional currency

                  note 2c and 38             financial instruments

                  note 2d 2e and 2f     useful lives of property plant and equipment intangible assets and investment property

                  note 36                      assets and obligations relating to employee benefits

                  note 30                      share based payments

                  note 2n 8 and 41          provision for income taxes and related tax contingencies and evaluation of recoverability of deferred tax
                                                 assets

      e    assumptions and estimation uncertainties

            information about assumptions and estimation uncertainties that have a significant risk of resulting in a material adjustment in the year ending
            march 31 2018 is included in the following notes




                                                                                                                                financial report            227

                 note 2n 8 and 41  recognition of deferred tax assets availability of future taxable profit against which tax losses carried forward can
                                        be used

                 note 38               impairment of financial assets

                 note 36               measurement of defined benefit obligations key actuarial assumptions

                 note 17 and 35        recognition and measurement of provisions and contingencies key assumptions about the likelihood and
                                         magnitude of an outflow of resources

     f    measurement of fair values

           a number of the groups accounting policies and disclosures require the measurement of fair values for both financial and nonfinancial assets
           and liabilities

           fair values are categorised into different levels in a fair value hierarchy based on the inputs used in the valuation techniques as follows

                 level 1 quoted prices unadjusted in active markets for identical assets or liabilities

                 level 2 inputs other than quoted prices included in level 1 that are observable for the asset or liability either directly ie as prices or
                  indirectly ie derived from prices

                 level 3 inputs for the asset or liability that are not based on observable market data unobservable inputs

           when measuring the fair value of an asset or a liability the group uses observable market data as far as possible if the inputs used to measure
           the fair value of an asset or a liability fall into different levels of the fair value hierarchy then the fair value measurement is categorised in its
           entirety in the same level of the fair value hierarchy as the lowest level input that is significant to the entire measurement

           the group recognises transfers between levels of the fair value hierarchy at the end of the reporting period during which the change has
           occurred

           further information about the assumptions made in measuring fair values is included in the following notes

                 note 30                       sharebased payment arrangements

                 note 4                        investment property and

                 note 2c and 38              financial instruments

2   significant accounting policies
     a    basis of consolidation

           i     subsidiaries

                  subsidiaries are entities controlled by the group the group controls an entity when it is exposed to or has rights to variable returns from its
                  involvement with the entity and has the ability to affect those returns through its power over the entity the financial statements of subsidiaries
                  are included in the consolidated financial statements from the date on which control commences until the date on which control ceases

                  the financial statements of the group are consolidated on linebyline basis intragroup transactions balances and any unrealised gains
                  arising from intragroup transactions are eliminated unrealised losses are eliminated but only to the extent that there is no evidence
                  of impairment all temporary differences that arise from the elimination of profits and losses resulting from intragroup transactions are
                  recognised as per ind as 12 income taxes

                  for the purpose of preparing these consolidated financial statements the accounting policies of subsidiaries have been changed where
                  necessary to align them with the policies adopted by the company

                  noncontrolling interests nci

                  nci are measured at their proportionate share of the acquirees net identifiable assets at the date of acquisition

                  changes in the groups equity interest in a subsidiary that do not result in a loss of control are accounted for as equity transactions

           ii    loss of control

                  when the group loses control over a subsidiary it derecognises the assets and liabilities of the subsidiary and any related nci and other
                  components of equity any interest retained in the former subsidiary is measured at fair value at the date the control is lost any resulting
                  gain or loss is recognised in statement of profit and loss

           iii   associates and joint arrangements equity accounted investees

                  the groups interests in equity accounted investees comprise interests in associates and a joint venture

                  an associate is an entity in which the group has significant influence but not control or joint control over the financial and operating
                  policies a joint venture is an arrangement in which the group has joint control and has rights to the net assets of the arrangement rather
                  than rights to its assets and obligations for its liabilities

                  interests in associates and joint ventures are accounted for using the equity method they are initially recognised at cost which includes
                  transaction costs subsequent to initial recognition the consolidated financial statements include the groups share of profit or loss and
                  oci of equity accounted investees until the date on which significant influence or joint control ceases




228      ahead of the curve  annual report 2017

                                                                                                                  biocon limited  subsidiaries



b   foreign currency

     i    foreign currency transactions

           transactions in foreign currencies are translated into the respective functional currencies of companies at the exchange rates at the dates
           of the transactions or an average rate if the average rate approximates the actual rate at the date of the transaction

           monetary assets and liabilities denominated in foreign currencies are translated into the functional currency at the exchange rate at the
           reporting date nonmonetary assets and liabilities that are measured at fair value in a foreign currency are translated into the functional
           currency at the exchange rate when the fair value was determined nonmonetary assets and liabilities that are measured based on
           historical cost in a foreign currency are translated at the exchange rate at the date of the transaction exchange differences are recognised
           in statement of profit and loss except exchange differences arising from the translation of the qualifying cash flow hedges to the extent
           that the hedges are effective which are recognised in oci

           under previous gaap exchange differences arising on restatement of longterm foreign currency monetary items related to acquisition of
           depreciable assets was added todeducted from the cost of the depreciable assets in accordance with ind as 101 first time adoption of
           indian accounting standards the group continues the above accounting treatment in respect of the longterm foreign currency monetary
           items recognised in the financial statements as on march 31 2016

     ii   foreign operations

           the assets and liabilities of foreign operations subsidiaries associates joint arrangements including goodwill and fair value adjustments
           arising on acquisition are translated into inr the functional currency of the group at the exchange rates at the reporting date the
           income and expenses of foreign operations are translated into inr at the exchange rates at the dates of the transactions or an average
           rate if the average rate approximates the actual rate at the date of the transaction

           foreign currency translation differences are recognised in oci and accumulated in equity as exchange differences on translating the
           financial statements of a foreign operation except to the extent that the exchange differences are allocated to nci

c   financial instruments

     i    recognition and initial measurement

           trade receivables and debt securities issued are initially recognised when they are originated all other financial assets and financial
           liabilities are initially recognised when the group becomes a party to the contractual provisions of the instrument

           a financial asset or financial liability is initially measured at fair value plus for an item not at fair value through profit and loss fvtpl
           transaction costs that are directly attributable to its acquisition or issue

     ii   classification and subsequent measurement

           financial assets

           on initial recognition a financial asset is classified as measured at

            amortised cost

            fvoci  debt investment

            fvoci  equity investment or

            fvtpl

           financial assets are not reclassified subsequent to their initial recognition except if and in the period the group changes its business
           model for managing financial assets

           a financial asset is measured at amortised cost if it meets both of the following conditions and is not designated as at fvtpl

            the asset is held within a business model whose objective is to hold assets to collect contractual cash flows and

            the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest
             on the principal amount outstanding

           a debt investment is measured at fvoci if it meets both of the following conditions and is not designated as at fvtpl

            the asset is held within a business model whose objective is achieved by both collecting contractual cash flows and selling financial
             assets and

            the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest
             on the principal amount outstanding

           on initial recognition of an equity investment that is not held for trading the group may irrevocably elect to present subsequent changes
           in the investments fair value in oci designated as fvoci  equity investment this election is made on an investment by investment
           basis

           all financial assets not classified as measured at amortised cost or fvoci as described above are measured at fvtpl this includes
           all derivative financial assets on initial recognition the group may irrevocably designate a financial asset that otherwise meets the
           requirements to be measured at amortised cost or at fvoci as at fvtpl if doing so eliminates or significantly reduces an accounting
           mismatch that would otherwise arise



                                                                                                                         financial report            229

                financial assets subsequent measurement and gains and losses

                 financial assets at fvtpl                these assets are subsequently measured at fair value net gains and losses including any
                                                          interest or dividend income are recognised in statement of profit and loss however see note 38
                                                          for derivatives designated as hedging instruments
                 financial assets at amortised cost       these assets are subsequently measured at amortised cost using the effective interest method
                                                          the amortised cost is reduced by impairment losses interest income foreign exchange gains
                                                          and losses and impairment are recognised in statement of profit and loss any gain or loss on
                                                          derecognition is recognised in statement of profit and loss
                 debt investments at fvoci                these assets are subsequently measured at fair value interest income under the effective
                                                          interest method foreign exchange gains and losses and impairment are recognised in statement
                                                          of profit and loss other net gains and losses are recognised in oci on derecognition gains and
                                                          losses accumulated in oci are reclassified to statement of profit and loss
                 equity investments at fvoci              these assets are subsequently measured at fair value dividends are recognised as income in
                                                          statement of profit and loss unless the dividend clearly represents a recovery of part of the cost
                                                          of the investment other net gains and losses are recognised in oci and are not reclassified to
                                                          profit or loss

                financial liabilities classification subsequent measurement and gains and losses

                financial liabilities are classified as measured at amortised cost or fvtpl a financial liability is classified as at fvtpl if it is classified as
                held for trading or it is a derivative or it is designated as such on initial recognition financial liabilities at fvtpl are measured at fair
                value and net gains and losses including any interest expense are recognised in statement of profit and loss other financial liabilities
                are subsequently measured at amortised cost using the effective interest method interest expense and foreign exchange gains and
                losses are recognised in statement of profit and loss any gain or loss on derecognition is also recognised in statement of profit and loss

         iii   derecognition of financial instruments

                financial assets

                the group derecognises a financial asset when the contractual rights to the cash flows from the financial asset expire or it transfers the
                financial asset and the transfer qualifies for derecognition under ind as 109 a financial liability or a part of financial liability is de
                recognised from the groups balance sheet when the obligation specified in the contract is discharged cancelled or expires

                financial liabilities

                the group derecognises a financial liabilities when its contractual obligations are discharged or cancelled or expire

                the group also derecognises a financial liability when its terms are modified and the cash flows under the modified terms are
                substantially different in this case a new financial liability based on the modified terms is recognised at fair value the difference
                between the carrying amount of the financial liability extinguished and the new financial liability with modified terms is recognised in
                statement of profit and loss

         iv    derivative financial instruments and hedge accounting

                the group holds derivative financial instruments to hedge its foreign currency and interest rate risk exposures embedded derivatives are
                separated from the host contract and accounted for separately if the host contract is not a financial asset and certain criteria are met

                derivatives are initially measured at fair value subsequent to initial recognition derivatives are measured at fair value and changes
                therein are generally recognised in statement of profit and loss

                the group designates certain derivatives as hedging instruments to hedge the variability in cash flows associated with highly probable
                forecast transactions arising from changes in foreign exchange rates and interest rates

                at inception of designated hedging relationships the group documents the risk management objective and strategy for undertaking the
                hedge the group also documents the economic relationship between the hedged item and the hedging instrument including whether
                the changes in cash flows of the hedged item and hedging instrument are expected to offset each other

                cash flow hedges

                when a derivative is designated as a cash flow hedging instrument the effective portion of changes in the fair value of the derivative is
                recognised in oci and accumulated in other equity under effective portion of cash flow hedges the effective portion of changes in the
                fair value of the derivative that is recognised in oci is limited to the cumulative change in fair value of the hedged item determined on
                a present value basis from inception of the hedge any ineffective portion of changes in the fair value of the derivative is recognised
                immediately in statement of profit and loss

                if a hedge no longer meets the criteria for hedge accounting or the hedging instrument is sold expires is terminated or is exercised then
                hedge accounting is discontinued prospectively when hedge accounting for cash flow hedges is discontinued the amount that has been
                accumulated in other equity remains there until for a hedge of a transaction resulting in recognition of a nonfinancial item it is included
                in the nonfinancial items cost on its initial recognition or for other cash flow hedges it is reclassified to profit or loss in the same period
                or periods as the hedged expected future cash flows affect profit or loss




230    ahead of the curve  annual report 2017

                                                                                                                  biocon limited  subsidiaries



             if the hedged future cash flows are no longer expected to occur then the amounts that have been accumulated in other equity are
             immediately reclassified to profit or loss

     v      treasury shares

             the group has created an employee welfare trust ewt for providing sharebased payment to its employees own equity instruments
             that are reacquired treasury shares are recognised at cost and deducted from equity when the treasury shares are issued to the
             employees by ewt the amount received is recognised as an increase in equity and the resultant gain loss is transferred to from
             securities premium

     vi     offsetting

             financial assets and financial liabilities are offset and the net amount presented in the balance sheet when and only when the group
             currently has a legally enforceable right to set off the amounts and it intends either to settle them on a net basis or to realise the asset
             and settle the liability simultaneously

     vii    cash and cash equivalents

             cash and cash equivalent in the balance sheet comprise cash at banks and on hand and shortterm deposits with an original maturity
             of three months or less which are subject to an insignificant risk of changes in value for the purpose of the statement of cash flows
             cash and cash equivalents consist of cash and shortterm deposits as defined above net of outstanding bank overdrafts as they are
             considered an integral part of the groups cash management

     viii   cash dividend to equity holders

             the group recognises a liability to make cash distribution to equity holders when the distribution is authorised and the distribution
             is no longer at the discretion of the group as per the corporate laws in india a distribution is authorised when it is approved by the
             shareholders a corresponding amount is recognised directly in equity interim dividends are recorded as a liability on the date of
             declaration by the companys board of directors

d   property plant and equipment

     i      recognition and measurement

             items of property plant and equipment are measured at cost less accumulated depreciation and accumulated impairment losses if any
             the cost of a selfconstructed item of property plant and equipment comprises the cost of materials and direct labour any other costs
             directly attributable to bringing the item to working condition for its intended use and estimated costs of dismantling and removing the
             item and restoring the site on which it is located

             if significant parts of an item of property plant and equipment have different useful lives then they are accounted for as separate items
             major components of property plant and equipment

             any gain or loss on disposal of an item of property plant and equipment is recognised in statement of profit and loss

             subsequent expenditure is capitalised only if it is probable that the future economic benefits associated with the expenditure will flow
             to the group

     ii     depreciation

             depreciation is calculated on cost of items of property plant and equipment less their estimated residual values over their estimated
             useful lives using the straightline method assets acquired under finance leases are depreciated over the shorter of the lease term and
             their useful lives unless it is reasonably certain that the group will obtain ownership by the end of the lease term freehold land is not
             depreciated

             the estimated useful lives of items of property plant and equipment for the current and comparative periods are as follows

             asset                                                                                 management estimate         useful life as per
                                                                                                   of useful life              schedule ii
             building                                                                              2530 years                 30 years
             roads                                                                                 5 years                     5 years
             plant and equipment including electrical installation and lab equipment             915 years                  820 years
             computers and servers                                                                 3 years                     36 years
             office equipment                                                                      5 years                     5 years
             research and development equipment                                                    9 years                     510 years
             furniture and fixtures                                                                6 years                     10 years
             vehicles                                                                              6 years                     610 years
             leasehold improvements                                                                5 years or lease period
                                                                                                   whichever is lower
             depreciation method useful lives and residual values are reviewed at each financial yearend and adjusted if appropriate based on
             technical evaluation and consequent advice the management believes that its estimates of useful lives as given above best represent
             the period over which management expects to use these assets

             depreciation on additions disposals is provided on a prorata basis ie from upto the date on which asset is ready for use disposed of



                                                                                                                          financial report           231

    e    goodwill and other intangible assets

          i     goodwill

                 for measurement of goodwill that arises on a business combination refer note 37 subsequent measurement is at cost less any
                 accumulated impairment losses

          ii    other intangible assets

                 internally generated research and development

                 expenditure on research activities is recognised in statement of profit and loss as incurred

                 development expenditure is capitalised as part of the cost of the resulting intangible asset only if the expenditure can be measured reliably
                 the product or process is technically and commercially feasible future economic benefits are probable and the group intends to and has
                 sufficient resources to complete development and to use or sell the asset otherwise it is recognised in statement of profit and loss as incurred
                 subsequent to initial recognition the asset is measured at cost less accumulated amortisation and any accumulated impairment losses

                 others

                 other intangible assets are initially measured at cost subsequently such intangible assets are measured at cost less accumulated
                 amortization and any accumulated impairment losses

          iii   subsequent expenditure

                 subsequent expenditure is capitalised only when it increases the future economic benefits embodied in the specific asset to which it
                 relates all other expenditure including expenditure on internally generated goodwill and brands is recognised in statement of profit
                 and loss as incurred

          iv    amortisation

                 goodwill is not amortised and is tested for impairment annually

                 other intangible assets are amortised on a straight line basis over the estimated useful life as follows

                       computer software                                  35 years

                       marketing and manufacturing rights                 510 years

                       customer related intangibles                       5 years

                 amortisation method useful lives and residual values are reviewed at the end of each financial year and adjusted if appropriate

    f    investment property

          investment property is property held either to earn rental income or for capital appreciation or for both but not for sale in the ordinary course of
          business use in the production or supply of goods or services or for administrative purposes upon initial recognition an investment property
          is measured at cost subsequent to initial recognition investment property is measured at cost less accumulated depreciation and accumulated
          impairment losses if any

          based on technical evaluation and consequent advice the management believes a period of 25 years as representing the best estimate of
          the period over which investment properties which are quite similar are expected to be used accordingly the group depreciates investment
          properties over a period of 25 years on a straightline basis the useful life estimate of 25 years is different from the indicative useful life of
          relevant type of buildings mentioned in part c of schedule ii to the act ie 30 years

          any gain or loss on disposal of an investment property is recognised in statement of profit and loss

    g    business combination

          in accordance with ind as 103 business combinations the group accounts for business combinations after acquisition date using the
          acquisition method when control is transferred to the company see note 37 the cost of an acquisition is measured at the fair value of the
          assets given equity instruments issued and liabilities incurred or assumed at the date of exchange the cost of acquisition also includes the fair
          value of any contingent consideration and deferred consideration if any any goodwill that arises is tested annually for impairment any gain
          on a bargain purchase is recognised in oci and accumulated in equity as capital reserve if there exists clear evidence of the underlying reasons
          for classifying the business combination as resulting in a bargain purchase otherwise the gain is recognised directly in equity as capital reserve
          transaction costs are expensed as incurred

    h    inventories

          inventories are measured at the lower of cost and net realisable value the cost of inventories is based on the firstin firstout formula and
          includes expenditure incurred in acquiring the inventories production or conversion costs and other costs incurred in bringing them to their
          present location and condition in the case of manufactured inventories and workinprogress cost includes an appropriate share of fixed
          production overheads based on normal operating capacity

          net realisable value is the estimated selling price in the ordinary course of business less the estimated costs of completion and selling
          expenses the net realisable value of workinprogress is determined with reference to the selling prices of related finished products

          raw materials components and other supplies held for use in the production of finished products are not written down below cost except in
          cases where material prices have declined and it is estimated that the cost of the finished products will exceed their net realisable value



232     ahead of the curve  annual report 2017

                                                                                                              biocon limited  subsidiaries



     the comparison of cost and net realisable value is made on an itembyitem basis

i   impairment

     i     impairment of financial assets

            in accordance with ind as 109 the group applies expected credit loss ecl model for measurement and recognition of impairment
            loss on following

             financial assets measured at amortised cost and

             financial assets measured at fvoci debt investments

            loss allowance for trade receivables with no significant financing component is measured at an amount equal to lifetime expected credit
            losses for all other financial assets ecl are measured at an amount equal to the 12month ecl unless there has been a significant
            increase in credit risk from initial recognition in which case those are measured at lifetime ecl

            loss allowance for financial assets measured at amortised cost are deducted from gross carrying amount of the assets for debt securities
            at fvoci the loss allowance is charged to statement of profit and loss and is recognised in oci

     ii    impairment of nonfinancial assets

            the group assesses at each reporting date whether there is any indication that the carrying amount may not be recoverable if any such
            indication exists then the assets recoverable amount is estimated and an impairment loss is recognised if the carrying amount of an
            asset or cgu exceeds its estimated recoverable amount in the statement of profit and loss

            goodwill is tested annually for impairment for the purpose of impairment testing goodwill arising from a business combination is
            allocated to cgus or groups of cgus that are expected to benefit from the synergies of the combination

            the groups nonfinancial assets inventories and deferred tax assets are reviewed at each reporting date to determine whether there
            is any indication of impairment if any such indication exists then the assets recoverable amount is estimated for impairment testing
            assets that do not generate independent cash inflows are grouped together into cashgenerating units cgus each cgu represents the
            smallest group of assets that generates cash inflows that are largely independent of the cash inflows of other assets or cgus

            impairment loss recognised in respect of a cgu is allocated first to reduce the carrying amount of any goodwill allocated to the cgu and
            then to reduce the carrying amounts of the other assets of the cgu or group of cgus on a pro rata basis

            an impairment loss in respect of goodwill is not subsequently reversed in respect of other assets for which impairment loss has been
            recognised in prior periods the group reviews at each reporting date whether there is any indication that the loss has decreased or no
            longer exists an impairment loss is reversed if there has been a change in the estimates used to determine the recoverable amount
            such a reversal is made only to the extent that the assets carrying amount does not exceed the carrying amount that would have been
            determined net of depreciation or amortisation if no impairment loss had been recognised

j   employee benefits

     i     gratuity

            the group provides for gratuity a defined benefit plan the gratuity plan covering the eligible employees of the company and its indian
            subsidiaries the gratuity plan provides a lumpsum payment to vested employees at retirement death incapacitation or termination of
            employment of an amount based on the respective employees salary and the tenure of the employment with the group

            liability with regard to the gratuity plan are determined by actuarial valuation performed by an independent actuary at each balance
            sheet date using the projected unit credit method the defined benefit plan is administered by a trust formed for this purpose through
            the group gratuity scheme

            the group recognises the net obligation of a defined benefit plan as a liability in its balance sheet gains or losses through re
            measurement of the net defined benefit liability are recognised in other comprehensive income and are not reclassified to profit and loss
            in the subsequent periods the actual return of the portfolio of plan assets in excess of the yields computed by applying the discount
            rate used to measure the defined benefit obligation is recognised in other comprehensive income the effect of any plan amendments
            are recognised in the statement of profit and loss

     ii    provident fund

            eligible employees of the company and its indian subsidiaries receive benefits from provident fund which is a defined contribution
            plan both the eligible employees and the respective companies make monthly contributions to the government administered provident
            fund scheme equal to a specified percentage of the eligible employees salary amounts collected under the provident fund plan are
            deposited with in a government administered provident fund the companies have no further obligation to the plan beyond its monthly
            contributions

     iii   compensated absences

            the group has a policy on compensated absences which are both accumulating and nonaccumulating in nature the expected cost of
            accumulating compensated absences is determined by actuarial valuation performed by an independent actuary at each balance sheet
            date using the projected unit credit method on the additional amount expected to be paidavailed as a result of the unused entitlement
            that has accumulated at the balance sheet date expense on nonaccumulating compensated absences is recognised is the period in
            which the absences occur



                                                                                                                      financial report           233

          iv    sharebased compensation

                 the grant date fair value of equity settled sharebased payment awards granted to employees is recognised as an employee expense
                 with a corresponding increase in equity over the period that the employees unconditionally become entitled to the awards the amount
                 recognised as expense is based on the estimate of the number of awards for which the related service and nonmarket vesting conditions
                 are expected to be met such that the amount ultimately recognised as an expense is based on the number of awards that do meet the
                 related service and nonmarket vesting conditions at the vesting date

    k    provisions other than for employee benefits

          a provision is recognised if as a result of a past event the group has a present legal or constructive obligation that can be estimated reliably
          and it is probable that an outflow of economic benefits will be required to settle the obligation provisions are determined by discounting the
          expected future cash flows representing the best estimate of the expenditure required to settle the present obligation at the balance sheet
          date at a pretax rate that reflects current market assessments of the time value of money and the risks specific to the liability the unwinding
          of the discount is recognised as finance cost expected future operating losses are not provided for

          onerous contracts

          a contract is considered to be onerous when the expected economic benefits to be derived by the group from the contract are lower than the
          unavoidable cost of meeting its obligations under the contract the provision for an onerous contract is measured at the present value of the
          lower of the expected cost of terminating the contract and the expected net cost of continuing with the contract before such a provision is
          made the group recognises any impairment loss on the assets associated with that contract

    l    revenue

          i     sale of goods

                 revenue is recognized when the significant risks and rewards of ownership have been transferred to the buyer recovery of the
                 consideration is probable the associated costs and possible return of goods can be estimate reliably there is no continuing management
                 involvement with the goods and the amount of revenue can be measured reliably the timing of transfers of risks and rewards varies
                 depending on the individual terms of sale revenue from the sale of goods includes excise duty and is measured at the fair value of the
                 consideration received or receivable net of returns sales tax and applicable trade discounts and allowances

          ii    milestone payments and out licensing arrangements

                 the company enters into certain dossier sales licensing and supply arrangements that in certain instances include certain performance
                 obligations based on an evaluation of whether or not these obligations are inconsequential or perfunctory we recognise or defer the
                 upfront payments received under these arrangements the deferred revenue is recognised in the consolidated statement of operations
                 in the period in which we complete our remaining performance obligations

                 these arrangements typically also consist of subsequent payments dependent on achieving certain milestones in accordance with the
                 terms prescribed in the agreement milestone payments which are contingent on achieving certain clinical milestones are recognized as
                 revenues either on achievement of such milestones if the milestones are considered substantive or over the period we have continuing
                 performance obligations if the milestones are not considered substantive if milestone payments are creditable against future royalty
                 payments the milestones are deferred and released over the period in which the royalties are anticipated to be paid

          iii   contract research and manufacturing services income

                 in respect of contracts involving research services in case of time and materials contracts contract research fee are recognised as
                 services are rendered in accordance with the terms of the contracts revenues relating to fixed price contracts are recognised based
                 on the percentage of completion method determined based on efforts expended as a proportion to total estimated efforts the group
                 monitors estimates of total contract revenue and cost on a routine basis throughout the contract period the cumulative impact of any
                 change in estimates of the contract revenue or costs is reflected in the period in which the changes become known in the event that a
                 loss is anticipated on a particular contract provision is made for the estimated loss

                 in respect of contracts involving sale of compounds arising out of contract research services for which separate invoices are raised
                 revenue is recognised when the significant risks and rewards of ownership of the compounds have passed to the buyer and comprise
                 amounts invoiced for compounds sold

                 in respect of services the group collects service tax as applicable on behalf of the government and therefore it is not an economic
                 benefit flowing to the group hence it is excluded from revenue

          iv    sales return allowances

                 the group accounts for sales return by recording an allowance for sales return concurrent with the recognition of revenue at the time of a
                 product sale the allowance is based on groups estimate of expected sales returns the estimate of sales return is determined primarily
                 by the groups historical experience in the markets in which the group operates

          v     dividends

                 dividend is recognised when the groups right to receive the payment is established which is generally when shareholders approve the
                 dividend




234     ahead of the curve  annual report 2017

                                                                                                                 biocon limited  subsidiaries



     vi    rental income

            rental income from investment property is recognised in statement of profit and loss on a straightline basis over the term of the lease
            except where the rentals are structured to increase in line with expected general inflation lease incentives granted are recognised as an
            integral part of the total rental income over the term of the lease

     vii   contribution received from customerscodevelopment partners towards plant and equipment

            contributions received from customerscodevelopment partners towards items of property plant and equipment which require an
            obligation to supply goods to the customer in the future are recognised as a credit to deferred revenue the contribution received is
            recognised as revenue from operations over the useful life of the assets the group capitalises the gross cost of these assets as the group
            controls these assets

m   government grants

     the group recognizes government grants only when there is reasonable assurance that the conditions attached to them will be complied with
     and the grants will be received government grants received in relation to assets are presented as a reduction to the carrying amount of the
     related asset grants related to income are deducted in reporting the related expense

n   income taxes

     income tax comprises current and deferred income tax income tax expense is recognised in statement of profit and loss except to the extent
     that it relates to an item recognised directly in equity in which case it is recognised in other comprehensive income current income tax for
     current year and prior periods is recognised at the amount expected to be paid or recovered from the tax authorities using the tax rates and
     laws that have been enacted or substantively enacted by the balance sheet date

     deferred income tax assets and liabilities are recognised for all temporary differences arising between the tax bases of assets and liabilities and
     their carrying amounts in the financial statements except when

           taxable temporary differences arising on the initial recognition of goodwill

           temporary differences arising on the initial recognition of assets or liabilities in a transaction that is not a business combination and that
            affects neither accounting nor taxable profit or loss at the time of transaction

           temporary differences related to investments in subsidiaries associates and joint arrangements to the extent that the group is able to
            control the timing of the reversal of the temporary differences and it is probable that they will not reverse in the foreseeable future

     deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable that the related tax benefit
     will be realized

     deferred income tax assets and liabilities are measured using the tax rates and laws that have been enacted or substantively enacted by
     the balance sheet date and are expected to apply to taxable income in the years in which those temporary differences are expected to be
     recovered or settled the effect of changes in tax rates on deferred income tax assets and liabilities is recognised as income or expense in the
     period that includes the enactment or substantive enactment date a deferred income tax assets is recognised to the extent it is probable that
     future taxable income will be available against which the deductible temporary timing differences and tax losses can be utilized deferred
     income taxes are not provided on the undistributed earnings of subsidiaries where it is expected that the earnings of the subsidiary will not be
     distributed in the foreseeable future the group offsets incometax assets and liabilities where it has a legally enforceable right to set off the
     recognised amounts and where it intends either to settle on a net basis or to realise the asset and settle the liability simultaneously

o   borrowing cost

     borrowing costs are interest and other costs including exchange differences relating to foreign currency borrowings to the extent that they
     are regarded as an adjustment to interest costs incurred in connection with the borrowing of funds borrowing costs directly attributable to
     acquisition or construction of an asset which necessarily take a substantial period of time to get ready for their intended use are capitalised as
     part of the cost of that asset other borrowing costs are recognised as an expense in the period in which they are incurred

p   earnings per share

     basic earnings per share is computed using the weighted average number of equity shares outstanding during the period adjusted for treasury
     shares held diluted earnings per share is computed using the weightedaverage number of equity and dilutive equivalent shares outstanding
     during the period using the treasury stock method for options and warrants except where the results would be antidilutive

q   operating segments

     an operating segment is a component of the group that engages in business activities from which it may earn revenues and incur expenses
     including revenues and expenses that relate to transactions with any of the groups other components and for which discrete financial
     information is available operating segments are reported in a manner consistent with the internal reporting provided to the chief operating
     decision maker the chairperson and managing director of the company is responsible for allocating resources and assessing performance of
     the operating segments and accordingly is identified as the chief operating decision maker codm all operating segments operating results
     are reviewed regularly by the codm to make decisions about resources to be allocated to the segments and assess their performance




                                                                                                                        financial report           235

3 property plant and equipment and capital workinprogress
                                              land buildings         leasehold          plant and research  furniture vehicles       total    capital work
                                                                  improvements         equipment development      and                            inprogress
                                                                                                  equipments fixtures
                                    refer note a                                refer note c                                          refer note f
gross carrying amount
at april 01 2015                            1362       5926                 5            19986        2028      552      59    29918           15582
additions                                      130         657                              2254              60    83       6     3190             7291
disposals                                                                                   85                         8      93          3190
other adjustments
 foreign currency translation                   59         24                                  15                                  98               914
at march 31 2016                            1551       6607                 5            22170        2088      635      57    33113           20597
additions                                      663       6288                             14806          113      218      20    22108             6728
disposals                                                 99                            1753                 58     7   1917         22108
other adjustments
 foreign currency translation                 22         4                                 9                                35              110
at march 31 2017                            2192     12792                  5            35214        2201      795      70    53269             5327
accumulated depreciation
at april 01 2015                                       1386                 4            11006        1184      337      19    13936                     
depreciation for the year                                 249                              1971          155       68       6     2449                     
disposals                                                                                   80                         4      84                    
other adjustments
 foreign currency translation                                                                 1                                   1                     
at march 31 2016                                       1635                 4            12898        1339      405      21    16302                     
depreciation for the year                                 282                              2176          142       85      10     2695                     
disposals                                                 36                            1158                 52     7   1253                    
other adjustments
 foreign currency translation                             1                                 3                                 4                    
at march 31 2017                                       1880                 4            13913        1481      438      24    17740                     
net carrying amount
at april 01 2015                            1362       4540                 1             8980          844      215      40    15982           15582
at march 31 2016                            1551       4972                 1             9272          749      230      36    16811           20597
at march 31 2017                            2192     10912                  1            21301          720      357      46    35529             5327


a     land includes land held on leasehold basis gross carrying amount  nil march 31 2016   236 net carrying amount  nil march 31 2016  236
b     during the year ended march 31 2016 the group had acquired the business of the pharmaceutical manufacturing unit of ms acacia lifesciences
        private limited located at vishakhapatnam with effect from october 01 2015 also refer note 37
c     plant and equipment include computers and office equipment
d     foreign exchange gain of  169 march 31 2016   21 on long term foreign currency monetary liabilities relating to acquisition of a depreciable
        capital asset has been adjusted with the cost of such asset and is being depreciated over the balance life of the asset
e     additions to property plant and equipment includes additions related to research and development amounting to  297 march 31 2016   80
f     capital workinprogress as on march 31 2017 mainly comprises new biopharmaceutical manufacturing units being constructed in india
g     for details of security on certain property plant and equipment refer note 15b d e and f




                                                       this space has been intentionally left blank




236        ahead of the curve  annual report 2017

                                                                                                                       biocon limited  subsidiaries



4 investment property

 gross carrying amount
 at april 01 2015                                                                                                                                          34
 at march 31 2016                                                                                                                                          34
 at march 31 2017                                                                                                                                          34

 accumulated depreciation
 at april 01 2015                                                                                                                                          23
 depreciation for the year                                                                                                                                   2
 at march 31 2016                                                                                                                                          25
 depreciation for the year                                                                                                                                   1
 at march 31 2017                                                                                                                                          26

 net carrying amount
 at april 01 2015                                                                                                                                          11
 at march 31 2016                                                                                                                                           9
 at march 31 2017                                                                                                                                           8

during the year the company has recognised rental income of  20 march 31 2016   20 and depreciation charge of  1 march 31 2016   2 in the
statement of profit and loss for investment properties

the fair value of the investment property as at march 31 2017 is  8 march 31 2016   9 april 01 2015   11

5 intangible assets

                                goodwill                                  intangible assets                                     intangible assets under
                                                                                                                                     development
                                                    other marketing and          ip under               customer total           product marketing        total
                                                intangible manufacturing commercialisation                related                  under    rights
                                                    assets        rights                               intangible           development
                                            refer note a refer note b                      refer note 37
 gross carrying amount
 at april 01 2015                  264                264                64                  81                    409            670       1048    1718
 additions                                             72              101                                   77    250          1082               1082
 other adjustments
  impairment refer note 32                                                                                                        1078 1078
  foreign currency                                                                                                            46          30         76
 translation
 at march 31 2016                  264                336              165                   81               77    659          1798               1798
 additions                                            169                                                        169          1342               1342
 other adjustments
  foreign currency                                                                                                           75                 75
 translation
 at march 31 2017                  264                505              165                   81               77    828          3065               3065

 accumulated amortisation
 at april 01 2015                                     88                12                  81                    181                                    
 amortisation for the year                             50                12                                   8      70                                   
 at march 31 2016                                    138                24                  81                8    251                                    
 amortisation for the year                             77                27                                  15    119                                    
 at march 31 2017                                    215                51                  81               23    370                                    

 net carrying amount
 at april 01 2015                  264                176                52                                       228            670       1048    1718
 at march 31 2016                  264                198              141                                   69    408          1798               1798
 at march 31 2017                  264                290              114                                   54    458          3065               3065
a   the group acquired the intellectual property rights in system biology and pharma services practice along with a team of data scientists from strand
      life sciences private limited for a sum of  120 with effect from august 1 2016

b   pursuant to an asset purchase agreement with a customer executed during the year ended march 31 2016 the group has acquired the marketing
      and manufacturing rights of a product for a sum of  101




                                                                                                                             financial report           237

6 noncurrent investments
                                                                                                     march 31 2017   march 31 2016    april 01 2015
i unquoted equity instruments
in others
energon kn wind power private limited  38500 march 31 2016  nil april 01 2015  nil equity               1                                   
shares of  10 each
less provision for decline other than temporary in the value of noncurrent investments                      1                                  
total unquoted investments in equity instruments                                                                                                    

ii unquoted preference shares
in associate company
iatrica inc usa  4285714 march 31 2016  4285714 april 01 2015  4285714 series a                131              131               131
preferred stock at us 070 each par value us  000001 each
less provision for decline other than temporary in the value of noncurrent investments                    131            131             131
                                                                                                                                                    
others
vaccinex inc usa  2722014 march 31 2016  2722014 april 01 2015  2722014 series b1              186              186               186
preferred convertible stock at us 155 each par value us 0001 each
vaccinex inc usa  217972 march 31 2016  217972 april 01 2015  217972 series b2                     32                32                32
preferred convertible stock at us 310 each par value us 0001 each
less provision for decline other than temporary in the value of noncurrent investments                    218            218             218
                                                                                                                                                    
energon kn wind power private limited  14666 march 31 2016  nil april 01 2015  nil                      1                                   
compulsorily convertible preference shares par value  100 each
less provision for decline other than temporary in the value of noncurrent investments                      1                                  
                                                                                                                                                    
total unquoted investments in preference shares                                                                                                     

iii unquoted debentures or bonds
others
lic housing finance co ltd  700 march 31 2016  nil april 01 2015  nil 751 bonds at                 701                                   
1001120 each par value  1000000 each
hdfc ltd  75 march 31 2016  nil april 01 2015  nil 815 bonds at  10090700 each par              757                                   
value  10000000 each
total unquoted investments in debentures or bonds                                                            1458                                   


total noncurrent investments                                                                                1458                                   
aggregate value of unquoted investments                                                                      1809              349               349
aggregate amount of impairment in value of investments                                                         351              349               349
a the company has invested in national savings certificates unquoted which are not disclosed above since amounts are rounded off to rupees million


7 other financial assets
                                                                                                     march 31 2017   march 31 2016    april 01 2015
a noncurrent
interest accrued but not due                                                                                                     26                  
deposits                                                                                                       197              232               193
                                                                                                               197              258               193


b current
interest accrued but not due                                                                                   173              241                 98
unbilled revenue                                                                                               243              679               296
other receivables                                                                                            1135              924                 74
                                                                                                             1551             1844              468




238         ahead of the curve  annual report 2017

                                                                                                            biocon limited  subsidiaries



8 deferred tax assets net
                                                                                                march 31 2017   march 31 2016    april 01 2015
deferred tax liability
property plant and equipment investment property and intangible assets                                  685              686               692
derivative asset                                                                                          201                                48
others                                                                                                     30                                  
gross deferred tax liability                                                                              916              686               740

deferred tax assets
employee benefit obligations                                                                              182              168               237
allowance for doubtful debts                                                                               20                14               29
other disallowable expenses                                                                               169              145                80
deferred revenue                                                                                                          162                69
mat credit entitlement                                                                                  2113              702               536
derivative liability                                                                                                        91                 
tax losses                                                                                                262                                  
others                                                                                                    145              119               109
gross deferred tax assets                                                                               2891             1401            1060
net deferred tax assets                                                                                 1975              715               320


9 other assets
a noncurrent
capital advances                                                                                          516              852               588
duty drawback receivable                                                                                  329              313               326
balances with statutory government authorities                                                         1589              951               965
prepayments                                                                                               341              171               244
                                                                                                        2775             2287            2123
b current
balances with statutory government authorities                                                           241              157               242
prepayments                                                                                             1348              495               419
                                                                                                        1589              652               661
10 inventories
raw materials including goodsinbond                                                                 1531             1354            1206
packing materials                                                                                         386              324               209
traded goods                                                                                              223              262               249
finished goods                                                                                          1747             1773            1656
workinprogress                                                                                        2466             1711            1436
                                                                                                        6353             5424            4756
 includes goods intransit  nil march 31 2016   151 april 01 2015   nil

writedown of inventories to net realisable value amounted to  3 march 31 2016   3 these were recognised as an expense during the year and
included in changes in inventories of traded goods finished goods and workinprogress in statement of profit and loss




                                                    this space has been intentionally left blank




                                                                                                                   financial report         239

                                                                                                             march 31 2017   march 31 2016   april 01 2015
11 current investments
unquoted
investment in mutual funds
birla sun life short term fund growth 14572296 march 31 2016  nil april 01 2015  nil units                   907                                 
dhfl pramerica banking  psu debt fund gr 6602593 march 31 2016  nil april 01 2015  nil units                  93                                 
axis liquid fund  daily dividend reinvestment nil march 31 2016  nil april 01 2015  98005                                                      98
units
dws banking  psu debt fund  weekly dividend reinvestment nil march 31 2016  70409716                                           724                 
april 01 2015  nil units
edelweiss banking and psu debt fund  regular plan growth 20407166 march 31 2016  nil                            276                                 
april 01 2015  nil units
hdfc liquid fund  daily dividend reinvestment nil march 31 2016  nil april 01 2015                                                              138
13566785 units
hdfc medium term opportunities fund  regular plan  growth 27762046 march 31 2016  nil                          503                                 
april 01 2015  nil units
hdfc short term opportunities fund  regular plan  growth 22489571 march 31 2016  nil                           405                                 
april 01 2015  nil units
idfc cash fund  daily dividend regular plan nil march 31 2016  nil april 01 2015  158344 units                                                159
jp morgan banking  psu debt fund  weekly dividend reinvestment option nil units march 31                                           258                 
2016  24569495 units april 01 2015  nil units
reliance banking  psu debt fund weekly dividend plan nil march 31 2016  46064513 april                                          465                 
01 2015  nil units
reliance banking  psu debt fund  growth 72201894 units march 31 2016  nil units april                          851                                 
01 2015  nil units
reliance liquidity fund  daily dividend reinvestment option nil march 31 2016  nil april 01                                                      135
2015  135112 units
sbi premier liquid fund  regular plan  daily dividend nil march 31 2016  154313 april 01                                       155                 
2015  nil units
tata fixed maturity plan series 47 scheme c  plan a  growth nil march 31 2016  nil april 01                                                     150
2015  15000000 units
tata liquid fund  plan a  daily dividend nil march 31 2016  nil april 01 2015  229233 units                                                  255
uti  treasury advantage fund  institutional plan  daily dividend reinvestment 91862 march 31                      92               42              175
2016  41818 april 01 2015  175000 units
uti treasury advantage fund 122052 march 31 2016 nil april 01 2015 nil units                                   274                                 
reliance money manager fund 69072 march 31 2016 nil april 01 2015 nil units                                    155                                 
kotak treasury advantage fund 7932353 march 31 2016 nil april 01 2015 nil units                               207                                 
hdfc floating rate income fund 27436866 march 31 2016 nil april 01 2015 nil units                             776                                 
franklin india ultra short bond fund  super institutional plan 27293310 march 31 2016 nil                       208                                 
april 01 2015 nil units
idfc ultra short term fund 26359631 march 31 2016 nil april 01 2015 nil units                                 607                                 
hdfc floating rate income fund 1828193 march 31 2016 nil april 01 2015 nil units                               52                                 
franklin india ultra short bond fund  super institutional plan 9353355 march 31 2016 nil april                  608                                 
01 2015 nil units
birla savings fund 2431913 march 31 2016 nil april 01 2015 nil units                                          775                                 
icici prudential flexible income fund 1947431 march 31 2016 nil april 01 2015 nil units                       606                                 
baroda pioneer liquid fund  plan a daily dividend nil march 31 2016 40637 april 01 2015 nil units                              41                 
axis liquid fund  daily dividend nil march 31 2016 200433 april 01 2015 nil units                                             201                 
utitreasury advantage fund  daily dividend reinvestment nil march 31 2016 252021 april                                          253                 
01 2015 nil units
birla sun life savings fund  daily dividend  regular plan 5303556 march 31 2016 5016970                      533              503              253
april 01 2015 2521502 units
birla sun life cash plus  daily dividend direct plan nil march 31 2016 nil april 01 2015                                                         9
93857 units
birla sun life cash plus  daily dividend nil march 31 2016 nil april 01 2015 748871 units                                                      75
icici fmp series 78  95 d plan k dividend nil march 31 2016 13003654 april 01 2015 nil units                                 130                 
icici prudential flexible income  daily dividend 5706959 march 31 2016 4689806 april 01                      602              496              253
2015 2391423 units
icici prudential liquid  regular plan  daily dividend nil march 31 2016 nil april 01 2015                                                       70
699774 units


240      ahead of the curve  annual report 2017

                                                                                                                  biocon limited  subsidiaries



                                                                                                      march 31 2017   march 31 2016    april 01 2015
jp morgan liquid fund  daily dividend nil march 31 2016 nil april 01 2015 4033108 units                                                  40
tata floater fund plan a  daily dividend nil march 31 2016 nil april 01 2015 125068 units                                               126
hdfc liquid fund  direct plan daily dividend nil march 31 2016 nil april 01 2015 1013825                                                10
units
hdfc liquid fund  regular plan  daily dividend nil march 31 2016 nil april 01 2015 266017                                                 3
units
hdfc liquid fund  daily dividend reinvestment nil march 31 2016 171988 april 01 2015                                    175                   
nil units
hdfc floating rate income fund short term dividend reinvestment nil march 31 2016                                          496               142
49241163 april 01 2015 14034587 units
kotak liquid scheme plan a  direct plan  daily dividend nil march 31 2016 nil april 01 2015                                                22
18308 units
kotak liquid fund plan a  regular plan  daily dividend nil march 31 2016 nil april 01 2015                                               122
99734 units
reliance money manager fund  daily dividend plan nil march 31 2016 151044 april 01 2015                                 152                   
nil units
reliance liquid fund  regular plan  daily dividend nil march 31 2016 154108 april 01 2015                              236               193
125892 units
reliance liquid fund  cash plan  daily dividend nil march 31 2016 nil april 01 2015 45147                                                50
units
                                                                                                              8530            4327              2478
in others
inter corporate deposits with financial institutions                                                          2120            4420                   
                                                                                                             10650            8747              2478
aggregate value of unquoted investments                                                                      10650            8747              2478


12 trade receivables
unsecured considered good                                                                                    8832            7145              6833
doubtful                                                                                                         90                56                90
                                                                                                              8922            7201              6923
allowance for credit loss                                                                                       90             56              90
                                                                                                              8832            7145              6833
the above includes 
due from narayana hrudayalaya limited nhl formerly known as narayana hrudayalaya private                     4                 8                 5
limited in which a director of the company is a member of board of directors of nhl

the groups exposure to credit and currency risks and loss allowances are disclosed in note 38


13 cash and bank balances
cash and cash equivalents
balances with banks
 on current accounts                                                                                          7096            7063              4569
 on unpaid dividend account                                                                                       6                10                 6
 deposits with original maturity of less than 3 months                                                                          540                   
total cash and cash equivalents                                                                               7102            7613              4575

other bank balances
 deposits with maturity of less than 12 months                                                                3338            7770              4626
 margin money deposit refer note a below                                                                      3                 3                 3
total other bank balances                                                                                     3341            7773              4629


total cash and bank balances                                                                                 10443           15386              9204
a   margin money deposits with carrying amount of  3 march 31 2016   3 april 01 2015   3 are subject to first charge against bank guarantees
      obtained
b   the group has cash on hand which are not disclosed above since amounts are rounded off to rupees million




                                                                                                                         financial report          241

                                                                                                            march 31 2017      march 31 2016      april 01 2015
14a equity share capital
authorised
220000000 march 31 2016  220000000 april 01 2015  220000000 equity shares of  5                         1100               1100              1100
each march 31 2016   5 each april 01 2015   5 each

issued subscribed and fully paidup
200000000 march 31 2016  200000000 april 01 2015  200000000 equity shares of  5                         1000               1000              1000
each march 31 2016   5 each april 01 2015   5 each

i reconciliation of the shares outstanding at the beginning and at the end of the reporting period

equity shares

                                                                                                  march 31 2017                         march 31 2016
                                                                                                     no            million                no            million
at the beginning of the year                                                               200000000                1000       200000000                1000
issued during the year                                                                                                                                          
outstanding at the end of the year                                                         200000000                1000       200000000                1000

ii termsrights attached to equity shares

the company has only one class of equity shares having a par value of  5 per share each holder of equity shares is entitled to one vote per share the
company declares and pays dividends in indian rupees the dividend proposed by the board of directors is subject to the approval of the shareholders in
the ensuing annual general meeting

in the event of liquidation of the company the holders of equity shares will be entitled to receive remaining assets of the company after distribution of all
preferential amounts if any the distribution will be in proportion to the number of equity shares held by the shareholders

iii details of shareholders holding more than 5 shares in the company

                                                                                                  march 31 2017                         march 31 2016
                                                                                                     no          holding                  no          holding
equity shares of  5 each fully paid
dr kiran mazumdarshaw                                                                       79287564             3964         79287564              3964
glentec international limited                                                                39535194             1977         39535194              1977

as per records of the company including its register of shareholders members the above shareholding represents both legal and beneficial ownerships of shares
iv shares reserved for issue under options
for details of shares reserved for issue under the employee stock option plan esop of the company refer note 30

14b other equity
securities premium reserve
securities premium is used to record the premium received on issue of shares it is utilised in accordance with the provisions of the companies act 2013
general reserve
general reserve is used from time to time to transfer profits from retained earnings for appropriation purposes
retained earnings
the amount that can be distributed by the company as dividends to its equity shareholders is determined based on the standalone financial statements of
the company and also considering the requirements of the act thus the amounts reported are not distributable in entirety
sez reinvestment reserve
the sez reinvestment reserve has been created out of profit of eligible sez units in terms of the provisions of section 10aa1ii of the incometax act 1961 the
reserve has been utilised for acquiring new plant and machinery for the purpose of its business in terms of section 10aa2 of the incometax act 1961
share based payment reserve
the group has established various equity settled sharebased payment plans for certain categories of employees of the group also refer note 30 for further
details on these plans
treasury shares
own equity instruments that are reacquired treasury shares are recognised at cost and deducted from equity
foreign currency translation reserve
exchange differences relating to the translation of the results and net assets of the groups foreign operations from their functional currencies to the groups
reporting currency ie  are accumulated in the foreign currency translation reserve
cash flow hedging reserves
the cash flow hedging reserve represents the cumulative effective portion of gains or losses net of taxes if any arising on changes in fair value of
designated portion of hedging instruments entered into for cash flow hedges



242       ahead of the curve  annual report 2017

                                                                                                                            biocon limited  subsidiaries



 15 longterm borrowings
                                                                                                             march 31 2017      march 31 2016       april 01 2015
 deferred sales tax liability unsecured refer note a below                                                                              65                195

 loans from banks secured
 term loan refer notes b d e and f below                                                                  21403              20090               8097
 buyers credit refer note c below                                                                                     611                624                 186

 other loans and advances unsecured
 nmitli  csir loan refer note g below                                                                                   1                  1                   1
 financial assistance from dsir refer note h below                                                                       3                  6                  10
 financial assistance from dst refer note i below                                                                      35                  42                  48
                                                                                                                      22053              20828               8537
 less amount disclosed under the head other current financial liabilities refer note 16b                         971               104               866
                                                                                                                      21082              20724               7671
 the above amount includes
 secured borrowings                                                                                                   22014              20714               8283
 unsecured borrowings                                                                                                      39                114                 254
 amount disclosed under the head other current financial liabilities refer note 16b                               971               104               866
 net amount                                                                                                           21082              20724               7671
a   on february 9 2000 the company obtained an order from the karnataka sales tax authority for allowing an interest free deferment of sales tax
      including turnover tax for a period upto 12 years with respect to sales from its hebbagodi manufacturing facility for an amount not exceeding 649
      this is an interest free liability the amount is repayable in 10 equal half yearly instalments of  65 each starting from february 2012 the loan was
      repaid during the year

b   during the year ended march 31 2016 the company has obtained an external commercial borrowing facility of usd 20 million from a bank the term
      loan facility is secured by first priority paripassu charge on the plant and machinery of the proposed expanded facility line in the existing facility the
      longterm loan is repayable in 4 equal quarterly instalments of usd 5 million each commencing from december 31 2018 and carries an interest rate
      of libor  095 pa the company has entered into interest rate swap to convert floating rate to fixed rate also refer note 38

c   syngene international limited syngene has obtained foreign currency denominated long term secured buyers credit loans of  611 usd 941
      million march 31 2016   624 usd 941 million april 01 2015   186 usd 3 million from hsbc bank mauritius limited that carry interest
      rate in the range of libor  060 to libor  080 pa the loan is guaranteed by hong kong and shanghai banking corporation limited india to
      hsbc bank mauritius limited all of the credit facilities provided by hong kong and shanghai banking corporation limited india is secured by a pari
      passu charge on the current assets and movable fixed assets of syngene the loans are repayable at end of 960 days to 1079 days from the date of
      its origination

d   i     syngene has entered into external commercial borrowing agreement with the hong kong and shanghai banking corporation limited the
              agent citibank na and hsbc bank mauritius limited the lead arrangers dated march 30 2016 to borrow  6628 usd 100 million
              comprising a usd 50 million term loan facility facility a and b usd 50 million term loan facility facility b the facilities are borrowed to
              incur capital expenditure at bangalore and mangalore premises of syngene

      ii    facility a of  3241 usd 50 million carries an interest rate of libor  104 pa and is repayable in two installments of usd 125 million in
              march 2019 and usd 375 million in march 2020 and facility b of  3240 usd 50 million carries an interest rate of libor  130 pa and
              is repayable in march 2021

      iii   the facilities provided are secured by first priority pari passu charge on fixed assets and second charge on current assets of syngene

e   during the year ended march 31 2016 biocon pharma limited bpl had obtained an external commercial borrowing of usd 20 million from a bank
      carrying interest of libor  175 pa the loan is payable in 11 unequal quarterly instalments commencing from june 28 2019 the loan is secured
      by first priority paripassu charge on the plant and machinery of the facility for the manufacture of pharmaceuticals bpl has entered into interest rate
      swap to convert floating rate to fixed rate

f   biocon sdn bhd malaysia biocon malaysia had obtained a term loan facility of usd 130 million from a consortium of banks during the year ended
      march 31 2016 biocon sdn bhd has refinanced the existing term loan from standard chartered bank hong kong limited the loan in repayable in
      quarterly installments commencing from march 2017 on july 6 2015 biocon sdn bhd has entered into a new term loan agreement with standard
      chartered bank hong kong limited for an amount of usd 70 million the loan is repayable in quarterly installments commencing from march 2017

      the term loans are denominated in usd and carries an interest rate of libor  325 pa the term loan is secured by a fixed and floating charge over
      all present and future assets and a charge over the freehold property of biocon malaysia

g   on march 31 2005 the company entered into an agreement with the council of scientific and industrial research csir for an unsecured loan of 3
      for carrying out part of the research and development project under the new millennium indian technology leadership initiative nmitli scheme
      the loan is repayable over 10 equal annual instalments of  03 starting from april 2009 and carry an interest rate of 3 pa




                                                                                                                                    financial report            243

h      on march 31 2009 the department of scientific and industrial research dsir sanctioned financial assistance for a sum of  17 to the company for
         part financing one of its research projects the assistance is repayable in the form of royalty payments for three years post commercialisation of the
         project in five equal annual instalments of  3 each starting from april 1 2013

i      on august 25 2010 the department of science and technology dst under the drugs and pharmaceutical research programme dprp has
         sanctioned financial assistance for a sum of  70 to the company for financing one of its research projects the loan is repayable over 10 annual
         instalments of  7 each starting from july 1 2012 and carries an interest rate of 3 pa

j      in respect of the financial assistance received under the aforesaid programmes refer note g to i above the company is required to utilise the
         funds for the specified projects and is required to obtain prior approvals from the said authorities for disposal of assets intellectual property rights
         acquired developed under the above programmes

k      the groups exposure to liquidity interest rate and currency risks are disclosed in note 38

                                                                                                           march 31 2017     march 31 2016      april 01 2015
 16 other financial liabilities
 a noncurrent
 interest accrued but not due                                                                                            2                  3                  6
                                                                                                                         2                  3                  6
 b current
 current maturities of longterm borrowings refer note 15                                                            971               104                866
 unpaid dividends                                                                                                        6                 10                  6
 payables for capital goods                                                                                          2284              1850             2544
 interim dividend on equity shares                                                                                                                      1000
                                                                                                                     3261              1964             4416
 17 provisions
 a noncurrent
 provision for employee benefits
      gratuity refer note 36                                                                                         360               299                150
                                                                                                                       360               299                150
 b current
 provision for employee benefits
      gratuity refer note 36                                                                                         131                 77               124
      compensated absences                                                                                             201               167                144
 provision for sales return                                                                                            136               130                130
                                                                                                                       468               374                398


 i movement in provisions                                                                                        gratuity    compensated          sales return
                                                                                                                                  absences
 opening balance                                                                                                       376               167                130
 provision recognised reversed during the year                                                                      115                 34                  6
 closing balance                                                                                                       491               201                136


                                                                                                           march 31 2017     march 31 2016      april 01 2015
 18 other liabilities
 a noncurrent
 deferred revenues                                                                                                   3516              3711             5601
                                                                                                                     3516              3711             5601
 b current
 deferred revenues                                                                                                     273               267              1245
 advances from customers                                                                                             2340              2427             2208
 book overdraft                                                                                                        824               255                  90
 statutory taxes and dues payable                                                                                      221               215                144
                                                                                                                     3658              3164             3687




244          ahead of the curve  annual report 2017

                                                                                                                          biocon limited  subsidiaries



                                                                                                              march 31 2017   march 31 2016   april 01 2015
19 shortterm borrowings
from banksfinancial institutions
        packing credit foreign currency loan unsecured refer notes i ii iii iv and v below             648            2253             2610
        packing credit foreign currency loan secured refer note vi and vii below                                324            1658                  
        cash credit secured refer note viii below                                                                                   2                  
        bank overdraft unsecured refer note ix below                                                                                36                 
                                                                                                                        972            3949             2610
the above amount includes
secured borrowings                                                                                                      324            1660                  
unsecured borrowings                                                                                                    648            2289             2610


i       during the year ended march 31 2016 the company had obtained unsecured foreign currency denominated loans of  597 usd 9 million april
          01 2015   nil usd nil carrying an interest rate of libor  020 pa from a bank the facility was repayable within 120 days from the date of
          its origination and has been repaid during the year
ii      during the year ended march 31 2016 the company had obtained unsecured foreign currency denominated loans of  1656 usd 25 million april
          01 2015   nil usd nil carrying an interest rate of libor  010 pa from a bank the facility was repayable within 180 days from the date of
          its origination and has been repaid during the year
iii     during the year ended march 31 2015 the company had obtained foreign currency denominated loan of  561 usd 9 million carrying an interest
          rate of libor  035 pa from a bank the facility was repayable within 180 days from the date of its origination and was repaid during the year
          ended march 31 2016
iv      biocon research limited brl had obtained foreign currency denominated loans of  685 usd 11 million carrying an interest rate of libor 
          035 to 050 pa from a bank as at april 01 2015 which has been repaid during the year ended march 31 2016
v       syngene has obtained foreign currency denominated short term unsecured preshipment credit loans of  648 usd 10 million march 31 2016 
          nil from hdfc bank limited that carries interest rate of libor  142 pa the loans are repayable after the end of 6 months from the date of its
          origination
vi      syngene has obtained foreign currency denominated short term secured preshipment credit loans of  324 usd 5 million march 31 2016  nil
          from the hong kong and shanghai banking corporation limited that carries interest rate of libor  142 pa the loans are repayable after the end
          of 6 months from the date of its origination the facility provided are secured by a pari passu charge on the current assets and movable fixed assets
          of syngene
vii     syngene had obtained foreign currency denominated short term secured preshipment credit loans of  1658 usd 25 million as of march 31 2016
          from the royal bank of scotland n v that carried interest rate of libor  010 pa the loans were repayable at the end of 6 months from the date
          of its origination the facility provided were secured by charge on fixed assets and current assets of syngene the loan has been fully repaid during
          the current year ended march 31 2017
viii the company has working capital facilities with a bank carrying interest rate ranging from 97  13 pa these facilities are repayable on demand
       secured by paripassu first charge on inventories and trade receivables
ix      bpl has obtained unsecured overdraft facility from a bank carrying interest rate of 925 pa


                                                                                                              march 31 2017   march 31 2016   april 01 2015
20 trade payables
trade payables                                                                                                        7397            6098             4126
                                                                                                                      7397            6098             4126

all trade payable are current the groups exposure to currency and liquidity risks related to trade payables is disclosed in note 38




                                                          this space has been intentionally left blank




                                                                                                                                 financial report         245

                                                                                  march 31 2017   march 31 2016
21 revenue from operations
sale of products
    finished goods                                                                       22193           19908
    traded goods                                                                          3741            1647
sale of services
    licensing and development fees                                                        1451              631
    contract research and manufacturing services income                                  11378           10730
other operating revenue
    sale of process waste                                                                   147              151
    others                                                                                  306              743
revenue from operations                                                                  39216           33810


22 other income
interest income on
    deposits with banks and financial institutions                                          994              398
    others                                                                                  121               30
dividend income from current investments                                                    156              191
net gain on sale of current investments                                                      39               16
net gain on financial assets measured at fair value through profit or loss                  132                 
other nonoperating income                                                                  129              157
                                                                                          1571              792


23 cost of raw materials and packing materials consumed
inventory at the beginning of the year                                                    1678            1415
add purchases                                                                           13463           12812
less inventory at the end of the year                                                   1917          1678
cost of raw materials and packing materials consumed                                     13224           12549


24 changes in inventories of traded goods finished goods and workinprogress
inventory at the beginning of the year
  traded goods                                                                              262              249
  finished goods                                                                          1773            1656
  workinprogress                                                                        1711            1436
                                                                                          3746            3341
inventory at the end of the year
  traded goods                                                                              223              262
  finished goods                                                                          1747            1773
  workinprogress                                                                        2466            1711
                                                                                          4436            3746
                                                                                           690            405


25 employee benefits expense
salaries wages and bonus                                                                 6502            5314
contribution to provident and other funds                                                   264              221
gratuity refer note 36                                                                     82               66
sharebased compensation expense refer note 30                                            266              186
staff welfare expenses                                                                      356              314
                                                                                          7470            6101


26 finance costs
interest expense on financial liability measured at amortised cost                          260              196
fair value changes on interest rate swap                                                                     30
exchange difference to the extent considered as an adjustment to borrowing cost                              67
                                                                                            260              293




246      ahead of the curve  annual report 2017

                                                                                                      biocon limited  subsidiaries



                                                                                                         march 31 2017   march 31 2016
27 depreciation and amortisation expense
depreciation of tangible assets refer note 3 and 4                                                             2696            2451
amortisation of intangible assets refer note 5                                                                   119               70
                                                                                                                 2815            2521
less expenses capitalised to tangible assets                                                                      43             34
                                                                                                                 2772            2487


28 other expenses
royalty and technical fees                                                                                          20               24
rent                                                                                                                34               29
communication expenses                                                                                              59               62
travelling and conveyance                                                                                          516              470
professional charges                                                                                               566              525
payment to auditors refer note a below                                                                          12               19
directors fees including commission                                                                                33               33
power and fuel                                                                                                   1564            1847
insurance                                                                                                           72               57
rates taxes and fees                                                                                              222              194
lab consumables                                                                                                    734              614
repairs and maintenance
      plant and machinery                                                                                          691              535
      buildings                                                                                                    212              143
      others                                                                                                       530              478
selling expenses
      freight outwards and clearing charges                                                                        270              303
      sales promotion expenses                                                                                     548              446
      commission and brokerage other than sole selling agents                                                    256              259
bad debts written off                                                                                                6                 8
provision reversal for doubtful debts net                                                                       34               47
foreign exchange fluctuation net                                                                                   23                95
printing and stationery                                                                                             69                57
research and development expenses refer note 29                                                                2724            2655
clinical trial  development expenses                                                                              134                80
csr expenditure refer note 46                                                                                    131              112
miscellaneous expenses                                                                                             369              285
                                                                                                                 9829            9283
less adjustment of product development expenses with deferred revenues                                                           152
less expenses capitalised to intangible assets                                                                 1366          1020
                                                                                                                 8463            8111

a payments to auditors
as auditor 
   statutory audit fee                                                                                               6                 6
   tax audit fee                                                                                                     2                 2
   limited review                                                                                                    2                 3
in other capacity
   other services certification fees                                                                               1                
   audit  limited review fee in relation to ipo of syngene                                                                          6
reimbursement of outofpocket expenses                                                                              1                2
                                                                                                                    12               19
 payments for the year ended march 31 2016 represents fees and reimbursements paid to the
predecessor auditor

29 research and development expenses
research  development expenses                                                                 a              2724            2655
other research  development expenses included in other heads                                   b              2587            2579
                                                                                              ab              5311            5234
less recovery of product development costs from codevelopment partners net                                  1283          1320
adjustment of product development expenses with deferred revenues                                                                 152
product development costs capitalised                                                                           1366          1020
                                                                                                                 2662            2742



                                                                                                           financial report        247

30 employee stock compensation
a   biocon esop plan

      on september 27 2001 biocons board of directors approved the biocon employee stock option plan esop plan 2000 for the grant of stock
      options to the employees of the company and its subsidiaries  joint venture company the nomination and remuneration committee remuneration
      committee administers the plan through a trust established specifically for this purpose called the biocon india limited employee welfare trust
      esop trust

      the esop trust shall make additional purchase of equity shares of the company using the proceeds from the loan obtained from the company other
      cash inflows from allotment of shares to employees under the esop plan and shall subscribe when allotted to such number of shares as is necessary
      for transferring to the employees the esop trust may also receive shares from the promoters for the purpose of issuance to the employees under the
      esop plan the remuneration committee shall determine the exercise price which will not be less than the face value of the shares

      grant iv

      in july 2006 the company approved the grant of 3478200 options face value of shares   5 each to its employees under the existing esop plan
      2000 the options under this grant would vest to the employees as 25 35 and 40 of the total grant at the end of first second and third year
      from the date of grant for existing employees and at the end of 3rd 4th and 5th year from the date of grant for new employees exercise period is 3
      years for each grant the conditions for number of options granted include service terms and performance grade of the employees these options are
      exercisable at a discount of 20 to the market price of companys shares on the date of grant

      details of grant iv

        particulars                                                                         march 31 2017                       march 31 2016
                                                                                        number of          weighted          number of          weighted
                                                                                          options           average            options           average
                                                                                                       exercise price                       exercise price
                                                                                                                                                     
        outstanding at the beginning of the year                                             3500                231            61625                185
        granted during the year                                                                                                                        
        forfeited during the year                                                                                                                      
        adjustment for issuance of bonus shares during the year
        exercised during the year                                                            2500                231            55250                179
        expired during the year                                                              1000                231             2875                154
        outstanding at the end of the year                                                                                      3500                231
        exercisable at the end of the year                                                                                      3500                231
        weighted average remaining contractual life in years                                                                     03                  
        range of exercise prices for outstanding options at the end of year                                                    231                   

      grant v

      in april 2008 the company approved the grant to its employees under the existing esop plan 2000 the options under this grant would vest to the
      employees as 25 35 and 40 of the total grant at the end of first second and third year from the date of grant for existing employees and at the
      end of 3rd 4th and 5th year from the date of grant for new employees exercise period is 3 years for each grant the conditions for number of options
      granted include service terms and performance grade of the employees these options are exercisable at the market price of companys shares on the
      date of grant

      details of grant v

        particulars                                                                         march 31 2017                       march 31 2016
                                                                                        number of           weighted         number of           weighted
                                                                                          options            average           options            average
                                                                                                        exercise price                       exercise price
                                                                                                                                                      
        outstanding at the beginning of the year                                           791875                343         1151975                336
        granted during the year                                                                                                                         
        forfeited during the year                                                           74625                344           269087                324
        adjustment for issuance of bonus shares during the year
        exercised during the year                                                          221388                307            91013                303
        expired during the year                                                                                                                         
        outstanding at the end of the year                                                 495862                357           791875                343
        exercisable at the end of the year                                                 135175                312           220638                310
        weighted average remaining contractual life in years                                  25                                 46                   
        range of exercise prices for outstanding options at the end of year            221471                             197531                     




248       ahead of the curve  annual report 2017

                                                                                                              biocon limited  subsidiaries



grant vi

in july 2014 the company approved the grant to its employees under the existing esop plan 2000 the options under this grant would vest to the
employees as 10 20 30 and 40 of the total grant at the end of first second third and fourth year from the date of grant respectively with an
exercise period ending one year from the end of last vesting the vesting conditions include service terms and performance grade of the employees
these options are exercisable at the closing market price of companys shares existing on the date preceding to the date of grant

particulars                                                                           march 31 2017                       march 31 2016
                                                                                  number of          weighted          number of          weighted
                                                                                    options           average            options           average
                                                                                                 exercise price                       exercise price
                                                                                                                                               
outstanding at the beginning of the year                                           1185839               470         1346152                470
granted during the year                                                               95000               477                                     
forfeited during the year                                                             61600               470           160313                470
exercised during the year                                                           258001                471                                     
expired during the year                                                                                                                          
outstanding at the end of the year                                                  961238                471         1185839                470
exercisable at the end of the year                                                  125026                470           116750                470
weighted average remaining contractual life in years                                    23                                 33                  
weighted average fair value of options granted                                        156                                                      
range of exercise prices for outstanding options at the end of year              470493                                  470                   

grant vii

in july 2014 the company approved the grant to its employees under the existing esop plan 2000 the options under this grant would vest to the
employees as 10 20 30 and 40 of the total grant at the end of first second third and fourth year from the date of grant respectively with an
exercise period ending one year from the end of last vesting the vesting conditions include service terms and performance grade of the employees
these options are exercisable at the closing market price of companys shares existing on the date preceding to the date of grant

particulars                                                                           march 31 2017                       march 31 2016
                                                                                  number of          weighted          number of          weighted
                                                                                    options           average            options           average
                                                                                                 exercise price                       exercise price
                                                                                                                                               
outstanding at the beginning of the year                                           1275500               461           293000                452
granted during the year                                                             200000                605         1077500                461
forfeited during the year                                                           238500                392             95000               472
exercised during the year                                                             16800               457                                     
expired during the year                                                                                                                          
outstanding at the end of the year                                                 1220200               482         1275500                461
exercisable at the end of the year                                                     9450               457                                     
weighted average remaining contractual life in years                                    52                                 60                  
weighted average fair value of options granted                                        251                                 185                   
range of exercise prices for outstanding options at the end of year              415741                             415518                    

grant viii

in july 2015 the company approved the grant to its employees under the existing esop plan 2000 the options under this grant would vest to the
employees as 10 20 30 and 40 of the total grant at the end of first second third and fourth year from the date of grant respectively with an
exercise period ending one year from the end of last vesting the vesting conditions include service terms and performance grade of the employees
these options are exercisable at the closing price as per national stock exchange as on the last day of the month preceding the month of first grant




                                             this space has been intentionally left blank




                                                                                                                     financial report           249

        particulars                                                                       march 31 2017                       march 31 2016
                                                                                      number of          weighted          number of          weighted
                                                                                        options           average            options           average
                                                                                                     exercise price                       exercise price
                                                                                                                                                   
        outstanding at the beginning of the year                                        312500                459                                     
        granted during the year                                                           55000               457           312500                459
        forfeited during the year                                                       105000                457                                     
        exercised during the year                                                          1000               457                                     
        expired during the year                                                                                                                      
        outstanding at the end of the year                                              261500                460           312500                459
        exercisable at the end of the year                                                16750               457                                     
        weighted average remaining contractual life in years                                38                                 46                  
        weighted average fair value of options granted                                    149                                 154                   
        range of exercise prices for outstanding options at the end of year          457481                             457481                    

    grant ix

    in june 2016 the company approved the grant to its employees under the existing esop plan 2000 the options under this grant would vest to the
    employees as 10 20 30 and 40 of the total grant at the end of first second third and fourth year from the date of grant respectively with an
    exercise period ending one year from the end of last vesting the vesting conditions include service terms and performance grade of the employees
    these options are exercisable at 50 of the closing price as per national stock exchange as on the preceding day to the date of grant

        particulars                                                                       march 31 2017                       march 31 2016
                                                                                      number of          weighted          number of          weighted
                                                                                        options           average            options           average
                                                                                                     exercise price                       exercise price
                                                                                                                                                   
        outstanding at the beginning of the year                                                                                                     
        granted during the year                                                         472500                495                                     
        forfeited during the year                                                          5000               467                                     
        exercised during the year                                                                                                                    
        expired during the year                                                                                                                      
        outstanding at the end of the year                                              467500                496                                     
        exercisable at the end of the year                                                                                                           
        weighted average remaining contractual life in years                                89                                                     
        weighted average fair value of options granted                                    617                                                      
        range of exercise prices for outstanding options at the end of year          415566                                                       

    grant x

    in june 2016 the company approved the grant to its employees under the existing esop plan 2000 the options under this grant would vest to the
    employees as 10 20 30 and 40 of the total grant at the end of first second third and fourth year from the date of grant respectively with an
    exercise period ending one year from the end of last vesting the vesting conditions include service terms and performance grade of the employees
    these options are exercisable at 50 of the closing price as per national stock exchange as on the preceding day to the date of grant

        particulars                                                                       march 31 2017                       march 31 2016
                                                                                      number of          weighted          number of          weighted
                                                                                        options           average            options           average
                                                                                                     exercise price                       exercise price
                                                                                                                                                   
        outstanding at the beginning of the year                                                                                                     
        granted during the year                                                         255000                388                                     
        forfeited during the year                                                         51250               373                                     
        exercised during the year                                                                                                                    
        expired during the year                                                                                                                      
        outstanding at the end of the year                                              203750                392                                     
        exercisable at the end of the year                                                                                                           
        weighted average remaining contractual life in years                                43                                                     
        weighted average fair value of options granted                                    442                                                      
        range of exercise prices for outstanding options at the end of year          371467                                                       




250       ahead of the curve  annual report 2017

                                                                                                                      biocon limited  subsidiaries



      assumptions used in determination of the fair value of the stock options under the black scholes model are as follows

      particulars                                                                                                          march 31 2017       march 31 2016
      weighted average exercise price                                                                                         388605              459461
      expected volatility                                                                                                  295 to 334       29 to 345
      historical volatility                                                                                                       3432               3418
      life of the options granted vesting and exercise period in years                                                           3065              3065
      expected dividends per share                                                                                                   500                  500
      average riskfree interest rate                                                                                              712                765
      expected dividend rate                                                                                                       110                110

      expected volatility is based on historical volatility of the market price of the companys publicly traded equity shares during the expected term of
      the option grant

b   rsu plan 2015

      on march 11 2015 biocons remuneration committee approved the biocon  restricted stock units rsus of syngene rsu plan 2015 for the grant
      of rsus to the employees of the company and its subsidiaries other than syngene the remuneration committee administers the plan through a trust
      established specifically for this purpose called the biocon limited employee welfare trust rsu trust for this purpose on march 31 2015 the
      company transferred 2000000 equity shares of syngene to rsu trust

      in april 2015 the company approved the grant to its employees under the rsu plan 2015 the rsus under this grant would vest to the employees
      as 10 20 30 and 40 of the total grant at the end of first second third and fourth year from the date of grant respectively with an exercise
      period ending one year from the end of last vesting the vesting conditions include service terms and performance grade of the employees exercise
      price of rsus will be nil

      particulars                                                                           march 31 2017                        march 31 2016
                                                                                        number of           weighted           number of            weighted
                                                                                            units            average               units             average
                                                                                                        exercise price                          exercise price
                                                                                                                                                         
      outstanding at the beginning of the year                                           1231803                                                          
      granted during the year                                                              193454                            1364148                      
      forfeited during the year                                                            117963                              132345                      
      exercised during the year                                                             10742                                                          
      expired during the year                                                                                                                              
      outstanding at the end of the year                                                 1296552                            1231803                      
      exercisable at the end of the year                                                    92320                                                          
      weighted average remaining contractual life in years                                    41                                  48                     
      weighted average fair value of options granted                                        468                                   162

      assumptions used in determination of the fair value of the stock options under the black scholes model are as follows

      particulars                                                                                                           march 31 2017      march 31 2016
      weighted average exercise price                                                                                                                            
      expected volatility                                                                                                 2992  4431              2992
      historical volatility                                                                                                       4431               2992
      life of the options granted vesting and exercise period in years                                                           5065              5065
      expected dividends per share                                                                                                       1                    1
      average riskfree interest rate                                                                                              712                765
      expected dividend rate                                                                                                       030                030

      expected volatility is based on historical volatility of the market price of the syngenes publicly traded equity shares during the expected term of the
      option grant

c   syngene esop plan

      on july 20 2012 syngene employee welfare trust trust was created for the welfare and benefit of the employees and directors of syngene the
      board of directors has approved the employee stock option plan of syngene on october 31 2012 the trust subscribed 1875000 equity shares face
      value of  5 per share of syngene using the proceeds from interest free loan of  150 obtained from syngene as at march 31 2017 the trust holds
      4513525 march 31 2016  5919219 march 31 2015  6680000 equity shares of face value of  10 each adjusted for the consolidation of
      shares and bonus issue as at march 31 2017 the trust transferred 2166475 march 31 2016  760781 march 31 2015  nil equity shares to the
      employees on exercise of their stock options




                                                                                                                              financial report            251

    grant

    pursuant to the scheme syngene has granted options to eligible employees of syngene under syngene employee stock option plan  2011 each
    option entitles for one equity share the options under this grant will vest to the employees as 25 35 and 40 of the total grant at end of
    second third and fourth year from the date of grant respectively with an exercise period of three years for each grant the vesting conditions include
    service terms and performance of the employees these options are exercisable at an exercise price of  2250 per share face value of  10 per
    share

    details of grant

        particulars                                                                             march 31 2017                        march 31 2016
                                                                                            number of            weighted          number of         weighted
                                                                                              options             average            options          average
                                                                                                             exercise price                      exercise price
                                                                                                                                                          
        outstanding at the beginning of the year                                            4942835                  225        5057100               225
        granted during the year                                                               166000                  225          930583               225
        forfeited during the year                                                              68684                  225          284067               225
        exercised during the year                                                           1405694                  225          760781               225
        outstanding at the end of the year                                                  3634457                  225        4942835               225
        exercisable at the end of the year                                                    668492                  225          434494               225
        weighted average remaining contractual life in years                                         14                               30                  
        weighted average fair value of options granted                                        4846                                3720                   
        weighted average share price at the date of exercise                                  5094                                3672                   

    assumptions used in determination of the fair value of the stock options under the black scholes model are as follows

        particulars                                                                                                            march 31 2017   march 31 2016
        dividend yield                                                                                                               03              03
        exercise price in                                                                                                            2250            2250
        volatility                                                                                                                     342            291
        life of the options granted vesting and exercise period                                                                        615              569
        average riskfree interest rate                                                                                                 67              75

                                                                                                                               march 31 2017   march 31 2016
        summary of movement in respect of the shares held by the esop trust is as follows
        opening balance                                                                                                            3876828        3674928
        add shares purchased by the esop trust                                                                                      152731           348163
        less shares exercised by employees                                                                                         499689        146263
        closing balance                                                                                                            3529870        3876828
        options granted and eligible for exercise at end of the year                                                                 286401           340888
        options granted but not eligible for exercise at end of the year                                                           3323649        3228326
        summary of movement in respect of equity shares of syngene held by the rsu trust is as follows
        opening balance                                                                                                            2000000        2000000
        less shares exercised by employees                                                                                          10742                 
        closing balance                                                                                                            1989258        2000000


                                                                                                                               march 31 2017   march 31 2016
        31 earnings per share eps
        earnings
        profit for the year attributable to the shareholders of the company                                                            6121             5504
        shares
        basic outstanding shares                                                                                                 200000000      200000000
        less weighted average shares held with the esop trust                                                                    3702196      3697436
        weighted average shares used for computing basic eps                                                                     196297804      196302564
        add effect of dilutive options granted but not yet exercised not yet eligible for exercise                               1376487           167870
        weighted average shares used for computing diluted eps                                                                   197674291      196470434
        earnings per share
               basic in                                                                                                             3118             2804
               diluted in                                                                                                           3097             2801



252        ahead of the curve  annual report 2017

                                                                                                                       biocon limited  subsidiaries



                                                                                                                           march 31 2017     march 31 2016
       32 exceptional items net
       impairment loss on intangible assets refer note a below                                                                                   1078
       recognition of deferred revenue refer note b below                                                                                          2684
       loss on account of fire refer note d below                                                                                  795                   
       less recoverable from insurance company                                                                                      795                   
                                                                                                                                                      1606

      a     pursuant to the uncertainty in respect of the ability of the group to license a product for development and commercialization in certain
              territories biocon sa recorded an impairment of the carrying value of the intangible asset amounting to  1078

      b     consequent to an agreement with a customer which resulted in changes to the nature of the groups future obligations on the rhinsulin
              program deferred revenue of  2684 relating to the program has been recognised as income in the consolidated financial statements for the
              year ended march 31 2016

      c     during the year ended march 31 2016 syngene international limited syngene completed its initial public offering ipo through an offer
              for sale of 22000000 equity shares of  10 each by the company gain arising from such sale of equity shares net of related expenses and
              cost of equity shares amounting to  3160 is recorded as credit in equity in the consolidated financial statements net off consequential tax of
               1042 on such gains

              mat credit on above transaction was not recorded in the previous year due to uncertainty of utilisation during the current year pursuant to
              change in the income tax law and other business restructuring the company believes that it will be able to utilize the mat credit entitlement
              accordingly during the year ended march 31 2017 the company has recorded mat credit entitlement of  1042 which is included in the
              income tax expense of the standalone financial statements however in the consolidated financial statements such entitlement is recognised
              as a credit in equity along with the underlying dilution gain on sale of equity stake in syngene as it did not impact groups control

      d     pursuant to a fire incident on december 12 2016 certain fixed assets inventory and other contents in one of the buildings at syngene was
              damaged syngene lodged an initial estimate of loss with the insurance company and the survey is currently ongoing during the year ended
              march 31 2017 syngene has written off the net book value of assets aggregating to  795 and recognised a minimum insurance claim receivable
              for an equivalent amount during the current year the group has received an initial disbursement of  200 from the insurance company and the
              same has been adjusted with the amount recoverable from the insurance company

              in addition the group is in the process of determining its claim for business interruption and has accordingly not recorded any claim arising
              therefrom at this stage

      e     during the current year biocon sa bsa and biocon sdn bhd biocon malaysia have entered into an assignment and license agreement
              pursuant to which bsa transferred all of its rights interests and obligations in insulin analogs ipr to biocon malaysia consequent to this
              transfer bsa recorded a net gain in its standalone books which is offered to tax under the swiss tax laws the above restructuring did not have
              any impact on consolidated financial statements except for an exceptional tax cost of  78 representing the tax payable by bsa locally which
              has been included within income tax expense for the year ended march 31 2017

33 disclosure on specified bank notes sbns
during the year the group had specified bank notes or other denomination note as defined in the mca notification gsr 308e dated march 30 2017 on
the details of specified bank notes sbn held and transacted during the period from november 8 2016 to december 30 2016 the denomination wise sbns
and other notes as per the notification is given below

                                                                                                                                                  amount in 

particulars                                                                                                       sbns            other                total
                                                                                                                            denomination
                                                                                                                                   notes


closing cash in hand as on november 8 2016                                                                    523000          1398946          1921946
 permitted receipts                                                                                                         1956642          1956642
 permitted payments                                                                                                        2556809       2556809
 amount deposited in banks                                                                                 523000                           523000
closing cash in hand as on december 30 2016                                                                                     798779            798779

 for the purposes of this clause the term specified bank notes shall have the same meaning provided in the notification of the government of india in
the ministry of finance department of economic affairs number so 3407e dated the november 8 2016




                                                                                                                              financial report           253

                                           34 related party transactions




254 
                                           related parties where control exists and related parties with whom transactions have taken place during the year are listed below
                                           sl name of the related party     relationship                       description of                april 1 2016 to         balance as at       april 1 2015 to     balance as at    balance as at
                                           no                                                                  transactions                  march 31 2017         march 31 2017        march 31 2016     march 31 2016    april 01 2015
                                                                                                                                          incomeexpenses              payable   incomeexpenses          payable       payable
                                                                                                                                            other transactions           receivable      other transactions       receivable       receivable
                                           a   remuneration paid to key management personnel refer note a below
                                           1   kiran mazumdarshaw          chairperson  managing director salary and perquisites                       20                                        16                                 
                                           2   john shaw                    vicechairman  director           salary and perquisites                    17                                        16                                 
                                           3   arun chandavarkar            joint managing director  ceo      salary and perquisites                    33                                        31                                 
                                           4   siddharth mittal             president  finance and chief salary and perquisites                         20                                        16                                 
                                                                             financial officer
                                           5   kiran kumar                  company secretary                  salary and perquisites                      7                                        6                                 
                                                                             upto dec 15 2016
                                           6   rajiv balakrishnan           company secretary                  salary and perquisites                      1                                                                           
                                                                             wef jan 24 2017
                                           b   others
                                           7   glentec international        enterprise owned     by       key rent expenses paid                                               1                                     1              1




ahead of the curve  annual report 2017
                                                limited                      management personnel
                                           8   biocon foundation            trust in which key management csr expenditure                               101                                        93                                 
                                                                             personnel are the board of
                                                                             trustees
                                           9   narayana hrudayalaya         enterprise in which a director sale of goods                                   41                                         52                                  
                                                limited formerly known      of the company is a member of trade receivables                                                     4                                       8                 5
                                                as narayana hrudayalaya      board of directors
                                                private limited

                                          a   the remuneration to key managerial personnel does not include the provisions made for gratuity and compensated absences as they are obtained on an actuarial basis for the company as a whole
                                          b   sharebased compensation expense allocable to key management personnel is  5 march 31 2016   10 which is not included in the remuneration disclosed above
                                          c   the above disclosures include related parties as per ind as 24 on related party disclosures and companies act 2013
                                          d   during the year there is no transaction with biocon india limited employees welfare trust trust in which key management personnel were the board of trustees
                                          e   all transactions with these related parties are priced on an arms length basis and none of the balances are secured
                                          f   the group has purchased consumables from mazumdar farms a proprietary firm of relative of director which are not disclosed above since the amounts are rounded off to rupees million




                                                                                                                          this space has been intentionally left blank

                                                                                                                     biocon limited  subsidiaries



                                                                                                        march 31 2017   march 31 2016   april 01 2015
35 contingent liabilities and commitments
to the extent not provided for
i     contingent liabilities
a     claims against the company not acknowledged as debt                                                      5272            5197             2840
the above includes
i     direct taxation                                                                                          4304            4132             1838
ii    indirect taxation includes matters pertaining to disputes on central excise custom duty and             575              668               610
        service tax
iii   other litigations                                                                                         393              397               392


the group is involved in taxation and other disputes lawsuits proceedings etc including patent and
commercial matters that arise from time to time in the ordinary course of business management is
of the view that above claims are not tenable and will not have any material adverse effect on the
groups financial position and results of operations


b     guarantees
i     corporate guarantees given to central excise department                                                   648              648               742
ii    guarantees given by banks on behalf of the group for contractual obligations of the group
                                                                                                                    20               60                65
ii commitments
a     estimated amount of contracts remaining to be executed on capital account and not provided
        for net of advances                                                                                     1925            2131             3313
b     operating lease commitments
where the company is a lessee
i     vehicles
the company has taken vehicles for certain employees under operating leases which expire over
a period upto january 2020 gross rental expenses for the year aggregate to  22 march 31 2016
  19
the committed lease rentals in future are as follows
not later than one year                                                                                             26               19                15
later than one year and not later than five years                                                                   36               33                27




                                                    this space has been intentionally left blank




                                                                                                                            financial report         255

36 employee benefit plans
i   the group has a defined benefit gratuity plan as per the payment of gratuity act 1972 for its employees in india under this legislation employee
      who has completed five years of service is entitled to specific benefit the level of benefit provided depends on the employees length of service and
      salary at retirementtermination age

      based on the actuarial valuation obtained in this respect the following table sets out the status of the gratuity plan and the amounts recognised in
      the groups financial statements as at balance sheet date

                                                                                                      defined benefit      fair value of       net defined
                                                                                                           obligation       plan assets             benefit
                                                                                                                                           assetliability
        balance as on april 01 2016                                                                              439               63               376
        current service cost                                                                                       54                                   54
        interest expenseincome                                                                                  33                5                 28
        amount recognised in statement of profit and loss                                                          87                5                 82
        remeasurements
        return on plan assets excluding amounts included in interest expense  income                                            2                 2
        actuarial gainloss arising from
          demographic assumptions                                                                                  3                                  3
          financial assumptions                                                                                    19                                   19
          experience adjustment                                                                                    43                                   43
        amount recognised in other comprehensive income                                                            59                2                 57
        employers contribution                                                                                                     24               24
        benefits paid                                                                                             34               34                    
        balance as at march 31 2017                                                                              551               60               491


                                                                                                      defined benefit      fair value of      net defined
                                                                                                           obligation       plan assets             benefit
                                                                                                                                           asset liability
        balance as on april 01 2015                                                                              353               79               274
        current service cost                                                                                       44                                   44
        interest expense income                                                                                 28                6                 22
        amount recognised in statement of profit and loss                                                          72                6                 66
        remeasurements
        return on plan assets excluding amounts included in interest expense income                                                                  
        actuarial gain loss arising from
        demographic assumptions                                                                                                                          
        financial assumptions                                                                                      10                                   10
        experience adjustment                                                                                      29                                   29
        amount recognised in other comprehensive income                                                            39                                   39
        employers contribution                                                                                                      3                 3
        benefits paid                                                                                             25               25                    
        balance as at march 31 2016                                                                              439               63               376


                                                                                                      march 31 2017     march 31 2016     april 01 2015
        noncurrent                                                                                               360               299                150
        current                                                                                                   131                77                124
                                                                                                                  491               376                274




                                                   this space has been intentionally left blank




256       ahead of the curve  annual report 2017

                                                                                                                        biocon limited  subsidiaries



ii    the assumptions used for gratuity valuation are as below

                                                                                                          march 31 2017     march 31 2016   april 01 2015
        interest rate                                                                                                69             75              88
        discount rate                                                                                                69             75              79
        expected return on plan assets                                                                               69             75              79
        salary increase                                                                                              90             90              90
        attrition rate                                                                                        7  30           7  26         7  26
        retirement age  years                                                                                         58               58                 58

        assumptions regarding future mortality experience are set in accordance with published statistics and mortality tables
        the weighted average duration of the defined benefit obligation was 8 years march 31 2016  8 years
        these defined benefit plans expose the group to actuarial risks such as longevity and interest rate risk
iii   sensitivity analysis
        the sensitivity of the defined benefit obligation to changes in the weighted principal assumptions are as below

        particulars                                                                            march 31 2017                       march 31 2016
                                                                                              increase          decrease           increase          decrease
        discount rate                                                                             26                 29              18                20
        salary increase                                                                             28                26              20               18
        attrition rate                                                                              4                 5               2                 3

        sensitivity of significant actuarial assumptions is computed by varying one actuarial assumption used for the valuation of defined benefit obligation
        by one percentage keeping all other actuarial assumptions constant although the analysis does not take account of the full distribution of the cash
        flows expected under the plan it does provide an approximation of the sensitivity of the assumptions shown
        as of march 31 2017 and march 31 2016 the plan assets have been invested in insurer managed funds and the expected contribution to the fund
        during the year ending march 31 2018 is approximately  95 march 31 2017   77

        maturity profile of defined benefit obligation

        particulars                                                                                                                                   million
        1st following year                                                                                                                                 95
        2nd following year                                                                                                                                 68
        3rd following year                                                                                                                                 61
        4th following year                                                                                                                                 67
        5th following year                                                                                                                                 51
        years 6 to 10                                                                                                                                    211

37 business combinations
during the year ended march 31 2016 the group acquired the business of pharmaceutical manufacturing unit of ms acacia lifesciences private limited
located at vishakhapatnam with effect from october 01 2015 on a going concern basis for a consideration of  531 paid in cash the transaction was
accounted under ind as 103 business combinations as a business combination with the purchase price being allocated to identifiable assets and liabilities
at fair value

following table presents the allocation of purchase price

 particulars                                                                                                                                          amount
 net tangible assets                                                                                                                                     454
 customer related intangibles                                                                                                                              77
 total purchase price                                                                                                                                    531




                                                      this space has been intentionally left blank




                                                                                                                               financial report          257

38 financial instruments fair value and risk managements
a accounting classification and fair values

                                                       carrying amount                               fair value
march 31 2017                                 fvtpl   fvtoci      amortised    total   level 1   level 2         level 3    total
                                                                        cost
financial assets
noncurrent investments                                              1458    1458                                         
derivative assets                                71     2080                  2151             2151                    2151
current investments                            8530                  2120   10650    8530                             8530
trade receivables                                                    8832    8832                                         
cash and cash equivalents                                            7102    7102                                         
other bank balances                                                  3341    3341                                         
other financial assets                                               1748    1748                                         
                                               8601    2080        24601    35282    8530     2151                   10681
financial liabilities
borrowings                                                         22054    22054                                         
trade payables                                                       7397    7397                                         
derivative liability                                         124                124                124                     124
other financial liabilities                                          3263    3263                                         
                                                            124     32714    32838               124                     124


march 31 2016                                 fvtpl   fvtoci      amortised    total   level 1   level 2         level 3    total
                                                                        cost
financial assets
derivative assets                               332          793               1125             1125                    1125
current investments                            4327                 4420     8747    4327                             4327
trade receivables                                                   7145     7145                                         
cash and cash equivalents                                           7613     7613                                         
other bank balances                                                 7773     7773                                         
other financial assets                                              2102     2102                                         
                                               4659         793     29053    34505    4327     1125                    5452
financial liabilities
borrowings                                                         24673    24673                                         
trade payables                                                      6098     6098                                         
derivative liability                             71          263                334                334                     334
other financial liabilities                                         1967     1967                                         
                                                 71          263     32738    33072               334                     334


april 01 2015                                 fvtpl   fvtoci      amortised    total   level 1   level 2         level 3    total
                                                                        cost
financial assets
derivative assets                               403          821               1224             1224                    1224
current investments                            2478                          2478    2478                             2478
trade receivables                                                   6833     6833                                         
cash and cash equivalents                                           4575     4575                                         
other bank balances                                                 4629     4629                                         
other financial assets                                                 661     661                                          
                                               2881         821     16698    20400    2478     1224                    3702
financial liabilities
borrowings                                                         10281    10281                                         
trade payables                                                      4126     4126                                         
derivative liability                            302                            302                302                     302
other financial liabilities                                         4422     4422                                         
                                                302                 18829    19131               302                     302




258       ahead of the curve  annual report 2017

                                                                                                                            biocon limited  subsidiaries



b measurement of fair values
fair value of liquid mutual funds are based on quoted price derivative financial instruments are valued based on quoted prices for similar assets and
liabilities in active markets or inputs that are directly or indirectly observable in the market place
sensitivity analysis
for the fair values of forward contracts of foreign currencies reasonably possible changes at the reporting date to one of the significant observable inputs
holding other inputs constant would have the following effects

                                                                                                  march 31 2017                         march 31 2016
                                                                                                  profit or loss                       profit or loss
 significant observable inputs                                                                   increase            decrease           increase            decrease
 spot rate of the foreign currency 1 movement                                                    222                223               173                187
 interest rates 100 bps movement                                                                  312                312               215                215

c financial risk management

the group has exposure to the following risks arising from financial instruments

 credit risk

 liquidity risk

 market risk

risk management framework

the groups risk management is carried out by the treasury department under policies approved by the board of directors the board provides written
principles for overall risk management as well as policies covering specific areas such as foreign exchange risk interest rate risk credit risk use of derivative
and nonderivative financial instruments and investment of excess liquidity

i    credit risk

       credit risk is the risk that the counterparty will not meet its obligation under a financial instrument or customer contract leading to financial loss the
       credit risk arises principally from its operating activities primarily trade receivables and from its financing activities including deposits with banks
       and financial institutions and other financial instruments

       customer credit risk is managed by each business unit subject to groups established policy procedures and control relating to customer credit
       risk management the audit and risk management committee of the respective companys has established a credit policy under which each new
       customer is analysed individually for creditworthiness before the groups standard payment and delivery terms and conditions are offered the
       groups review includes external ratings where available and other publicly available financial information outstanding customer receivables are
       regularly monitored and any shipments to major customers are generally covered by letters of credit or other forms of credit insurance

       the group establishes an allowance for impairment that represents its estimate of expected losses in respect of trade and other receivables the
       maximum exposure to credit risk as at reporting date is primarily from trade receivables amounting to  8832 march 31 2016   7145 april 01
       2015   6833 the movement in allowance for impairment in respect of trade and other receivables during the year was as follows

       allowance for credit loss                                                                                                march 31 2017     march 31 2016
       opening balance                                                                                                                        56                 90
       allowance for credit loss recognised  reversed                                                                                      34                34
       closing balance                                                                                                                        90                 56

       no single customer accounted for more than 10 of the trade receivables as of march 31 2017 and 2016 there is no significant concentration of
       credit risk

       credit risk on cash and cash equivalent and derivatives is limited as the group generally transacts with banks and financial institutions with high credit
       ratings assigned by international and domestic credit rating agencies investments primarily include investment in liquid mutual fund units bonds and
       nonconvertible debentures

ii   liquidity risk

       liquidity risk is the risk that the group will encounter difficulty in meeting the obligations associated with its financial liabilities that are settled
       by delivering cash or another financial asset the groups approach to managing liquidity is to ensure as far as possible that it will have sufficient
       liquidity to meet its liabilities when they are due under both normal and stressed conditions without incurring unacceptable losses or risking damage
       to the companys reputation




                                                                                                                                   financial report            259

        the group believes that the working capital is sufficient to meet its current requirements accordingly no liquidity risk is perceived in addition the
        group maintains the following line of credit

        a      syngene has obtained long term secured buyers credit loans of  611 usd 941 million march 31 2016   624 usd 941 million as of
                 march 31 2017 carrying interest rate in the range of libor  060 pa to libor  080 pa and are repayable at end of 960 days to 1079
                 days from the date of its origination

        b      syngene has obtained short term secured preshipment credit loans of  324 usd 5 million march 31 2016  nil that carries interest rate of
                 libor  142 pa and is repayable after the end of 6 months from the date of its origination

        c      syngene has obtained short term unsecured preshipment credit loans of  648 usd 10 million march 31 2016  nil that carries interest rate
                 of libor  142 pa and is repayable after the end of 6 months from the date of its origination

        d      cash credit facility from banks carrying interest rate ranging from 97  13 pa these facilities were repayable on demand and secured by
                 paripassu charge on inventories and trade receivables

        e      bpl has obtained unsecured overdraft facility from a bank carrying interest rate of 925 pa

        the table below provides details regarding the undiscounted contractual maturities of significant financial liabilities as of march 31 2017

         particulars                                                 less than 1 year         12 years           25 years        57 years              total
         longterm borrowings                                                    971              3418             15230             2434            22053
         shortterm borrowings                                                   972                                                                    972
         trade payables                                                        7397                                                                   7397
         other financial liabilities                                           2353                 63                                                 2416
         total                                                                11693              3481             15230             2434            32838

        the table below provides details regarding the undiscounted contractual maturities of significant financial liabilities as of march 31 2016

         particulars                                                 less than 1 year         12 years           25 years        57 years              total
         longterm borrowings                                                    104               871              14773             5080            20828
         shortterm borrowings                                                 3949                                                                   3949
         trade payables                                                        6098                                                                   6098
         other financial liabilities                                           2003               194                                                  2197
         total                                                                12154              1065             14773             5080            33072

        the table below provides details regarding the undiscounted contractual maturities of significant financial liabilities as of april 01 2015

         particulars                                                 less than 1 year         12 years           25 years        57 years              total
         longterm borrowings                                                    866              1435              4692             1544              8537
         shortterm borrowings                                                 2610                                                                   2610
         trade payables                                                        4126                                                                   4126
         other financial liabilities                                           3680               178                                                  3858
         total                                                                11282              1613              4692             1544            19131

iii   market risk

        market risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market prices such as
        foreign exchange rates interest rates and equity prices

        foreign currency risk

        the group operates internationally and a major portion of the business is transacted in several currencies and consequently the group is exposed
        to foreign exchange risk through operating and borrowing activities in foreign currency the group holds derivative instruments such as foreign
        exchange forward and option contracts to mitigate the risk of changes in exchange rates and foreign currency exposure




                                                       this space has been intentionally left blank




260          ahead of the curve  annual report 2017

                                                                                                                 biocon limited  subsidiaries



the currency profile of financial assets and financial liabilities as at march 31 2017 and march 31 2016 are as below

march 31 2017                                                                            usd                  eur             others                 total
financial assets
trade receivables                                                                       4098                  299                279                4676
cash and cash equivalents                                                               4075                  196                 83                4354
other financial assets                                                                  1051                   23                276                1350
financial liabilities
noncurrent borrowings                                                               21054                                                   21054
current borrowings                                                                       972                                                     972
derivative liability                                                                     124                                                     124
trade payables                                                                         1528                527             983              3038
other financial liabilities                                                            2069                221               53             2343
net financial assets liabilities                                                  16523                 230             398             17151


march 31 2016                                                                            usd                  eur             others                 total
financial assets
trade receivables                                                                       4517                  395                 11                4923
cash and cash equivalents                                                               2996                  306                 60                3362
other financial assets                                                                  1589                   32                                  1621
financial liabilities
noncurrent borrowings                                                               20685                                                   20685
current borrowings                                                                     3911                                                   3911
derivative liability                                                                     236                                                     236
trade payables                                                                         1733                393             414              2540
other financial liabilities                                                              616                  8               18               642
net financial assets liabilities                                                  18079                  332              361             18108

sensitivity analysis

the sensitivity of profit or loss to changes in exchange rates arises mainly from foreign currency denominated financial instruments and the impact
on other components of equity arises from foreign exchange forwardoption contracts designated as cash flow hedges

particulars                                                                        impact on profit or loss                  impact on other
                                                                                                                           components of equity
                                                                              march 31 2017     march 31 2016       march 31 2017     march 31 2016
usd sensitivity
inrusd  increase by 1                                                                 165                181             387                354
inrusd  decrease by 1                                                                  165                  181                388                  368
eur sensitivity
inreur  increase by 1                                                                   2                   3                 2                   3
inreur  decrease by 1                                                                     2                  3                 2                   3

derivative financial instruments

the following table gives details in respect of outstanding foreign exchange forward and option contracts

particulars                                                                                                           march 31 2017     march 31 2016
                                                                                                                                 in million
foreign exchange forward contracts to buy                                                                                     usd 30               usd 34
                                                                                                                           inr 1946          inr 2722
european style option contracts with periodical maturity dates                                                               usd 320              usd 386
                                                                                                                        inr 20703        inr 25581
european style option contracts with periodical maturity dates                                                                 usd 2                usd 8
 conversion to myr                                                                                                           inr 97           inr 530
european style option contracts with periodical maturity dates                                                                  eur 6              eur 12
                                                                                                                            inr 434            inr 899




                                                                                                                        financial report              261

      cash flow and fair value interest rate risk

      the companys main interest rate risk arises from longterm borrowings with variable rates which expose the company to cash flow interest rate risk
      during the year ended march 31 2017 and march 31 2016 the companys borrowings at variable rate were mainly denominated in usd

      a     interest rate risk exposure

              the exposure of the companys borrowing to interest rate changes at the end of the reporting period are as follows

              particulars                                                                                march 31 2017     march 31 2016       april 01 2015
              variable rate borrowings                                                                            22989             24732             11098
              fixed rate borrowings                                                                                    36                 45                 49
              total borrowings                                                                                    23025             24777             11147

      b     sensitivity

              the company policy is to maintain most of its borrowings at fixed rate using interest rate swaps to achieve this when necessary they are
              therefore not subject to interest rate risk as defined under ind as 107 since neither the carrying amount nor the future cash flows will fluctuate
              because of change in market interest rates

39 capital management
the key objective of the groups capital management is to ensure that it maintains a stable capital structure with the focus on total equity to uphold investor
creditor and customer confidence and to ensure future development of its business the group focused on keeping strong total equity base to ensure
independence security as well as a high financial flexibility for potential future borrowings if required without impacting the risk profile of the group

the companys goal is to continue to be able to return excess liquidity to shareholders by continuing to distribute annual dividends in future periods

the amount of future dividends of equity shares will be balanced with efforts to continue to maintain an adequate liquidity status

the capital structure as of march 31 2017 and 2016 was as follows

particulars                                                                                                                 march 31 2017     march 31 2016
total equity attributable to owners of the company                                                                                   48377             40338
as a percentage of total capital                                                                                                       68                62
longterm borrowings                                                                                                                 22053             20828
shortterm borrowings                                                                                                                   972              3949
total borrowings                                                                                                                     23025             24777
as a percentage of total capital                                                                                                       32                38
total capital equity and borrowings                                                                                                71402             65115

40   firsttime adoption of ind as
these consolidated financial statements have been prepared in accordance with the ind as for the purpose of transition from previous gaap to ind as the
group has followed the guidance prescribed under ind as 101  first time adoption of indian accounting standards ind as 101 with effect from april
01 2015 transition date

in preparing its ind as balance sheet as at april 1 2015 and in presenting the comparative information for the year ended march 31 2016 the group
has adjusted amounts reported previously in financial statements prepared in accordance with previous gaap this note explains how the transition from
previous gaap to ind as has affected the groups balance sheet financial performance

a   optional exemptions availed and mandatory exceptions

      in preparing these consolidated financial statements the group has applied the below mentioned optional exemptions and mandatory exceptions

      optional exemptions availed

      1     deemed cost

              joint ventures

              as per ind as 101 when changing from proportionate consolidation method to equity method an entity may measure its investment in a joint
              venture at date of transition at the aggregate of the carrying amounts of the assets and liabilities that the entity had previously proportionately
              consolidated including any goodwill arising from acquisition the resultant amount is regarded as the deemed cost of the investment in the
              joint venture at initial recognition the group has opted to avail this exemption

      2     business combination

              ind as 101 provides the option to apply ind as 103 business combinations prospectively from the transition date or from a specific date prior
              to the transition date




262        ahead of the curve  annual report 2017

                                                                                                                biocon limited  subsidiaries



      the group has elected to apply ind as 103 prospectively to business combinations occurring after its transition date business combinations
      occurring prior to the transition date has not been restated

3   share based payments

      ind as 102 sharebased payment has not been applied to equity instruments in sharebased payment transactions that vested before april 1
      2014 for cashsettled sharebased payment transactions the group has not applied ind as 102 to liabilities that were settled before april 1
      2014

      mandatory exemptions availed

      1   estimates

            as per ind as 101 an entitys estimates in accordance with ind as at the date of transition to ind as shall be consistent with estimates
            made for the same date in accordance with the previous gaap unless there is objective evidence that those estimates were in error

            the groups estimates under ind as are consistent with the above requirement key estimates considered in preparation of the financial
            statements that were not required under the previous gaap are listed below

             fair valuation of financial instruments carried at fvtpl and or fvoci

             impairment of financial assets based on the expected credit loss model

             determination of the discounted value for financial instruments carried at amortised cost

      2   classification and measurement of financial assets

            ind as 101 requires an entity to assess classification of financial assets on the basis of facts and circumstances existing as on the date of
            transition further the standard permits measurement of financial assets accounted at amortised cost based on facts and circumstances
            existing at the date of transition if retrospective application is impracticable

            accordingly the group has determined the classification of financial assets based on facts and circumstances that exist on the date of
            transition measurement of the financial assets accounted at amortised cost has been done retrospectively except where the same is
            impracticable

      3   hedge accounting

            hedge accounting can only be applied prospectively from the transition date to transactions that satisfy the hedge accounting criteria
            in ind as 109 financial instruments at the date of transition hedging relationships cannot be designated retrospectively and the
            supporting documentation cannot be created retrospectively as a result only hedging relationships that satisfied the hedge accounting
            criteria as on the date of transition are reflected as hedges in the consolidated financial statements under ind as




                                             this space has been intentionally left blank




                                                                                                                       financial report           263

b   reconciliations

      the following reconciliations provides the effect of transition to ind as from previous gaap in accordance with ind as 101  firsttime adoption of
      ind as
                                                                                                      previous gaap        adjustments              ind as
i reconciliation of equity as at april 01 2015
assets
noncurrent assets
property plant and equipment                                                                                 15807               175             15982
capital workinprogress                                                                                      14938               644             15582
investment property                                                                                                                11                 11
goodwill                                                                                                         264                                 264
other intangible assets                                                                                          228                                 228
intangible assets under development                                                                            1828              110             1718
investment in associates and a joint venture                                                                                      384                384
financial assets
i derivative assets                                                                                          1143              269               874
ii other financial assets                                                                                      303              110               193
incometax assets net                                                                                          935                45              890
deferred tax assets net                                                                                        142               178                320
other noncurrent assets                                                                                       2123                               2123
total noncurrent assets                                                                                      37711               858             38569
current assets
inventories                                                                                                    4527                229             4756
financial assets
i investments                                                                                                2303                175             2478
ii trade receivables                                                                                         7705              872             6833
iii cash and cash equivalent                                                                                 4626                51            4575
iv other bank balances                                                                                       4749              120             4629
v derivative assets                                                                                            561              211               350
vi other financial assets                                                                                      532                64              468
other current assets                                                                                             623                 38               661
total current assets                                                                                          25626              876            24750
total                                                                                                         63337               18            63319

equity and liabilities
equity
equity share capital                                                                                           1000                               1000
other equity                                                                                                  31706                84           31622
equity attributable to owners of the company                                                                  32706               84            32622
noncontrolling interests                                                                                      1722              601             1121
total equity                                                                                                  34428              685            33743
noncurrent liabilities
financial liabilities
i borrowings                                                                                                 7696                25            7671
ii derivative liability                                                                                                          174               174
iii other financial liabilities                                                                                  6                                   6
provisions                                                                                                       150                                 150
other noncurrent liabilities                                                                                  5510                 91             5601
total noncurrent liabilities                                                                                 13362                240            13602
current liabilities
financial liabilities
i borrowings                                                                                                 2610                               2610
ii trade payables                                                                                            4293              167             4126
iii derivative liability                                                                                                        128                128
iv other financial liabilities                                                                               4323                 93             4416
provisions                                                                                                       284               114                398
income tax liability net                                                                                       298               311                609
other current liabilities                                                                                      3739                52            3687
total current liabilities                                                                                     15547               427             15974
total                                                                                                         63337               18            63319



264       ahead of the curve  annual report 2017

                                                                biocon limited  subsidiaries



                                                     previous gaap   adjustments        ind as
ii reconciliation of equity as at march 31 2016
assets
noncurrent assets
property plant and equipment                              16539           272         16811
capital workinprogress                                   19989           608         20597
investment property                                                          9             9
goodwill                                                      264                        264
other intangible assets                                       423           15          408
intangible assets under development                         1886           88         1798
investment in associates and a joint venture                               259           259
financial assets
i derivative assets                                         823          209          614
ii other financial assets                                   340           82          258
incometax assets net                                       906           54          852
deferred tax assets net                                     379           336           715
other noncurrent assets                                    2489          202         2287
total noncurrent assets                                   44038           834         44872
current assets
inventories                                                 5114           310          5424
financial assets
i investments                                             8705            42          8747
ii trade receivables                                      8229        1084         7145
iii cash and cash equivalent                              7944          331         7613
iv other bank balances                                    7349           424          7773
v derivative assets                                         650          139          511
vi other financial assets                                 1789            55          1844
other current assets                                          652                        652
total current assets                                       40432          723        39709
total                                                      84470           111         84581


equity and liabilities
equity
equity share capital                                        1000                       1000
other equity                                               39556          218        39338
equity attributable to owners of the company               40556          218        40338
noncontrolling interests                                   3112          454         2658
total equity                                               43668          672        42996


noncurrent liabilities
financial liabilities
i borrowings                                             20724                      20724
ii derivative liability                                                  191           191
iii other financial liabilities                               5            2            3
provisions                                                    299                        299
other noncurrent liabilities                               3498           213          3711
total noncurrent liabilities                              24526           402         24928
current liabilities
financial liabilities
i borrowings                                              3949                       3949
ii trade payables                                         6300          202         6098
iii derivative liability                                                 143           143
iv other financial liabilities                            1881            83          1964
provisions                                                    270           104           374
income tax liability net                                    607           358           965
other current liabilities                                   3269          105         3164
total current liabilities                                  16276           381         16657
total                                                      84470           111         84581




                                                                     financial report     265

                                                                                           previous gaap         adjustments           ind as
iii reconciliation of statement of profit and loss for the year ended march 31 2016
income
revenue from operations                                                                           34854              1044          33810
other income                                                                                          845                53             792
total income                                                                                      35699              1097          34602


expenses
cost of raw materials and packing materials consumed                                              12549                              12549
purchases of traded goods                                                                           1070               310             760
increase decrease in inventories of finished goods traded goods and workinprogress            318                87           405
excise duty                                                                                                             336              336
employee benefits expense                                                                           6363               262           6101
finance costs                                                                                         102                191              293
depreciation and amortisation net                                                                 2423                 64            2487
other expenses                                                                                      8310               199           8111
                                                                                                  30499                267          30232
less recovery of product development costs from codevelopment partners net                    1320                             1320
total expenses                                                                                    29179                267          28912
profit before tax share of profit and exceptional item                                             6520               830           5690
share in net profit of joint venture                                                                                    217              217
profit before tax and exceptional item                                                              6520               613           5907
exceptional item net                                                                              5754             4148           1606
profit before tax                                                                                 12274              4761           7513
tax expenses
current tax                                                                                         2806               993           1813
less mat credit entitlement                                                                        166                              166
deferred tax                                                                                          71              154           225
total tax expense                                                                                   2569             1147           1422
profit for the year                                                                                 9705             3614           6091
other comprehensive income
i items that will not be subsequently reclassified to profit or loss
remeasurement gainslosses on defined benefit plans                                                                  39             39
income tax effect                                                                                                         9                9
                                                                                                                        30             30
ii items that may be subsequently reclassified to profit or loss
net movement on cash flow hedges                                                                                        21             21
income tax effect                                                                                                        5              5
                                                                                                                        26             26
total other comprehensive income for the year net of tax                                                               56             56


total comprehensive income for the year                                                             9705             3670           6035


iv reconciliation of total equity
                                                                                                     note      march 31 2016   april 01 2015
equity under previous gaap attributable to shareholders of the company                                                40556           32706
adjustments
difference on account of revenue recognition net of related costs                                       i            752           552
impact of derivative accounting translations adjustments and exchange gainloss               ii  viii             297              171
impact of borrowing cost                                                                               iii            152                
consolidation of esop trust                                                                             x              475              526
other adjustments                                                                                      iv              24             47
income tax on above adjustments and corrections for earlier years                                      vi              62           182
total adjustments                                                                                                       218             84
equity under ind as attributable to shareholders of the company                                                       40338           32622




266       ahead of the curve  annual report 2017

                                                                                                                     biocon limited  subsidiaries



 v reconciliation of the net profit


 net profit reconciliation                                                                                                     note             year ended
                                                                                                                                            march 31 2016
 net profit attributable to owners of the company as per previous gaap a                                                                            8961
 adjustments
 difference on account of revenue recognition net of related costs                                                             i                   230
 impact of derivative accounting and exchange gainloss                                                                         ii                       3
 impact of borrowing cost                                                                                                      iii                  152
 other adjustments                                                                                                             iv                     59
 impact on profit on sale of syngene shares net of tax                                                                         v                 3106
 income tax impact of above adjustments and corrections for earlier years                                                      vi                      87
 total adjustments b                                                                                                                              3457
 profit for the year c ab                                                                                                                         5504
 other comprehensive income oci
 actuarial loss on defined benefit obligations  gratuity                                                                      vii                    30
 effective portion of cash flow hedges                                                                                         viii                   26
 noncontrolling interest                                                                                                      ix                      2
 subtotal d                                                                                                                                         58
 total comprehensive income for the year c  d                                                                                                      5446

notes to reconciliation

i     difference on account of revenue recognition net of related costs is primarily due to difference in timing of revenue recognition under ind as as
        compared to previous gaap and deferral of licensing income on account of continuing obligations

ii    impact due to derivative accounting as per ind as 109 and exchange gains and losses on account of change in functional currency of a subsidiary

iii   impact on account of restructuring of debt

iv    other adjustments on account of employee benefit expenses share based payments actuarial gainslosses mark to market adjustments on mutual
        funds

v     profit on sale of syngene shares recognised as a credit in equity as it did not impact groups control

vi    income tax impact of above adjustments and corrections for earlier years

vii   actuarial loss on defined benefit obligations gratuity taken to other comprehensive income under ind as as compared to statement of profit and loss
        under previous gaap

viii effective portion of cash flow hedges taken to other comprehensive income

ix    impact of ind as adjustments on noncontrolling interest

x     the group has consolidated the esop trust and deconsolidated neobiocon fz llc pursuant to ind as  110 on consolidated financial statements




                                                      this space has been intentionally left blank




                                                                                                                            financial report           267

41 tax expenses
                                                                                                       march 31 2017   march 31 2016
a     amount recognised in statement of profit and loss
        current tax                                                                                            2082            1813
        mat credit entitlement                                                                                  369            166
        deferred tax expense  income related to
        origination and reversal of temporary differences                                                        97            225
        tax expense for the year                                                                               1616            1422


b     reconciliation of effective tax rate
        profit before tax                                                                                      8497            7513
        less exceptional items net                                                                                          1606
        profit before tax and exceptional item                                                                 8497            5907
        tax at statutory income tax rate 3461 march 31 2016  3461                                      2941            2044


        tax effects of amounts which are not deductibletaxable in calculating taxable income
        difference in overseas tax rates                                                                         203              26
        weighted deduction on research and development expenditure                                              520            432
        exempt income and other deductions                                                                    1020          1086
        nondeductible expense                                                                                   123               82
        tax losses                                                                                              237             499
        tax on exceptional items                                                                                  78              123
        share in profit of joint venture                                                                         56             75
        others                                                                                                   104              293
        income tax expense                                                                                     1616            1422


c     tax losses
        unused tax losses for which no deferred tax asset has been recognised                                  1809            2519
        potential tax impact                                                                                     350              647
        expiry date financial year                                                                      202223 to       202223 to
                                                                                                            202324          202324
        tax losses which will never expire                                                                                       166




                                                      this space has been intentionally left blank




268       ahead of the curve  annual report 2017

                                                                                                                  biocon limited  subsidiaries



d   recognised deferred tax assets and liabilities
      the following is the movement of deferred tax assets  liabilities presented in the consolidated balance sheet
      for the year ended                                               opening      recognised in       recognised      recognised        closing
      march 31 2017                                                   balance       profit or loss          in oci       in equity       balance
      deferred tax liability
      property plant and equipment investment property                   686                  1                                        685
      and intangible assets
      derivative assets                                                                                       201                         201
      others                                                                                   30                                          30
      gross deferred tax liability                                         686                  29              201                         916
      deferred tax assets
      defined benefit obligations                                          168                  1              15                         182
      allowance for doubtful debts                                           14                  6                                          20
      other disallowable expenses                                          145                  24                                         169
      deferred revenue                                                     162               162                                            
      mat credit entitlement                                               702                369                           1042         2113
      derivative liability                                                   91               29              62                           
      tax losses                                                                             262                                          262
      others                                                               119                  26                                         145
      gross deferred tax assets                                           1401               495               47         1042         2891
                                                                           715                466              248         1042         1975


      for the year ended                                               opening      recognised in       recognised      recognised        closing
      march 31 2016                                                   balance       profit or loss          in oci       in equity       balance
      deferred tax liability
      property plant and equipment investment property                   692                  6                                        686
      and intangible assets
      derivative assets                                                      48               48                                            
      gross deferred tax liability                                         740                54                                         686
      deferred tax assets
      defined benefit obligations                                          237                78                 9                        168
      allowance for doubtful debts                                           29               15                                          14
      other disallowable expenses                                            80                 65                                         145
      deferred revenue                                                       69                 93                                         162
      mat credit entitlement                                               536                166                                          702
      derivative liability                                                                     96               5                         91
      tax losses                                                                                                                            
      others                                                               109                  10                                         119
      gross deferred tax assets                                           1060               337                  4                      1401
                                                                           320                391                  4                        715




                                                  this space has been intentionally left blank




                                                                                                                       financial report     269

42 interest in other entities
a subsidiaries

the groups subsidiaries as at march 31 2017 are set out below unless otherwise stated they have share capital consisting solely of equity shares that
are held by the group and proportion of ownership interests held equals the voting rights held by the group the country of incorporation or registration
is also their principal place of business

name of entity                    country of       ownership interest held by the      ownership interest held by the           principal activities
                                  incorporation               group                      noncontrolling interest
                                                     march       march     april 01     march      march     april 01
                                                   31 2017    31 2016       2015     31 2017   31 2016       2015
                                                                                                               
syngene international limited     india                 735       735        845        265       265        155 research services
biocon research limited           india               1000       1000      1000                                   research and development
biocon pharma limited             india               1000       1000      1000                                   biopharmaceutical manufacturing
biocon biologics india limited    india               1000          nil         nil                                 biopharmaceutical manufacturing
biocon academy                    india               1000       1000      1000                                   not for profit organisation
biocon sa                         switzerland         1000       1000      1000                                   research and development
biocon sdn bhd                    malaysia            1000       1000      1000                                   biopharmaceutical manufacturing
biocon biologics limited          united              1000       1000          nil                                 sale of biosimilar products
                                  kingdom
biocon pharma inc                united states       1000       1000          nil                                 sale of pharmaceutical products
biocon fz llc                    dubai               1000       1000          nil                                 trading of biopharmaceutical
                                                                                                                        products

b noncontrolling interests

below is the summarised financial information for syngene international limited that has noncontrolling interests that is material to the group the amounts
disclosed for the subsidiary are before intercompany eliminations

summarised balance sheet

particulars                                                                                           march 31 2017      march 31 2016     april 01 2015
noncurrent assets                                                                                             12507             10208                8145
current assets                                                                                                 15231             13347                5535
total assets                                                                                                   27738             23555               13680
noncurrent liabilities                                                                                          7614             7968                  971
current liabilities                                                                                              5993             5340                4752
total liabilities                                                                                              13607             13308                5723
net assets                                                                                                     14131             10247                7957
accumulated noncontrolling interest                                                                            3761              2658                1121
summarised statement of profit and loss
particulars                                                                                                               march 31 2017    march 31 2016
revenue from operations                                                                                                           12009               11070
profit for the year                                                                                                                2873                2408
other comprehensive income                                                                                                           848                    6
total comprehensive income                                                                                                         3721                2414
total comprehensive income allocated to noncontrolling interests                                                                    984                  589
dividends paid to noncontrolling interests                                                                                                               53

summarised statement of cash flows
particulars                                                                                                               march 31 2017    march 31 2016
cash flows from used in operating activities                                                                                    3977                3081
cash flows from used in investing activities                                                                                   4691              7512
cash flows from used in financing activities                                                                                     808               7161
net increase decrease in cash and cash equivalents                                                                             1522               2730




270       ahead of the curve  annual report 2017

                                                                                                                 biocon limited  subsidiaries



c interest in joint venture

the group had only one joint venture in the name of neobiocon fz llc neobiocon  incorporated in dubai as at march 31 2017 holding 49 march 31
2016  51 of the equity stake and accounted for using the equity method in the opinion of the directors is material to the group neobiocon has share
capital solely consisting of equity shares which are held directly by ownership interest in the same proportion of voting rights held

summarised balance sheet of neobiocon is as follows

particulars                                                                                        march 31 2017    march 31 2016      april 01 2015
noncurrent assets                                                                                              14                20                 7
current assets                                                                                               1266               878             1032
total assets                                                                                                 1280               898             1039
noncurrent liabilities                                                                                         34                25                16
current liabilities                                                                                            299               235               204
total liabilities                                                                                              333               260               220

net assets                                                                                                     947               638               819
percentage ownership interest                                                                                 49               51               51
accumulated groups share of net assets                                                                        422               259               384
summarised statement of profit and loss of neobiocon
particulars                                                                                                          march 31 2017     march 31 2016
revenue from operations                                                                                                        1250             1196
profit for the year                                                                                                              333               425
other comprehensive income                                                                                                                           
total comprehensive income                                                                                                       333               425
share of profits from joint venture                                                                                              163               217
dividends received                                                                                                                                342




                                                  this space has been intentionally left blank




                                                                                                                        financial report          271

43 segment reporting
based on the management approach as defined in ind as 108 the chief operating decision maker codm evaluates the groups performance based
on an analysis of various performance indicators by business segments and geographic segments accordingly information has been presented both along
business segments and geographic segments the accounting principles used in the preparation of the financial statements are consistently applied to
record revenue and expenditure in individual segments and are as set out in the significant accounting policies

business segments of the group are primarily enterprises in small molecules smv  biologics branded formulations bf and research services
research

april 1 2016 to march 31 2017

particulars                                     smv         biologics             bf       research     unallocated     eliminations           total
revenues
external revenue                              16330           5793           5489         11604                                        39216
intersegment revenue                             75           1225                           321                         1621               
total revenues                                16405           7018           5489         11925                         1621         39216
costs
segment costs                               11511          4641        3886         7849                                     27887
intersegment costs                                           321         1300                                        1621                
results
corporate expenses                                                                                       1534                        1534
other income including interest                                                              707             864                          1571
operating profit                                                                                                                             11366
depreciation amortisation                      752          659              3        1143           215                        2772
finance costs                                                                               175            85                         260
share of profit of joint venture                                              163                                                          163
segment results                                4142           1397            463           3465            970                         8497
income taxes  current and deferred                                                                      1616                        1616
noncontrolling interests                                                                                  760                         760
profit after taxes                                                                                                                            6121
other information
segment assets                                16116          34111           2386         27738                                        80351
unallocable corporate assets                                                                             13591                         13591
total assets                                                                                                                                 93942
segment liabilities                            3548           8251           1650         13607                                        27056
unallocable corporate liabilities                                                                        14748                         14748
noncontrolling interests                                                                                 3761                          3761
total liabilities                                                                                                                            45565




                                                 this space has been intentionally left blank




272       ahead of the curve  annual report 2017

                                                                                                                     biocon limited  subsidiaries



april 1 2015 to march 31 2016
particulars                                        smv         biologics              bf        research      unallocated     eliminations             total
revenues
external revenue                                14546            4046            4409          10809                                           33810
intersegment revenue                                37           1250                             261                           1548                
total revenues                                  14583            5296            4409          11070                          1548           33810
costs
segment costs                                  11387          3654          2534         7266                                         24841
intersegment costs                                               261          1287                                          1548                 
results
corporate expenses                                                                                             1303                          1303
other income including interest                                                                     63             741                              804
operating profit                                                                                                                                      8470
depreciation amortisation                        690            617              1           973            206                          2487
finance costs                                                                                     84            209                            293
share of profit of joint venture                                                   217                                                             217
segment results                                   2506             764              804            2810            977                           5907
exceptional items                                                                                               1606                            1606
income taxes  current and deferred                                                                            1422                          1422
noncontrolling interests                                                                                        587                            587
profit after taxes                                                                                                                                    5504
other information
segment assets                                  14831           28758            1698          23555                                           68842
unallocable corporate assets                                                                                   15739                           15739
total assets                                                                                                                                         84581
segment liabilities                               2906           5527              601          13308                                           22342
unallocable corporate liabilities                                                                              19243                           19243
noncontrolling interests                                                                                       2658                            2658
total liabilities                                                                                                                                    44243

geographical segments
revenues net                                                                                                          april 01 2016 to april 01 2015 to
                                                                                                                        march 31 2017 march 31 2016
india                                                                                                                            11799              11649
united states of america                                                                                                          8997               9331
rest of the world                                                                                                                18420              12830
total                                                                                                                            39216              33810


noncurrent assets                                                                                                      march 31 2017        march 31 2016
india                                                                                                                            26823              22808
malaysia                                                                                                                         20031              18423
rest of the world                                                                                                                 1889               2054
total                                                                                                                            48743              43285
note noncurrent assets excludes financial instruments and deferred tax
significant clients
no customer individually account for more than 10 of the revenue in the year ended march 31 2017 and march 31 2016
segment revenue and results
the expenses that are not directly attributable and that can not be allocated to a business segment on a reasonable basis are shown as unallocated
corporate expenses
segment assets and liabilities
segment assets include all operating assets used by the business segment and consist principally of fixed assets and current assets segment liabilities
comprise of liabilities which can be directly allocated against the respective segments assets and liabilities that have not been allocated between segments
are shown as part of unallocated corporate assets and liabilities respectively




                                                                                                                             financial report          273

                                          44 additional information as required under schedule iii of the act of enterprises consolidated as subsidiaryassociatesjoint venture




274 
                                          name of entity                                       net assets as at             share in profit or loss            share in other comprehensive          share in total comprehensive
                                                                                               march 31 2017                for the year ended                 income for the year ended             income for the year ended
                                                                                                                               march 31 2017                         march 31 2017                        march 31 2017
                                                                                               as a  of      amount         as a  of           amount                as a  of        amount               as a  of        amount
                                                                                            consolidated                  consolidated                        consolidated other                     consolidated total
                                                                                               net assets                 profit or loss                         comprehensive                         comprehensive
                                                                                                                                                                         income                                income
                                          holding company
                                          biocon limited                                           71        65411              56                 5193                 8                 85                 51           5278
                                          subsidiaries
                                          indian
                                          syngene international limited                            11        10370              23                 2113                63                624                 27           2737
                                          biocon research limited                                                213             7                 661                                    2                 6               659
                                          biocon pharma limited                                                   131                                  4                  3                 27                                   31
                                          biocon biologics india limited                                             
                                          biocon academy                                                             
                                          foreign
                                          biocon sa                                                  5           4436             7                 684                                                       7               684




ahead of the curve  annual report 2017
                                          biocon sdn bhd                                             4           3531                                 5                  3                 30                                   35
                                          biocon biologics limited                                   5           4229            2                189                                                     2           189
                                          biocon pharma inc                                                       8            1                 98                                                     1               98
                                          biocon fz llc                                                          15                               21                                                                      21
                                          joint venture
                                          foreign
                                          neobiocon fz llc                                                       422              2                 163                                                       2               163
                                          associates
                                          foreign
                                          iatrica inc usa                                                                                                                                                                     
                                          noncontrolling interest                                   4           3761             8                 760                 23                224                 10               984
                                          gross total                                             100        92055             100                 9275              100                 988               100           10263
                                          adjustment arising on consolidation                                39917                             2394                                                                     2394
                                          total                                                               52138                                  6881                                   988                               7869

                   44 additional information as required under schedule iii of the act of enterprises consolidated as subsidiaryassociatesjoint venture contd
                   name of entity                                       net assets as at             share in profit or loss            share in other comprehensive          share in total comprehensive
                                                                        march 31 2016                for the year ended                 income for the year ended             income for the year ended
                                                                                                        march 31 2016                         march 31 2016                        march 31 2016
                                                                        as a  of      amount         as a  of           amount                as a  of        amount               as a  of        amount
                                                                     consolidated                  consolidated                        consolidated other                     consolidated total
                                                                        net assets                 profit or loss                         comprehensive                         comprehensive
                                                                                                                                                  income                                income
                   holding company
                   biocon limited                                           74        59966              46                 3686                18                10                46           3676
                   subsidiaries
                   indian
                   syngene international limited                              9           7589           23                 1821                7                  4                 23           1825
                   biocon research limited                                   1           873           10                  832                  4                 2                10               830
                   biocon pharma limited                                                    30                                22                2                  1                                  21
                   biocon biologics india limited                                                                                                                                                        
                   biocon academy                                                                                                                                                                        
                   foreign
                   biocon sa                                                  5           3858           15                 1228                                                     15           1228
                   biocon sdn bhd                                             4           2756            4                332                91                51                5           383
                   biocon biologics limited                                   6           4513             1                  71                                                       1                71
                   biocon pharma inc                                                       23                                 3                                                                       3
                   biocon fz llc                                                            5                                  3                                                                         3
                   joint venture
                   foreign
                   neobiocon fz llc                                                       259              2                 217                                                       3               217
                   associates
                   foreign
                   iatrica inc usa                                                                                                                                                                     
                   noncontrolling interest                                   3           2658             7                 587                 4                  2                  7               589
                   gross total                                              88        80784             100                 8088              100                 56              100            8032
                   adjustment arising on consolidation                                37788                             1997                                                                     1997
                   total                                                               42996                                  6091                                   56                              6035




financial report
 275
                                                                                                                                                                                                                    biocon limited  subsidiaries

45 other notes
a     the company had entered into transactions of sale of products to a private company during the year ended march 31 2013 and 2012 amounting to
         28 and  17 respectively that required prior approval from central government under section 297 of the companies act 1956 these transactions
        entered into at prevailing market prices were approved by the board of directors of the company during the year ended march 31 2014 the
        company had filed application with the central government for approval of such transactions and for compounding of such noncompliance and same
        is pending with central government as at march 31 2017

46 corporate social responsibility
as per section 135 of the companies act 2013 a company meeting the applicability threshold needs to spend at least 2 of its average net profit for the
immediately preceding three financial years on corporate social responsibility csr activities

a     gross amount required to be spent by the company during the year is  131 and

b     amount spent during the year on

 sl    particulars                                                                                    in cash         yet to be paid                  total
 no                                                                                                                          in cash
 i    construction acquisition of any asset                                                                                                           
 ii   on purposes other than i above                                                                  131                                          131

47 events after reporting period
a     on april 27 2017 the board of directors of the company approved issue of bonus shares in the proportion of 21 ie 2 two bonus equity shares of
         5 each for every 1 one fully paidup equity shares held as on the record date subject to the approval by the shareholders of the company through
        postal ballot

b     on april 27 2017 the board of directors of the company has proposed a final dividend of  3 per equity share on a prebonus share basis the
        proposed dividend is subject to the approval of the shareholders in the annual general meeting


as per our report of even date attached
for b s r  co llp                                                                            for and on behalf of the board of directors of biocon limited
chartered accountants
firm registration number 101248ww100022
s sethuraman                                                                                   kiran mazumdarshaw            arun chandavarkar
partner                                                                                        managing director              joint managing director  ceo
membership no 203491                                                                         din 00347229                  din 01596180
                                                                                               siddharth mittal               rajiv balakrishnan
                                                                                               president  finance  chief    company secretary
                                                                                               financial officer              membership no f6326
bengaluru                                                                                      bengaluru
april 27 2017                                                                                 april 27 2017




                                                     this space has been intentionally left blank




276        ahead of the curve  annual report 2017

forward looking statement
biocon fy17 annual report
in this annual report we have disclosed forwardlooking information to enable investors to comprehend our prospects and
take informed investment decisions this report and other statements  written and oral  that we periodically make contain
forward looking statements that set out anticipated results based on the managements plans and assumptions we have tried
wherever possible to identify such statements by using words such as anticipates estimates expects projects intends
plans believes and words of similar substance in connection with any discussion of future performance the market data 
rankings used in the various chapters are based on several published reports and internal company assessment
we cannot guarantee that these forward looking statements will be realized although we believe we have been prudent in
our assumptions the achievement of results is subject to risks uncertainties and even inaccurate assumptions should known
or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate actual results could vary
materially from those anticipated estimated or projected readers should bear this in mind we undertake no obligation to
publicly update any forwardlooking statements whether as a result of new information future events or otherwise




                                           conceptualized  developed by
                  team corporate communications biocon  seemaahujabioconcom
                                  trisys communications  infotrisyscomcom

biocon limited
20th km hosur road electronic city bangalore  560 100 india
t  91 80 2808 2808

e  corporatecommunicationsbioconcom
w  wwwbioconcom
